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Abbreviations 
AAM Amino acid medium 
AAMM Amino acid medium modified 
ACh ASM-Chelex 
ACP Acyl carrier protein 
Ado Adenosine 
AHL N-acylhomoserine lactone 
AMC Activated methyl circle 
Anr 
Anaerobic regulation of arginine deiminase and nitrate 
reduction 
Apr Ampicillin resistance 
ASL Airway surface liquid 
ASM Artificial sputum medium 
ATP Adenosine triphosphate 
BHL N-butyryl homoserine lactone 
BICP 5-Brom-4-chlor-3-indoxyl phosphate 
bp Base pair(s) 
BSA Bovine serum albumin 
°C Degree Celsius 
13C Carbon-13, stable isotope of carbon 
CAMP Cationic antimicrobial peptide 
c-di-GMP Cyclic di-guanylate 
cDNA Copy DNA 
CF Cystic fibrosis 
CFTR Cystic fibrosis transmembrane conductance regulator 
CM Cytoplasmic membrane 
Da Dalton 
DNA Deoxyribonucleic acid 
Dnr Dissimilatory nitrate respiration regulator 
DTNB 5,5'-dithiobis-(2-nitrobenzoic acid) 
DTPA Diethylene triamine pentaacetic acid 
E4P Erytrose-4-phosphate 
ECF sigma factor Extracytoplasmatic function sigma factor 
EV Ex vivo 
FRT Flp recombinase target 
Fur Ferric uptake regulator 
Fxxx Relative Fluorescence at xxx nm 
g Centrifugation: earth gravity (x g); weight: gram (g) 
Gmr Gentamycin resistance 
GO Guanine 8-oxo-2-deoxyguanosine 
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h Hour(s) 
Hcy L-homocysteine 
His- Histidine tagged 
IPTG Isopropyl !-D-1-thiogalactopyranoside 
l Liter 
LPS Lipopolysaccharide 
M Molar [Mol /l ], or mega in Mbp 
m Milli 
MCC Mucocilliary clearance  
MCS Multiple cloning site 
MDR Multi-drug resistant  
Me- Methyl- 
Met L-methionine 
min Minute 
MMR Methyl-directed DNA mismatch repair 
n Nano 
NBT Nitro blue tetrazolium 
OM Outer membrane 
odDHL N-3-oxododecanoyl homoserine lactone 
ODxxx Optical density at xxx nm 
Pa Pseudomonas aeruginosa  
PCR Polymerase chain reaction(s) 
PMF Proton motive force 
p-value Probability value 
PVDF Polyvinylidene fluoride 
qRT-PCR Quantitative real-time PCR 
RNA Ribonucleic acid 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SAH S-adenosyl-L-homocysteine 
SahH S-adenosylhomocysteine hydrolase 
SAM S-adenosyl-L-methionine 
SNP Single-nucleotide polymorphism(s) 
T3SS Type three secretion system 
TCA Tricarboxylic acid cycle 
THF Tetrahydrophosphate 
THP Tetrahydropteroyltriglutamate 
TNB2- 5-thio-2-nitrobenzoate 
Tris Tris-(hydroxymethyl)-aminomethane  
UV Ultraviolet 
vs. Versus 
wt Wild type 
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Zusammenfassung 
Im ersten Teil dieser Arbeit wurde der Einfluss der Wachstumsbedingungen in den zystische 
Fibrose (CF) Luftwegen auf die infizierenden Pseudomonas aeruginosa Stämme untersucht. 
Eine globale Transkriptionsanalyse der P. aeruginosa Genexpression wurde sowohl unter 
simulierten Respirationstraktbedingungen in artifiziellem Sputum-Medium (ASM) als auch unter 
ex vivo CF Lungeninfektionsbedingungen durchgeführt. Dabei wurde Eisenmangel als der 
entscheidende Faktor in den CF Luftwegen in vivo identifiziert. Daraufhin wurde ASM-Chelex 
mit erhöhter Eisenlimitierung entwickelt. Interessanterweise scheint die transkriptionelle Antwort 
auf Eisenlimitierung eine generelle Antwort von P. aeruginosa auf Infektionsbedingungen zu 
sein. Unter ex vivo Bedingungen waren die P. aeruginosa Stämme metabolisch sehr inaktiv. Die 
Geneexpression deutet auf die Nutzung der Denitrifikation zur Engergieerzeugung während 
mikroaerober bis anaerober Wachstumsbedingungen ex vivo hin. Cholin-, Methionin- und SAM-
Stoffwechsel wurden als wichtige Faktoren unter ex vivo Bedingungen ermittelt. 
Unerwarteterweise wurden Flagellen und Typ-III-Sekretionssystem (T3SS) Gene unter ex vivo 
Bedingungen exprimiert gefunden. Zusammenfassend imitiert ASM-Chelex die in vivo 
Lungeninfektionsbedingungen präziser.  
 
Im zweiten Teil wurde die Methioninauxotrophie als Anpassungsstrategie von P. aeruginosa an 
die chronische CF Lungeninfektion untersucht. Insgesamt wurden 30 P. aeruginosa Stämme 
von 15 verschiedenen CF Patienten isoliert und durch Einzelnukleotid-Polymorphismen (SNP) 
klassifiziert. Als genetische Ursache für die Methioninauxotrophie wurde das Gen metF der 
Kofaktorbiosynthese für die Mehrheit der untersuchten klinischen Isolate identifiziert. Das Gen 
metF kodiert für eine Methylentetrahydrofolat-Reduktase. Es wurde bewiesen, dass die 
Methioninauxotrophie unabhängig vom Mutatorphänotyp selektioniert wird. Die Produktion des 
bedeutenden Virulenzfaktors Pyocyanin war in allen methioninauxotrophen klinischen Isolaten, 
in PAO1 "metF und in verschiedenen Methioninstoffwechseldeletionsmutaten reduziert. Als 
Grund wurde der mögliche verringerte SAM-Spiegel diskutiert. Die Transkriptomanalyse von 
PAO1 "metF zeigte, dass eisenregulierte Gene stärker exprimiert wurden. Der Einfluss der 
Methioninauxotrophie auf die Eisenhomöostase und mögliche Eisenbeschaffungsvorteile für 
PAO1 "metF wurde diskutiert.  
 
Im dritten Teil wurde die antimikrobielle Aktivität von Ribavirin gegen P. aeruginosa PAO1 
nachgewiesen. Die S-Adenosylhomocystein-Hydrolase SahH scheint nicht der 
Hauptangriffspunkt von Ribavirin in P. aeruginosa zu sein. Die Inhibition des Enzyms SahH 
durch Ribavirin war sehr gering. Es wurde jedoch gezeigt, dass das Enzym SahH ein 
essentieller Bestandteils des bakteriellen Stoffwechsels ist und sich daher besonders gut als 
Ziel für Antibiotika eignet. Eine Deletion des sahH Genes hat drastischen Auswirkungen auf das 
bakterielle Wachstum. Der unausgeglichene intrazelluläre SAH-/SAM-Spiegel wurde als 
möglicher Grund diskutiert.  
 
Diese Arbeit trägt zum Verständnis der zugrunde liegenden Anpassungsstrategien von 
P. aeruginosa während der CF Infektion bei und zeigt mögliche therapeutische Strategien auf. 
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Summary 
The first part of this study investigated the influence of the growth conditions in the cystic 
fibrosis (CF) airways on the infecting Pseudomonas aeruginosa strains. A global transcriptional 
analysis of P. aeruginosa gene expression under simulated respiratory tract conditions in vitro in 
artificial sputum medium (ASM) and under ex vivo CF lung infection conditions was performed. 
Iron limitation was identified as the crucial factor in the CF airways in vivo. Therefore, ASM-
Chelex with increased iron limitation was developed. Interestingly, the transcriptional answer to 
iron limitation seems to be a general answer of P. aeruginosa towards infection conditions.  
Under ex vivo conditions P. aeruginosa strains were metabolically very inactive. The gene 
expression indicates the use of denitrification for energy generation during microaerobic to 
anaerobic growth conditions ex vivo. Choline, methionine and SAM metabolism were 
determined as important factors during ex vivo conditions. Unexpectedly, flagella and Type 
three secretion system (T3SS) genes were detected upregulated under ex vivo conditions. In 
conclusion ASM-Chelex mimics in vivo lung infection conditions more precisely. 
 
In the second part methionine auxotrophy as adaptation strategy of P. aeruginosa towards the 
chronic CF lung infection was investigated. In total 30 P. aeruginosa strains isolated from 15 
different CF patients were classified by single-nucleotide polymorphisms analysis (SNP). As 
genetic cause of methionine auxotrophy the gene metF of the cofactor biosynthesis was 
identified in the majority of investigated clinical isolates. The gene metF encodes for a 
methylenetetrahydrofolate reductase. It was verified that the methionine auxotrophy is selected 
independently of the mutator phenotype. Notably, the production of the major virulence factor 
pyocyanin was reduced in all methionine auxotrophic clinical isolates, in PAO1 "metF and 
several methionine metabolism deletion strains. The possible reduced intracellular SAM level 
was discussed as cause. A transcriptome analysis of PAO1 "metF showed upregulation of iron 
regulated genes. The influence of methionine auxotrophy on iron homeostasis and the possible 
advantage in iron acquisition of PAO1 "metF was discussed.  
 
In the third part the antimicrobial activity of ribavirin against P. aeruginosa PAO1 was verified. 
S-Adenosylhomocysteine hydrolase SahH seems not to be the main target of ribavirin in 
P. aeruginosa. The inhibition of the enzyme SahH by ribavirin was very low. However, it was 
shown that the enzyme SahH is an essential part of bacterial metabolism and therefore a 
powerful drug target candidate. The deletion of the sahH gene has drastic effects on bacterial 
growth. The unbalanced intracellular SAH- / SAM-level was discussed as possible reason.  
 
In summary this thesis contributes to the understanding of the underlying adaptation strategies 
of P. aeruginosa during the CF infection and indicates possible therapeutic strategies. 
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1 Introduction 
The need for new antibiotic substances and new antibiotic targets is undeniable especially in 
the times of multi-drug resistant (MDR) bacteria. Antibiotics target essential life processes such 
as cell-wall biosynthesis and the cell envelope, protein biosynthesis, RNA and DNA replication 
and the folate metabolism (Walsh, 2003).  
Treatment of MDR bacteria is particularly difficult during the reoccurring bacterial lung infections 
of cystic fibrosis (CF) patients. CF is the most common lethal genetic disease in the white 
population (O'Sullivan and Freedman, 2009). 
Resistance against commonly used CF antibiotics such as tobramycin and ciprofloxacin is 
increasing in Pseudomonas aeruginosa, therefore new therapeutical approaches, new effective 
substances and new targets are necessary (Amini et al., 2011; Brazas et al., 2007; Wu et al., 
1999). In this context it is essential to understand the underlying conditions of the chronic 
P. aeruginosa CF lung infection.  
1.1 Cystic fibrosis and Pseudomonas aeruginosa infection 
CF is a recessive autosomal hereditary disease caused by a mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene with a prevalence of 1 in 2500 live births in 
populations of European ancestry (Kerem et al., 1989; O'Sullivan and Freedman, 2009; Riordan 
et al., 1989; Rommens et al., 1989). Approximately 70 000 children and young adults are 
affected worldwide with the majority of cases in the European Union and in the United States 
(Becker et al., 2010). The prevalence in Africa and Asia is much less with 1 in 15 000 to 20 000 
and 1 in 350 000 in Japan, respectively (O'Sullivan and Freedman, 2009). The median life 
expectancy in 1969 was 8 years. Due to constant antibiotic treatment and improvements in 
medical therapy the median life expectancy for patients born in the 2000s will likely be 40 to 50 
years (Folkesson et al., 2012; Foundation, 2013; O'Sullivan and Freedman, 2009). 
Currently, 1500 possible mutations in the CFTR gene are described (O'Sullivan and Freedman, 
2009). The most common mutation is "F508 a deletion of phenylalanine 508 (Jaffe and Bush, 
2001). The different mutations result in a loss-of-function or malfunction of the CFTR protein, 
which mainly operates as chloride ion channel besides other possible functions (Darling et al., 
2004; Roomans, 2003). CFTR is described to have regulatory functions in ATP and chloride ion 
channels, in inhibition of sodium transport through the epithelial sodium channels and in 
inhibition of calcium-dependent chloride ion channels (O'Sullivan and Freedman, 2009). 
Moreover, CFTR is important for regulation of intracellular vesicle transport and acidification of 
intracellular organelles (O'Sullivan and Freedman, 2009). CFTR is present on most epithelial 
surfaces and at the surface of blood cells (O'Sullivan and Freedman, 2009).  
The impaired CFTR function results in thick dehydrated mucus in all exocrine glands particularly 
of the respiratory, the gastrointestinal and the reproductive tract (Hogardt and Heesemann, 
2013; Riordan et al., 1989). Depending on the type of mutation and the severity of the condition 
the clinical symptoms vary among patients (Hauser et al., 2011; Lyczak et al., 2002). Different 
hypotheses exist trying to explain the underlying reasons for the high viscosity of mucus in the 
CF airways (O'Sullivan and Freedman, 2009; Verkman et al., 2003). Besides, the mutation in 
the CFTR gene, a variety of innate immune system dysfunctions have been reported, which all 
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together lead to the chronic bacterial infection of the lung and excessive pulmonary 
inflammation (Doring and Gulbins, 2009; Hogardt and Heesemann, 2013).  
The mucocilliary clearance (MCC), the cationic antimicrobial peptides (CAMPs), the CFTR, and 
moreover, neutrophils and macrophages are impaired (Doring and Gulbins, 2009) (Fig. 1 A&B). 
Recently, ceramide accumulation as effect of CFTR mutation was discovered (Becker et al., 
2010; Teichgräber et al., 2008).  
The MCC is impaired due to the high viscosity of the mucus compared to the thin airway surface 
liquid (ASL) of the healthy lung (Fig. 1 A&B) (Boucher, 2007). This condition allows bacterial 
pathogens to colonise the nutrient rich mucus. The mucus is rich in amino acids of degraded 
proteins, glycoproteins (e.g. mucins), DNA, phospholipids, electrolytes, cellular debris from 
neutrophils and bacteria (Barth and Pitt, 1996; Palmer et al., 2005; Whitchurch et al., 2002). 
Nitrate concentrations up to 700 #M were detected in the CF sputum (Grasemann et al., 1998). 
The release of bacteriolytic enzymes and CAMPs such as !-defensins and cathelicidins is 
probably reduced due to the high viscosity of mucus (Verkman et al., 2003). Additionally, the 
probably hypertonic salt concentrations in the mucus might inactivate the salt-sensitive CAMPs 
(Boucher, 2007). 
Furthermore, CFTR was shown to be responsible for the internalization of P. aeruginosa and is 
therefore essential for clearance of P. aeruginosa from the epithelial surface (Pier, 2000). The 
high viscosity of mucus also influences migration of neutrophils (Matsui et al., 2005), which 
results in delayed eradication of pathogens and therefore in higher bacterial cell numbers (Fig. 
1B). Besides bacteria have more time to adapt to the environment.  
In contrast the neutrophil levels in the CF lung are 380-fold higher than in the lungs of the 
uninfected controls (Konstan et al., 1994). In addition, the neutrophil activation results in the 
release of granule stored enzymes such as neutrophil elastase, myeloperoxidase and in the 
generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) (Hogardt and 
Heesemann, 2013). The imbalance between protease / antiprotease and oxidants / antioxidants 
activity results in further tissue damage (Doring, 1999; Ratjen et al., 2002). Additionally, 
neutrophil necrosis enhances extracellular DNA concentrations. 
Recently, it was demonstrated that CFTR in the lysosome participates in pH control. Since the 
chloride ion transport by CFTR positively stimulates the hydrogen ion transport into the 
lysosomal lumen by the V-type H+-ATPase (Di et al., 2006). This results in a pH of < 5 which is 
necessary for optimal bactericidal activity of degenerative enzymes during fusion of the 
lysosome with the phagosome.  
A defective CFTR results in increased pH. The elevated pH causes an imbalance of acid 
sphingomyelinase and acid ceramidase. Ceramide accumulation is the consequence. The cell 
death rates are increased resulting in extracellular DNA deposition (Teichgräber et al., 2008).  
An increase in proinflammatory molecules such as interleukin 8, interleukin 6 and tumor 
necrosis factor $ has been detected in CF patients (Colombo et al., 2005). Nuclear factor-%B 
pathway, platelet hyper-reactivity, and abnormalities in neutrophil apoptosis have also been 
reported (O'Sullivan and Michelson, 2006; Rottner et al., 2007). Native anti-inflammatory 
substances such as interleukin 10, lipoxin, and docosahexaenoic acid are reduced, leading to 
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an imbalance between proinflammatory and anti-inflammatory response. This imbalance leads 
to undiminished inflammation (Bonfield et al., 1999). 
 
 
Fig. 1: Clearance of bacteria from the airways of healthy individuals and cystic fibrosis patients 
(adapted from Doring and Gulbins, 2009 and Worlitzsch et al., 2002) 
The clearance of bacterial airway infections is shown for healthy individuals (A) and cystic fibrosis 
(CF) patients (B). 
(A) Bacteria reaching the respiratory tract of healthy individuals are efficiently trapped by the 
thin airway surface liquid (ASL) layer, which is constantly removed by the mucocilliary 
clearance (MCC). Bacteria are killed by the cationic antimicrobial peptides (CAMPs) 
released from the submucosal glands or from epithelial cells. Eradication of bacteria can 
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take place via internalization by a functional CFTR or via uptake by neutrophils or 
macrophages. Neutrophils can eliminate bacteria by the formation of reactive oxygen or 
nitrogen species (ROS; NOS) or non-oxidative by CAMPs. The conditions in the ASL are 
aerobic. 
(B) In the respiratory tract of CF patients bacteria can survive in the highly viscous nutrient rich 
mucus, due to impaired MCC and impaired CAMPs release. The migration of neutrophils 
and macrophages is decreased. Depending on the type of CFTR gene mutation CFTR is 
not functional or not present on the epithelial surface at all. Therefore, no uptake of bacteria 
takes place. Due to the CTFR induced pH shift in the lysosomes of epithelial cells, 
neutrophils and macrophages bacterial pathogens are not killed in the phagolysosomes. 
Instead the pH shift and CFTR lead to ceramide accumulation, which results in cell death 
and DNA deposition. In addition, cytokine release leads to further neutrophil recruitment. 
The mucus is microaerobic to anaerobic, which induces phenotypic changes in the 
colonizing pathogens e.g. microcolony and biofilm formation by P. aeruginosa and the 
conversion to the mucoid phenotype. The oxygen gradient (pO2) in the ASL and in the 
mucus is indicated with blue for oxygen saturation and red for oxygen depletion. 
_____________________________________________________________________________ 
 
The microaerobic to anaerobic conditions in the CF airways (Worlitzsch et al., 2002) cause the 
abolishment of the generation of reactive oxygen species (ROS) by the neutrophils and 
macrophages. Oxygen depletion is probably due to the high viscosity of the mucus, rapid 
bacterial oxygen consumption and probably also due to increased oxygen consumption by the 
epithelial cells (Stutts et al., 1986; Worlitzsch et al., 2002). Phagocytosis of P. aeruginosa is 
prevented by the mucoid phenotype and biofilm formation (Worlitzsch et al., 2002). Moreover, 
alginate protects bacteria from and the effects of non-oxidative killing by antimicrobial peptides 
and other granule-stored enzymes (Hampton et al., 1998; Matsui et al., 2006; Worlitzsch et al., 
2002). Similarly, Staphylococcus aureus is producing a polysaccharide capsule, which protects 
from non-oxidative killing (McKenney et al., 1999). Burkholderia cepacia complex is intrinsically 
resistant to non-oxidative killing (Sousa et al., 2007). 
Infants with CF are rapidly infected with Haemophilus influenzae or S. aureus, or both 
organisms. Approximately 80 % of CF patients are positive for P. aeruginosa in their late 
twenties (Hauser et al., 2011). The airways of CF patients can be colonized by other pathogens 
besides P. aeruginosa, such as e.g. Burkholderia cepacia complex, Stenotrophomonas 
maltophilia, methicillin-resistant S. aureus (MRSA), atypical mycobacteria and Aspergillus 
fumigatus (Hauser et al., 2011; O'Sullivan and Freedman, 2009). Also anaerobic organisms 
were detected mostly belonging to the genera Prevotella, Veillonella, Propionibacterium and 
Actinomyces (Tunney et al., 2008). 
As described CF airways colonizing P. aeruginosa are confronted with a highly selective and 
heterogeneous environment, which is characterised by various stress conditions such as 
antibiotics, host immune response and oxidative and osmotic stress (Folkesson et al., 2012). 
Once a chronic P. aeruginosa airway infection is established, the infection is nearly impossible 
to cure and often associated with the decline of lung function and a reduced life expectancy 
(Doring and Gulbins, 2009; Hauser et al., 2011).  
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1.1.1 Treatment of cystic fibrosis patients 
At present the surveillance for P. aeruginosa is the most common strategy in combination with 
early eradication by inhaled antibiotics and with or without oral quinolone therapy (O'Sullivan 
and Freedman, 2009). 
Currently, treatment with inhaled recombinant human deoxyribonuclease I and inhaled 
tobramycin is beneficial in many patients. The Cystic Fibrosis Foundation guidelines also 
support the use of inhaled hypertonic saline, the macrolide azithromycin and ibuprofen, in 
specific patient populations (Foundation, 2013; O'Sullivan and Freedman, 2009). Intravenous 
colistin has been found to be beneficial in the acute setting when combined with other 
antipseudomonal antibiotics (Foundation, 2013; O'Sullivan and Freedman, 2009). Most patients 
with exacerbations are most likely infected with P. aeruginosa and are therefore treated with a 
combination of !-lactams and aminoglycosides during in-hospital therapy. 
  
Introduction 
 
 15 
1.2 Pseudomonas aeruginosa 
1.2.1 The bacterium Pseudomonas aeruginosa  
P. aeruginosa is a ubiquitously spread versatile Gram-negative bacterium, which is polar 
flagellated and belongs to the group of &-proteobacteria (Stover et al., 2000). Very characteristic 
for P. aeruginosa is the production of the blue pigment pyocyanin, which is known as major 
virulence factor in different infection models (Lau et al., 2004), and the green fluorescent 
siderophore pyoverdin (Meyer, 2000; Meyer et al., 1996; Schalk and Guillon, 2012). 
P. aeruginosa produces the volatile molecule 2-aminoacetophenone (Cox and Parker, 1979). 
This substance is responsible for the grape like sweet odour of P. aeruginosa cultures. 
Recently, 2-aminoacetophenone was described to have immuno modulatory effects, which 
influence the host signaling towards the establishment of a chronic infection in mice 
(Bandyopadhaya et al., 2012). 
Stover et al. (2000) determined the relatively large genome of P. aeruginosa PAO1 with a size 
of 6.3 Mbp and with currently 5671 predicted open reading frames (Winsor et al., 2011). In 
addition Stover et al. (2000) observed that P. aeruginosa nearly possesses 300 cytoplasmic 
membrane transport systems. The majority of them seem to be involved in import of nutrients. 
This is in accordance with its enormous versatility in the environment.  
Notably, 9,4 % of the open reading frames encode regulatory genes and two-component 
systems (Stover et al., 2000). This number is much higher than in other bacterial species such 
as, Escherichia coli or Bacillus subtilis and enables P. aeruginosa to respond to a variety of 
changing environmental conditions (Stover et al., 2000). The genome size of other so far 
sequenced P. aeruginosa strains ranges from 5 - 7 Mbp suggesting adaptations to different 
environmental niches (Schmidt et al., 1996). 
P. aeruginosa is capable to degrade various carbon sources, e.g. such as sugars, fatty acids, 
alcohols, glycols, aromatic compounds, amines and also amino acids (Palleroni, 1992; Palmer 
et al., 2005; Son et al., 2007). For the degradation of glucose P. aeruginosa uses the Entner-
Doudoroff-pathway, which also favours the degradation of organic acids (Palleroni, 1992). 
P. aeruginosa prefers as facultative anaerobe oxygen as terminal electron acceptor. Growth of 
P. aeruginosa under anaerobic conditions can be supported by either nitrate or nitrite respiration 
and by arginine fermentation (Hassett et al., 2009; Vander Wauven et al., 1984; Zumft, 1997). 
Anaerobic respiration consists of the sequential reduction of the alternative electron acceptor 
nitrate (NO3) via nitrite (NO2), nitric oxide (NO) and nitrous oxide (N2O) to molecular nitrogen 
(N2) (Zumft, 1997). Anaerobic survival without growth is possible via pyruvate fermentation 
(Eschbach et al., 2004).  
In addition, P. aeruginosa is able to form biofilms. Biofilms are structured communities of 
surface adherent bacteria covered in a polymeric matrix (Costerton et al., 1999). Biofilm 
formation is important for the survival in various environments and during infection.  
P. aeruginosa is known as opportunistic and nosocomial pathogen causing infections of the 
urinary tract, of burn wounds and particularly infections in immunocompromised patients, due to 
its intrinsic antibiotic resistances (Bielecki et al., 2008; Chugani and Greenberg, 2007; Hancock, 
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1998). Furthermore, acute and persistent infections caused by P. aeruginosa are common in 
the lungs of CF patients (Hauser et al., 2011; Lyczak et al., 2002). 
1.2.2 Quorum sensing and virulence in Pseudomonas aeruginosa 
Quorum sensing regulates the expression of approximately 10 % of all genes in P. aeruginosa 
(Heurlier et al., 2006). This includes genes encoding for functions such as virulence, motility, 
chemotaxis and metabolism. The quorum sensing network of P. aeruginosa is subdivided in the 
LasI / LasR and RhlI / RhlR system, which interact with the Pseudomonas quinolone signal 
(PQS) system, several global regulators, two-component systems and sigma factors (Fig. 2). 
The LasI / LasR system is regulating the RhlI / RhlR system and PQS production (Venturi, 
2006).  
The LasI / LasR and RhlI / RhlR system use the N-acyl-homoserine lactones (AHL) as signalling 
molecules. N-butyryl homoserine lactone (BHL) is synthesized by RhlI and N-3-oxododecanoyl 
homoserine lactone (odDHL) by LasI. Both AHLs synthases are constitutively expressed.  
The transcriptional regulator LasR / odDHL positively regulates lasI gene and rhlR expression 
(Seed et al., 1995). LasR forms multimers and binds in the presence of odDHL to las-boxes in 
the genome (Kiratisin et al., 2002). RhlR dimerizes and binds DNA in the presence and absence 
of BHL (Medina et al., 2003). Several global regulators have been identified to influence and 
regulate quorum sensing in P. aeruginosa (Venturi, 2006) (Fig. 2). This allows P. aeruginosa to 
regulate gene expression growth phase dependent, in regard to BHL and odDHL concentration 
and in accordance to the environmental conditions. 
 
Fig. 2: Quorum sensing and regulatory network of P. aeruginosa (from Venturi, 2006) 
Arrows indicate positive regulation. The short parallel lines show negative regulation. 
_____________________________________________________________________________ 
 
Additionally, cyclic di-guanylate (c-di-GMP) seems to be important for swarming, twitching, 
surface attachment and biofilm formation. Accumulation of c-di-GMP promotes biofilm formation 
of P. aeruginosa, while its breakdown results in motility and detachment from biofilm towards 
planktonic lifestyle (Lory et al., 2009).  
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The LasI / LasR quorum sensing system regulates the expression of the virulence factors such 
as elastase LasB, staphylolytic protease LasA, Exotoxin A and components of Xcp secretion 
machinery (Hentzer and Givskov, 2003; Juhas et al., 2004; Schuster et al., 2003; Wagner et al., 
2003). The RhlI / RhlR system regulates its own expression via RhlI. Moreover, the expression 
of sigma factor RpoS, rhamnolipid encoded by rhlAB operon, LasB, LasA, hydrogen cyanide 
encoded by the hcnABC operon, pyocyanin encoded by phzABCDEFG operon, lipase and 
alkaline protease AprA are regulated by the RhlI / RhlR system. PQS also regulates its own 
production by expression of the pqsABCDE operon and via PqsR (Dekimpe and Deziel, 2009). 
Moreover, PQS regulates the expression of elastase, rhamnolipid, PA-IL lectin LecA and 
pyocyanin (Diggle et al., 2007b; Gallagher et al., 2002; Haussler and Becker, 2008). 
A mutation in any quorum sensing system leads to attenuated virulence of P. aeruginosa. 
Interestingly, RhlR can compensate a lasR mutation by activating essential LasR controlled 
functions (Dekimpe and Deziel, 2009). 
It is also described that quorum sensing signalling molecules have immuno modulating 
functions. Neutrophil apoptosis and cytokine release is reported to be induced by odDHL (Smith 
et al., 2001). Quorum sensing signalling molecules probably allow the cross talk between 
different bacterial species (Federle and Bassler, 2003). 
1.2.3 Adaptation strategies and virulence of Pseudomonas aeruginosa during chronic 
cystic fibrosis infection 
Adaptive evolution due to genetic variation seems to be one of the key aspects of P. aeruginosa 
survival in the challenging environment of the CF lung during chronic infection (D'Argenio et al., 
2007; Mena et al., 2008; Smith et al., 2006).  
Host immune response and reoccurring antibiotic treatment create selective pressure. Oxygen 
limitation and the microaerobic to anaerobic conditions in the CF lung are also important factors 
shaping the P. aeruginosa phenotype (Alvarez-Ortega and Harwood, 2007; Worlitzsch et al., 
2002). This environment leads to the known phenotypes of mucoidy and the formation of 
microcolonies and biofilms (Boucher et al., 1997; Costerton et al., 1999; Govan and Deretic, 
1996; Lam et al., 1980). 
Clinically relevant phenotypic changes are detectable, as P. aeruginosa colonizes the nutrient 
rich mucus of the CF airways, such as colony variation (von Gotz et al., 2004), loss of motility 
(Amiel et al., 2010; Mahenthiralingam et al., 1994), modification of LPS (Hancock et al., 1983), 
loss of quorum sensing (D'Argenio et al., 2007; Smith et al., 2006), reduced virulence (Luzar 
and Montie, 1985) and increased antibiotic resistance (Ciofu et al., 2001; Wiegand et al., 2008) 
(Fig. 3). In addition, it was shown that the mutator phenotype is widely spread among 
P. aeruginosa CF isolates and very important for adaptation (Ciofu et al., 2005; Hogardt et al., 
2006; Oliver et al., 2000).  
Mutator phenotypes arise due to mutations in the methyl-directed DNA mismatch repair (MMR) 
and the guanine 8-oxo-2-deoxyguanosine (GO) system (Ciofu et al., 2010). Most of the 
frequently isolated mutators in CF carry mutations in mutS and mutL genes belonging to the 
MMR type. Strong mutators display a mutation frequency of at least 100 to 1000-fold increased.
Defects in the GO system genes result in a weak mutator phenotype (<2 x 10-7 and ' 2 x 10-8 for 
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rifampicin) (Ciofu et al., 2010). The GO system is involved in the repair of DNA damaged by 
oxidation. It is encoded by mutT, mutY and mutM genes. 
 
Fig. 3: Phenotypic adaptation of Pseudomonas aeruginosa during acute and chronic cystic fibrosis 
infection 
(A) During acute infection P. aeruginosa strains are motile by flagella. Many strains express type 
IV pili for surface attachment. Quorum sensing molecules odDHL and BHL are produced and 
secreted. Upon threshold achievement, regulation of gene expression of certain genes is 
taking place. Type three secretion system (T3SS) is used for the translocation of effector 
molecules into the host cells. Several enzymes such as e.g. phospholipase C, elastase LasB, 
staphylolytic protease LasA and alkaline protease are secreted into the mucus to degrade 
nutrients. Iron scavenger as the siderophores pyoverdin and pyochelin are secreted. 
(B) During chronic infection P. aeruginosa strains are often non-motile. Overproduction of alginate 
and loss of quorum sensing are the characteristics of transition to chronic CF infection. The P. 
aeruginosa lasR mutants are frequently isolated, which do not produce odDHL. Modifications 
of LPS are also detected. Mutations in the genome are also very common and the mutator 
phenotype is frequently observed. Few strains require certain nutrients for growth e.g. amino 
acids. Bacteria attach to each other and form microcolonies and biofilms. During growth in the 
microaerobic to anaerobic environment arginine fermentation or anaerobic nitrate respiration 
are used. Very different phenotypes are isolated form the airways of CF patients. The mucus is 
rich in amino acids of degraded proteins, glycoproteins, DNA, phospholipids, electrolytes, 
cellular debris from neutrophils and bacteria. Nitrate concentrations up to 700 #M were 
detected in the CF sputum. 
_____________________________________________________________________________ 
 
Loss of function mutations in the genes of mucA and lasR are frequently observed. The 
mutations result in either mucoidy or the partial loss of quorum sensing. Both are evidence for 
the transition to chronic P. aeruginosa infection (Fig. 3 B).  
The excessive production of alginate, which is the main component of the biofilm matrix, results 
in reduced oxygen diffusion to the bacteria and causes a switch to microaerobic and anaerobic 
metabolism (Boucher et al., 1997). The diffusion barrier protects the bacteria also from 
antibiotics (Ratjen and Doring, 2003), oxygen radicals (Mathee et al., 1999) and prevents 
phagocytosis (Schwarzmann and Boring, 1971; Worlitzsch et al., 2002). Therefore, the loss of 
function mutation of the mucA gene leads to diminished possibility of P. aeruginosa eradication 
by either antibiotics or host immune system. Interestingly, during the end-stage of CF the 
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domination of the mucoid phenotype is reverted to the non-mucoid phenotype. This is indicating 
a change of selective pressure (Bragonzi et al., 2009).  
The loss-of-function mutation of lasR gene results in reduced expression of virulence factor 
genes and allows on the contrary more efficient utilization of certain carbon sources such as 
phenylalanine and other aromatic and branched-chain amino acids (D'Argenio et al., 2007; 
Hoffman et al., 2010; Sandoz et al., 2007). This is probably due to the upregulation of the 
transcriptional metabolism regulator cbrB gene (D'Argenio et al., 2007). Hoffmann et al. (2010) 
detected increased utilization of nitrate and nitrite but decreased utilization of oxygen of the lasR 
mutants. Resistance towards oxidative stress, including antibiotics such as tobramycin and 
ciprofloxacin was also increased in lasR mutants. Moreover, lasR mutants are frequently 
detected in the sputum of CF patients without co-isolation of wild type (wt) strains (D'Argenio et 
al., 2007; Smith et al., 2006).  
Moreover, pyocyanin-negative strains were isolated. Hogardt and Heesemann (2013) assumed 
that this might reduce the auto-oxidation stress of P. aeruginosa and might lead to reduced 
recognition by the host immune system. 
Previous studies investigated the influence of nutrient availability and its direct influence on 
bacterial metabolism, on growth and virulence factor production (Palmer et al., 2007a; Palmer et 
al., 2005; Son et al., 2007; Sriramulu et al., 2005). In addition, it was frequently observed that 
some P. aeruginosa strains isolated from the CF lung were unable to synthesise particular 
growth factors (Taylor et al., 1992). Strains were auxotrophic for certain nutrients. The most 
common source of auxotrophy was amino acids in P. aeruginosa. Most frequently methionine 
auxotrophic P. aeruginosa strains were isolated (Barth and Pitt, 1995; Barth and Pitt, 1996; 
Barth et al., 1998; Thomas et al., 2000). Other less frequently observed auxotrophies were 
identified as auxotrophies for the amino acids leucine, arginine and for both isoleucine and 
valine (Barth and Pitt, 1995; Barth and Pitt, 1996; Taylor et al., 1992).  
Biofilm development has been shown to be influenced by carbon and nitrogen sources in vitro 
(Hoffman et al., 2010; Klausen et al., 2003; Shrout et al., 2006; Sriramulu et al., 2005). 
Furthermore, cell-to-cell signalling is also influenced by the nutrient availability (Palmer et al., 
2005; Shrout et al., 2006; Wagner et al., 2003).  
Especially, 2-heptyl-3-hydroxyl-4-quinolone the PQS signal seems to be an important signalling 
molecule under CF conditions. Several studies suggest that the PQS production is increased 
due to the moiety of aromatic amino acids in the CF sputum (Palmer et al., 2007a; Palmer et al., 
2005).  
1.2.4 Iron acquisition and uptake by Pseudomonas aeruginosa 
Iron is one of the important factors for P. aeruginosa to establish and maintain an infection. 
Therefore, acquisition and storage of iron are essential under iron limiting conditions such as in 
the environment or during infection. Iron concentrations range from < 0.1 #M in the soil to 10-9 
#M in mammals (Vasil and Ochsner, 1999). The host tightly regulates iron availability by binding 
it to proteins such as ferritin, lactoferrin, transferrin or as heme to haemoglobin. 
Typically bacteria e.g. E. coli need approximately 0.3 -1.8 #M iron for optimal growth (Braun and 
Killmann, 1999). Free iron is usually limited in an aerobic environment, since it is highly 
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insoluble as Fe3+ but also harmful hydroxyl radicals can be easily generated via Fenton-type 
reactions (Miller and Britigan, 1997). Iron acquisition is essential for every bacterium, since 
especially redox-dependent enzymes need iron to be functional. In order to circumvent these 
limitations P. aeruginosa possesses a variety of different mechanisms, ranging from 
siderophore production, over heme uptake to extracellular toxin generation. Exotoxin A is 
inhibiting protein biosynthesis of the eukaryotic cell by ADP-ribosylation of elongation factor-2 
(Iglewski and Kabat, 1975). It is strongly induced by iron depletion (Vasil and Ochsner, 1999).  
Several studies observed, that shortage of iron led to increased expression of iron acquisition 
genes, such as the genes of the siderophores pyoverdin and pyochelin (Oglesby et al., 2008; 
Palma et al., 2003; Vasil and Ochsner, 1999).  
Iron acquisition, uptake and storage are directly and indirectly controlled by the global ferric 
uptake regulator Fur, extracytoplasmic function (ECF) sigma factors or other types of regulators 
such as two-component regulatory systems and AraC-type regulators in P. aeruginosa. At iron 
availability the Fur protein is loaded with Fe2+. The ferrated Fur binds to the Fur box in the 
promoter region of genes e.g. necessary for iron uptake, and thereby preventing transcription 
(Oglesby et al., 2008). Several microarray studies have been performed to investigate iron 
regulated genes and the influence of iron starvation (Ochsner et al., 2002; Palma et al., 2003).  
Previous studies reported that PQS is able to chelate iron, besides being a signaling molecule 
and being necessary for the formation of outer membrane vesicles (Bredenbruch et al., 2005; 
Mashburn and Whiteley, 2005; Mashburn-Warren et al., 2009). Thereby leading to activation of 
iron acquisition genes and genes necessary for oxidative stress protection (Bredenbruch et al., 
2005). But it is also indicated that PQS itself does not function as a siderophore, but might 
simplify siderophore mediated uptake (Diggle et al., 2007b). 
1.2.5 Methionine metabolism of Pseudomonas aeruginosa 
An essential part of bacterial metabolism is the methionine and S-adenosylmethionine (SAM) 
metabolism, which are inseparable linked to one another (Fig. 17). Methionine and ATP are 
converted by S-adenosylmethionine synthetase MetK to SAM in P. aeruginosa. SAM is the 
second most frequently used enzyme substrate after ATP (Fontecave et al., 2004; Loenen, 
2006). The majority of estimated 95 % of SAM is used for methylation reactions (Griffith, 1987). 
Methylation is one of the most ubiquitous chemical reactions in cellular metabolism (Stepkowski 
et al., 2005). S-adenosylhomocysteine (SAH) is the product of these reactions and a potent 
inhibitor of transmethylation reactions and therefore efficiently converted to homocysteine (Hcy) 
and adenosine (Ado) by S-adenosylhomocysteine hydrolase SahH. The methylation of 
macromolecules and small molecules is dependent on the intracellular SAM / SAH equilibrium. 
Recently, the intracellular SAM and SAH level for the E. coli wild type strain MG1665 (OD600 of 
1.62 ± 0.16) was determined with a ratio of 300:1 with 0.4 mM and 1.3 #M, respectively 
(Halliday et al., 2010). Hcy can also be generated by MetZ from O-succinyl-homoserine. The 
last step of methionine biosynthesis is the conversion of Hcy via either MetE or MetH to 
methionine. MetH is a cobalamin dependent and MetE a cobalamin independent methionine 
synthase. Both enzymes use the cofactor N5-methyl-tetrahydrofolate (Me-THF) and N5-methyl-
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tetrahydropteroyltriglutamate (Me-THP) as methyl-group donor, respectively. Methionine can 
then be directly incorporated into biosynthesis or it can be converted to SAM as described. 
 
Fig. 4: Methionine metabolism and SAM recycling in Pseudomonas aeruginosa 
Methionine and ATP are converted by S-adenosylmethionine synthetase MetK into SAM, 
phosphate and diphosphate. SAM is used for various metabolic reactions in the cell. If SAM is used 
for methylation the remaining SAH is hydrolysed by SahH into Ado and Hcy. Hcy can be generated 
out of O-succinyl-homoserine by MetZ. Hcy can be converted by either cobalamin-independent 
methionine synthase MetE or cobalamin-dependent methionine synthase MetH back into 
methionine. Both enzymes use the cofactor N5-methyl-tetrahydrofolate (Me-THF) and N5-methyl-
tetrahydropteroyltriglutamate (Me-THP) as methyl-group donor, respectively (only THF is shown). 
MetF converts N5,N10-methylene-tetrahydrofolate to Me-THF or N5,N10-methylene-
tetrahydropteroyltriglutamate to Me-THP. GlyA1 and GlyA2 are serine hydroxymethyl transferases, 
which convert serine into glycine and thereby produce N5,N10-methylene-tetrahydrofolate from THF. 
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The GcvT2H2P2 glycine cleavage system produces also N5,N10-methylene-tetrahydrofolate from 
THF and glycine. 
If SAM is used for other reactions e.g. by AHL synthase or as source of an amino propyl group for 
the generation of spermidine these reactions yield 5´-methylthioadenosine (MTA). MTA is recycled 
by 5´-methylthioadenosine phosphorylase MtnP and by several other enzymes to methionine. N-
butyryl homoserine lactone (BHL) is synthesized by RhlI and N-3-oxododecanoyl homoserine 
lactone (odDHL) by LasI. Several genes encoding for methionine metabolism enzymes are 
positively regulated by quorum sensing (indicated by orange plus). Adapted from (Fontecave et al., 
2004; Heurlier et al., 2006; Parveen and Cornell, 2011; Sekowska et al., 2004). 
_____________________________________________________________________________ 
 
Approximately 2-5% of cellular SAM is used for decarboxylation reactions e.g. for the production 
of polyamines, for quorum sensing molecule biosynthesis for N-acylhomoserine lactones 
(AHLs) or as source of 5´deoxyadenosyl radicals, which are necessary for the production of 
vitamins e.g. biotin and lipoate etc. (Griffith, 1987; Parveen and Cornell, 2011). These reactions 
yield 5´-methylthioadenosine (MTA) or 5´deoxyadenosine (5´dAdo), respectively. 
Guan et al. (2011) propose that MTA is converted into 5´-methylthioinosine (MTI), which is 
further metabolised into hypoxanthine and 5´-methylthioribose-1-phosphate (MTR-1-P). MTR-1-
P is further recycled into methionine by the gene products of mtnA, mtnB, mtnC, mtnD and tyrB 
(Heurlier et al., 2006). 
P. aeruginosa is one of the few bacteria, which possesses a SAH hydrolase as well as a MTA 
phosphorylase (MtnP, EC 2.4.2.28) for recycling of SAH and MTA, and probably for 5´dAdo 
(Challand et al., 2010; Challand et al., 2009; Choi-Rhee and Cronan, 2005). The narrow 
substrate specificity of both enzymes for the recycling of either SAH or MTA seems to be an 
advantage for survival of P. aeruginosa under the varying environmental conditions (Stepkowski 
et al., 2005). This is very similar to what can be found in eukaryotes, including mammals, 
besides it is found several Archaea and other bacterial species with relatively large genomes 
(>6 Mb) (Stepkowski et al., 2005). 
Interestingly, AHL biosynthesis is connected to the methionine and SAM metabolism. AHLs are 
synthesized from SAM and an intermediate of fatty acid biosynthesis by the AHL synthases of 
the LuxI family (Heurlier et al., 2006). N-butyryl homoserine lactone (BHL) is synthesized by 
RhlI and N-3-oxododecanoyl homoserine lactone (odDHL) by LasI. BHL can diffuse freely 
(Wagner et al., 2003; Williams and Camara, 2009). odDHL can also diffuse but its transport is 
increased by mexAB-oprM and probably other efflux pumps. 
Interestingly, several genes of methionine and SAM metabolism are described to be under 
positive quorum sensing control such as the genes encoding for the cleavage system 
gcvT2H2P2, glyA1 hydroxy-methyltransferase, pvdQ and metE (Schuster et al., 2003; Wagner 
et al., 2003).  
1.2.6 Riboswitches in methionine metabolism of Pseudomonas aeruginosa 
Other regulating factors seem to have an important impact on methionine and SAM metabolism 
genes and might be potentially targeted by drugs. Riboswitches are mRNA structures that 
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regulate gene expression (Blount and Breaker, 2006). Blount and Breaker (2006) proposed that 
metabolite sensing RNAs (riboswitches) could also be potential targets. 
For several bacterial species SAM and SAH dependent riboswitches were shown or were 
predicted in the mRNAs of the genes involved in the methionine and SAM metabolism. For 
Pseudomonas syringae a SAH dependent riboswitch in the mRNA of the sahH operon was 
described (Wang et al., 2008). Wang et al. (2008) proposed that SAH binding activates gene 
expression. Furthermore, 15 SAH RNA motifs were identified in the Pseudomonadales (Wang 
et al., 2008). Recently, a SAM-III box was identified in the 5´untranslated region (5´ UTR) of 
metK in Enterococcus faecalis (Smith et al., 2010). 
So far it is predicted and partly verified for some organisms that the genes of S-
adenosylhomocysteine hydrolase (sahH), cobalamin-dependent methionine synthase (metH) 
and methylenetetrahydrofolate reductase (metF) are possessing possible SAH elements in the 
5´ UTR (Wang et al., 2008; Weinberg et al., 2007). 
1.2.7 Potential drug targets in Pseudomonas aeruginosa 
Ribavirin (1-!-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a purine analogue. It is 
structurally very similar to adenosine (Ado), e.g. inter alia the product of the hydrolysis of SAH 
into Hcy and Ado (Fig. 5). Ribavirin is an approved drug against DNA and RNA viruses, e.g. for 
hepatitis C treatment in combination with interferon (Davis et al., 1998). Recently, ribavirin’s 
impact on Trypanosmoma cruzi´s S-adenosylhomocysteine hydrolase SAHH was successfully 
tested (Cai et al., 2010; Cai et al., 2007). Ribavirin resulted in total inhibition of the enzyme in an 
in vitro assay. Furthermore, looking for antimicrobial activity in non-antibiotic drugs Kruszewska 
et al. (2002) tested ribavirin successfully in their study. In addition Kruszewska et al. showed an 
effect against P. aeruginosa. 
S-Adenosylhomocysteine hydrolase (SahH, EC 3.3.1.1) has been identified as a potential drug 
target in one of the essential metabolic pathways the recycling of SAM. Due to narrow substrate 
specificity SahH is predicted to be an excellent drug target. 
 
 
Fig. 5: Chemical structure of ribavirin, adenosine and S-adenosylhomocysteine 
Ribavirin (1-!-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is as a purine analogue structurally 
very similar to adenosine. Adenosine is e.g. inter alia the product of the hydrolysis of S-
adenosylhomocysteine (SAH) into homocysteine (Hcy) and adenosine (Ado). 
_____________________________________________________________________________ 
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1.3 Aim of this study  
The aim of this study is divided into three parts. The first part focuses on the in vivo situation 
during the chronic CF airway infection by Pseudomonas aeruginosa. Still very little is known 
about the impact of the CF airways and its nutrient availability as surrounding growth 
environment on the infecting P. aeruginosa strains. 
Transcriptional profiling should be employed to inverstigate the difference in gene expression of 
P. aeruginosa grown under ex vivo CF airway conditions or under simulated respiratory tract 
conditions in an existing artificial sputum medium (ASM) by Sriramulu et al. (2005). Besides 
understanding the underlying adaptation strategies, insights into regulatory networks, the 
environmental responses and the identification of crucial factors, it was the goal to modify the 
existing ASM to simulate the ex vivo conditions more precisely. 
 
The second part deals with the question of the high frequency of methionine auxotrophic 
P. aeruginosa strains among the CF isolates. The main goal was the identification of the genetic 
cause of methionine auxotrophy. A representative number of isolates should be analysed. The 
influence of methionine auxotrophy on virulence factor production should be investigated.  
To understand the underlying adaptation strategies, several methionine metabolism gene 
deletion mutants in PAO1 should be constructed. A phenotypic characterisation of the 
methionine auxotrophic strains and PAO1 methionine metabolism deletion mutants should be 
performed in order to determine the advantages of methionine auxotrophy  
 
The third part of the study reports about both, a new antibiotic target and about an already 
known viral drug effective against P. aeruginosa, since multidrug resistance is spreading new 
targets and substances are necessary. 
The possibility of ribavirin usage against P. aeruginosa PAO1 should be elucidated. SahH as 
potential drug target in P. aeruginosa should be investigated and the mode of action of ribavirin 
should be analysed. Therefore, it would also be of importance to investigate the influence of 
SahH and MtnP on bacterial phenotype. In addition, the presence of new regulatory elements 
such as riboswitches in the 5´ UTR of methionine metabolism genes in P. aeruginosa should be 
analysed. An in vitro assay should be established to analyse the impact of the inhibitor ribavirin 
on the activity of enzyme SahH of P. aeruginosa PAO1. 
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2 Iron limitation - the abiotic factor dominating the cystic 
fibrosis lung infection 
2.1 Introduction 
Still very little is known about the in vivo situation during the chronic cystic fibrosis (CF) airway 
infection by Pseudomonas aeruginosa. Although it has been extensively studied for years.  
CF is an autosomal hereditary disease (Kerem et al., 1989; Riordan et al., 1989; Rommens et 
al., 1989). Besides the mutation in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene (Hauser et al., 2011; Lyczak et al., 2002) a variety of innate immune system 
dysfunctions have been reported, which all together promote a chronic bacterial lung infection 
(Doring and Gulbins, 2009). Once a chronic P. aeruginosa airway infection is established, the 
infection is nearly impossible to cure and often associated with the decline of lung function and 
a reduced life expectancy (Doring and Gulbins, 2009; Hauser et al., 2011).  
P. aeruginosa is a ubiquitously spread versatile Gram-negative bacterium (Stover et al., 2000). 
Moreover, P. aeruginosa is known as opportunistic and nosocomial pathogen, especially of 
immunocompromised patients, due to its intrinsic resistances (Hancock, 1998), besides its 
prevalence in CF. But the question remains, how do the CF airways and its nutrient availability 
as surrounding growth environment affect the P. aeruginosa infection? 
Clinically relevant phenotypic changes are detectable, as P. aeruginosa colonizes the nutrient 
rich mucus of the CF airways, such as colony variation, loss of motility, modification of LPS and 
auxotrophy (Amiel et al., 2010; Barth and Pitt, 1995; Barth and Pitt, 1996; Hancock et al., 1983; 
von Gotz et al., 2004). This special environment leads to the known phenotypes of mucoidy and 
the formation of microcolonies and biofilms (Boucher et al., 1997; Govan and Deretic, 1996; 
Lam et al., 1980). Oxygen limitation and the microaerobic to anaerobic conditions in the CF lung 
are also important factors shaping the P. aeruginosa phenotype (Alvarez-Ortega and Harwood, 
2007; Worlitzsch et al., 2002). 
Several studies have investigated the influence of nutrient availability and its direct influence on 
bacterial metabolism and the resulting influence on growth behaviour and virulence factor 
production (Palmer et al., 2007a; Palmer et al., 2005; Son et al., 2007; Sriramulu et al., 2005). 
Biofilm development has been shown to be influenced by carbon and nitrogen sources in vitro 
(Hoffman et al., 2010; Klausen et al., 2003; Shrout et al., 2006; Sriramulu et al., 2005). 
Furthermore cell-to-cell signalling (quorum sensing) is also affected by the nutrient availability 
(Palmer et al., 2005; Shrout et al., 2006; Wagner et al., 2003). Especially, 2-heptyl-3-hydroxyl-4-
quinolone the Pseudomonas quinolone signal (PQS), seems to be an important signalling 
molecule under CF conditions. Several studies suggest that the PQS production is increased 
due to the moiety of aromatic amino acids in the CF sputum (Palmer et al., 2007a; Palmer et al., 
2005). Besides, being a signal molecule, PQS is also necessary for the formation of outer 
membrane vesicles (Mashburn and Whiteley, 2005; Mashburn-Warren et al., 2009). Other 
studies report also that PQS is able to chelate iron (Bredenbruch et al., 2005) and thereby 
leading to the activation of iron acquisition genes and genes necessary for oxidative stress 
protection. But it is also indicated that PQS itself does not function as a siderophore, but might 
simplify siderophore mediated uptake (Diggle et al., 2007b). 
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Iron is one of the important factors, not only for P. aeruginosa, to establish and maintain an 
infection. Acquisition and storage of iron are essential under iron limiting conditions such as in 
the environment or during infection. Iron concentrations range from < 0.1 #M in the soil to 10-9 
#M in mammals (Vasil and Ochsner, 1999). The host tightly regulates iron availability by binding 
it to proteins such as ferritin, lactoferrin, transferrin or as heme to haemoglobin. 
Typically bacteria e.g. Escherichia coli need approximately 0.3 -1.8 #M iron for optimal growth 
(Braun and Killmann, 1999). Free iron is usually limited in an aerobic environment, since it is 
highly insoluble as Fe3+, but also harmful hydroxyl radicals can be easily generated via Fenton-
type reactions (Miller and Britigan, 1997). Iron acquisition is essential for every bacterium. 
Especially redox-dependent enzymes need iron to be functional. In order to circumvent these 
limitations P. aeruginosa possesses a variety of different mechanisms, ranging from 
siderophore production, over heme uptake to extracellular toxin generation. Exotoxin A is 
inhibiting protein biosynthesis of the eukaryotic cell by ADP-ribosylation of elongation factor-2 
(Iglewski and Kabat, 1975). It is strongly induced by iron depletion (Vasil and Ochsner, 1999).  
Several studies observed, that shortage of iron led to increased expression of iron acquisition 
genes, such as siderophores pyoverdin and pyochelin biosynthesis genes (Oglesby et al., 2008; 
Palma et al., 2003; Vasil and Ochsner, 1999).  
Iron acquisition, uptake and storage are directly or indirectly controlled by the global ferric 
uptake regulator Fur, extracytoplasmic function (ECF) sigma factors or other types of regulators 
such as two-component regulatory systems and AraC-type regulators in P. aeruginosa. At iron 
availability the Fur protein is loaded with Fe2+. The ferrated Fur binds to the Fur box in the 
promoter region of genes e.g. necessary for iron uptake, and thereby preventing transcription 
(Oglesby et al., 2008). Several microarray studies have been performed to investigate iron 
regulated genes and the influence of iron starvation (Ochsner et al., 2002; Palma et al., 2003). 
CF airways colonizing P. aeruginosa are confronted with a highly selective and heterogeneous 
environment, which is characterised by various stress conditions such as antibiotics, host 
immune response and oxidative and osmotic stress (Folkesson et al., 2012). 
Transcriptional profiling of P. aeruginosa under CF airway conditions in ex vivo sputum samples 
and under simulated respiratory tract conditions in the existing artificial sputum medium (ASM) 
by Sriramulu et al. (2005) was used. Besides understanding the underlying adaptation 
strategies, insights into regulatory networks, the environmental responses and the identification 
of crucial factors, it is the goal to modify the existing ASM to simulate the in vivo conditions 
precisely. 
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2.2 Results & Discussion  
2.2.1 Pseudomonas aeruginosa isolates from cystic fibrosis patients 
In order to understand and identify the important factors, which allow the chronic colonization of 
the cystic fibrosis airways by P. aeruginosa, the colonizing strains of two independent CF 
patients were isolated by Dr. Piotr Bielecki. Furthermore, the RNA obtained from the patient’s 
sputum using microarrays designed for P. aeruginosa PAO1 genome analysis were examined 
(Bielecki et al., 2013). Besides understanding the underlying adaptation strategies and the 
identification of crucial factors, it was the goal to compare the growth conditions in the existing 
artificial sputum medium (ASM) by Sriramulu et al. (2005) to ex vivo sputum samples of 
P. aeruginosa strains directly isolated from CF-patients’ airways. 
The clinical strains were tested for clonal variability using binary arrays based on o single-
nucleotide polymorphisms (SNPs) genotypes (Wiehlmann et al., 2007). The isolate CFCZ 
(patient A) and the isolates CF-1 to CF-4 (patient B) belong to clonally distinct groups. CFCZ is 
grouped into the clonal group E59A. A clone form this group is already present in the MHH-
collection. The previous isolate was obtained in 1985 from a CF patient in Hanover (Germany) 
(Wiehlmann et al., 2007).  
The isolates CF-1, CF-2, CF-3 and CF-4 belong to the clonal group 6C2A, which are 
representatives of the clone P. All four clones show the same SNP pattern in the array. 
However, the colonies appear morphologically different. The clone P is also present in the MHH 
collection and the MHH isolates were isolated form CF patients in various places in Germany 
during the last 17 years. 
2.2.2 Iron limitation is stronger ex vivo than in artificial sputum medium  
The transcriptional profiles of ex vivo sputum samples of the strains CFCZ and CF-1 to CF-4 
were compared to those determined in ASM. The transcriptional profiles for each strain and 
each condition were performed in duplicate. The five clinical P. aeruginosa strains used in this 
study were considered as one data set for the purpose of analysis, thereby creating a more 
general picture of P. aeruginosa characteristics, rather than strain specific features. Genes that 
showed significant difference in expression (percentage of false-positives pfp < 0.05) were 
further analysed and functionally classified according to “Pseudomonas Genome Database” 
(Fig. 6) (Winsor et al., 2011). 
404 genes were regulated differently during growth in ASM compared to ex vivo sputum 
samples. That means that 7.3 % of the 5570 predicted open reading frames (ORFs) (Stover et 
al., 2000) were expressed differently in ASM compared to ex vivo sputum samples. 205 genes 
were upregulated in ASM compared to ex vivo. 199 genes were downregulated. Significant 
induction was seen for genes classified as carbon compound catabolism genes. The same was 
observed for energy metabolism and putative enzymes genes (Fig. 6). Genes concerning 
adaptation and protection were downregulated, just as membrane protein genes and genes 
regarding the transport of small molecules. 
A detailed look into the data revealed that the majority of genes regulated, were indeed 
regulated by iron. Genes were downregulated in ASM, whereas they were clearly upregulated 
under ex vivo conditions (Table 3 or Appendix Table 30), especially genes of transcriptional 
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regulators e.g. pvdS, vreA, femI, foxI, pchR and pfeR (Table 1 and Fig. 11), which are 
repressed by Fur in the presence of Fe2+, were downregulated. 
Table 1: Fold change of gene expression of selected iron regulated transcriptional regulators in 
ASM compared to ex vivo sputum samples 
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 - 4 grown in artificial sputum medium ASM (A) in comparison with ex vivo (EV) sputum 
samples. 
Gene IDa Gene 
namea 
Functiona  FC 
 
A / EV 
PA0674 
PA1300 
PA1912 
PA2426 
PA2468 
PA3899 
PA4227 
PA4896 
PA2686 
vreA 
 
femI 
pvdS 
foxI 
 
pchR 
 
pfeR 
VreA 
probable sigma-70 factor, ECF subfamily 
ECF sigma factor, FemI 
sigma factor PvdS 
ECF sigma factor FoxI 
probable sigma-70 factor, ECF subfamily 
transcriptional regulator PchR 
probable sigma-70 factor, ECF subfamily 
two-component response regulator PfeR 
-21,4 
-42,2 
-11,1 
-71,9 
-7,9 
-20,7 
-70,9 
-21,5 
-5,1 
a Gene ID, gene name, function and PseudoCAP Function Class (PCFC) are according to the 
“Pseudomonas Genome Database” (Winsor et al., 2011). 
 
In total 77 genes, which are involved in iron uptake and storage, were downregulated. This 
indicates that one fifth of all regulated genes are iron regulated. Iron starvation is one of the 
important factors in the airways of CF patients, whereas the effect of iron limitation is not that 
strong in ASM. Although ASM contains diethylene triamine pentaacetic acid (DTPA), as 
chelating substance in order to sequester free metal ions such as free iron. 
 
Fig. 6: Functional classification of genes differentially regulated during growth in ASM compared 
to ex vivo sputum samples of the the clinical Pseudomonas aeruginosa strains CFCZ and CF1 - 4 
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Differentially regulated genes (pfp < 0.05) are classified according to “Pseudomonas Genome 
Database” (Winsor et al., 2011). Black bars represent downregulated genes, whereas white bars 
represent upregulated genes in ASM compared to ex vivo conditions. 
____________________________________________________________________________ 
2.2.3 Quantitative real-time polymerase chain reaction to establish iron limitation in 
ASM 
Since iron limitation is one of the obstacles P. aeruginosa has to overcome in order to establish 
and maintain an infection in the CF airways, the approach focused on selected genes 
necessary for iron acquisition and uptake as marker genes. Therefore, different compounds 
were tested in ASM to increase the iron limitation response. ASM contains the iron chelator 
diethylene triamine pentaacetic acid (DTPA). But previously conducted experiments indicated 
that P. aeruginosa is able to metabolise DTPA. Therefore, DTPA was not further analysed as 
possible iron chelator. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to monitor the degree of 
iron limitation in modified ASMs. On the one hand naturally occurring iron chelating compounds 
such as lactoferrin and conalbumin were applied and on the other hand a chemically generated 
compound the resin Chelex with a high preference for iron was applied. Iron regulated genes for 
further investigation were selected, which were clearly downregulated in ASM compared to ex 
vivo samples (Table 2). These genes are involved in the biosynthesis and uptake of the 
siderophores pyoverdine (pvdA, pvdF, fpvA) and pyochelin (fptA, pchG). The expression of the 
pvdS gene was monitored. The transcriptional regulator PvdS regulates the expression of 
pyoverdine biosynthesis and uptake genes, as well as the expression of the virulence factor 
exotoxin A and other genes (Vasil, 2007).  
Table 2: Fold change of gene expression of selected iron regulated genes chosen for further 
investigation by qRT-PCR to establish iron limitation in modified ASM 
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 - 4  grown in artificial sputum medium ASM (A) in comparison with ex vivo (EV) sputum 
samples. 
Gene IDa Gene 
namea 
Functiona PseudoCAP Function Class (PCFC) FC 
 
A / EV 
PA2386 
PA2396 
PA2398 
PA2426 
PA4221 
PA4224 
pvdA 
pvdF 
fpvA 
pvdS 
fptA 
pchG 
L-ornithine N5-oxygenase 
pyoverdine synthetase F 
ferripyoverdine receptor 
sigma factor PvdS 
Fe(III)-pyochelin o.m. receptor precursor 
pyochelin biosynthetic protein PchG 
Adaptation, Protection 
Secreted Factors; Adaptation, Protection 
Transport of small molecules 
Transcriptional regulators 
Transport of small molecules 
Transport of small molecules ; 
Membrane proteins 
-62,5 
-18,8 
-101,0 
-71,9 
-41,7 
-76,3 
a Gene ID, gene name, function and PseudoCAP Function Class (PCFC) are according to the 
“Pseudomonas Genome Database” (Winsor et al., 2011). 
 
P. aeruginosa was grown for 24 h in the modified ASMs, the RNA was isolated, cDNA was 
generated to perform qRT-PCR and the degree of iron limitation was analysed by monitoring 
the above-mentioned genes. The selected genes were compared under each condition to 
unmodified ASM and the fold difference was determined. All compounds selected for the 
modification of ASM induced expression of the investigated genes (Fig. 7). Thereby, it was 
Iron limitation - the abiotic factor dominating the cystic fibrosis lung infection 
 
 30 
confirmed that lactoferrin, conalbumin and Chelex are capable of inducing iron limitation in 
ASM. 
0.5 mg/ml and 1 mg/ml of iron-unsaturated lactoferrin were used. This reflects the naturally 
occuring lactoferrin concentrations within the airway respiratory secretions of 0.1 - 1 mg/ml 
(Harbitz et al., 1984; Singh et al., 2002).  
Furthermore, the effect of 3 mg/ml and 4 mg/ml iron-unsaturated conalbumin in ASM was 
investigated. Conalbumin is also a lactoferrin-like host defence protein from chicken eggs 
(Singh et al., 2002). 3 mg/ml and 4 mg/ml conalbumin led to induction of all investigated genes. 
For nearly all genes 3 mg/ml resulted in the same activation as 4 mg/ml, except for fptA. 
Conalbumin caused a stronger induction of investigated genes than lactoferrin. 0.1 mg/ml of the 
resin Chelex induced less iron limitation than 3 mg/ml and 4 mg/ml conalbumin, but more than 
0.5 mg/ml and 1 mg/ml lactoferrin. 
 
 
Fig. 7: Fold difference in gene expression of Pseudomonas aeruginosa iron limitation marker 
genes in differently supplemented artificial sputum media  
In order to establish iron limitation in ASM it was modified by addition of 0.5 mg/ml lactoferrin (light 
grey bars), 1 mg/ml lactoferrin (dark grey bars), 0.1 g/ml Chelex (white bars), 3 mg/ml conalbumin 
(light grey dotted bars) or 4 mg/ml conalbumin (dark grey dotted bars), respectively. The genes 
pvdA, pvdF, fpvA, pvdS, fptA and pchG were monitored via qRT PCR for induction in response of 
iron starvation. PAO1 was grown for 24 h in modified ASMs. RNA was prepared and cDNA 
generated. Unmodified ASM was used as reference condition and acpP as reference gene for 
normalisation. The standard deviation of the mean is shown. For 0.5 mg/ml and 1 mg/ml lactoferrin 
pvdA was not determined. The strongest induction was observed for ASM-Chelex and ASM-
Conalbumin. 
____________________________________________________________________________ 
Roger et al. (2004) reported that lactoferrin inhibited the biofilm formation of P. aeruginosa. 
Singh et al. (2002) confirmed the same effect for conalbumin. They assumed that iron chelation 
led to increased surface motility by twitching motility and thereby inhibiting biofilm formation 
(Singh et al., 2002). Other studies report that lactoferrin is released from neutrophil granules in 
inflamed areas (Rogan et al., 2006; Rogan et al., 2004). Furthermore, lactoferrin is suspected to 
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destabilise the outer membrane of Gram-negative bacteria. On the other hand it is predicted to 
possess anti-inflammatory activity (Rogan et al., 2006). Besides it was shown that 
bronchoalveolar lavage (BAL) from CF patients with P. aeruginosa infection was depleted of 
lactoferrin (Britigan et al., 1993; Rogan et al., 2004). The studies suggested that lactoferrin 
degradation might be either due to proteases produced by P. aeruginosa or by host proteases, 
which are strongly induced during the constant inflammation during infection.  
Therefore, it was decided to use ASM-Chelex (ACh) for further studies since iron starvation 
cannot be abolished during prolonged incubation by protease degradation. On the other hand, 
addition of a glycoprotein would add more nutrients to the medium besides induction of iron 
limitation.  
2.2.4 Transcriptional profiles of Pseudomonas aeruginosa in ASM and ASM-Chelex 
compared to ex vivo  
The ex vivo transcriptional profile of two different P. aeruginosa clonal groups isolated from two 
CF patients were compared with those determined in ASM, which simulates the respiratory tract 
conditions of the CF lung. It was discovered that the iron starvation is one of the major factors in 
vivo, but not that strong in ASM. Therefore, the medium was modified by adding 0.1 mg/ml of 
the resin Chelex to ASM and obtained ASM-Chelex. In total 633 genes were differently 
regulated under these three investigated conditions ex vivo, ASM and ASM-Chelex. 
 
Fig. 8: Scatter plots and correlation values between the growth conditions of ex vivo, ASM and 
ASM-Chelex of the clinical Pseudomonas aeruginosa strains CFCZ and CF1 - 4 
The scatter plot is a comparison of the regulation of all genes under the investigated conditions. 
Each condition represents four microarray chips, two of CFCZ and two of the strains CF-1 - 4. This 
study shows the three conditions ex vivo, ASM and ASM-Chelex (ASMCH) in total 12 microarrays 
are displayed.  
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The similarity in scatter plots and the very high correlation values of 0.89 for both comparisons 
demonstrate how well ASM and ASM-Chelex mimic the ex vivo environment of the CF airways 
(Fig. 8). The resulting high correlation value for both ASM and ASM-Chelex might be due to still 
very similar gene regulation in both media compared to the ex vivo conditions. 
2.2.5 Transcriptional profile of ASM-Chelex vs. ex vivo sputum samples 
The transcriptome of the growth conditions in ASM-Chelex was compared to ex vivo sputum 
samples. Genes that showed significant difference in expression (percentage of false-positives 
pfp < 0.05) were further analysed and functionally classified according to “Pseudomonas 
Genome Database” (Fig. 9) (Winsor et al., 2011). 
468 genes were regulated differently during growth in ASM-Chelex compared to ex vivo sputum 
samples. Upregulated were 247 genes in ASM-Chelex compared to ex vivo sputum samples. 
221 genes were downregulated. Significant induction was seen for genes classified as amino 
acid biosynthesis and metabolism genes. The same was observed for energy metabolism and 
putative enzyme genes. Genes concerning adaptation and protection were downregulated as 
well as translation, post-translational modification and degradation.  
 
Fig. 9: Functional classification of genes differentially regulated during growth in ASM-Chelex 
compared to ex vivo sputum samples of the clinical Pseudomonas aeruginosa strains CFCZ and 
CF1 - 4 
Differentially regulated genes (pfp < 0.05) are classified according to “Pseudomonas Genome 
Database” (Winsor et al., 2011). Black bars represent downregulated genes, whereas white bars 
represent upregulated genes in ASM-Chelex compared to ex vivo sputum samples. 
____________________________________________________________________________ 
Approximately the same amount of membrane protein genes was up- and downregulated with 
30 to 31 genes, respectively. The same was observed for transcriptional regulators. 
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Upregulated were also general stress response regulator sigma factor gene rpoS (Suh et al., 
1999) and the phosphate uptake regulating transcriptional regulator gene phoP und phoB. 
Downregulated were the sigma factor rpoD and the choline metabolism regulator betI. As 
previously described the iron dependent regulators femI, pvdS, foxI and pchR were repressed. 
Nearly 40% of the upregulated genes are classified as hypothetical, unclassified, unknown 
genes. Selected important genes and regulons are discussed in detail in the following sections. 
2.2.6 Transcriptional profile of ASM-Chelex vs. ASM 
The transcriptome of the growth conditions in ASM-Chelex were compared to ASM. Genes 
were selected and classified as previously described (Fig. 10). 
Only 190 genes were regulated differently during growth in ASM-Chelex compared to ASM. 143 
genes were upregulated in ASM-Chelex. Only 47 genes were downregulated. Significant 
induction was seen for genes classified as membrane protein genes. The same was observed 
for transcriptional regulator and two-component regulatory system genes. Furthermore, genes 
related to phage, transposon or plasmid were upregulated. Genes concerning carbon 
compound catabolism were downregulated as well as putative enzyme genes. 
 
Fig. 10: Functional classification of genes differentially regulated during growth in ASM-Chelex 
compared to growth in ASM the clinical Pseudomonas aeruginosa strains CFCZ and CF1 - 4 
Differentially regulated genes (pfp < 0.05) are classified according to “Pseudomonas Genome 
Database” (Winsor et al., 2011). Black bars represent downregulated genes, whereas white bars 
represent upregulated genes in ASM-Chelex compared to ASM samples. 
____________________________________________________________________________ 
Furthermore, the transcriptional regulators such as ptrB gene an indirect regulator of the type 
three secretion system (T3SS) and the phosphate uptake regulating transcriptional regulator 
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gene phoB (Wu and Jin, 2005) were upregulated in ASM-Chelex. The iron dependent 
transcriptional regulators vreA and pchR and other genes typically induced by iron limitation 
were upregulated in ASM-Chelex. 
2.2.7 Predicted and proven Fur regulon of genes involved in iron acquisition, uptake, 
storage and metabolism 
Since free iron can easily induce the generation of toxic cell damaging radicals its acquisition 
and storage is tightly regulated. In general, iron acquisition, uptake and storage are directly or 
indirectly controlled by the global ferric uptake regulator Fur, extracytoplasmic function (ECF) 
sigma factors or other types of regulators such as two-component regulatory systems and 
AraC-type regulators in P. aeruginosa. Bacteria need to obtain iron in order to grow, to survive, 
to produce virulence factors and to establish and maintain an infection. Moreover, iron uptake is 
an energy consuming process. Siderophore production, but also the transport through the outer 
and cytoplasmatic membrane are both energy driven processes (Braun and Killmann, 1999; 
Llamas et al., 2008). Therefore, it is even more important to express all genes involved in iron 
acquisition and uptake only when it is necessary. 
With the modified Fig. 11 and Fig. 12 from Cornelis et al. (2009) an overview of the genes is 
given (green and red dashed lines), which were discovered regulated in ASM-Chelex vs. ex vivo 
and their position in the complex Fur regulatory network.  
 
Fig. 11: Direct and indirect control of TonB-dependent genes by Fur modified from 
Cornelis et al. (2009) 
The first line shows the ECFs factors that are under control of Fur. The second line shows the 
additional genes under control of Fur. Furthermore, genes encoding TonB-dependent receptors 
(yellow), transcription regulators (red) and the genes of the pyoverdine locus (green) are indicated. 
Arrows indicate activation, while broken lines represent repression. Black lines represent 
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experimentally verified interactions and red lines are predicted by the van Oeffelen et al. (2008) 
analysis. Stippled lines are suggested, but not experimentally confirmed, interactions. Green 
dashed lines represent downregulated genes detected in this study, whereas red dashed lines 
represent upregulated genes in ASM-Chelex vs. ex vivo. 
_______________________________________________________________________________ 
Fur acts as repressor of iron uptake genes when Fe2+ is bound (Vasil and Ochsner, 1999). The 
ECF sigma factors frequently consist of three proteins. One is a TonB-dependent outer 
membrane receptor. The others are a cytoplasmic membrane protein that functions as an 
antisigma factor and the ECF sigma factor. The outer membrane receptor is involved in 
transport of the siderophore but moreover it is involved in signal transduction (Llamas et al., 
2008; Ogierman and Braun, 2003). 
The ECF iron-starvation class sigma factors genes of pvdS, fiuI, PA1300, femI, foxI, fecI and 
PA4896 were downregulated in ASM-Chelex vs. ex vivo in this study (Fig. 11). But also only 
predicted Fur regulated genes were also downregulated in ASM-Chelex vs. ex vivo, which 
further confirms the fact that these genes are probably Fur regulated (Fig. 12). This also 
indicates that the iron limitation is much stronger in vivo than in ASM-Chelex. 
 
Fig. 12: Predicted Fur regulation of genes involved in iron uptake and storage modified from 
Cornelis  et al. (2009) 
Non-experimentally proven interactions are shown as red arrows (van Oeffelen et al., 2008). 
Protein categories are colour coded as indicated in the figure. Green dashed lines represent 
downregulated genes detected in this study, whereas red dashed lines represent upregulated 
genes in ASM-Chelex vs. ex vivo. 
_______________________________________________________________________________ 
The Fur regulon is a very important regulon under the ex vivo CF conditions, since many of the 
proven and predicted genes of this regulon are upregulated under ex vivo conditions.  
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2.2.8 Iron starvation - a characteristic condition of cystic fibrosis airway ex vivo 
infection and also induced in ASM-Chelex 
In order to overcome iron limitation, P. aeruginosa produces a wide range of factors such as 
siderophores, proteases, heme uptake systems and virulence factors such as exotoxin A 
(Ochsner et al., 2002). Many of these genes were identified in the here presented microarray 
study comparing the ex vivo sputum samples to ASM and ASM-Chelex samples (Cornelis et al., 
2009; Klein et al., 2008; Llamas et al., 2008; Ochsner et al., 2002; Palma et al., 2003; Vasil and 
Ochsner, 1999). A large number of predicted or proven iron regulated genes, in total 101 genes, 
were differently regulated in our study (Table 3). But neither ASM nor ASM-Chelex was able to 
induce the same level of iron limitation as the ex vivo conditions.  
The ECF sigma factor gene encoding for PvdS, which controls the expression of pyoverdine 
biosynthesis genes and reacts to the presence of the siderophore, is upregulated under ex vivo 
conditions and downregulated in ASM and ASM-Chelex. The majority of iron regulated genes 
were downregulated in ASM vs. ex vivo and ASM-Chelex vs. ex vivo. The same expression 
pattern was observed for the genes encoding for other ECF sigma factors belonging to the iron-
starvation class as FiuI, PA1300, FemI, FoxI, FecI and PA4896 were identified, which are 
involved in ferrichrome uptake, heme uptake, mycobactin/carboxymycobactin uptake, 
ferrioxamine uptake, iron citrate uptake and siderophore uptake, respectively (Cornelis et al., 
2009; Llamas et al., 2008). The pyochelin receptor fptA gene and the pyochelin biosynthesis 
genes, which are regulated by the AraC-type transcriptional regulator PchR, were regulated by 
the same pattern described before. And also the expression of tonB1 (PA5531) gene and 
several genes involved in heme uptake e.g. hasAp, hasR and PA4708-PA4710 were 
downregulated in ASM and ASM-Chelex vs. ex vivo. Moreover, the genes PA4357-PA4359, 
which transport ferrous iron, were downregulated. 
As expected in ASM-Chelex vs. ex vivo the degree of downregulation was less for the majority 
of genes than in ASM vs. ex vivo, which can bee seen for fptA which is -41,7-fold (A/EV) and - 
5,2-fold in (ACh/EV) or pvdS with - 71,9-fold (A/EV) and - 37,6-fold in (ACh/EV) (Table 3).  
Moreover all iron regulated genes were upregulated in ASM-Chelex (ACh/A). This indicates that 
the degree of iron limitation and the iron starvation rate of bacteria was much higher in ASM-
Chelex than in ASM as intended by the design of the ASM-Chelex medium. Iron limitation was 
definitely induced in ASM-Chelex by Chelex. But the comparison of the transcriptional profile to 
the ex vivo CF conditions reveals also that the iron limitation was much stronger ex vivo. This is 
also supported by the comparison of ex vivo vs. LB conditions of selected genes (Bielecki, 
2008). When ex vivo vs. LB conditions were compared eight of nine genes were upregulated, 
which were detected under these conditions (Table 3). The highest induction was observed for 
hasAP, which is involved in heme uptake. This indicates that the uptake of heme is a very 
important factor in iron acquisition under ex vivo conditions. 
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Table 3: Fold change of gene expression of selected* iron regulated genes in ASM, ASM-Chelex 
and ex vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 - 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated during growth in ASM compared to ex vivo (A / EV), ASM-Chelex compared to 
ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A) and selected genes of ex vivo 
compared to LB (EV / LB). The qRT-PCR investigated genes are highlighted in bold letters. ECF 
sigma factors are shown in bold grey letters. 
Gene IDa* Gene 
namea 
Functiona  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
 
EV / 
LBc 
Iron starvation:      
PA0472 
PA0672 
PA0674 
PA0929 
PA0930 
PA1134 
PA1300 
PA1301 
PA1302 
PA1911 
PA1912 
PA1922 
PA2033 
PA2034 
PA2384 
PA2385 
PA2386 
PA2393 
PA2394 
PA2395 
PA2396 
PA2397 
PA2398 
PA2399 
PA2400 
PA2402 
PA2403 
PA2404 
PA2405 
PA2406 
PA2407 
PA2408 
PA2409 
PA2411 
PA2412 
PA2413 
PA2424 
PA2426 
PA2427 
PA2467 
PA2468 
PA2686 
PA3397 
PA3407 
PA3408 
PA3530 
PA3531 
PA3768 
PA3899 
PA4221 
PA4222 
PA4223 
PA4224 
PA4225 
PA4226 
PA4227 
PA4228 
 
 
fiuI  
hemO 
vreA 
 
 
 
 
 
hxuC 
femR 
femI 
 
viuB 
 
 
pvdQ 
pvdA 
 
pvdN 
pvdO 
pvdF 
pvdE 
fpvA 
pvdD 
pvdJ 
 
 
 
 
 
 
 
 
 
 
pvdH 
pvdL 
pvdS 
 
foxR 
foxI 
pfeR 
fpr 
hasAp 
hasR 
bfd  
bfrB 
 
fecI 
fptA 
 
 
pchG 
pchF 
pchE 
pchR 
pchD 
 
probable sigma-70 factor, ECF subfamily 
heme oxygenase 
VreA 
two-component response regulator 
two-component sensor 
Predicted thiol-disulphide oxidoreductase 
probable sigma-70 factor, ECF subfamily 
probable transmembrane sensor 
probable heme utilization protein precursor 
sigma factor regulator, FemR 
ECF sigma factor, FemI 
probable TonB-dependent receptor 
catecholate siderophore uptake 
precorrin methylase 
hypothetical Fur-like regulator 
3-oxo-C12-homoserine lactone acylase PvdQ 
L-ornithine N5-oxygenase 
probable dipeptidase precursor 
PvdN 
PvdO 
pyoverdine synthetase F 
pyoverdine biosynthesis protein PvdE 
ferripyoverdine receptor 
pyoverdine synthetase D 
PvdJ 
probable non-ribosomal peptide synthetase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable adhesion protein 
probable ATP-binding component of ABC transporter 
probable permease of ABC transporter 
probable thioesterase 
conserved hypothetical protein 
L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase 
PvdL 
sigma factor PvdS 
hypothetical protein 
Anti-sigma factor FoxR 
ECF sigma factor FoxI 
two-component response regulator PfeR 
ferredoxin--NADP+ reductase 
heme acquisition protein HasAp 
Haem uptake o.m. receptor HasR precursor 
bacterioferritin-associated ferredoxin 
bacterioferritin 
probable metallo-oxidoreductase 
probable sigma-70 factor, ECF subfamily 
Fe(III)-pyochelin o.m. receptor precursor 
probable ATP-binding component of ABC transporter 
probable ATP-binding component of ABC transporter 
pyochelin biosynthetic protein PchG 
pyochelin synthetase 
dihydroaeruginoic acid synthetase 
transcriptional regulator PchR 
pyochelin biosynthesis protein PchD 
 
-9,0 
-133,3 
-21,4 
-22,6 
-8,1 
 
-42,2 
-14,5 
-5,6 
-7,4 
-11,1 
-8,8 
-16,4 
-26,8 
-17,8 
-11,4 
-62,5 
-9,2 
-20,4 
-6,6 
-18,8 
-17,8 
-101,0 
-13,1 
-8,6 
-13,3 
-9,2 
-12,1 
-22,1 
-13,5 
-28,2 
-6,3 
-10,5 
-20,0 
-29,0 
-6,2 
-7,9 
-71,9 
 
-15,5 
-7,9 
-5,1 
-6,9 
-250,0 
-7,0 
 
8,4 
-5,4 
-20,7 
-41,7 
-4,8 
-23,4 
-76,3 
-19,2 
-47,8 
 
-27,9 
 
 
-48,5 
 
 
 
5,1 
-37,5 
-12,0 
-5,6 
-5,1 
-7,7 
 
-12,5 
-24,3 
-15,4 
-11,4 
-62,5 
-9,2 
-20,7 
-6,6 
-24,9 
-17,8 
-80,0 
-14,0 
-8,5 
-13,4 
-5,8 
-10,3 
-13,1 
-13,4 
-28,5 
-6,8 
-7,3 
-20,0 
-25,9 
-6,0 
-7,9 
-37,6 
 
-8,6 
-4,9 
-5,1 
-10,0 
-227,3 
-7,0 
 
 
 
-16,7 
-5,2 
 
 
 
-4,4 
 
-13,9 
 
 
 
 
8,7 
10,0 
 
6,2 
 
 
 
 
 
15,6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5,2 
 
 
 
 
 
 
10,2 
-4,3 
 
 
8,0 
 
5,8 
18,0 
4,3 
11,9 
5,1 
6,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62,6 
 
 
 
10,7 
 
98,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16,8 
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Continued:      
Gene IDa Gene 
namea 
Functiona  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
 
EV / 
LBc 
 
PA4229 
PA4230 
PA4231 
PA4357 
PA4358 
PA4859 
PA4370 
PA4373 
PA4467 
PA4468 
PA4469 
PA4470 
PA4471 
PA4515 
PA4570 
PA4708 
PA4709 
PA4710 
PA4834 
PA4835 
PA4836 
PA4837 
PA4895 
PA4896 
PA5217 
PA5531 
 
 
pchC 
pchB 
pchA 
 
 
 
icmP 
 
 
sodM 
 
fumC1 
 
piuC 
 
phuT 
 
phuR 
 
 
 
 
 
 
 
tonB1 
 
pyochelin biosynthetic protein PchC 
salicylate biosynthesis protein PchB 
salicylate biosynthesis isochorismate synthase 
conserved hypothetical protein 
probable ferrous iron transport protein 
conserved hypothetical protein 
Insulin-cleaving metalloproteinase o.m. protein precursor 
hypothetical protein 
hypothetical protein 
superoxide dismutase 
hypothetical protein 
fumarate hydratase 
hypothetical protein 
Uncharacterized iron-regulated protein 
HUU; weak similarity to IclR repressor family 
Heme-transport protein, PhuT 
probable hemin degrading factor 
Haem/Haemoglobin uptake o.m. receptor PhuR precursor 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable o.m. protein precursor 
probable transmembrane sensor 
probable sigma-70 factor, ECF subfamily 
probable binding protein component of ABC iron transp. 
TonB protein 
 
-45,7 
-38,8 
-18,4 
-23,4 
-63,3 
-9,6 
-6,1 
-8,2 
-38,2 
-20,2 
-14,1 
-42,4 
-6,1 
-6,8 
-43,3 
-7,2 
-7,4 
-9,7 
-15,0 
-36,9 
-27,9 
-43,7 
-6,0 
-21,5 
-5,8 
-5,5 
 
-7,7 
 
-11,3 
-5,1 
-5,4 
 
 
-4,9 
-31,4 
-15,6 
-10,7 
-24,7 
-6,1 
-5,4 
-5,1 
-8,1 
-15,7 
-25,8 
 
-9,2 
-5,2 
-6,1 
-6,0 
-19,0 
 
 
 
5,9 
9,9 
 
 
4,6 
11,6 
 
 
 
 
 
 
 
 
8,4 
 
 
 
 
 
5,4 
7,2 
 
 
5,1 
6,2 
 
 
 
 
 
 
 
 
 
 
11,9 
 
34,6 
 
 
 
 
 
 
 
 
 
 
 
19,1 
 
 
Regulated by PA4896b (all genes classified as “related to phage, transposon, or plasmid”):   
PA0614 
PA0622 
PA0623 
PA0624 
PA0627 
PA0631 
PA0633 
PA0634 
PA0635 
PA0636 
PA0637 
PA0638 
PA0639 
PA0647 
PA0648 
 
 Putative holin 
R-type pyocin, related to P2 phage; tail sheath 
R-type pyocin, related to P2 phage; tail tube 
R-type pyocin, related to P2 phage 
R-type pyocin, related to P2 phage; tail formation 
Related to phage, lysis control 
F-type pyocin, related to ( phage; major tail protein 
F-type pyocin, related to ( phage 
F-type pyocin, related to ( phage  
F-type pyocin, related to ( phage; tail length determination  
F-type pyocin, related to ( phage; tail formation  
F-type pyocin, related to ( phage; tail formation conserved 
F-type pyocin, related to ( phage; tail formation 
hypothetical protein 
hypothetical protein 
 14,4 
6,2 
7,6 
10,6 
7,1 
5,7 
5,5 
11,4 
29,2 
6,4 
6,2 
6,2 
6,0 
7,2 
18,2 
6,8 
 
8,2 
7,3 
7,6 
5,7 
5,2 
8,7 
22,6 
5,3 
5,4 
 
5,6 
4,0 
19,3 
 
Predicted Fur regulation by (van Oeffelen et al., 2008):     
PA5503 
PA5504 
PA3931 
PA4296 
 
 
nlpA 
pprB 
probable ATP-binding component of ABC transporter 
D-methionine ABC transporter membrane protein 
conserved hypothetical protein 
two-component response regulator 
 
 
 
15,7 
-5,0 
-5,8 
-6,3 
 
 
 
 
-4,6 
 
 
 
-34,3 
a Gene ID, gene name, function and PseudoCAP Function Class (PCFC) are according to the 
“Pseudomonas Genome Database” (Winsor et al., 2011). 
b Functions for genes regulated by PA4896 are annotated according to (Llamas et al., 2008) 
c The study was performed together with Piotr Bielecki (HZI). Selected genes from the comparison 
EV/ LB are shown (Bielecki, 2008).  
* Several studies and the ProdoNet data base were applied to obtain the list of iron regulated genes 
shown here (Cornelis et al., 2009; Klein et al., 2008; Llamas et al., 2008; Ochsner et al., 2002; 
Palma et al., 2003; Vasil and Ochsner, 1999). 
 
A total of 78 genes were regulated in ASM-Chelex vs. ex vivo. 58 genes were downregulated 
and 16 genes were induced. These 16 genes are mostly characterised as hypothetical genes 
and especially upregulated in ASM-Chelex. The majority of upregulated genes (PA0614-
PA0648) were regulated by PA4896 (van Oeffelen et al., 2008). PA4896 is 63 % similar to E. 
coli FecI. Llamas et al. 2008 proposed that PA4896 is involved in siderophore uptake. They 
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confirmed that the PA4896 regulated genes encoded for the pyocins P2 and F2, which we also 
identified as upregulated under ASM-Chelex conditions. 
It cannot be excluded that the pyocin induction was due to a general stress response. But on 
the other hand pyocin S2 (PA1150), which is normally induced by SOS-response (Llamas et al., 
2008; Michel-Briand and Baysse, 2002), is not induced under the investigated conditions.  
Llamas et al. proposed that by using pyocins P. aeruginosa is killing competing bacteria, while 
using the system for “stealing” their siderophores. Why this system was upregulated only in 
ASM-Chelex has to be further investigated. 
The genes PA4834-PA4837 were downregulated in ASM and ASM–Chelex, which means that 
they are upregulated under ex vivo conditions. These genes are predicted to encode a novel 
siderophore system (Bielecki, 2008). PA4837 encodes for a predicted TonB dependent 
siderophore receptor (Winsor et al., 2011). Moreover, PA4837 has been shown to be 
upregulated in P. aeruginosa in in vivo burn wound patients’ samples, in 10% CF sputum 
medium and in an in vivo peritoneal rat infection model (Bielecki et al., 2011; Mashburn et al., 
2005; Palmer et al., 2005). 
2.2.9 Other genes closely connected to iron metabolism 
Unexpectedly the PQS biosynthesis genes were downregulated under ex vivo conditions and 
upregulated in ASM and ASM-Chelex, especially the genes pqsA and pqsD (Table 4). The 
phnAB operon (Fig. 13) encoding for anthranilate biosynthesis was also upregulated in ASM-
Chelex vs. ex vivo and ASM-Chelex vs. ASM. Several studies suggest that PQS is one of the 
molecules closely connected to iron metabolism (Bredenbruch et al., 2005; Diggle et al., 2007b; 
Schertzer et al., 2009). The PQS quorum sensing system uses 2-heptyl-3-hydroxyl-4-quinolone 
as signalling molecule (Diggle et al., 2007b). As well as being a signalling molecule PQS is also 
predicted to have iron chelating ability and thereby leading to activation of iron acquisition genes 
and genes necessary for oxidative-stress protection (Table 3). But the induction in ASM and 
ASM-Chelex probably correlates with the previously reported fact that PQS synthesis might be 
triggered by the high availability of aromatic amino acids (Haussler and Becker, 2008; Palmer et 
al., 2007a; Palmer et al., 2005). This might indicate that the availibility of aromatic amino acids 
might be higher in ASM and ASM-Chelex than under ex vivo conditions. 
In vivo PQS biosynthesis might be also decreased due to high concentrations of PQS in the 
lung (Collier et al., 2002), compared to ASM or ASM-Chelex. Clearly, the iron level in ASM-
Chelex is reduced to ASM but clearly not as low as in the in vivo environment.  
The predicted pcaIJF, pcaTBDC and antRABC operon genes (Fig. 13) are also involved in 
anthranilate metabolism and degradation and were upregulated in ASM vs. ex vivo, but 
downregulated in ASM-Chelex vs. ASM.  
The antRABC operon is predicted to be regulated by small regulatory RNAs prrF1 and prrF2. 
PrrF1 and PrrF2 RNAs contribute to iron homeostasis under depleted conditions by inducing 
degradation of mRNAs encoding for iron-containing proteins (Cornelis et al., 2009; Oglesby et 
al., 2008; Vasil, 2007). Oglesby et al. (2007) demonstrated that anthranilate availability is tightly 
regulated for either PQS or energy production depending on the iron level of the cell. During 
iron limitation antABC is repressed by PrrF, which can be observed for ASM-Chelex (ACh/A).  
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Table 4: Fold change of gene expression of selected PQS biosynthesis, anthranilate metabolism 
and sigma factor genes in ASM, ASM-Chelex and ex vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 – 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) CF 
patients’ samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes during growth in ASM compared to ex vivo (A / EV), ASM-Chelex 
compared to ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A).  
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
PQS-Biosynthesis:     
PA0996 
PA0997 
PA0998 
PA0999 
PA1000 
PA1001 
PA1002 
pqsA 
pqsB 
pqsC 
pqsD 
pqsE 
phnA 
phnB 
probable coenzyme A ligase 
Homologous to beta-keto-acyl-acyl-carrier protein synthase 
Homologous to beta-keto-acyl-acyl-carrier protein synthase 
3-oxoacyl-[acyl-carrier-protein] synthase III 
Quinolone signal response protein 
anthranilate synthase component I 
anthranilate synthase component II 
5,3 
 
 
4,1 
 
 
 
34,3 
30,6 
39,0 
34,7 
23,5 
34,1 
26,7 
6,4 
14,7 
13,1 
8,4 
12,9 
19,5 
10,9 
Anthranilate-Metabolism:    
PA0226 
PA0227 
PA0228 
PA0229 
PA0230 
PA0231 
PA0232 
PA2507 
PA2508 
PA2509 
PA2511 
PA2512 
PA2513 
PA2514 
pcaI 
pcaJ 
pcaF 
pcaT 
pcaB 
pcaD 
pcaC 
catA 
catC 
catB 
antR 
antA 
antB 
antC 
probable CoA transferase, subunit A 
probable CoA transferase, subunit B 
beta-ketoadipyl CoA thiolase PcaF 
dicarboxylic acid transporter PcaT 
3-carboxy-cis,cis-muconate cycloisomerase 
beta-ketoadipate enol-lactone hydrolase 
gamma-carboxymuconolactone decarboxylase 
catechol 1,2-dioxygenase 
muconolactone delta-isomerase 
muconate cycloisomerase I 
probable transcriptional regulator 
anthranilate dioxygenase large subunit 
anthranilate dioxygenase small subunit 
anthranilate dioxygenase reductase 
95,1 
53,3 
55,6 
5,6 
6,6 
10,6 
31,11
82,0 
159,8 
55,1 
21,8 
102,5 
241,7 
83,5 
 -64,1 
-42,6 
-54,9 
-5,4 
-6,5 
-10,2 
-19,6 
-103,1 
-56,8 
-51,5 
-14,1 
-80,0 
-65,8 
-80,0 
 
Sigma factor: 
   
PA3622 
PA0576 
rpoS 
rpoD 
sigma factor RpoS 
sigma factor RpoD 
4,6 
 
9,8 
-4,9 
 
 
In ASM vs. ex vivo antABC is induced. This indicates that iron repleted conditions under which 
both PQS synthesis and anthranilate degradation for energy production take place seem to be 
present in ASM (Table 4) from the microarray results, which needs to be further verified by other 
techniques.  
Anthranilate metabolism is further regulated by the AHL dependent LasI / LasR and RhlI / RhlR 
quorum sensing systems and in addition by AntR the anthranilate-dependent activator (Chugani 
and Greenberg, 2010; Oglesby et al., 2008; Williams and Camara, 2009).  
The alternative sigma factor RpoS, which was induced in ASM vs. ex vivo and ASM-Chelex vs. 
ex vivo, regulates also AHL quorum sensing dependent genes such as virulence genes as 
pyocyanin and exotoxin A, during the onset of stationary phase (Potvin et al., 2008; Schuster et 
al., 2004). In contrast rpoD, which gene product mainly regulates the expression of 
housekeeping genes, was downregulated in ASM-Chelex vs. ex vivo. 
PQS and PQS biosynthesis and metabolism and degradation of anthranilate are potent 
indicators of the iron status of the cell and thereby for the surrounding environment. 
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Fig. 13: Schematic overview of PQS synthesis and anthranilate degradation (modified after (Bundy 
et al., 1998; Farrow and Pesci, 2007) 
Chorismatic acid is converted by the anthranilate synthase (encoded by phnAB) to anthranilic acid. 
Anthranilic acid can be converted by gene products encoded by the pqsABCD operon to 2-heptyl-4-
quinolone. The reaction to 2-heptyl-3-hydroxyl-4-quinolone (PQS) is catalysed by the gene product 
of pqsH.  
Moreover, anthranilic acid can be degraded by the anthranilate dioxygenase (encoded by antABC) 
to catechol, which can be further converted by catechol dioxygenase encoded by catABC operon to 
cis,cis-muconate. Muconate can be further degraded to tricarboxylic acid cycle intermediates via !-
ketoadipate pathway. 
____________________________________________________________________________ 
2.2.10 Sulphur, molybdenum, zinc and phosphate are important factors for survival in 
cystic fibrosis lung  
Microelements such as sulphur, molybdenum and zinc are important cofactors of enzymes 
necessary for infection and survival. But in ASM and ASM-Chelex the upregulation of genes 
encoding proteins involved in the uptake of none of these factors was observed (Table 5). 
Therefore, these uptake systems and binding proteins were upregulated only under ex vivo 
conditions. A recent study suggests that zinc is also taken up via pyochelin, but the affinity for 
iron is significantly higher (Brandel et al., 2012). Enzymes important under infection conditions, 
such as LasA protease and LasB elastase are zinc metallo proteases and need zinc to be 
functional (Olson and Ohman, 1992). But zinc limitation was only observed under ex vivo 
conditions not in ASM nor ASM-Chelex.  
The sulphur supply during CF infection might be replenished by desulphuration of mucin 
residues, which are highly sulphated and sialylated (Robinson et al., 2012; Tralau et al., 2007). 
Besides the sulphur pool might be refilled by uptake of the sulphur containing amino acids 
methionine and cysteine. In ASM and ASM-Chelex sulphur is probably obtained by the uptake 
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of mucine, methionine or cysteine. No limitation of sulphur was observed after 24 h of growth in 
ASM and ASM-Chelex.  
Furthermore, a recent study showed that CysB the central regulator of sulphur metabolism in 
P. aeruginosa is crucial for PvdS expression (Imperi et al., 2010). One well-known connection 
between iron and sulphur metabolism are the iron-sulphur clusters, which are essential 
prosthetic groups for electron transfer, gene regulation and environmental sensing. Therefore, 
assembly is carefully regulated to avoid toxicity of free iron and sulphide (Ayala-Castro et al., 
2008). On the other hand energy is saved, when uptake and assembly are coregulated. This 
might be the connection between CysB and PvdS and hence between iron and sulphur 
metabolism. 
 
Table 5: Fold change of gene expression of selected sulphur, molybedenum, zinc and phosphate 
regulated genes in ASM, ASM-Chelex and ex vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 – 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes during growth in ASM compared to ex vivo (A / EV), ASM-Chelex 
compared to ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A).  
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
Sulphur:     
PA0283 sbp sulfate-binding protein precursor  -6,0  
Molybdenum:     
PA3441 
PA3915 
 
moaB1 
probable molybdopterin-binding protein 
molybdopterin biosynthetic protein B1 
-5,1  
-15,4 
 
Zinc:     
PA5500 
PA5503 
znuC zinc transport protein ZnuC 
probable ATP-binding component of ABC transporter 
-6,5 
 
 
-5,0 
 
Phosphate:     
PA1178 
PA1179 
PA1180 
PA2657 
PA3280 
PA3382 
PA5360 
PA5365 
PA5366 
PA5367 
PA5368 
PA5369 
oprH 
phoP 
phoQ 
 
oprO 
phnE 
phoB 
phoU 
pstB 
pstA 
pstC 
pstS 
PhoP/Q, low Mg2+ inducible o.m. prot. H1 prc. 
two-component response regulator PhoP 
two-component sensor PhoQ 
probable two-component response regulator 
Pyrophosphate-specific outer membrane porin OprO precursor 
phosphate transport protein PhnE 
two-component response regulator PhoB 
phosphate uptake regulatory protein PhoU 
ATP-binding component of ABC phosphate transporter 
membrane protein component of ABC phosphate transporter 
membrane protein component of ABC phosphate transporter 
phosphate ABC transporter, periplasmic phosphate-binding 
protein 
 
 
 
 
-5,5 
 
 
 
 
 
 
 
5,6 
7,6 
9,4 
 
 
9,3 
38,4 
7,3 
15,4 
12,6 
7,4 
16,5 
 
 
 
4,8 
21,7 
9,6 
41,4 
14,2 
33,5 
16,7 
7,4 
22,3 
 
Molybdenum is needed for the molybdenum cofactor biosynthesis. The cofactor is an important 
part of enzymes of the denitrification such as NarG and NapA (Zumft, 1997). Both enzymes are 
part of the dissimilatory nitrate reductases. P. aeruginosa harbours two systems one is the 
NarGHI and the second is NapABC. The napA gene and the napABC operon were detected 
upregulated in ASM vs. ex vivo and ASM-Chelex vs. ex vivo (Table 6). Molybdenum is an 
important component for the bacterial energy production as molybdenum cofactor, but 
molybdenum limitation was only observed under ex vivo conditions.  
In ASM-Chelex (ACh/EV; ACh/A) the phosphate uptake system genes such as the two-
component response regulator gene phoB, the phosphate uptake regulatory protein gene phoU, 
the predicted operon pstBAC genes and the periplasmic phosphate-binding protein gene pstS 
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were induced (Hancock et al., 1992; Siehnel et al., 1992) (Table 5). Besides the predicted oprH, 
phoPQ operon, which is associated with phosphate metabolism (Groisman et al., 1989), was 
upregulated under the ASM-Chelex vs. ex vivo conditions. Phosphate starvation is reported to 
induce the virulence factor production of P. aeruginosa associated with phosphate, quorum 
sensing, and iron signalling in a Caenorhabditis elegans model system (Zaborin et al., 2009). 
Zaborin et al. (2009) also observed a connection between phosphate depletion and increased 
pyoverdine production, which led to a more lethal phenotype in C. elegans. The response to 
phosphate depletion could therefore be investigated in ASM-Chelex.  
Only the gene oprO, which is only expressed under phosphate-starvation conditions, was 
induced under ex vivo conditions (A/EV) (Hancock et al., 1992; Siehnel et al., 1992). In this 
study phosphate depletion in ASM-Chelex (ACh/EV; ACh/A) might be an effect indirectly 
connected to the Chelex resin. Previous studies describe the interaction of the divalent 
phosphate anion HPO42- with polyvalent metal ions such as Cu (II), Fe(III), Mo(IV) (Wu et al., 
2007; Zhao and Sengupta, 1998). Moreover, Wu et al. (2007) describe the efficient removal of 
phosphate by lanthanum (III) bound to Chelex resin from water. One can discuss if the metal 
ions in ASM-Chelex, which are chelated by the Chelex resin, were acting in combination with 
Chelex probably as very efficient phosphate scavengers. Thereby probably introducing the 
observed phosphate limitation in ASM-Chelex. 
2.2.11 Energy metabolism ex vivo, in ASM and in ASM-Chelex 
P. aeruginosa is capable to use a wide range of carbon and energy sources for the production 
of energy. Energy conservation as adenosine triphosphate (ATP) is possible via aerobic or 
anaerobic respiration or fermentation of arginine or pyruvate (Davies et al., 1989; Eschbach et 
al., 2004; Vander Wauven et al., 1984; Yoon et al., 2002; Zannoni, 1989) 
For the complete oxidation of organic compounds during respiration an external electron 
acceptor is necessary. Electrons are transferred to the external electron acceptor via an 
electron transport chain, which translocates protons into the periplasm and thereby generates 
an electrochemical gradient (proton motive force, PMF) across the cytoplasmic membrane, 
which is essential for ATP production. Without an available electron acceptor, fermentation of 
organic substances via substrate-level phosphorylation can be used for ATP synthesis. 
During growth under ex. vivo conditions (A/EV ; ACh/EV) parts of the narK1K2GHJI operon, 
which encodes for NarGHI and the two transmembrane proteins NarK1K2, were upregulated 
(Table 6 and Fig. 14). This clearly indicates that P. aeruginosa uses the narK1K2GHJI operon 
to obtain energy facing the microaerobic to anaerobic conditions in vivo. 
Only NarK2 seems to be essential for nitrate/nitrite transport (Sharma et al., 2006). NarJ is 
involved in assembly of the enzyme, but is not part of the nitrate reductase (Zumft, 1997). 
Expression of the narK1K2GHJI operon depends on the oxygen-sensing regulator Anr, the NO- 
sensing regulator Dnr and the nitrate response two-component system NarX-NarL, respectively 
(Schreiber et al., 2007). The observed regulation is in accordance with literature, which 
described microaerobic till anaerobic growth conditions in the CF airways (Moreau-Marquis et 
al., 2008; Worlitzsch et al., 2002).  
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Neither ASM nor ASM-Chelex were incubated under anaerobic conditions but under aerobic 
conditions with limited oxygenation. Both media were supplemented with nitrate and nitrite 
concentrations of 260 #M and 130 #M, respectively.  
In accordance to aerobic incubation and nitrate/nitrite availability the second dissimilatory nitrate 
reductase operon napABC was induced in ASM and ASM-Chelex (A/EV ; ACh/EV). The 
periplasmatic NapABC is not involved in translocation of protons and therefore not used for 
energy generation as NarGHI. In contrast NapABC reduces nitrate under both aerobic and 
anaerobic conditions (Davies et al., 1989). Furthermore, it might function as terminal oxidase 
maintaining the redox balance of the cell during transitions from aerobic to anaerobic conditions 
or aerobic denitrification (Philippot and Hojberg, 1999).  
The conditions in vivo might supplement more nitrate. Physiological nitrate and nitrite 
concentrations in patient’s sputum vary from 73 #M to 792 #M (Grasemann et al., 1998; 
Hassett, 1996; Linnane et al., 1998; Palmer et al., 2007b). 
 
Table 6: Fold change of gene expression of selected energy metabolism genes in ASM, ASM-
Chelex and ex vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 – 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes during growth in ASM compared to ex vivo (A / EV), ASM-Chelex 
compared to ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A).  
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
Denitrification:     
PA0105 
PA0106 
PA0107 
PA0108 
PA0524 
PA1172 
PA1173 
PA1174 
PA1175 
PA1176 
PA1177 
PA1555 
PA1556 
PA1557 
PA3873 
PA3874 
PA3876 
PA3877 
PA4587 
PA4810 
PA4811 
PA4812 
coxB 
coxA 
 
coIII 
norB 
napC 
napB 
napA 
napD 
napF 
napE 
 
 
 
narJ 
narH 
narK2 
narK1 
ccpR 
fdnI 
fdnH 
fdnG 
cytochrome c oxidase, subunit II 
cytochrome c oxidase, subunit I 
conserved hypothetical protein 
cytochrome c oxidase, subunit III 
nitric-oxide reductase subunit B 
cytochrome c-type protein NapC 
cytochrome c-type protein NapB precursor 
periplasmic nitrate reductase protein NapA 
NapD protein of periplasmic nitrate reductase 
ferredoxin protein NapF 
periplasmic nitrate reductase protein NapE 
probable cytochrome c (cbb3-type) 
probable cytochrome c oxidase subunit (cbb3-type) 
probable cytochrome oxidase subunit (cbb3-type) 
respiratory nitrate reductase delta chain 
respiratory nitrate reductase beta chain 
nitrite extrusion protein 2 
nitrite extrusion protein 1 
cytochrome c551 peroxidase precursor 
nitrate-inducible formate dehydrogenase, gamma subunit 
nitrate-inducible formate dehydrogenase, beta subunit 
formate dehydrogenase-O, major subunit 
23,3 
35,7 
25,0 
43,7 
-6,9 
5,6 
6,9 
28,3 
8,0 
15,0 
26,8 
 
 
4,2 
-8,0 
-7,8 
-12,6 
-13,3 
7,1 
12,9 
20,4 
28,6 
26,2 
42,8 
33,2 
48,5 
-6,9 
 
5,0 
16,0 
4,9 
12,3 
35,0 
12,4 
8,5 
10,6 
-8,4 
-7,8 
-11,7 
-14,0 
6,3 
10,0 
17,1 
19,7 
 
 
 
 
 
 
 
 
 
 
 
5,9 
5,9 
Arginine fermentation:    
PA5173 arcC carbamate kinase -4,6   
Pyruvate metabolism:    
PA2382 
PA3415 
PA3416 
PA3417 
lldA L-lactate dehydrogenase 
probable dihydrolipoamide acetyltransferase 
probable pyruvate dehydrogenase E1 component, beta chain 
probable pyruvate dehydrogenase E1 component, alpha subunit 
 
12,0 
8,2 
5,8 
-5,0 
16,7 
9,3 
9,4 
 
Central intermediary metabolism:    
PA5288 glnK nitrogen regulatory protein P-II 2 4,6   
 
For the conversion from nitrite to nitric oxide by the nitrite reductase NirS, a cytochrome cd1 
reductase located in the periplasm, no significant change in expression (pfp > 0.05) was 
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observed. The next step the reduction of highly toxic nitric oxide to nitrous oxide is performed by 
the membrane bound nitric oxide reductase NorCB. The gene norB, encoding for a cytochrome 
b (Arai et al., 1995), was upregulated under ex vivo conditions (A/EV ; ACh/EV). Nitrous oxide is 
converted to molecular nitrogen by the nitrous oxide reductase NosZ, which is located in the 
periplasm. The expression of nosZ gene was not significantly changed (pfp > 0.05) under the 
investigated conditions.  
 
 
Fig. 14: Schematic depiction of denitrification and arginine fermentation pathways in P. aeruginosa 
Nitrate is transported via NarK2 into the bacterial cell, where NarGHI catalyses the first step in 
denitrification, the reduction of nitrate to nitrite. Nitrate can be reduced to nitrite in the periplasm by 
NapABC. The periplasmic NirS reductase reduces nitrite to nitric oxide, followed by the conversion 
to nitrous oxide via the NorCB reductase. As final step the NosZ reductase converts nitrous oxide 
to molecular nitrogen. 
The transport of arginine into the cytoplasm via ArcD is coupled with the export of ornithine. The 
conversion of arginine via the arginine deaminase pathway is catalysed by ArcA, ArcB and ArcC 
and provides one molecule of ATP per one molecule arginine (Gamper et al., 1991). 
Cytoplasmic membrane (CM) and outer membrane (OM) are indicated. The up- (red), 
downregulation (green) and stable (white) expression of the genes encoding for the depicted 
proteins is shown for the ex vivo sputum sample compared to ASM and ASM-Chelex. 
____________________________________________________________________________ 
The predicted nitrate-inducible formate dehydrogenase operon genes fdnIHG was induced in 
ASM and ASM-Chelex (A/EV ; ACh/EV). In accordance with previous studies the cytochrome c 
oxidase operon coxBA, PA0107 and colll was upregulated in ASM and ASM-Chelex (A/EV ; 
ACh/EV). The cox operon coding for the aa3-type low-affinity oxidase is shown to be 
preferentially expressed in the stationary phase in an aerobic environment and is moreover 
RpoS regulated (Alvarez-Ortega and Harwood, 2007; Schuster et al., 2004). Moreover, the 
cbb3-type 2 oxidase operon was upregulated in ASM-Chelex (ACh/EV ; ACh/A). The cbb3-type 
2 oxidase is predicted to have a high affinity for oxygen and is expressed at low oxygen levels 
(Alvarez-Ortega and Harwood, 2007; Kawakami et al., 2010). In addition, the cbb3-type 2 
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oxidase operon is positively regulated by Anr and RoxSR. This is indicating that oxygen-limiting 
conditions were also present in the ASM-Chelex culture.  
Only the gene arcC was detected upregulated under ex vivo conditions (A/EV) of the genes 
essential for arginine fermentation of the arcDABC operon (Fig. 14). The carbamate kinase 
ArcC, which catalyses the reaction of carbamoylphosphate to ammonia and carbon dioxide and 
leads to the generation of ATP (Vander Wauven et al., 1984), was downregulated in ASM and 
therefore upregulated under ex vivo conditions. Expression of the operon depends on oxygen 
limitation and Anr (Galimand et al., 1991; Gamper et al., 1991). Besides, transcription of the 
operon is stimulated by the presence of exogenous arginine via the arginine responsive 
regulator ArgR (Lu et al., 1999).  
The genes involved in pyruvate metabolism as the predicted pyruvate dehydrogenase operon 
PA3415-PA3417 were upregulated in ASM and ASM-Chelex. In contrast the L-lactate 
dehydrogenase lldA was upregulated ex vivo (ACh/EV).  
The comparison of ASM and ASM-Chelex with the ex vivo conditions, especially the expression 
of the narGHI operon, the arcC gene and the lldA gene indicate that energy generation via 
denitrification, arginine fermentation and pyruvate fermentation are a very important source of 
energy generation in vivo.  
2.2.12 Nutrient sources in the ex vivo sputum sample – metabolism, biosynthesis and 
uptake 
Closely connected to energy generation are metabolism and uptake. The question remains, 
which nutrient sources allow P. aeruginosa to reach concentrations of ' 108 bacteria/ml sputum 
(Palmer et al., 2007a; Son et al., 2007). Upregulated under ex vivo conditions (ACh/EV) was the 
amino acid transport gene aroP1, which is especially involved in the transport of aromatic amino 
acids. In contrast, five amino acid transport genes including the aroP2 gene were upregulated in 
ASM and ASM-Chelex (Table 7). Furthermore, genes encoding for the amino acid biosynthesis 
and metabolism proteins were induced in ASM and ASM-Chelex. This is indicating that amino 
acids are predominantly used in ASM and ASM-Chelex whereas during ex vivo conditions other 
nutrients are preferred.  
The iscS gene an L-cysteine desulphurase, which degrades cysteine to pyruvate, was 
upregulated ex vivo (ACh/EV). The genes of the methionine and SAM metabolism were 
upregulated under ex vivo conditions (A/EV ; ACh/EV). This indicates the importance of 
methionine and the formation of SAM under in vivo conditions. The gene glyA3 of the glycin 
cleavage system, which is necessary for the formation of N5, N10-methylene-tetrahydrofolate out 
of serine and glycine, was upregulated under ex vivo conditions (A/EV ; ACh/EV). 
The strongest induction of 417-fold was seen for the tRNA gene of serine followed by 328-fold 
induction of tRNA gene of cysteine in ASM-Chelex vs. ex vivo. That indicates that P. aeruginosa 
is probably more active in proteins translation in ASM and ASM-Chelex than under ex vivo 
conditions. 
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Table 7: Fold change of gene expression of gene expression of selected metabolism genes in ASM, 
ASM-Chelex and ex vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 – 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes during growth in ASM compared to ex vivo (A / EV), ASM-Chelex 
compared to ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A).  
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
Amino acid transport:    
PA0866 
PA1339 
PA1340 
PA1342 
PA3000 
PA5153 
aroP2 
 
 
 
aroP1 
 
aromatic amino acid transport protein AroP2 
amino acid ABC transporter ATP binding protein 
amino acid ABC transporter membrane protein 
probable binding protein component of ABC transporter 
aromatic amino acid transport protein AroP1 
amino acid (lysine/arginine/ornithine/histidine/octopine) ABC 
transporter periplasmic binding protein 
6,4 
6,7 
10,6 
12,1 
 
3,8 
21,6 
4,7 
9,4 
9,5 
-5,8 
6,3 
 
Amino acid biosynthesis and metabolism:    
PA0132 
PA0782 
PA0865 
PA0870 
PA0871 
PA0872 
PA1337 
PA1338 
PA1999 
PA2000 
PA2247 
PA2248 
PA2249 
PA3118 
PA3120 
PA3121 
PA3216 
PA3418 
PA3570 
PA3792 
PA3814 
PA5410 
PA5429 
 
putA 
hpd 
phhC 
phhB 
phhA 
ansB 
ggt 
dhcA 
dhcB 
bkdA1 
bkdA2 
bkdB 
leuB 
leuD 
leuC 
 
ldh 
mmsA 
leuA 
iscS 
gbcA 
aspA 
beta-alanine--pyruvate transaminase 
proline dehydrogenase PutA 
4-hydroxyphenylpyruvate dioxygenase 
aromatic amino acid aminotransferase 
pterin-4-alpha-carbinolamine dehydratase 
phenylalanine-4-hydroxylase 
glutaminase-asparaginase 
gamma-glutamyltranspeptidase precursor 
DhcA, dehydrocarnitine CoA transferase, subunit A 
DhcB, dehydrocarnitine CoA transferase, subunit B 
2-oxoisovalerate dehydrogenase (alpha subunit) 
2-oxoisovalerate dehydrogenase (beta subunit) 
branched-chain alpha-keto acid dehydrogenase  
3-isopropylmalate dehydrogenase 
3-isopropylmalate dehydratase small subunit 
3-isopropylmalate dehydratase large subunit 
probable aspartate-semialdehyde dehydrogenase 
leucine dehydrogenase 
methylmalonate-semialdehyde dehydrogenase 
2-isopropylmalate synthase 
L-cysteine desulphurase (pyridoxal phosphate-dependent) 
GbcA 
aspartate ammonia-lyase 
5,4 
-6,1 
13,7 
 
4,5 
 
8,9 
5,5 
 
 
 
 
 
4,9 
13,3 
12,1 
10,4 
10,4 
3,9 
29,7 
 
8,3 
 
5,0 
 
29,3 
5,8 
12,8 
9,8 
7,0 
 
8,8 
7,3 
12,7 
8,2 
10,0 
 
 
 
13,3 
16,4 
4,7 
 
-5,8 
 
4,9 
 
 
 
 
 
 
 
 
6,4 
4,8 
 
 
 
 
-9,7 
-10,5 
 
 
 
-20,1 
 
 
13,3 
Methionine and SAM metabolism:    
PA0316 
PA0430 
PA0546 
PA1843 
PA1927 
PA2442 
PA2444 
PA2444 
PA2445 
PA2446 
PA4602 
PA5415 
serA 
metF 
metK 
metH 
metE 
gcvT2 
glyA2 
glyA2 
gcvP2 
gcvH2 
glyA3 
glyA1 
D-3-phosphoglycerate dehydrogenase 
5,10-methylenetetrahydrofolate reductase 
methionine adenosyltransferase 
methionine synthase 
methionine synthase 
glycine cleavage system protein T2 
serine hydroxymethyltransferase 
serine hydroxymethyltransferase 
glycine cleavage system protein P2 
glycine cleavage system protein H2 
serine hydroxymethyltransferase 
serine hydroxymethyltransferase 
-6,3 
 
-8,4 
 
-13,4 
 
 
 
 
 
-5,4 
 
-15,2 
-5,5 
-8,8 
-6,0 
-13,7 
 
5,8 
 
 
 
-12,3 
4,8 
 
 
 
 
 
4,9 
 
27,8 
23,1 
16,2 
 
4,3 
tRNAs:      
tRNA-Cys 
tRNA-Pro 
tRNA-Val 
tRNA-Ser 
tRNA-Pro 
tRNA-Asn 
tRNA-Arg 
tRNA-Leu 
tRNA-Thr 
tRNA-Tyr 
tRNA-Met 
tRNA-Phe 
 PA2581.1 
PA2736.1/PA3031.1/ PA4541.2 
PA2775.1/PA3094.3/PA3262.2 
PA2852.1/PA0905.1/ PA1013.1/PA2603.1 
PA3031.1 
PA3139.1/PA4541.3 
PA3368.1/PA4581.1/PA0905.2/PA0905.3/PA1796.1/PA0263.1 
PA3824.1 /PA4937.1/ PA4937.2/ PA1796.3/PA2570.1/ PA4746.2 
PA4277.1/PA4524.1/ PA5160.1 
PA4277.3 
PA4746.1/PA4673.1/ PA0574.1/PA0922.1 
PA5149.1 
24,7 
6,1 
4,2 
212,9 
 
 
 
23,2 
 
 
 
7,3 
327,9 
27,9 
 
416,9 
 
5,3 
7,8 
59,4 
46,5 
5,1 
27,9 
53,6 
13,3 
 
 
 
4,6 
 
 
 
12,3 
4,2 
25,5 
7,4 
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Continued: 
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
Choline metabolism:     
PA3933 
PA5372 
PA5373 
PA5374 
 
betA 
betB 
betI 
probable choline transporter 
choline dehydrogenase 
betaine aldehyde dehydrogenase 
transcriptional regulator BetI 
-5,2 
-6,8 
-10,3 
-9,5 
-8,6 
-12,4 
-25,4 
-33,0 
 
Fatty acid and phospholipid metabolism:    
PA4351 
PA0447 
PA0228 
 
gcdH 
pcaF 
probable acyltransferase 
glutaryl-CoA dehydrogenase 
beta-ketoadipyl CoA thiolase PcaF 
 
 
55,5 
31,4 
7,0 
 
31,4 
3,6 
-54,9 
Nucleotide biosynthesis and metabolism:    
PA0441 
PA0444 
PA0849 
PA4670 
PA5541 
dht 
 
trxB2 
prs 
pyrQ 
dihydropyrimidinase 
N-carbamoyl-beta-alanine amidohydrolase 
thioredoxin reductase 2 
ribose-phosphate pyrophosphokinase 
dihydroorotase 
8,6 
22,3 
-8,4 
 
-47,2 
 
6,5 
-6,9 
-5,4 
-5,5 
 
-3,4 
 
 
8,6 
 
The betAB operon, which is regulated by betI, and a probable choline transporter PA3933 were 
upregulated under ex vivo conditions (A/EV ; ACh/EV). These genes have been reported to be 
involved in the utilization of choline as a carbon and nitrogen source (Son et al., 2007). 
Moreover, betB as betaine aldehyde dehydrogenase is also involved in the production of glycine 
betaine, one of the major osmoprotectants of bacterial cells (Csonka and Hanson, 1991). Under 
ex vivo conditions these genes were upregulated compared to medium conditions, although 
high salt conditions are present in both environments, somehow the need for osmoprotectants 
in the CF airways might be increased. On the other hand phosphatidylcholine concentration 
could be limiting in the medium compared to the CF airways, although the medium contains egg 
yolk as source of lecithin.  
The genes trxB2, prs, pyrQ seem to be more important under ex vivo conditions, since they are 
upregulated under ex vivo conditions. PyrQ is involved in de novo pyrimidine biosynthesis 
(Brichta et al., 2004). In contrast, the genes dht encoding for a dihydropyrimidinase and PA0444 
encoding for a N-carbamoyl-beta-alanine amidohydrolase were upregulated in ASM and ASM-
Chelex. These genes are described to encode for proteins involved in the degradation of 
pyrimidine (Kim and West, 1991). This is indicating that more nucleotides are metabolismed in 
ASM and ASM-Chelex than under ex vivo conditions.  
 
ASM and ASM-Chelex contain egg yolk, DNA, amino acids and mucin as nutrient sources to 
simulate the sputum composition of the CF airways. In the ex vivo sputum sample an 
upregulation of the genes betAB, betI and PA3933 indicates a strong prevalence of 
P. aeruginosa for choline as nutrient source. Nucleotides were hardly metabolised during ex 
vivo conditions. Methionine and SAM metabolism were induced under ex vivo conditions. That 
is very interesting since the most common auxotrophy reported for P.  aeruginosa CF isolates is 
the methionine auxotrophy (Barth and Pitt, 1995; Barth and Pitt, 1996; Thomas et al., 2000). 
Fatty acid and glycerol uptake and degradation might take place to the same degree ex vivo 
and under simulated conditions and therefore genes were not differently expressed. 
Compared to the medium conditions less tRNAs were generated ex vivo that indicates that less 
protein biosynthesis took place. Moreover, amino acid transport, biosynthesis and metabolism 
were also decreased under ex vivo conditions.  
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2.2.13 Amino acid uptake from amino acid medium 
Amino acid uptake was analysed. For this reason amino acid medium (AAM) was used, which 
reflects the amino acid composition of ASM but without DNA, mucin and egg yolk for easier 
analysis of the metabolic footprint. P. aeruginosa PAO1 was grown aerobically in AAM (Fig. 15). 
Interestingly, the amino acids glutamine and asparagine were consumed first. After 6 h of 
growth, only concentrations ) 30 #M of both amino acids remained. Palmer et al. (2007) did not 
detect these amino acids in their sputum samples and, therefore, did not include glutamine and 
asparagine in synthetic CF sputum medium (SCFM). The reason behind this fact might be the 
preferred uptake of glutamine and asparagine by P. aeruginosa as carbon and nitrogen source. 
The amino group of glutamine can be transferred via transaminase reaction to an $-keto acid. 
Furthermore, glutamine and asparagine can be easily used as energy source, if converted to 
glutamate and channelled via TCA cycle. Both amino acids contain one atom of nitrogen as an 
amide and another atom of nitrogen as an amine and are therefore perfect nitrogen sources for 
the cell for the synthesis of nucleotides, amino acids, amino-sugars and vitamins.  
Aspartate, glutamate, alanine and arginine, were taken up to concentrations of ) 100 #M after 
14 h of growth of PAO1 in AAM. This is according to the study performed by 
Behrends et al. (2009), which used NMR for time-resolved metabolic footprinting of metabolites 
in SCFM. They did not detect glutamine and asparagine, since it is not included in SCFM. 
Nonetheless, the fitted t50 values of the metabolites, which are the summarized uptake 
characteristics, are available for comparison (Behrends et al., 2009). The t50 values show 
exactly the same order of uptake for the four amino acids. Only the time points vary between 
the studies due to different presentation. Most likely due to different methods employed, the 
uptake of the next four amino acids threonine, glycine, serine and lysine is different between the 
studies. Threonine, glycine, serine and lysine were consumed between 14 h – 24 h to 
concentrations ) 20 #M. Serine and glycine were also taken up in the study of Behrends et al. 
(2009) after the uptake of the first four amino acids. Leucine and isoleucine remained still at 
concentrations ' 100 #M after 24 h of P. aeruginosa PAO1 in AAM.  
Ornithine concentration in the medium increased from 30 #M up to 80 #M -100 #M after 6 h and 
remained there till 14 h. Ornithine remained at ' 70 #M after 24 h. Ornithin is a degradation 
product of amino acids and of the amino acid catabolism, which is probably secreted by 
P. aeruginosa.  
48 % of histidine, 41% of phenylalanine and 32 % of valine were taken up after 24 h. Only 10% 
of methionine and only 4% of tyrosine were consumed in the same time. Valine and methionine 
are also consumed very late in SCFM. Another interesting fact is that Behrends et al. (2009) did 
not detect uptake of methionine in LB medium.  
Very interesting is also the correlation between growth behaviour and uptake. After 7 h with the 
depletion of glutamine and asparagine the culture entered early stationary phase. Afterwards 
only a slight increase in OD578 was detected. The growth behaviour also reflects the uptake and 
depletion of certain amino acids. 
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Fig. 15: Amino acid concentrations during growth of P. aeruginosa PAO1 in amino acid medium 
(AAM) 
P. aeruginosa PAO1 (black dashed line, open circles) was grown in AAM for 24 h and medium 
samples were taken to determine the amino acid concentration in the AAM and OD578 of the culture 
was measured. The concentration over time of 18 of 20 the proteinogenic amino acids were 
measured, except for cysteine and proline, which were not detected in this approach. In addition 
ornithine formation was also determined. 
____________________________________________________________________________ 
Therefore, in media containing several nutrient sources expression and translation of 
transporter systems and catabolic pathways need to be regulated. Approximately 300 known or 
predicted nutrient uptake systems are found in the genomes of the Pseudomonas species 
(Tamber and Hancock, 2003). Some of them are also regulated in ASM as we have seen 
previously (Table 7). 
Uptake requires energy and also catabolic pathways require certain amount of energy. As a 
result, the expressed pathways are tightly regulated, as we can observe in the uptake pattern. 
Not all amino acids were taken up at the same time and in the same amount. For example ArgR 
controls the aerobic catabolism of arginine (Park et al., 1997), but also the level of OprD. OprD 
is a porine for basic amino acids (Ochs et al., 1999) and moreover a serine transporter (Lu et 
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al., 2004). Furthermore Ochs et al. (1999) reported that oprD was induced by glutamate and 
alanine as sole carbon and nitrogen source. This is also reflected in the uptake pattern (Fig. 14) 
arginine, glutamate and alanine are taken up together and serine is consumed later. 
2.2.14 Motility is reduced in ASM and ASM-Chelex compared to ex vivo sputum samples 
The chemotaxis proteins PA0177 and PA1608 were induced in the ex vivo sputum sample and 
were therefore downregulated in ASM and ASM-Chelex (Table 8). PA0177 is 78% similar to 
chemotaxis protein CheW of E. coli and probably involved in purine detection. PA1608 is a 
probable chemotaxis transducer. The other probable chemotaxis transducer PA2573, PA4290 
and PA4915 were upregulated in ASM and ASM-Chelex. 
In contrast, to the predicted biofim and microcolony growth style during in vivo conditions the 
genes encoding for the flagella flgC (PA1078) and flgE (PA1080) were detected upregulated 
under ex vivo conditions (A/EV ; ACh/EV) (Table 8), since the genes were downregulated in 
ASM and ASM-Chelex. Both genes are predicted to be part of the flgBCDE operon. Under ex 
vivo conditions also the predicted flgFGHI operon was upregulated. Amiel et al. (2010) showed 
that the loss of flagella function and not the loss of the flagella apparatus itself is the critical 
factor associated with resistance to nonopsonic phagocytosis. Thereby, explaining the observed 
advantage of motility loss associated with higher bacterial burden in the lung. Therefore, the 
flagella might be still present on the clinical isolates CFCZ and CF-1 – 4 but not necessarily 
functional. The functionality of the flagella of both strains has to be verified.  
On the other hand Roger et al. (2004) and Singh et al. (2002) reported that lactoferrin and 
conalbumin inhibited the biofilm formation of P. aeruginosa. They assumed that iron chelation 
led to increased surface motility by twitching motility and thereby inhibiting biofilm formation 
(Singh et al., 2002).  
An induction of the type IV pili genes pilW and pilX was observed in ASM-Chelex vs. ex vivo 
and ASM-Chelex vs. ASM conditions. Both proteins are located in the periplasm and belong to 
the minor pilins, which are the base for PilA (Giltner et al., 2010; Mattick, 2002). Type IV pili 
mediate both attachment to host epithelial cells and flagella-independent twitching motility (Alm 
et al., 1996). But type IV pili were not induced under ex vivo conditions.  
Upregulation of tpbA a tyrosine phosphatase was observed under ex vivo conditions (A/EV ; 
ACh/EV). TpbA upregulation results in increased swimming, swarming and decreased 
attachment (Ueda and Wood, 2009; Yang et al., 2010). All this indicates a planktonic life-style 
and less exopolysaccharide production under ex vivo conditions and biofilm formation under 
ASM and ASM-Chelex conditions. PA3885 protein is a negative regulator of c-di-GMP 
production. Uedo and Woods (2009) also showed a connection to LasR, which activates tpbA 
expression. Thereby, biofilm structure is linked to environment and cell density. 
Motility and chemotaxis recognition were detected as important factors in vivo. Unexpectedly 
fagella genes seem to be expressed under ex vivo conditions indicating plantonic growth style. 
Type IV pili were repressed or decreased in expression under ex vivo conditions. One can 
speculate about the reasons for the planktonic life-style.  
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Table 8: Fold change of gene expression of selected motility genes in ASM, ASM-Chelex and ex 
vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 – 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes during growth in ASM compared to ex vivo (A / EV), ASM-Chelex 
compared to ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A).  
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
Chemotaxis:    
PA0177 
PA1608 
PA2573 
PA4290 
PA4915 
 probable purine-binding chemotaxis protein 
probable chemotaxis transducer 
probable chemotaxis transducer 
probable chemotaxis transducer 
probable chemotaxis transducer 
 
-5,1 
 
10,2 
6,3 
 
-5,1 
4,9 
 
6,7 
-3,7 
 
 
 
 
Motility and attachment:    
PA1077 
PA1078 
PA1079 
PA1080 
PA1081 
PA1082 
PA1083 
PA1084 
PA3885 
PA4552 
PA4553 
Pae_flgK
M57501 
flgB 
flgC 
flgD 
flgE 
flgF 
flgG 
flgH 
flgI 
tpbA 
pilW 
pilX 
flgK 
flaA 
flagellar basal-body rod protein FlgB 
flagellar basal-body rod protein FlgC 
flagellar basal-body rod modification protein FlgD 
flagellar hook protein FlgE 
flagellar basal-body rod protein FlgF 
flagellar basal-body rod protein FlgG 
flagellar L-ring protein precursor FlgH 
flagellar P-ring protein precursor FlgI 
protein tyrosine phosphatase TpbA 
type 4 fimbrial biogenesis protein PilW 
type 4 fimbrial biogenesis protein PilX 
flagellar hook protein 
Pseudomonas aeruginosa flagellin (flaA) gene 
 
-5,9 
-4,8 
-7,4 
-6,9 
 
 
 
-5,7 
 
 
 
13,6 
-6,8 
-20,2 
-11,7 
-35,6 
-8,2 
-7,5 
-5,2 
-6,7 
-7,0 
5,7 
5,3 
-6,2 
5,7 
 
-3,4 
 
-4,8 
 
 
 
 
 
4,4 
5,1 
 
 
 
2.2.15 Secretion and virulence factors 
Not many virulence factors were expressed differently in ASM vs. ex vivo, ASM-Chelex vs. ex 
vivo and ASM-Chelex vs. ASM. That might be due to the fact that the conditions in ASM and 
ASM-Chelex were very similar to the ex vivo conditions and thereby to the in vivo conditions. 
For example, genes involved in alginate, cyanide, phospholipase C, protease and rhamnolipid 
production were not differently expressed compared to ex vivo sputum samples.  
The expression of these virulence factors is also partly regulated by quorum sensing. The N-
acylhomoserine lactone (AHLs) dependent quorum sensing systems LasI/LasR and RhlI/RhlR 
must be similarly regulated under the investigated conditions, since they show no difference in 
expression. Interestingly, the only difference in expression was observed for PQS system 
(Table 4), probably due to excess of aromatic amino acids in ASM and ASM-Chelex and the 
probably high PQS concentrations in the CF sputum compared to ex vivo (Palmer et al., 2005). 
Several studies describe the loss of virulence factors during chronic CF infection (Barth and Pitt, 
1995; D'Argenio et al., 2007; Smith et al., 2006).  
In contrast, the upregulation of the type III secretion system (T3SS) genes and associated 
genes PA1698 - PA1725 (Table 9) was observed under ex vivo conditions.  
Furthermore, the expression of the effector genes exoS, encoding for a ADP-ribosyltransferase 
and Rho GTPase-activating protein (GAP) and exoT gene, encoding for ADP-ribosyltransferase 
and Rho GAP (Yahr et al., 1997) was upregulated under ex vivo conditions. The carriage of the 
exoS gene is more prevalent among P. aeruginosa clinical isolates (Kulasekara et al., 2006). 
ExoS and ExoT confer anti-phagocytic abilities to P. aeruginosa mostly through their action on 
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the actin cytoskeleton (Bleves et al., 2010). T3SS is an important factor during in vivo infection 
conditions. T3SS expression was detected upregulated under ex vivo conditions. 
 
Table 9: Fold change of gene expression of selected virulence associated genes in ASM, ASM-
Chelex and ex vivo sputum samples  
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 – 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes during growth in ASM compared to ex vivo (A / EV), ASM-Chelex 
compared to ex vivo (ACh / EV), ASM-Chelex compared to ASM (ACh / A).  
Gene ID Gene 
name 
Function  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
Secreted factors (toxins, enzymes, alginate):    
PA0044 
PA0085 
PA1707 
PA3841 
PA3842 
exoT 
hcp1 
pcrH 
exoS 
 
exoenzyme T 
Hcp1 
regulatory protein PcrH 
exoenzyme S 
probable chaperone 
-13,5 
 
-9,0 
-7,7 
-13,9 
-13,2 
 
-10,8 
-10,7 
-14,3 
 
-7,0 
 
 
 
Protein secretion/export apparatus:    
PA1698 
PA1699 
PA1700 
PA1701 
PA1702 
PA1706 
PA1707 
PA1708 
PA1710 
PA1711 
PA1712 
PA1713 
PA1714 
PA1715 
PA1716 
PA1717 
PA1718 
PA1722 
popN 
 
 
 
 
pcrV 
pcrH 
popB 
exsC 
exsE 
exsB 
exsA 
exsD 
pscB 
pscC 
pscD 
pscE 
pscI 
Type III secretion outer membrane protein PopN precursor 
conserved hypothetical protein in type III secretion 
conserved hypothetical protein in type III secretion 
conserved hypothetical protein in type III secretion 
conserved hypothetical protein in type III secretion 
type III secretion protein PcrV 
regulatory protein PcrH 
translocator protein PopB 
ExsC, exoenzyme S synthesis protein C precursor. 
ExsE 
exoenzyme S synthesis protein B 
transcriptional regulator ExsA 
ExsD 
type III export apparatus protein 
Type III secretion outer membrane protein PscC precursor 
type III export protein PscD 
type III export protein PscE 
type III export protein PscI 
 
-7,5 
-9,0 
-9,5 
-18,9 
-9,3 
-9,0 
-15,7 
-4,6 
-8,5 
-16,3 
-5,6 
-9,4 
-16,2 
-12,7 
-7,6 
-12,6 
-7,2 
-4,5 
-7,5 
-10,3 
-9,5 
-18,5 
-9,4 
-10,8 
-16,1 
-6,2 
-19,2 
-20,3 
-5,3 
-12,7 
-16,2 
-14,7 
-8,1 
-12,6 
-7,2 
 
 
 
 
Adaptation and protection:    
PA4110 ampC beta-lactamase precursor -48,3 -33,7  
Exopolysaccharide formation:    
PA2231 
PA2232 
pslA 
pslB 
PslA exopolysaccharide biosynthesis 
PslB exopolysaccharide biosynthesis 
4,1 
3,8 
  
 
In vivo, T3SS functioning is triggered by the contact with the eukaryotic cell, which leads to 
effector injection (Bleves et al., 2010; Hauser, 2009). Moreover, T3SS transcription is induced 
by calcium limiting conditions (Bleves et al., 2010). The presence of epithelial cells might trigger 
the induction of T3SS under in vivo conditions (Hueck, 1998; Miller, 2002; Rietsch et al., 2004). 
The in ASM and ASM-Chelex observed repression is probably due to the lack of epithelial cell 
contact, as T3SS genes are expressed under ex vivo conditions.  
Interestingly, the upregulation of pslAB expression for the biosynthesis of the exopolysaccharide 
in ASM vs. ex vivo was observed. Both genes are required for Psl synthesis and furthermore 
pslA is necessary for solid surface attachment (Byrd et al., 2009). A probable glycosyl 
transferase is encoded by pslA, whereas pslB encodes for a phosphomannose isomerase/GDP-
D-mannose pyrophosporylase.  
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2.3 Conclusions 
This study investigated how the growth conditions in the CF airways affect the infecting and 
persisting P. aeruginosa strains and how well these growth conditions can be simulated using 
ASM and ASM-Chelex. The global analysis of P. aeruginosa gene expression under simulated 
respiratory tract conditions in vitro in ASM and under ex vivo CF lung infection conditions is 
reported. Besides, Son et al. (2007) and the recently published ex vivo CF lung infection 
transcriptome data (Bielecki et al., 2013) this is one of the few studies presenting ex vivo 
sputum sample transcriptome data. Moreover, this study is the first to compare the ex vivo 
expression results to simulated respiratory tract conditions in the model medium ASM by 
Sriramulu et al. (2005).  
Iron limitation was identified as one of the crucial stress factors in the CF airways in vivo. As a 
result increased iron limitation was introduced in ASM and ASM-Chelex obtained, but the level 
of limitation has not reached the ex vivo level.  
Two clonally distinct isolates of two independent CF patients were analysed. The transcriptional 
profile of theses strains was compared under ex vivo conditions to ASM and ASM-Chelex. A 
graphical summary of the findings is shown in Fig. 16. The model represents the transcriptional 
response of the clinical P. aeruginosa isolates CFCZ and CF1-4 under ex vivo vs. ASM and 
ASM-Chelex conditions (Fig. 16 A.), ASM vs. ex vivo conditions (Fig. 16 B.) and under ASM-
Chelex vs. ex vivo conditions (Fig. 16 C.). The pathways and specific genes mentioned in the 
results and discussion section are reported. Furthermore, the up- (red) and downregulation 
(green) and stable (white) expressions of the genes encoding for the depicted proteins is 
shown. The genes and functional groups displayed are functionally classified according to 
“Pseudomonas Genome Database” (Winsor et al., 2011).  
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Fig. 16: Model of genes regulated in CF1-4 and CFCZ under ex vivo conditions, in ASM and ASM-
Chelex 
Model of genes regulated in CF1-4 and CFCZ under ex vivo conditions vs. ASM / ASM-Chelex (A), 
under ASM vs. ex vivo conditions (B) and under ASM-Chelex vs. ex vivo conditions (C). Colours 
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indicate the up- (red) and downregulation (green) and stable (white) expressions of the genes 
encoding for the depicted proteins. 
____________________________________________________________________________ 
 
The most interesting and important findings are discussed below. 
Development of ASM-Chelex 
The comparison of the transcriptional profile of ASM vs. ex vivo showed that ASM contained 
higher amounts of iron than available under ex vivo conditions (2.2.3 and Table 2). Initial testing 
using qRT-PCR revealed induction of iron limitation marker genes in ASM-Chelex by the 
addition of Chelex (Fig. 7). In accordance with the qRT-PCR the stronger induced marker genes 
were also identified by the conducted microarray in ASM-Chelex (Table 3). 
Is ASM-Chelex simulating iron limitation more closely than ASM? 
The scatter plots and correlation values indicate no higher correlation rate between ASM-
Chelex vs. ex vivo than ASM vs. ex vivo (Fig. 8). As iron limitation is only influencing a relatively 
small number of genes, no change of correlation values is observed.  
The comparison of the transcriptional profiles of ASM-Chelex vs. ex vivo, ASM vs. ex vivo and 
ASM-Chelex vs. ASM revealed that the expression level of several iron-regulated genes in 
ASM-Chelex was closer to ex vivo conditions compared to ASM (Table 3). Especially the 
comparison of ASM-Chelex vs. ASM showed the significant upregulation of pyochelin 
biosynthesis genes in ASM-Chelex. However, many of observed other changes in expression 
were only minor. 
In general, iron limitation is increased in ASM-Chelex compared to ASM, although the degree of 
iron limitation is not as high as expected.  
Iron limitation might not be as strong as under ex vivo conditions since the response to iron 
limitation might be intensified in stationary phase, when the P. aeruginosa strains are 
completely depleted of iron. The P. aeruginosa strains grown in ASM and ASM-Chelex are 
probably “younger cultures” than the strains isolated from the ex vivo samples (see below). 
Moreover, host proteins chelating iron with very high affinity such as ferritin, lactoferrin, 
transferrin or heme are present under in vivo conditions increasing the iron limitation. 
Expression of non-iron regulated genes in P. aeruginosa in ASM-Chelex 
Unexpectedly, the expression of other non-iron regulated genes was more heterogeneously in 
ASM-Chelex vs. ex vivo. The expression of anthranilate metabolism genes was ex vivo-like in 
ASM-Chelex (Table 4). In contrast the PQS biosynthesis genes were detected upregulated in 
ASM vs. ex vivo and ASM-Chelex vs. ex vivo, probably due to excess of aromatic amino acids 
in ASM and ASM-Chelex and the probably high PQS concentrations in the CF sputum 
compared to ex vivo (Palmer et al., 2005). 
Moreover, an unexpected induction of phosphate starvation gene response was observed in 
ASM-Chelex vs. ex vivo (Table 5). The Chelex treatment did probably not only remove the iron 
ions but also decreased the amount of available phosphate. One can discuss if the metal ions in 
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ASM-Chelex, which are chelated by the Chelex resin, were acting in combination with Chelex 
probably as very efficient phosphate scavengers (Wu et al., 2007; Zhao and Sengupta, 1998). 
The gene expression in ASM and ASM-Chelex indicates that the P. aeruginosa strains were 
metabolically active. Especially, the induction of the t-RNAs genes and amino acid transporter 
genes confirmed this observation (Table 7).  
The growth conditions were aerobic to microaerobic in ASM and ASM-Chelex, which was also 
indicated by the expression of the different oxidases with different oxygen affinities. The cox 
operon coding for the aa3-type low-affinity oxidase is preferably expressed in the stationary 
phase in an aerobic environment (Alvarez-Ortega and Harwood, 2007; Schuster et al., 2004). 
The cbb3-type 2 oxidase operon, which is positively regulated by Anr and RoxSR and 
expressed at low oxygen levels (Alvarez-Ortega and Harwood, 2007; Kawakami et al., 2010), 
was upregulated in ASM-Chelex as well, indicating microaerobic conditions. 
Physiology of P. aeruginosa under ex vivo conditions 
Unexpectedly, the strains grown under ex vivo conditions were metabolically more inactive than 
strains grown in ASM or ASM-Chelex for 24 h. Strains under both, medium and ex vivo 
conditions, reached stationary phase. Under ex vivo condtions the P. aeruginosa strains CFCZ 
and CF1-4 must have been in a different maybe much later state of stationary phase compared 
to the same strains grown in ASM or ASM-Chelex.  
During ex vivo conditions P. aeruginosa strains were growing and surviving by denitrification 
(Table 6) under microaerobic to anaerobic conditions. This is in accordance with literature, 
which describes the microaerobic to anaerobic conditions for the CF lung and the possibility of 
denitrification (Moreau-Marquis et al., 2008; Worlitzsch et al., 2002; Zumft, 1997). The 
conditions in vivo might supplement more nitrate than ASM or ASM-Chelex, since physiological 
nitrate and nitrite concentrations in patient’s sputum vary from 73 #M to 792 #M (Grasemann et 
al., 1998; Hassett, 1996; Linnane et al., 1998; Palmer et al., 2007b). This might allow the very 
slow growth indicated by gene expression for the strains CFCZ and CF1-4. 
Although the P. aeruginosa strains are metabolically very inactive the gene aroP1 encoding for 
a transporter, was induced under ex vivo conditions and not in ASM and ASM-Chelex (Table 7). 
Not much is know about the AroP1 transporter. It is annotated to transport aromatic amino acids 
(Winsor et al., 2011). Therefore, it would be interesting to investigate, which substances are 
transported during ex vivo conditions.  
The induction of methionine and SAM metabolism under ex vivo conditions (Table 7) correlates 
with the observed late uptake of methionine during growth in AAM (Fig. 15). It would be 
interesting to investigate, why the greater amount of methionine uptake is only taking place 
during stationary phase. Hence methionine is needed for metabolism during all growth phases. 
Moreover, methionine auxotrophy is reported as the most common amino acid auxotrophy in 
P. aeruginosa CF isolates (Barth and Pitt, 1995; Barth and Pitt, 1996). The investigated strain 
CFCZ is a methionine auxotrophic strain (Chapter 3), whereas the strains CF1-4 are 
prototrophic strains. Therefore, especially the CFCZ strains might have been facing methionine 
limitation under ex vivo conditions. The methionine auxotrophic strains seem to possess a 
selection advantage of a yet unknown kind. By using these patient isolates` the study is 
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reflecting common CF phenotypes and is presenting their transcriptomic adaptations for the first 
time. 
As described above iron limitation is the major stress condition for P. aeruginosa in the CF lung 
infection. Therefore, Fur - the ferric uptake regulator - as major regulator of iron acquisition, 
uptake and storage induces a complex regulatory network to obtain iron during CF infection. 
The majority of iron seems to be bound to heme during ex vivo conditions, since the gene 
hasAp, which is encoding for the heme acquisition protein, was the gene with the highest 
induction under ex vivo conditions (Table 3). One can assume that the transcriptional answer to 
iron limitation reflects the more general answer of P. aeruginosa towards infection. 
Unexpectedly, the genes encoding for the flagella biosynthesis were found induced under ex 
vivo conditions (Table 8). This is in contrast to literature, which describes the loss of flagella 
during chronic CF infection (Amiel et al., 2010; Mahenthiralingam et al., 1994). Amiel et al. 
(2010) showed that the loss of flagella function and not the loss of the flagella apparatus itself is 
the critical factor associated with resistance to nonopsonic phagocytosis. Therefore, the flagella 
might still be present on the clinical isolates CFCZ and CF-1 – 4 but not necessarily functional. 
Moreover the P. aeruginosa strains seem to represent more a planktonic than a biofilm life-style 
under ex vivo conditions (Table 8). This is also a very interesting new observation in contrast to 
common literature (Costerton et al., 1999; Govan and Nelson, 1993; Lam et al., 1980)  
The genes encoding for the T3SS system were also detected upregulated under ex vivo 
conditions. This is also a new an unexpected finding. Vfr is described to regulate T3SS system 
expression, while downregulating flagella biosynthesis at the same time (Dasgupta et al., 2002; 
Wolfgang et al., 2003). On can assume that the regulation might be altered in the clinical 
P. aeruginosa strains CFCZ and CF-1- 4. 
Implications of metabolic inactivity during ex vivo conditions 
Due to the metabolic inactivity the P. aeruginosa strains might be protected from antibiotics. 
Active uptake of antibiotics is prevented by the reduced expression of transporters. Many life-
processes, which are targeted by antibiotics such as cell-wall biosynthesis, protein biosynthesis 
and DNA and RNA replication might not be taking place or only to a very limited degree. This is 
indicating why a P. aeruginosa infection is so difficult to treat once this state of metabolic 
inactivity is reached. Interestingly, the beta-lactamase precursor gene ampC, which was 
induced under ex vivo conditions, indicates that the patients have been treated with antibiotics 
prior to sampling or that the strains are constitutively expressing the ampC gene and are 
therefore resistant to !-lactam and cephalosporin antibiotics. 
It is not known if there are substances present in the sputum leading to the very inactivated 
metabolism. On the other hand nutrients limitation and reduced availability of external electron 
acceptors or sources for substrate-phosphorylation might also lead to the metabolic inactivity. 
Therefore, it would be interesting to analyse the sputum composition as well as to perform a 
transcriptional analysis in the future. Moreover, antimicrobial peptides and other 
microorganisms might be present in the sputum influencing the metabolic activity of the 
P. aeruginosa strains. 
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With ASM-Chelex a powerful medium to investigate P. aeruginosa under simulated respiratory 
tract conditions was obtained, which is even closer to in vivo conditions than ASM, although 
little modifications have to be implemented such as increased phosphate addition to overcome 
the phosphate limitation, induced by Chelex to get closer to ex vivo conditions. Moreover, the 
incubation times of the P. aeruginosa strains have to be optimized. 
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2.4 Material and Methods 
2.4.1 Bacterial strains and growth conditions 
All bacterial strains used in this study are shown in Table 10. P. aeruginosa strains were grown 
in artificial sputum medium (ASM) and amino acid medium (AAM) to simulate the conditions of 
the cystic fibrosis lung. 
Cultures were inoculated at OD578 of 0.05 and shaken at 200 rpm at 37°C, if not indicated 
otherwise. ASM (pH 6.9) consists of 86 mM NaCl, 29 mM KCl, 20 mM Hepes, 15 #M diethylene 
triamine pentaacetic acid (DTPA; Fluka), 39.7 mM amino acids [2.7 mM alanine, 1.6 mM 
glutamate, 1.8 mM isoleucine, 1.2 mM tryptophan, 1.8 mM leucine, 1.8 mM aspartate, 2.1 mM 
proline, 1.6 mM lysine, 2.3 mM serine, 1.6 mM methionine, 1.5 mM phenylalanine, 1.3 mM 
tyrosine, 2.6 mM valine, 2.5 mM threonine, 2.5 mM cysteine, 2.3 mM asparagine, 2.1 mM 
glutamine, 1.7 mM arginine, 3.3 mM glycine, 1.5 mM histidine (Sigma)], 4 g/l DNA, (Serva) 5 g/l 
mucin (Sigma) and 0.5 % sterile egg yolk (Fluka) (Sriramulu et al., 2005). The pH was adjusted 
with HCl and NaOH. DNA and amino acids were sterilised by filtration. Nitrate and nitrite 
concentrations of 260 #M and 130 #M were supplemented, respectively. For solid medium 15 
g/l agar were used.  
AAM (pH 6.9) contains 86 mM NaCl, 29 mM KCl, 20 mM Hepes, 15 #M DTPA, 1.75 mM CaCl2, 
0.61 mM MgCl2, 0.271 mM MgSO4 and 2.55 mM Na2HPO4/ NaH2PO4 (pH 6.9) and 39.7 mM 
amino acids (as described for ASM). The pH was adjusted with HCl and NaOH. 
For growth experiments in ASM an over night culture in LB medium was prepared. For modified 
iron-free ASM the medium was incubated for 24 h with 3 and 4 mg/ml conalbumin (Sigma) or 
0.5 and 1 mg/ml lactoferrin (Sigma), respectively. For ASM-Chelex the Chelex resin (Biorad) 
was autoclaved separately in MilliQ with 17 mM NaCl, 20 mM Hepes (pH 6.8). 500 #l Chelex 
solution (0.1 g/ml) was mixed with 500 #l double concentrated ASM. 
Cultures were grown in 1 ml medium in a 24 well plate (Thermo Fisher Scientific) and sealed 
with sealing film Breath-easy (Roth) for gas exchange and shaken at 300 rpm (Thermo Shaker 
PST-60 HL-4, Lab4You) at 37°C. Bacteria were harvested after 24 h.  
2.4.2 Determination of amino acid uptake from AAM 
P. aeruginosa PAO1 was grown in AAM for the determination of amino acid uptake. During 
growth OD578 was determined routinely. Amino acids were quantified by HPLC (Agilent), as 
described previously (Kromer et al., 2005). Culture supernatants were sterilised by filtration and 
diluted 1:10 on a microbalance (ALJ 160-4NM; Kern & Sohn) with an aqueous standard solution 
of $-aminobutyrate. After automated pre-column derivatization using O-phthaldialdehyde (OPA), 
detection was performed by fluorescence detection (340 nm excitation, 540 nm emission, 
Agilent). 
Separation of culture supernatants and cell extracts was carried out on a reversed-phase (RP) 
column (Gemini 5 # C18 110 Å, 150 * 4.6 mm, Phenomenex) equipped with a pre-column 
(Gemini C18, MAX-RP, 4 mm * 3 mm, Phenomenex) and a flow rate of 1 ml/min using 40 mM 
NaH2PO4 (eluent A, pH 7.8, adjusted with NaOH) as polar phase and a 
methanol/acetonitrile/water mixture (45:45:10, eluent B) and 40 °C.  
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2.4.3 RNA isolation and bacterial RNA enrichment  
For RNA isolation 1 ml of bacterial culture grown in ASM was incubated with RNAprotect® 
Bacteria Reagent (Qiagen) according to the manufacturer’s instructions. Samples were either 
processed directly or stored at - 80°C. RNA was isolated using RNeasy® Mini Kit (Qiagen). The 
RNA isolation was performed as described previously with minor modifications (Bielecki et al., 
2011). Bacteria were lysed using 400 #l TE buffer containing 1 mg/ml lysozyme with periodic 
vortexing every 2 min for 15 sec for 10 min. 700 #l RLT puffer containing 1% !-mercaptoethanol 
were added. Afterwards samples were centrifuged at maximal speed (14.100 x g) for 2 min. The 
same amount of ethanol was added to the samples. The samples were loaded to a spin column, 
washed with RW1 buffer afterwards DNA was digested using RNase-free DNase I. RNA was 
eluted in 50 #l and 30 #l of RNase-free water. Eluted RNA was treated a second time with 
DNase I to ensure that all traces of genomic DNA were removed. The isolated RNA was stored 
at – 80°C. The yield of the isolated RNA was measured by light absorption at 260 nm using a 
Nanodrop ND-1000-UV/VIS (Peqlab). Integrity and purity was checked by formaldehyde gel 
electrophoresis or by 2100 BioAnalyzer (Agilent Technologies). 
2.4.4 RNA enrichment and amplification of cDNA for microarrays 
Since the isolated RNA of the strains CFCZ and CF-1, CF-2, CF-3 and CF-4 should be 
compared to the ex vivo patient’s samples, which contained both bacterial and eukaryotic RNA, 
the samples were enriched for bacterial RNA with the MicrobEnrich Kit® (Ambion), as described 
previously (Bielecki et al., 2011). 
P. aeruginosa GeneChip from Affymetrix requires 7,5 - 10 #g of RNA per microarray. It is not 
often possible to obtain these amounts from ex vivo patient’s samples, therefore bacterial RNA 
amplification was used. This was performed using the MessageAmp Bacteria Kit® (Ambion). 
The first step was to treat the total enriched bacterial RNA with a polyadenylation polymerase to 
produce polyA tails. The single stranded cDNA was produced using reverse transcriptase and 
oligo dT primers. Afterwards a second strain cDNA was produced, and the double stranded 
cDNA served as a template for in vitro transcription using T7 RNA polymerase and T7 
oligonucleotides. During the in vitro transcription reaction the modified nucleotides biotin-11-
CTP (PerkinElmer Life Sciences) and biotin-16-UTP (Roche Applied Science) were used. As a 
result antisense biotinylated RNA ready to use for GeneChip® hybridization was obtained. 
2.4.5 Microarray hybridisation and data normalisation 
Amplified RNA is commonly used for eukaryotic microarrays, but the original procedure for 
P. aeruginosa Gene-Chip® (Affymetrix) was for single stranded terminally labelled cDNA. As 
described previously, no difference in results for microarray analysis were observed for the 
standard procedure (without amplification) RNA procession or amplified RNA (Francois et al., 
2007). The hybridization and washing steps were performed in the Affymetrix Array facility at 
Helmholtz Centre for Infection Research (HZI) Braunschweig (Dr. Robert Geffers). Since the 
RNA had been amplified, some changes were introduced to the original Affymetrix protocol, 
such as that the RNA was fragmented using 5 x fragmentation buffer instead of DNase I 
treatment. Hybridisation was performed as described previously (Bielecki et al., 2011). 
Furthermore data normalisation and calculation of differential expression was performed with 
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software from Bioconductor microarray analysis suite (Gentleman et al., 2004). Other aspects 
as quality analysis, the distribution, relative log expressions, normalised unscaled standard 
errors and expression values were computed, as described by Bielecki et al. (2011). 
2.4.6 cDNA amplification for quantitative real-time polymerase chain reaction  
Quantitative real-time PCR (qRT-PCR) was performed with SsoFast Evagreen Supermix (Bio-
Rad) according to manufacturer's instructions. The PCR reactions were recorded with CFX96 
Real-Time System (Bio-Rad). Cells were harvested and total RNA was prepared. cDNA was 
used as template for qRT-PCR and generated from 10-15 µg total RNA. 15 µg random primers 
and MilliQ water were added to the RNA to a final volume of 16 µl. Primer annealing was 
performed for 10 min at 70 °C. Afterwards 6 µl 5 x first strand buffer, 3 µl 100 mM DTT, 1 µl 
dNTPs (25 mM each) 20 U Superase*In were added and the reaction mixture was incubated for 
2 min at 25 °C. Subsequent cDNA synthesis was carried out by addition of 600 U SuperScript II 
and incubation for 2 h at 42 °C. To remove RNA templates after reverse transcription, 10 µl 1 M 
NaOH and 10 µl 0.5 M EDTA solution (pH 8.0) were added. After 15 min at 65 °C 25 µl 1 M 
HEPES (pH 7.5) and 50 µl 3 M sodium acetate (pH 5.2) were used to neutralize the samples. 
cDNA was purified with QIAquick PCR Purification Kit according to manufacturer's instructions. 
For qRT-PCR 1 ng and 10 ng of cDNA were used as a template. All reactions were performed 
in triplicate, and no template and no reverse transcription controls were carried out in parallel. 
Standard qRT-PCR programs were carried out with an initial denaturation step at 98°C for 3.5 
min, followed by 40 x repeated cycles of denaturation for 5 sec at 98°C, primer annealing for 15 
sec at 59°C and elongation for 15 sec at 60°C. A plate read followed each cycle. Melting curves 
were generated by a final denaturation step for 10 sec at 98°C and recorded within the range of 
65 - 98°C. Primer design was performed with Primer3Plus (Untergasser et al., 2007) according 
to the following criteria: 100 - 150 bp product length, 18 - 30 bp primer length, 45 – 65 % GC 
content, 63 - 67 °C primer melting temperature and 65 - 85 °C product melting temperature. 
Table 11 lists the primers used for detection of genes associated with iron starvation genes in 
PAO1. We monitored pvdA, pvdF, pvdS, fpvA, fptA and pchG and used acpP as reference 
gene. 
2.4.7 qRT-PCR data normalisation 
Relative quantification was used to determine the ratio between the quantity of the target genes 
pvdA, pvdF, pvdS, fpvA, fptA and pchG in ASM and in the three modified putative iron-free 
ASMs (ASM-Conalbumin, ASM-Lactoferrin and ASM-Chelex) and the reference gene acpP. 
Several mathematical models have been formulated for the calculation of the expression of 
target genes compared to reference genes. Calculations are based on the comparison of 
distinct threshold cycle values (Ct) at a particular fluorescence level. We used the ""Ct method 
(Livak and Schmittgen, 2001). Therefore the obtained relative gene expression data were 
normalised against the reference gene acpP. ASM was used as reference sample, further 
referred to as calibrator. 
First the "Ct values for the ASM-Conalbumin, ASM-Lactoferrin and ASM-Chelex (1) and the 
calibrator sample (2) were calculated, as follows: 
(1) "Ct treated = Ct target treated - CT reference treated   
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(2) "Ct calibrator = Ct target calibrator - CT reference calibrator 
Then the ""Ct value for each of the treated samples (3) was calculated.  
(3) ""Ct treated sample = "Ct treated sample - "Ct calibrator sample 
Afterwards the target gene expression in each of the treated samples was related to the 
calibrator sample. The change in gene expression is 2-""Ct, which is the relative quantity (RQ). 
Results are also be shown as fold difference Log2(RQ) = -""Ct. 
 
Table 10: Pseudomonas aeruginosa strains  
Bacterial strains  Genotype Reference 
PAO1 Wild type (Dunn and Holloway, 1971) 
CFCZ Clinical cystic fibrosis isolate from patient A, Medizinische 
Hochschule Hannover 
(Bielecki et al., 2013) 
CF-1 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
CF-2 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
CF-3 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
CF-4 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
 
Table 11: Primers used for detection of transcript levels of Pseudomonas aeruginosa PAO1 iron 
starvation genes pvdA, pvdF, pvdS, fpvA, fptA and pchG during qRT-PCR 
Gene Primer name Primer sequence (5’ - 3’) Product size 
pvdA 
(PA2386) 
oAW083 
oAW084 
GTCTTCTACCGCCAGAAAGTCTCC 
CGTCGTAGGTCTCTACGCTTAGCTC 
147 bp 
pvdF 
(PA2396) 
oAW087 
oAW088 
GGCCTATATCTGGTCCCTGAGAAAC 
AAGGACTCCAGTACCGACTTCATGT 
102 bp 
pvdS 
(PA2426) 
oAW095 
oAW096 
GATAACCGTACGATCCTGGTGAAGA 
AGGTAGCTGAGCTGTGCCTTGAAC 
143 bp 
fpvA 
(PA2398) 
oAW091 
oAW092 
GCTGGCTATACCCACAAGATCATTC 
GCCCTTGAACTTGTAGCTGGTGTAG 
105 bp 
fptA 
(PA4221) 
oAW097 
oAW098 
GTATGTCAGCTACGCCGAGGTCTAC 
CTTGATCCCGGTTTCGTAGGTCTT 
106 bp 
pchG 
(PA4227) 
oAW101 
oAW102 
CTCAACACCTTCTATCCGCAGTTG 
GATGTCCAGGGTGGCGAAAC 
135 bp 
acpP 
(PA2966) 
oAS175  
oAS176 
GAAGGAAGAAGAAGTCACCAACAGC 
TTCAGCTTTCTCGTCAGGGATTTC 
130 bp 
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3 Methionine auxotrophy - An adaptation strategy of 
Pseudomonas aeruginosa towards the cystic fibrosis lung  
3.1 Introduction 
Adaptive evolution due to genetic variation seems to be one of the key aspects of 
Pseudomonas aeruginosa survival in the challenging environment of the cystic fibrosis (CF) 
lung during chronic infection (D'Argenio et al., 2007; Mena et al., 2008; Smith et al., 2006).  
Host immune response and reoccurring antibiotic treatment create selective pressure. Oxygen 
limitation and the microaerobic to anaerobic conditions in the CF lung are also important factors 
shaping the P. aeruginosa phenotype (Alvarez-Ortega and Harwood, 2007; Worlitzsch et al., 
2002). This environment leads to the known phenotypes of mucoidy and the formation of 
microcolonies and biofilms (Boucher et al., 1997; Costerton et al., 1999; Govan and Deretic, 
1996; Lam et al., 1980). 
Clinically relevant phenotypic changes are detectable, as P. aeruginosa colonizes the nutrient 
rich mucus of the CF airways, such as colony variation (von Gotz et al., 2004), loss of motility 
(Amiel et al., 2010; Mahenthiralingam et al., 1994), modification of LPS (Hancock et al., 1983), 
loss of quorum sensing (D'Argenio et al., 2007; Smith et al., 2006), reduced virulence (Luzar 
and Montie, 1985) and increased antibiotic resistance (Ciofu et al., 2001; Wiegand et al., 2008). 
It was shown that the mutator phenotype is widely spread among P. aeruginosa CF isolates and 
very important for adaptation (Ciofu et al., 2005; Hogardt et al., 2006; Oliver et al., 2000). 
Previous studies investigated the influence of nutrient availability and its direct influence on 
bacterial metabolism, on growth and virulence factor production (Palmer et al., 2007a; Palmer et 
al., 2005; Son et al., 2007; Sriramulu et al., 2005). In addition, it was frequently observed that 
some P. aeruginosa strains isolated from the CF lung were unable to synthesise particular 
growth factors (Taylor et al., 1992). Strains were auxotrophic for certain nutrients. The most 
common source of auxotrophy was amino acids in P. aeruginosa. Most frequently methionine 
auxotrophic P. aeruginosa strains were isolated (Barth and Pitt, 1995; Barth and Pitt, 1996; 
Barth et al., 1998; Thomas et al., 2000). The question remains, which pathways are blocked in 
in the methionine auxotrophic P. aeruginosa strains.  
Methionine and S-adenosylmethionine (SAM) metabolism are linked to one another (Fig. 25). 
Methionine and ATP are converted by S-adenosylmethionine synthetase MetK into SAM. SAM 
is the second most frequently used enzyme substrate after ATP (Fontecave et al., 2004; 
Loenen, 2006). The majority of estimated 95 % of SAM is used for methylation reactions 
(Griffith, 1987). Methylation is one of the most ubiquitous chemical reactions in cellular 
metabolism (Stepkowski et al., 2005). S-Adenosylhomocysteine (SAH) is the product of these 
reactions and a potent inhibitor of transmethylation reactions and therefore efficiently converted 
to homocysteine (Hcy) and adenosine (Ado) by S-adenosylhomocysteine hydrolase SahH. The 
methylation of macromolecules and small molecules is dependent on the intracellular SAM / 
SAH equilibrium. Recently, the intracellular SAM and SAH level for the Escherichia coli wild 
type strain MG1665 (OD600 of 1.62 ± 0.16) was determined with a ratio of 300:1 with 0.4 mM 
and 1.3 #M, respectively (Halliday et al., 2010). Hcy can also be generated by MetZ from O-
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succinyl-homoserine. The last step of methionine biosynthesis is the conversion of Hcy via 
either MetE or MetH to methionine. MetH is a cobalamine dependent and MetE a cobalamine 
independent methionine synthase. Both enzymes use the cofactor N5-methyl-tetrahydrofolate 
(Me-THF) and N5-methyl-tetrahydropteroyltriglutamate (Me-THP) as methyl-group donor, 
respectively. Methionine can be directly incorporated into biosynthesis or it can be converted to 
SAM as described. 
Approximately 2-5% of cellular SAM is used for decarboxylation reactions e.g. for the production 
of polyamines or quorum sensing molecules synthesis such as N-acylhomoserine lactones 
(AHLs) or as source of 5´deoxyadenosyl radicals, which are used for the production of vitamins 
e.g. biotin and lipoate etc. (Griffith, 1987; Parveen and Cornell, 2011). These reactions yield 5´-
methylthioadenosine (MTA) or 5´deoxyadenosine (5´dAdo), respectively. 
Guan et al. (2011) propose that MTA is converted into 5´-methylthioinosine (MTI), which is 
further metabolised into hypoxanthine and 5´-methylthioribose-1-phosphate (MTR-1-P). MTR-1-
P is further recycled into methionine by the gene products of mtnA, mtnB, mtnC, mtnD and tyrB 
(Heurlier et al., 2006). 
Interestingly, AHL biosynthesis is connected to the methionine and SAM metabolism. AHLs are 
synthesized of SAM and an intermediate of fatty acid biosynthesis by the AHL synthases of the 
LuxI family (Heurlier et al., 2006). N-butyryl homoserine lactone (BHL) is synthesized by RhlI 
and N-3-oxododecanoyl homoserine lactone (odDHL) by LasI. BHL can diffuse freely (Wagner 
et al., 2003; Williams and Camara, 2009). odDHL can diffuse but its transport is increased by 
mexAB-oprM and other efflux pumps. 
Interestingly, several genes of methionine and SAM metabolism are described to be under 
positive quorum sensing control such as the genes encoding for the cleavage system 
gcvT2H2P2, glyA1 hydroxy-methyltransferase, pvdQ and metE (Schuster et al., 2003; Wagner 
et al., 2003).  
This study aimed at the identification of the genetic cause of methionine auxotrophy. To address 
this question 30 methionine auxotrophic P. aeruginosa CF stains from 15 different patients were 
isolated. Interestingly, a gene of the cofactor biosynthesis was identified as cause of methionine 
auxotrophy in the majority of strains. Unexpectedly, all methionine auxotrophic strains did not 
produce pyocyanin. To understand the underlying adaptation strategies several methionine 
metabolism gene deletion mutants in PAO1 were constructed. In accordance numerous PAO1 
methionine metabolism gene deletion mutants showed reduced to abolished pyocyanin 
production. Methionine auxotrophy was identified as a new factor influencing pyocyanin 
biosynthesis in this study. 
Moreover, the methionine auxotrophic strains and PAO1 methionine metabolism deletion 
mutants were phenotypically characterised. Another important factor during infection is the 
availability of iron. Iron was identified as influencing factor in the P. aeruginosa PAO1 cofactor 
biosynthesis deletion strain.  
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Fig. 17: Methionine metabolism and SAM recycling in Pseudomonas aeruginosa 
Methionine and ATP are converted by S-adenosylmethionine synthetase MetK into SAM, 
phosphate and diphosphate. SAM is used for various metabolic reactions in the cell. If SAM is used 
for methylation the remaining SAH is hydrolysed by SahH into Ado and Hcy. Hcy can be generated 
out of O-succinyl-homoserine by MetZ. Hcy can be converted by either cobalamin-independent 
methionine synthase MetE or cobalamin-dependent methionine synthase MetH back into 
methionine. Both enzymes use the cofactor N5-methyl-tetrahydrofolate (Me-THF) and N5-methyl-
tetrahydropteroyltriglutamate (Me-THP) as methyl-group donor, respectively (only THF is shown). 
MetF converts N5,N10-methylene-tetrahydrofolate to Me-THF or N5,N10-methylene-
tetrahydropteroyltriglutamate to Me-THP. GlyA1 and GlyA2 are serine hydroxymethyl transferases, 
which convert serine into glycine and thereby produce N5,N10-methylene-tetrahydrofolate from THF. 
The GcvT2H2P2 glycine cleavage system produces also N5,N10-methylene-tetrahydrofolate from 
THF and glycine. 
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If SAM is used for other reactions e.g. by AHL synthase or as source of an amino propyl group for 
the generation of spermidine these reactions yield MTA. MTA is recycled by 5´-
methylthioadenosine phosphorylase MtnP and by several other enzymes to methionine. N-butyryl 
homoserine lactone (BHL) is synthesized by RhlI and N-3-oxododecanoyl homoserine lactone 
(odDHL) by LasI. Several genes encoding for methionine metabolism enzymes are positively 
regulated by quorum sensing (indicated by orange plus). Adapted from (Fontecave et al., 2004; 
Heurlier et al., 2006; Parveen and Cornell, 2011; Sekowska et al., 2004)  
____________________________________________________________________________ 
3.2 Results & Discussion  
3.2.1 Isolation of methionine auxotrophic clinical Pseudomonas aeruginosa cystic 
fibrosis isolates  
During routine examinations samples were taken to investigate the frequency of methionine 
auxotrophic P. aeruginosa CF isolates in the respiratory tract of CF patients’ (Fig. 18 A). 
Complex media was used for the selection of P. aeruginosa strains. The isolated P. aeruginosa 
strains were further analysed for growth on minimal media. Strains, which did not grow on 
minimal media were tested for growth on minimal media supplemented with methionine. 
Methionine auxotrophic strains, which did not grow on minimal media, but grew on minimal 
media containing methionine were further analysed. Prototrophic strains, which grew on minimal 
media itself, were not further analysed. 
 
Fig. 18: Isolation of methionine auxotrophic clinical Pseudomonas aeruginosa cystic fibrosis 
isolates and identification of the mutation causing methionine auxotrophy  
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From patient 1-12 and patient A-D in total 35 clinical P. aeruginosa CF strains were isolated, of 
which 30 were identified as methionine auxotrophic. 14 strains were successfully complemented by 
pUCP20T::metF. 
(A.) The strains were isolated from CF patients’ during routine examinations (1). Isolated strains 
were selected on complex medium (M1) and were analysed for growth on minimal medium 
(M2) and minimal medium containing methionine (M3) (2). Strains, which grew on minimal 
medium containing methionine (M3) and did not grow on minimal medium (M2), were selected 
for identification of the cause of methionine auxotrophy (orange arrow) (3). Prototrophic strains, 
which grew on both minimal medium were not further analysed (grey arrow). 
(B.) The methionine auxotrophic strains appeared morphologically very diverse (1). To identify the 
mutation causing methionine auxotrophy a diparental mating with E. coli ST18 carrying the 
pST10 (pUCP20T::metF) was performed (2). Successfully by pST10 plasmid complemented 
methionine auxotrophic P. aeruginosa strains (red and purple) were selected (3) and verified 
by growth on minimal medium containing carbenicillin (M2) (4). Successfully complemented 
strains (red) were able to grow on minimal medium (M2) (5). Strains (purple), which were not 
successfully complemented by pST10 failed to grow on minimal medium (M2) (4). These non-
complemented strains containing the pST10 plasmid were complemented by diparental mating 
with a cosmid library (6). Successful complementation was verified by growth of the respective 
strains on the minimal medium (M2) containing carbenicillin and tetracycline (orange arrows) 
(7). 
 
Depiction of human airway model (A) was modified (Folkesson et al., 2012; Kleinstreuer et al., 
2008). 
____________________________________________________________________________ 
35 clinical P. aeruginosa strains were isolated in total, of which 30 were identified as methionine 
auxotrophic. The strains CF-1 to CF-4 (patient B) and KI-AW 13 (patient 6) were not methionine 
auxotrophic. 
3.2.2 Single-nucleotide polymorphisms analysis of clinical Pseudomonas aeruginosa 
cystic fibrosis isolates 
The clinical CF strains were tested for clonal variability using binary arrays based on single-
nucleotide polymorphism (SNP) genotypes, as described previously (Wiehlmann et al., 2007). 
The clinical isolates KI-AW 1 to KI-AW 28, CFCZ, CF-1 to CF-4, 65 and BT72 were grouped 
according to the patients they were isolated from (Table 12). Moreover, clone and clone type 
were determined, if possible with SNP analysis.  
13 different clone types were isolated from 15 different patients. Patient B with the strains CF-1 
to 4 and KI-AW 13 of patient 6 were not methionine auxotrophic and were therefore not further 
analysed. From the remaining 14 patients the clones A, B, E, I, M and P were isolated (Fig. 19 
A. & B.). From nine patients (patient 1, 5, 7, 9, 10, 11, 12, A, C) only one P. aeruginosa strain 
was isolated. In contrast, seven methionine auxotrophic P. aeruginosa strains were obtained 
from patient 3.  
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Table 12: Single-nucleotide polymorphism analysis of clinical P. aeruginosa cystic fibrosis isolates 
Patient Colonizing strains CloneA Clone typeA 
Patient 1 KI-AW 1 P 2C2A 
Patient 2 KI-AW 2, KI-AW 3 B E429 
Patient 3 KI-AW 4, KI-AW 5, KI-AW 6, KI-AW 7, KI-AW 8,  
KI-AW 9, KI-AW 21 
P 6C2A 
Patient 4 KI-AW 10, KI-AW 11 I F429 
Patient 5 KI-AW 12 I F429 
Patient 6 KI-AW 13°, KI-AW 14, KI-AW 15, KI-AW 26, KI-AW 27 E 1BAE 
Patient 7 KI-AW 16  3BAA 
Patient 8 KI-AW 17, KI-AW 18, KI-AW 19, KI-AW 23, KI-AW 24  441A 
Patient 9 KI-AW 20 M 6E12 
Patient 10 KI-AW 22  2D92 
Patient 11 KI-AW 25  6862 
Patient 12 KI-AW 28  2F82 
Patient A CFCZ  E59A 
Patient B CF-1°, CF-2°, CF-3°, CF-4° P 6C2A 
Patient C 65 A D421 
Patient D BT72 ND ND 
A Clone and clone type according to single-nucleotide polymorphism (SNP) of seven conserved loci 
and two multiallelic loci (Wiehlmann et al., 2007) 
°These strains are not methionine auxotrophic. 
 
Fig. 19: Distribution of clone and clone type of methionine auxotrophic P. aeruginosa cystic 
fibrosis isolates 
30 methionine auxotrophic strains of 14 different patients were characterised by SNP analysis. Six 
different clones (A) and 13 different clone types (A,B,C) were obtained from patient 1-12, patient A 
and patient C. From each patient one up to a maximum of seven methionine auxotrophic strains 
were isolated. Each patient was only colonized by one methionine auxotrophic clone type. The 
different clones with clone type are shown (A). The distribution of clone types of clone P is indicated 
(B). Ten strains did not correspond to any previously described clones (reference clone) and were 
therefore only characterised by clone type (C). The strains CF-1, CF-2, CF-3 and CF-4 of patient B 
and KI-AW 13 of patient 6 are not depicted here, since the strains are not methionine auxotrophic. 
___________________________________________________________________________ 
A. 
B. 
C. A. 
B. 
C. 
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Only one clone and/or clone type was isolated for each patient, respectively. The characterised 
strains of each patient showed the same SNP pattern in the array. However, the colonies 
appeared morphologically very different (Fig. 18 B). Notably, KI-AW 13 is a prototrophic strain, 
whereas the other colonizing strains of patient 6 are methionine auxotrophic. But all strains of 
patient 6 are classified as clone E and clone type 1BAE. Characterisation of the isolates 
revealed that ten strains did not correspond to any previously described clones (reference 
clone) (Wiehlmann et al., 2007). Therefore only the clone type could be determined (Fig. 19 C.). 
The clone types 441A, 3BAA and 2D92 were not described by their previous study. Moreover, 
the clone type of 2C2A of clone P was also not represented in their previous study. The most 
frequent strain in this study belonged to clone P with 8 isolates (Fig. 19 B.). The majority of 
clone P strains of in total 7 strains belonged to the clone type 6C2A. 6C2A was isolated form CF 
patients in various places in Germany during the last 17 years (Wiehlmann et al., 2007). 
 
Fig. 20: Clonal complex structures of 240 P. aeruginosa strains (adapted from Wiehlmann et al. 
(2007)) 
240 P. aeruginosa strains were collected from various habitats and geographical sources by 
Wiehlmann et al. (2007). The clones high lighted in orange were identified in our study of 30 
methionine auxotrophic clinical P. aeruginosa CF isolates from CF centres in Germany (Hannover, 
Munich and Tübingen). 
Clones shaded in grey contain oriC allele 1 and clones encircled by dots are exoU-positive 
(Wiehlmann et al., 2007).  
____________________________________________________________________________ 
Most isolates in this study were already present in the MHH strain library. Exceptions are 
mentioned above. The majority of the MHH strain library was isolated from clinical sources or 
directly from CF patients in the US and European countries (Wiehlmann et al., 2007). Clone A, 
which represents the PA14 group was the most prevalent strain in the study by Wiehlmann et 
al. (2007) and also the clone M was very frequent. This study also detected one strain of each 
clone. 
Despite the small sample size of 30 methionine auxotrophic CF isolates and very limited 
geographical sampling this study is in accordance with previous studies (Fig. 20), which 
reported that the major clones were detectable in representative samples from both clinical and 
environmental habitats (Pirnay et al., 2002; Pirnay et al., 2005; Wiehlmann et al., 2007). 
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3.2.3  Phenotypic characterisation of methionine auxotrophic clinical Pseudomonas 
aeruginosa cystic fibrosis isolates 
The mutator frequency among the methionine auxotrophic clinical P. aeruginosa CF isolates 
was investigated. Rifampicin resistance was used as indicator for the mutator phenotype and 
was determined as colony forming units (CFU) of rifampicin 100 #g/ml (RA-100) resistant 
bacteria versus total CFU after growth for 24 h. Mutation frequency of clinical P. aeruginosa CF 
isolates showed a strong variation in previous studies (Ciofu et al., 2010; Hall and Henderson-
Begg, 2006; Hogardt et al., 2007; Mena et al., 2008; Oliver et al., 2000). Therefore, the terms 
defined by Ciofu et al. (2010) were modified in accordance with the results for PAO1 and PAO1 
"mutS strain. All strains with a mutation frequency ' 1.5 x 10-7 were classified as strong 
mutators. Strains with lower mutation frequency of < 1.5 x 10-7 to ' 1.5 x 10-8 were described as 
weak mutators. A mutation frequency of < 1.5 x 10-8 similar to the P. aeruginosa PAO1 was 
considered as non-mutator. 57 % of the investigated methionine auxotrophic clinical isolates 
were characterised as strong mutators. 11 % were classified as weak mutators and 32 % as 
non-mutators (Table 14). P. aeruginosa PAO1 "mutS (Hogardt et al., 2006) was used as a 
strong mutator phenotype reference strain with a mutation frequency of 5 x 10-6 in this study . 
The methionine auxotrophic deletion mutant PAO1 "metF was used as a reference strain for 
the methionine auxotrophic clinical isolates. The gene metF was identified as genetic origin of 
methionine auxotrophy for the majority of isolates (see 3.2.4). 
The production of the P. aeruginosa quorum sensing molecules the AHLs was investigated. 
Only 18 % of the investigated methionine auxotrophic clinical isolates produced an average 
BHL concentration of > 20 ± 8 #M/OD578 (Table 13). PAO1 produced 48.3 ±16.4 #M/OD578 BHL 
(Table 14).  
Table 13: Summary of positive phenotypic characteristics according to phenotype 
Phenotype BHL 
positive* 
odDHL  
positive* 
Swimming 
positive* 
Swarming 
positive* 
Twitching 
positive* 
Mutator phenotype  
(16/28) 
19 % 13 % 13 % 25 % 6 % 
Weak mutator phenotype 
(3/28) 
0 % 33 % 33 % 33 % 33 % 
Non-mutator phenotype 
(9/28) 
22 % 11 % 55 % 33 % 11 % 
Total positive strains 
(phenotype independent) 
18 % 14 % 29 % 25 % 11 % 
* Positive phenotypic characteristics according to definitions in Table 14. 
 
In addition 14 % of the investigated methionine auxotrophic clinical isolates produced an 
average odDHL concentration of > 10 ± 3 nM/OD578. In contrast, the detected average odDHL 
concentration for PAO1 was 147.3 ± 3.9 nM/OD578. For PAO1 "metF an average odDHL 
concentration of 188.9 ± 26.9 nM/OD578 was determined. For 86 % of the investigated 
methionine auxotrophic clinical isolates nearly any odDHL was detectable (Table 13).  
KI-AW 1 (weak mutator) and KI-AW 20 (non-mutator) were the only strains, for which both BHL 
and odDHL were detected (Table 13).  
The motility among the methionine auxotrophic clinical CF strains was investigated. 29 % 
showed swimming motility comparable to the PAO1. 25 % of the methionine auxotrophic clinical 
isolates were able to swarm like the PAO1. 11 % of the methionine auxotrophic clinical isolates 
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were able to twitch like the PAO1. P. aeruginosa PAO1 and PAO1 "metF showed comparable 
motility. KI-AW 22 was the only methionine auxotrophic clinical CF strain, which was positive for 
swimming, swarming and twitching.  
The majority of the methionine auxotrophic clinical CF strains possessed a weak mutator (11%) 
to mutator phenotype (57%). No correlation between mutator phenotype and the frequency of 
reduced production of BHL and odDHL was observed (Table 13). Interestingly, the average 
BHL concentration was 2- to 3-fold decreased in the majority of the methionine auxotrophic 
clinical isolates compared to PAO1 wt. In contrast, the average odDHL concentration was 30- to 
50-fold decreased in the majority of the methionine auxotrophic clinical isolates compared to 
PAO1. 
This is in accordance with other studies, which described the loss of a functional quorum 
sensing system, especially of the LasI / LasR system (D'Argenio et al., 2007; Diggle et al., 
2007a; Heurlier et al., 2006; Smith et al., 2006; Tingpej et al., 2007).  
Ciofu et al. (2010) performed a genetic analysis of late phase chronic CF infection isolates and 
proposed that the mutator phenotype is independent of the selection of lasR mutants, since the 
lasR mutants possess a growth advantage due to better nutrient utilization (D'Argenio et al., 
2007; Sandoz et al., 2007; Wilder et al., 2011).  
We also observed the by Ciofu et al. (2010) proposed mutator phenotype independent selection 
of mucoid phenotype. The exopolysaccharide probably protects the mucoid strains from 
reactive oxygen species, the host´s immune response and antibiotics (Govan and Nelson, 
1993). 
The loss of swimming motility was more frequently observed in mutators and weak mutators 
than among non-mutators (Table 13). For twitching and swarming motility no such effect was 
observed. In previous studies the abolishment of swimming motility was described to confer 
resistance to phagocytosis in vitro and in vivo (Amiel et al., 2010; Balloy et al., 2007). Amiel et 
al. (2010) showed that the loss of flagella function and not the loss of the flagella apparatus 
itself was the critical factor associated with resistance to nonopsonic phagocytosis. Thereby, 
explaining the observed advantage of motility loss associated with higher bacterial burden in the 
lung.  
The strong mutator phenotype and weak mutator phenotype were more frequently detected 
among the methionine auxotrophic clinical CF isolates than the non-mutator phenotype. The 
metF mutation, which was identified as origin of methionine auxotrophy for the majority of 
strains, itself does not seem to enhance the mutator frequency since PAO1 "metF does not 
show an increased mutator frequency compared to PAO1. Therefore, it is proposed that the 
methionine auxotrophy is also selected independently of the mutator phenotype. 
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Table 14: Summary of phenotypic characterisation of methionine auxotrophic clinical 
P. aeruginosa CF isolates sorted according to patient and mutator phenotype 
Patient Colonizing 
strain 
CloneA Clone 
typeA 
Mutator 
pheno-
typeB* 
BHLC* 
[#M / 
OD578] 
odDHLD* 
[nM / 
OD578] 
Swimming
E* [mm] 
Swarming 
F* [mm] 
Twitching 
G* [mm] 
Patient 1 KI-AW 1 P 2C2A 1.09E-07 28.9 26.0 5.3 6.0 3.0 
Patient 4 KI-AW 10 I F429 4.64E-07 18.3 77.9 14.7 4.5 2.2 
Patient 7 KI-AW 16  3BAA 7.15E-07 15.3 1.7 3.3 1.8 8.7 
Patient 8 KI-AW 23  441A 7.23E-07 23.2 2.2 4.7 5.3 5.3 
Patient 9 KI-AW 20 M 6E12 2.80E-08 38.2 70.8 2.2 3.0 3.3 
Patient 10 KI-AW 22  2D92 4.33E-08 18.0 3.2 21.0 10.7 8.3 
Patient 11 KI-AW 25  6862 2.36E-08 48.3 3.2 1.7 2.3 3.3 
Patient A CFCZ  E59A 3.16E-08 21.2 2.2 5.0 2.7 3.0 
Patient 3 
 
KI-AW 4 P 6C2A 8.76E-08 13.1 0.9 7.0 5.3 3.0 
KI-AW 5 P 6C2A 2.97E-08 13.1 4.5 13.7 6.0 3.2 
KI-AW 6 P 6C2A 8.20E-06 20.9 46.6 3.0 1.8 3.2 
KI-AW 7 P 6C2A 1.54E-08 27.9 6.0 12.0 3.3 2.8 
KI-AW 8 P 6C2A 1.67E-08 26.2 0.3 13.7 7.3 3.3 
KI-AW 9 P 6C2A 1.45E-07 7.1 1.1 11.0 8.3 3.3 
 KI-AW 21 P 6C2A 2.33E-08 28.0 7.2 12.7 5.3 3.7 
Patient 2 
 
KI-AW 2 B E429 1.31E-06 5.7 3.3 4.3 1.5 8.3 
KI-AW 3 B E429 1.57E-06 16.7 4.4 3.7 0.5 6.7 
Patient 4 KI-AW 11 I F429 2.77E-06 32.3 7.0 13.0 8.3 1.7 
Patient 5 KI-AW 12 I F429 1.92E-06 11.2 1.9 1.5 3.3 3.8 
Patient 6 KI-AW 14 E 1BAE 2.67E-06 6.8 3.7 3.7 6.3 5.7 
 KI-AW 15 E 1BAE 8.08E-06 10.3 2.4 3.3 8.0 4.7 
 KI-AW 26 E 1BAE 5.09E-06 18.0 2.3 2.3 4.3 5.3 
 KI-AW 27 E 1BAE 1.52E-06 12.9 2.4 4.0 5.0 4.7 
Patient 8 
 
KI-AW 17  441A 1.67E-05 6.4 2.5 3.7 5.3 5.7 
KI-AW 18  441A 3.71E-06 18.4 1.9 4.0 4.0 4.3 
KI-AW 19  441A 1.83E-05 11.6 0.3 2.7 1.8 4.3 
 KI-AW 24  441A 1.77E-06 20.0 2.1 1.7 3.3 4.3 
Patient 12 KI-AW 28  2F82 2.61E-06 32.9 2.2 1.8 2.3 3.7 
Patient C 65 A D421 ND ND ND ND ND ND 
Patient D BT72 ND ND ND ND ND ND ND ND 
PAO1 +mutS ND ND 4.94E-06 ND ND ND ND ND 
PAO1 +metF ND ND 7.16E-08 45.1 188.9 24.7 19.7 6.3 
PAO1 ND ND 1.54E-08 48.3 147.3 25.3 19.7 8.0 
A Clone and clone type according to single-nucleotide polymorphisms (SNPs) at seven conserved 
loci and two multiallelic loci (Wiehlmann et al., 2007) 
B Mutator phenotype was determined as CFU of rifampicin 100 #g/ml (RA-100) resistant bacteria 
vs. CFU. Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (bold 
black). Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak 
mutators (bold grey). Strains with mutator frequency of < 1.5 x 10-8 (plain black) were classified as 
non-mutator. Experiments were performed by Matthias Rottmann (this laboratory, unpublished 
work).  
C BHL as #M / OD578 was determined. Results above the average BHL concentration of > 20 ± 8 
#M / OD578 are marked in bold letters. 
D odDHL as nM / OD578 was determined. Results above the average odDHL concentration of > 10 ± 
3 nM / OD578 are marked in bold letters. 
E Swimming as the radius [mm] of the respective swimming halo was determined. Results above 
the average radius of > 6.5 ± 1 mm are marked in bold letters.  
F Swarming as the radius [mm] of the respective swarming halo was determined. Results above the 
average radius of > 4.5 ± 1 mm are marked in bold letters. 
G Twitching as the radius [mm] of the respective twitching halo was determined. Results above the 
average radius of > 4.5 ± 1 mm are marked in bold letters. 
* Results of at least three independent experiments are shown. For the standard deviation of the 
mean see Appendix Table 31. 
ND, not determined 
____________________________________________________________________________ 
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3.2.4 Identification of the mutation causing methionine auxotrophy  
In order to identify the mutation causing the methionine auxotrophy, clinical P. aeruginosa CF 
isolates were investigated on minimal media. Auxotrophic strains, which did not grow on M9 
20 mM succinate minimal medium (M2), but grew with supplementation of 50 #M methionine 
(M3) were further analysed (Fig. 18 A). 
Strains were also analysed for growth on L-serine, L-homoserine, O-succinyl-L-homoserine, L-
cysteine or Hcy supplemented M9 minimal medium, respectively. P. aeruginosa PAO1 was able 
to take up the respective compounds. But none of the investigated methionine biosynthesis 
precursors was able to support growth on M9 minimal medium. All strains required methionine 
exclusively for growth. Therefore, the methionine auxotrophy causing defect seemed to be 
located at the end of the methionine biosynthesis pathway (Fig. 17). Since none of the early 
precursors was able to complement the methionine auxotrophic strains. 
The final step of methionine biosynthesis is the conversion of Hcy via either metE or metH gene 
product to methionine. Both enzymes use the cofactor Me-THF and Me-THP as methyl-group 
donor, respectively.  
The mutated gene causing methionine auxotrophy in the strains 65 and BT72 was identified by 
complementation with a P. aeruginosa PAO1 cosmid library (Schobert and Görisch, 1999). A 
16.3 kb fragment (genomic position 474648 – 490920) was isolated and sequenced (Thoma, 
2009; unpublished). The identified genomic region contained the metF (PA0430) gene. PA0430 
encodes for a 5,10-methylene tetrahydrofolate reductase (MTHFR). Deletion of metF was 
already described to result in methionine auxotrophy for E. coli (Ahmed, 1973). Barth & Pitt 
(1995) also investigated the high frequency of methionine auxotrophy in strains isolated from 
the sputum of CF patients. They assumed that the common defect is probably in the conversion 
of Hcy to Met, but they did not prove it (Barth et al., 1998). 
The mutation causing methionine auxotrophy was assumed to be located in the cofactor 
biosynthesis, most likely in the metF gene. MetF converts N5,N10-methylene-tetrahydrofolate to 
Me-THF or N5,N10-methylene-tetrahydropteroyltriglutamate to Me-THP. Both Me-THF and Me-
THP are used as cofactors for methionine biosynthesis. To investigate if metF can complement 
methionine auxotrophy in strain 65 and BT72, the plasmid pST10 (pUCP20T::metF) was 
constructed. The complementation of strain 65 and BT72 was verified by growth on M9 minimal 
medium containing carbenicillin. In addition all methionine auxotrophic strains were 
complemented with pST10. 14 strains were complemented by metF gene (pST10), 2 strains 
were not complemented by pST10 but were complemented by a plasmid containing the genes 
metF and metH (pFH04) and 14 strains were not complemented (Table 15). 
The nucleotide sequence and length of the metF gene of all methionine auxotrophic isolates 
was determined and analysed for deviations. The nucleotide sequence length of the wt metF 
gene is 873 bp. The average nucleotide sequence length of the metF gene was 868 ± 17 bp in 
the 30 investigated methionine auxotrophic strains. 
The majority of isolates had one up to six mutations in the nucleotide sequence of the metF 
gene. For patient 3 several isolates with the varying frequency of five (KI-AW 5, KI-AW 9, KI-AW 
21), six (KI-AW 6, KI-AW 7, KI-AW 8) and twelve (KI-AW 4) mutations in the metF gene were 
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obtained. The frequency of mutator phenotype among the clinical isolates was determined. But 
no correlation between frequency of mutations and mutator phenotype was observed (Table 15 
& Table 16). Interestingly, KI-AW 4 (twelve mutations in the metF gene) was not identified as 
mutator, but KI-AW 6 and KI-AW 9 were identified as strong mutators.  
The average nucleotide mutation frequency in the metF gene was 3.7 ±2.4 in the 30 
investigated methionine auxotrophic strains. Besides the detection of the deviation in nucleotide 
sequence, the deviations were further classified either as point mutation, as deletion or as 
insertion. The average frequency of point mutations in the metF gene was 3.1 ±2.5. So the 
majority of deviations were point mutations. Eight deletions and seven insertions were detected 
in total. KI-AW 17 metF harbours both an insertion and a deletion. All other strains encountered 
either deletion or insertion in the metF gene, besides point mutations. KI-AW 18, KI-AW 22, KI-
AW 23, and KI-AW 24 had only a deletion as mutation. In general the mutations on nucleotide 
level in the metF gene were very diverse and no mutational hotspot was identified. For a 
detailed analysis see Appendix Table 32. 
The outcome of the nucleotide mutations on the amino acid level was analysed (Table 16). 
Deviations were classified either as amino acid exchange, as frame shift or as stop codon. The 
amino acid sequence length of the P. aeruginosa PAO1 wt MetF protein is 290 aa. A drastic 
influence of the mutations on the probable average MetF protein length was observed, which 
was reduced to 147 ± 82 bp in the 30 investigated methionine auxotrophic strains. Most 
investigated MetF proteins were probably truncated by the stop codon, resulting in shortened 
proteins.  
The shortest protein length identified was 29 aa of strain KI-AW 3, followed by 40 aa for KI-AW 
4. The longest truncated protein had an amino acid length of 284 aa determined for KI AW-16, 
but with 2 amino acid exchanges. This was followed by 178 aa for KI-AW 1. KI-AW 1 was 
complemented by pST10. 
This effect is also reflected by the average total amino acid deviation frequency. Included was 
the amino acid exchange, frame shift and stop codon insertion in the respective MetF protein. 
The average total amino acid deviation frequency was 1.9 ±0.9 incidents per MetF protein in 
the 30 investigated methionine auxotrophic strains.  
Moreover, the strains KI-AW 16 and KI-AW 28 had two and KI-AW 19 had even three amino 
acid exchanged. 11 of 30 methionine auxotrophic strains had one amino acid exchanged. 
Frame shift occurred in 16 strains, and was always counted as one event. Due to changed 
nucleotide sequence, insertions and deletions stop codons were observed in 24 of 30 
investigated cases. CFCZ of patient A was the only strain with silent mutations in the nucleotide 
sequence without any resulting amino acid deviations.  
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Table 15: Summary of sequence analysis of mutations in the metF gene (PA0340) on nucleotide 
level of clinical methionine auxotrophic P. aeruginosa CF isolates 
Patient Colonizing 
strain 
Mutator 
pheno-
typeA 
Length of 
nucleotide 
seq. [bp] 
Mutations 
totalB 
Point 
mutationsC 
DeletionC Insertions
C 
Compl. 
by 
pST10/
pFH04D 
Patient 1 KI-AW 1 ++ 873 4 4 0 0 + 
Patient 2 KI-AW 2 ++ 874 5 4 0 1  
 KI-AW 3 ++ 788 6 5 0 1  
Patient 3 KI-AW 4 - 894 12 11 0 1  
 KI-AW 5 - 860 5 5 0 0  
 KI-AW 6 ++ 860 6 6 0 0  
 KI-AW 7 - 860 6 6 0 0 + 
 KI-AW 8 - 860 6 6 0 0  
 KI-AW 9 ++ 860 5 5 0 0  
 KI-AW 21 - 860 5 4 1 0  
Patient 4 KI-AW 10 + 873 3 3 0 0 + 
 KI-AW 11 ++ 873 4 4 0 0 + 
Patient 5 KI-AW 12 ++ 872 4 3 1 0 ++ 
Patient 6 KI-AW 14 ++ 873 3 3 0 0 + 
 KI-AW 15 ++ 873 4 4 0 0 + 
 KI-AW 26 ++ 873 2 2 0 0 + 
 KI-AW 27 ++ 873 2 2 0 0 + 
Patient 7 KI-AW 16 + 874 3 2 0 1  
Patient 8 KI-AW 17 ++ 873 2 0 1 1 + 
 KI-AW 18 ++ 872 1 0 1 0 + 
 KI-AW 19 ++ 872 4 3 1 0 ++ 
 KI-AW 23 + 863 1 0 1 0  
 KI-AW 24 ++ 872 1 0 1 0 + 
Patient 9 KI-AW 20 - 874 3 2 0 1  
Patient 10 KI-AW 22 - 863 1 0 1 0  
Patient 11 KI-AW 25 - 873 1 1 0 0  
Patient 12 KI-AW 28 - 874 2 1 0 1 + 
Patient A CFCZ  873 2 2 0 0  
Patient C 65 ND 873 4 4 0 0 + 
Patient D BT72 ND 873 4 4 0 0 + 
 PAO1 - 873  0 0 0 0  
For detailed analysis see Appendix Table 32. 
A Mutator phenotype was determined as CFU of rifampicin 100 #g/ml (RA-100) resistant bacteria 
vs. CFU. Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (++). 
Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak mutators (+). 
Strains with mutator frequency of < 1.5 x 10-8 were classified as non-mutator (-). For detailed 
information see Table 14. 
B Mutations total is the sum of all point mutations, deletions and insertions occurring in the metF 
gene of the respective strain. 
C Point mutation is the exchange of a single nucleotide with another nucleotide. Deletion is the 
removal of a single nucleotide or several nucleotides. Insertion is the addition of a single nucleotide 
or several nucleotides. 
D Clinical isolates were complemented with pST10 (pUCP20T::metF) and selected for growth on 
minimal media. Successful complementation with pST10 is indicated as (+). Strains, which were 
non-complemented by pST10 but successfully complemented with pFH04 (pUCP20T:: metF::metH) 
are indicated as (++).  
Methionine auxotrophy - An adaptation strategy of Pseudomonas aeruginosa towards the cystic fibrosis 
lung 
 
 77 
Table 16: Summary of sequence deviations in the MetF protein (PA0340) on amino acid level of 
clinical methionine auxotrophic P. aeruginosa CF isolates 
Patient Colonizing 
strain 
Mutator 
pheno-
typeA 
Length of 
amino acid 
seq. [aa] 
Total 
amino acid 
deviationsB 
Amino 
acids 
exchanged
C 
Frame 
shiftC 
Stop 
codonC 
Compl. by 
pST10/ 
pFH04D 
Patient 1 KI-AW 1 ++ 178 1 0 0 1 + 
Patient 2 KI-AW 2 ++ 159 2 0 1 1  
 KI-AW 3 ++ 29 2 0 1 1  
Patient 3 KI-AW 4 - 40 2 0 1 1  
 KI-AW 5 - 164 2 0 1 1  
 KI-AW 6 ++ 164 3 1 1 1  
 KI-AW 7 - 164 3 1 1 1 + 
 KI-AW 8 - 164 3 1 1 1  
 KI-AW 9 ++ 164 2 0 1 1  
 KI-AW 21 - 164 2 0 1 1  
Patient 4 KI-AW 10 + 290 1 1 0 0 + 
 KI-AW 11 ++ 290 1 1 0 0 + 
Patient 5 KI-AW 12 ++ 168 3 1 1 1 ++ 
Patient 6 KI-AW 14 ++ 84 1 0 0 1 + 
 KI-AW 15 ++ 84 2 0 0 1 + 
 KI-AW 26 ++ 84 1 0 0 1 + 
 KI-AW 27 ++ 84 1 0 0 1 + 
Patient 7 KI-AW 16 + 284 2 2 0 1  
Patient 8 KI-AW 17 ++ 61 2 0 1 1 + 
 KI-AW 18 ++ 61 2 0 1 1 + 
 KI-AW 19 ++ 61 2 0 1 1 ++ 
 KI-AW 23 + 61 2 0 1 1  
 KI-AW 24 ++ 61 2 0 1 1 + 
Patient 9 KI-AW 20 - 160 2 1 0 1  
Patient 10 KI-AW 22 - 165 2 0 1 1  
Patient 11 KI-AW 25 - 290 1 1 0 0  
Patient 12 KI-AW 28 - 156 4 3 0 1 + 
Patient A CFCZ - 290 0 0 0 0  
Patient C 65 ND 290 1 1 0 0 + 
Patient D BT72 ND 290 1 1 0 0 + 
 PAO1 - 290 0 0 0 0  
For detailed analysis see Appendix Table 33 
A Mutator phenotype was determined as CFU of rifampicin 100 #g/ml (RA-100) resistant bacteria 
vs. CFU. Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (++). 
Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak mutators (+). 
Strains with mutator frequency of < 1.5 x 10-8 were classified as non-mutator (-). For detailed 
information see Table 14 
B The total amino acid deviations are the sum of all amino acid exchanged, frame shifts and stop 
codon occurring in the MetF protein of the respective strain. 
C The amino acid exchanged are the replacement of one amino acid by another amino acid due to 
a change in the triplet codon caused by a nucleotide exchange. The frame shift is a change in the 
reading frame of the triplet codon caused by an insertion of deletion of a nucleotide, which results in 
a completely different translation. The stop codon is a triplet in the mRNA, which indicates 
termination of translation encoded by the codons TAG, TAA and TGA. 
D Clinical isolates were complemented with pST10 (pUCP20T::metF) and selected for growth on 
minimal media. Successful complementation with pST10 is indicated as (+). Strains, which were 
non-complemented by pST10 but successfully complemented with pFH04 (pUCP20T:: metF::metH) 
are indicated as (++). For detailed analysis see Appendix Table 32. 
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KI-AW 10, KI-AW 11, KI-AW 25, 65 and BT72 had only one amino acid exchange in an 
otherwise not mutated protein. Amino acid 271 tyrosine was exchanged by histidine (Y 271 H) 
in KI-AW 10 and KI-AW 11 of patient 4. An uncharged amino acid with polar residues (hydroxyl 
group) was exchanged by a charged amino acid with polar residues (amino group). Amino acid 
80 leucine was exchanged by proline (L 80 P) in KI-AW 25. Proline acts as a structural 
disruptor. In strain 65 amino acid 110 glycine was exchanged by serine (G 110 S). In BT72 
valine 203 was exchanged by glutamate (V 203 E).  
Interestingly, all of the above mentioned strains except for KI-AW 25 were complemented by the 
pST10. Four different loci were discovered, which seem to lead to inactivation of the MetF 
protein at amino acid position 80, 110, 203 and 271 (Appendix Table 33). 
The complementation by a functional MetF protein might have not been successful in several 
methionine auxotrophic clinical isolates, since other studies described the tetrameric structure of 
the MetF protein (Guenther et al., 1999; Sheppard et al., 1999). The presence of truncated 
proteins might interfere with the formation of functional MetF protein complexes.  
No mutational hot spot was identified for the amino acid deviations. 
3.2.5 Virulence factors and quorum sensing in methionine metabolism 
Pseudomonas aeruginosa PAO1 deletion strains  
The production of the virulence factor pyocyanin, the iron chelator pyoverdin and the AHL 
quorum sensing molecules BHL and odDHL was investigated for P. aeruginosa strains grown in 
M9 0.5 % caseinate without further methionine supplementation under microaerobic conditions 
in stationary phase after 24 h. Stationary phase was used as sampling time point in order to 
minimize differences caused by slow growing deletion mutants PAO1 "sahH and PAO1 "mtnP 
"sahH since they reached comparable cell density after 24 h (Supplemental Material Fig. 24). 
For the growth experiments M9 20 mM succinate with 50 #M methionine supplementation was 
used. 
The methionine auxotrophic deletion mutants PAO1 "metF, PAO1 "metZ, PAO1 "metE !metH 
and PAO1 "metE !metH !metF were investigated. Previously, it was discovered that PAO1 
"sahH and PAO1 "mtnP "sahH were impaired in growth without methionine supplementation 
(see 4.2.2). PAO1 "metE, PAO1 "metH and PAO1 "mtnP are not methionine auxotrophic. As 
control strain for pyocyanin production PA14 !phz was used, in which both phenazine operons 
phzABCDEFG were deleted.  
The pyocyanin production was decreased in all methionine auxotrophic deletion strains (Fig. 
21 A). PAO1 "metF produced 50 % of the PAO1. For PAO1 "metZ no pyocyanin was 
detectable. The double deletion mutant PAO1 "metE !metH and the triple deletion mutant 
PAO1 "metE !metH !metF showed decreased pyocyanin production of 20 % and 10 %, 
respectively. Interestingly, PAO1 "metE and PAO1 "metH and PAO1 "mtnP produced wt like 
and even increased amounts of pyocyanin. For PAO1 "sahH, PAO1 "mtnP "sahH and the 
control strain PA14 !phz no pyocyanin was detectable. 
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Wild type like pyoverdin production of 2086 ± 142 F460/ OD578 was observed for PAO1 "metF 
and PAO1 "metZ (Fig. 21 B). PAO1 "sahH and PAO1 "mtnP "sahH produced only 20 % of the 
wt. All other strains produced 50 - 60 % of the PAO1 pyoverdin amount.  
The production of AHL quorum sensing molecules BHL and odDHL was determined (Fig. 21 C 
&D). The PAO1 produced 41 ± 6 #M/ OD578 BHL. PAO1 "metE, PAO1 "metH, PAO1 "metE 
"metH and PAO1 metE "metH "metF produced wt like amounts of BHL. Interestingly, the 
double and triple mutant produced slightly increased amounts. PAO1 "metF and PAO1 "metZ 
produced approximately 170 % of the wt with 72 ± 5 #M/ OD578 and 68 ± 10 #M/ OD578, 
respectively. PAO1 "mtnP also produced increased amounts of BHL of 60 ± 4 #M/ OD578. 
PAO1 "sahH and PAO1 "mtnP "sahH produced only 44 % and 20 % of the wt BHL amount, 
respectively. 
The PAO1 produced 962 ± 89 nM/ OD578 odDHL. Unexpectedly, the PAO1 "metF produced 
increased amounts of odDHL of 1297 ± 116 nM/ OD578. In contrast, all other deletion mutants 
produced only 30 – 40 % of the odDHL normally produced by the PAO1. 
The reduced pyocyanin production in the methionine auxotrophic deletion strains was probably 
due to decreased cellular methionine level or decreased recycling of methionine. This most 
likely results in an imbalance of the intracellular SAM / SAH level.  
A. 
 
B. 
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C. 
 
D. 
 
Fig. 21: Production of virulence factors and quorum sensing molecules by the methionine 
metabolism P. aeruginosa deletion strains 
In PAO1, PAO1 "metF, PAO1 "metZ, PAO1 "metE, PAO1 "metE !metH, PAO1 "metE !metH 
!metF, PAO1 "mtnP, PAO1 "sahH and PA14 !phz the production of the virulence factors 
pyocyanin [OD695/ OD578] (A) and pyoverdine [F460*/ OD578] (B) was investigated. We analysed the 
production of the quorum sensing molecules BHL [#M/ OD578] (C) and odDHL [nM/ OD578] (D). 
Strains were grown in M9 0.5 % caseinate without further methionine supplementation under 
microaerobic conditions. Virulence factors were analysed after 24 h of growth. 
The standard deviation of three representative experiments is shown.  
*F460 (Emission of relative fluorescence at 460 nm; Excitement at 405 nm) 
____________________________________________________________________________ 
Pyocyanin synthesis itself is SAM dependent. Phenazine-1-carboxylic acid is synthesized from 
chorismic acid via the two phzABCDEFG operons (Parsons et al., 2007) (Fig. 22). Phenazine-1-
carboxylic acid is methylated by PhzM using SAM to 5-methylphenazine-1-carboxylic acid 
betaine. 5-Methylphenazine-1-carboxylic acid betaine is further converted by the probable FAD-
dependent monooxygenase PhzS in the presence of oxygen and NADH to pyocyanin (Parsons 
et al., 2007). 
The methylation step catalysed by PhzM might be impaired in methionine auxotrophic strains, 
due to reduced SAM availability. Another possibility might be a low affinity of PhzM towards 
SAM, which might result in reduced synthesis at low SAM concentrations. Other more essential 
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cellular reactions might be still catalysed by the respective enzymes, due to the enzymes higher 
affinity towards SAM. Furthermore, high intracellular SAH concentrations might lead to inhibition 
of the methylation reactions. Quorum sensing is regulating pyocyanin formation (Gallagher et 
al., 2002; Lau et al., 2004). 
In PAO1 "metF pyocyanin formation was still possible, but reduced. Even more decreased was 
the pyocyanin formation in PAO1 "metE "metH and PAO1 "metE "metH "metF probably due 
to the changed intracellular SAM / SAH level.  
In contrast, pyocyanin formation was not detected for PAO1 "metZ, PAO1 "sahH and PAO1 
"mtnP "sahH. The assumption is that the SAM / SAH level might prevent the formation in these 
strains. The quorum sensing molecules BHL and odDHL levels do not seem to be the regulating 
factor, since other strains with similar odDHL and BHL levels produced pyocyanin. This was e.g. 
the case for PAO1 "mtnP, which produced pyocyanin, whereas PAO1 "metZ did not. The 
methionine auxotrophic strains are dependent on external methionine, to refill their methionine 
pool and thereby refilling the SAM pool to be able to grow. 
 
Fig. 22: Pyocyanin synthesis (adapted from Lau et al., 2004) 
Pyocyanin is synthesized from chorismatic acid by the phzABCDEFG operons. Phenazine-1- 
carboxylic acid is methylated by PhzM using SAM to 5-methylphenazine-1-carboxylic acid betaine. 
5-methylphenazine-1- carboxylic acid betaine is further converted by the probable FAD-dependent 
monooxygenase PhzS in the presence of oxygen and NADH to pyocyanin (Parsons et al., 2007).  
____________________________________________________________________________ 
Pyoverdin is a powerful iron Fe3+ scavenger and transporter (Schalk and Guillon, 2012). It 
consists of a peptide moiety of diverse structure, and a conserved fluorescent chromophore, 
which can carry a variable acyl chain (Meyer, 2000). Pyoverdin synthesis is controlled by the 
ECF sigma factor PvdS (Vasil, 2007). Pyoverdin synthesis is neither influenced by the deletion 
of metF nor metZ, whereas all other deletions reduced its synthesis. All experiments were 
conducted under iron limiting conditions. During growth in the CF lung with cooperative strains 
producing the public good pyoverdin these strains would not be influenced in iron availability. 
PAO1 "metF and PAO1 "metZ did not act as a cheater per se. With methionine 
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supplementation as in M9 0.5% caseinate pyoverdin synthesis was not influenced. But during 
growth in a methionine depleted environment as during the chronic CF infection this might 
change. 
The odDHL production was only increased in PAO1 "metF, whereas BHL production was also 
increased in PAO1 "metF, PAO1 "metZ and PAO1 "mtnP. Due to the deletion PAO1 "metF 
probably accumulates Hcy and methylene-THF, PAO1 "metZ probably accumulates O-
succinyl-homoserine and PAO1 "mtnP cannot recycle MTA. 
We propose that these strains might use the synthesis of quorum sensing molecules as salvage 
pathway to dispose not recyclable Met and SAM reaction residues or to balance the intracellular 
SAM and methionine level.  
Interestingly, odDHL production of the PAO1 wt was 7-fold increased during growth in M9 0.5% 
caseinate compared to MHB (Table 14), while BHL production remained unchanged. Palmer et 
al. (2007) showed the positive influence of aromatic amino acids on the PQS biosynthesis, 
previously. The growth medium M9 0.5% caseinate is very rich in amino acids and also in 
aromatic amino acids. AHL biosynthesis is assumed to take place via fatty acid biosynthesis not 
via !-oxidation pathway (Dickschat, 2010). The most frequently used starter unit in fatty acid 
biosynthesis is acetyl-CoA. Dickschat (2010) proposed that also amino acids might serve as 
starter units for methyl branched AHLs, similar to methyl branched fatty acids from the amino 
acid-derived starter units. The signaling molecule odDHL is not methyl branched, but 
biosynthesis is not completely elucidated. Therefore, it can be discussed if odDHL expression is 
influenced by nutrient availability. But further studies have to be performed to verify this 
assumption. 
3.2.6 Transcriptome analysis of Pseudomonas aeruginosa PAO1 and PAO1 !metF in 
M9 0.5 % caseinate under microaerobic to anaerobic conditions 
The transcriptional profiles of PAO1 were compared to PAO1 "metF grown in M9 0.5% 
caseinate under microaerobic to anaerobic conditions. M9 0.5% caseinate was used to simulate 
the high amino acid content of the sputum of CF patients. The transcriptional profiles were 
analysed after 4 h and after 12 h of growth. Previous experiments have shown a reduced 
pyocyanin production by PAO1 "metF (3.2.5). 
The optical density OD578 was measured and the colony forming units (CFU) were determined 
for PAO1 and PAO1 "metF during growth in M9 0.5% caseinate (Fig. 23 A). Moreover, the 
protein concentration [mg/ml] and the DNA concentration [#g/ml] were determined (Fig. 23 B). 
No significant differences in growth behaviour, protein or DNA concentration between PAO1 
and PAO1 "metF were detected. Defined growth conditions were chosen, which did not result 
in a detectable growth phenotype of PAO1 "metF. The casein protein was used as source of 
methionine and supported wt-like growth of PAO1 "metF without additional methionine 
supplementation. Therefore, the experiment focused on the transcriptional differences induced 
by the metF deletion. Moreover, the effect of reduced pyocyanin production by PAO1 "metF 
was investigated in this model system. 
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A.        B.  
    
C. 
 
Fig. 23: Transcriptome analysis for PAO1 wt and PAO1 !metF in M9 0.5 % caseinate under 
microaerobic to anaerobic conditions  
The OD578 (circles, dashed line) was determined and the CFU (squares, solid line) for PAO1 (black) 
and PAO1 "metF (grey) were determined (A). Moreover, the protein concentration [mg/ml] 
(squares, dashed line) and DNA concentration [#g/ml] (circles, solid line) was determined for PAO1 
(black) and PAO1 "metF (grey) (B).  
The oxygen concentration [#mol/l] was measured during growth of PAO1 wt (black dotted line) and 
PAO1 "metF (grey dotted line) in M9 0.5 % caseinate (C). Sampling points for the transcriptome 
analysis during late exponential phase (4 h) and stationary phase (12 h) are indicated by black 
arrows. Representative experiments are shown.  
____________________________________________________________________________ 
The OD578 and the CFU showed rapid increase until 3 h (Fig. 23 A). Afterwards OD578 increased 
only 1.7-fold between 3 h and 6 h and remained constant until oxygen depletion at 12 h. 
Similarly the CFU remained constant between 4 h and 24 h for both PAO1 and PAO1 "metF. 
The oxygen consumption of PAO1 and PAO1 "metF was evaluated (Fig. 23 C). The conditions 
ranged form microaerobic after 4 h of growth to anaerobic conditions after 12 h. No significant 
differences in oxygen consumption between PAO1 and PAO1 "metF were observed. The 
PAO1 "metF culture contained a little less oxygen between 4 h and 12 h than the PAO1 wt. 
Both strains showed a strong local decrease in oxygen concentration after 3 h. Oxygen was 
consumed slowly after 4 h. Oxygen was depleted to < 5 #mol after 12 h.  
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The protein concentration [mg/ml] increased 1.6-fold between 3 h and 4 h (Fig. 23 B). After 4 h 
the protein concentration remained stable and the DNA concentration increased only very 
slowly.  
The local minimum in oxygen concentration after 3 h might be an indicator of the strong 
metabolic activity of both strains and the high growth rates. Moreover, the switch from one 
nutrient source to another due to the depletion of the utilized nutrient source might also be 
indicated by the local minimum of oxygen concentration followed by the repletion of the oxygen 
concentration. In a previous study it was observed that different amino acids were taken up und 
were utilized at different time points from amino acid medium (AAM) (Chapter 2.2.13).  
Although medium composition and direct amino acid availability are different between AAM and 
M9 0.5 % caseinate, switch from one nutrient source to another combined with the end of 
exponential phase and the entry of stationary phase could be indicated by decrease in oxygen 
concentration after 3 h. Between 4 h to 12 h bacteria were consuming oxygen, but less rapidly. 
The protein concentration remained stable. DNA concentration remained also stable between 4 
h and 6 h, but increased 3-fold between 6 h and 12 h for both strains, while the CFU remained 
constant. Several genomes per bacteria are described as an indicator of stationary phase 
(Akerlund et al., 1995). Therefore, one can assume that both cultures were in late exponential 
phase or rather at the entry to stationary phase at 4h and in stationary phase after 12 h. 
Comparison of the two strains and two time points identified that 1389 genes were differently 
expressed (Appendix Table 34). 213 genes were upregulated and 82 genes downregulated for 
PAO1 4 h vs. PAO1 "metF 4 h (W4 / M4). The comparison of PAO1 12 h vs. PAO1 "metF 12 h 
(W12 / M12) identified 137 genes as upregulated and 126 as downregulated in total. 356 genes 
were upregulated in PAO1 "metF 12 h vs. PAO1 "metF 4 h (M12 / M4). 351 genes were 
downregulated (M12 / M4). 469 genes were upregulated and 571 genes were downregulated in 
PAO1 12 h vs. PAO1 wt 4 h (W12 / W4). 
Energy generation and stress response  
During microaerobic to anaerobic growth conditions without supplementation of nitrate or nitrite, 
arginine normally serves as energy source for growth. Under anaerobic to microaerobic 
conditions, P. aeruginosa can degrade arginine to ornithine via the arginine deaminase (ADI) 
pathway, which is linked to the generation of ATP by substrate-level phosphorylation (Lu et al., 
2004; Mercenier et al., 1980; Vander Wauven et al., 1984). Our complex medium contained 
other amino acids to serve as carbon sources to allow growth since ornithine is excreted 
(Vander Wauven et al., 1984).  
Interestingly, the arcDABC operon was found induced in the PAO1 after 4 h, but was 
downregulated in PAO1 after 12 h (Table 17). The same expression pattern was observed for 
the ArgR regulator in PAO1. In contrast the arcDABC operon was induced in PAO1 "metF after 
12 h. A similar expression pattern was detected for the arginine succinyltransferase (AST) 
pathway genes. With the exception that no regulation of the AST pathway genes was observed 
for PAO1 "metF (M12 / M4). The AST pathway converts arginine and ornithine to glutamate 
under aerobic conditions (Itoh, 1997; Park et al., 1997).  
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Table 17: Microarray analysis of selected genes in PAO1 compared to PAO1 !metF in M9 0.5 % 
caseinate  
Differentially regulated genes of P. aeruginosa PAO1 compared to PAO1 "metF after 4 h and after 
12 h in M9 0.5 % caseinate under microaerobic to anaerobic conditions. Shown are the gene ID, 
gene name, function and the fold change (FC) of genes differently regulated of PAO1 wt 4 h vs. 
PAO1 "metF 4 h (W4 / M4), PAO1 wt 12 h vs. PAO1 "metF wt 12 h (W12 / M12), PAO1 "metF 12 
h vs PAO1 "metF 4 h (M12 / M4) and PAO1 wt 12 h vs PAO1 wt 4 h (W12 / W4).  
Gene IDA Gene 
nameA 
FunctionA  
W4 / 
M4 
FC 
W12 / 
M12 
 
M12 / 
M4 
 
W12 / 
W4 
Adaptation and Protection:     
PA0059 
PA0382 
PA3309 
PA2532 
osmC 
micA 
uspK 
tpx 
osmotically inducible protein OsmC 
DNA mismatch repair protein MicA 
Usp-type stress protein UspK 
thiol peroxidase 
2,3 
-2,2 
 
 
 
 
-4,9 
2,3 
 
 
12,1 
-2,3 
-2,4 
2,2 
2,2 
 
Energy metabolism & denitrification:     
PA0105 
PA0106 
PA0107 
PA0108 
PA0110 
PA0111 
PA0112 
PA0113 
PA0114 
PA0509 
PA0510 
PA0515 
PA1172 
PA1173 
PA1174 
PA1175 
PA1176 
PA1177 
PA1546 
PA1555 
PA1556 
PA1557 
PA3930 
PA4494 
coxB 
coxA 
 
coIII 
 
 
 
 
senC 
nirN 
nirE 
nirD 
napC 
napB 
napA 
napD 
napF 
napE 
hemN 
 
 
 
cioA 
roxS 
cytochrome c oxidase, subunit II (aa3-type) 
cytochrome c oxidase, subunit I (aa3-type) 
conserved hypothetical protein 
cytochrome c oxidase, subunit III 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable cytochrome c oxidase assembly factor 
SenC 
probable c-type cytochrome 
probable uroporphyrin-III c-methyltransferase 
probable transcriptional regulator 
cytochrome c-type protein NapC 
cytochrome c-type protein NapB precursor 
periplasmic nitrate reductase protein NapA 
NapD protein of periplasmic nitrate reductase 
ferredoxin protein NapF 
periplasmic nitrate reductase protein NapE 
oxygen-independent coproporphyrinogen III oxidase 
probable cytochrome c 
probable cytochrome c oxidase subunit 
probable cytochrome oxidase subunit (cbb3-type) 
cyanide insensitive terminal oxidase 
probable two-component sensor 
2,5 
3,3 
3,6 
3,1 
2,4 
2,9 
3,0 
3,5 
3,2 
 
 
 
2,9 
3,4 
3,0 
3,1 
2,3 
 
 
 
 
 
 
 
3,5 
3,7 
3,5 
2,2 
3,2 
2,4 
2,7 
 
-2,3 
-2,4 
-3,0 
 
 
 
 
 
-2,0 
-2,8 
-8,3 
-6,7 
-6,4 
 
-2,3 
-3,4 
-7,2 
-8,6 
-6,4 
-3,2 
-5,9 
-4,7 
-5,2 
-3,5 
2,4 
2,4 
3,6 
 
 
-2,1 
-2,0 
-2,2 
 
6,5 
16,3 
13,9 
12,8 
 
-4,9 
-6,9 
-8,3 
-5,7 
-3,4 
-5,3 
-6,1 
-6,7 
-6,7 
 
 
 
-5,7 
-6,8 
-6,8 
-6,9 
-6,8 
-2,6 
2,5 
2,3 
2,3 
2,3 
-2,9 
 
Arginine fermentation:     
PA0893 
PA5170 
PA5171 
PA5172 
PA5173 
argR 
arcD 
arcA 
arcB 
arcC 
transcriptional regulator ArgR 
arginine/ornithine antiporter 
arginine deiminase 
ornithine carbamoyltransferase, catabolic 
carbamate kinase 
 
2,7 
3,3 
3,4 
3,2 
 
-2,0 
-2,6 
-2,6 
-2,5 
 
2,6 
2,8 
2,7 
3,8 
-2,3 
-2,1 
-3,1 
-3,1 
-2,1 
Metabolism:     
PA0897 
PA0898 
PA0899 
PA0901 
PA2113 
PA2114 
PA4501 
PA0887 
PA2862 
PA3366 
PA4813 
PA5427 
aruG 
aruD 
aruB 
aruE 
opdO 
 
opdD 
acsA 
lipA 
amiE 
lipC 
adhA 
arginine/ornithine succinyltransferase AII subunit 
succinylglutamate 5-semialdehyde dehydrogenase 
succinylarginine dihydrolase 
succinylglutamate desuccinylase 
pyroglutamate porin OpdO 
probable major facilitator superfamily (MFS) transporter 
Glycine-glutamate dipeptide porin OpdD 
acetyl-coenzyme A synthetase 
lactonizing lipase precursor 
aliphatic amidase 
lipase LipC 
alcohol dehydrogenase 
2,1 
2,0 
2,1 
 
2,4 
2,2 
 
 
 
2,2 
2,2 
 
-2,1 
-2,0 
-2,2 
-2,1 
 
 
3,6 
-5,4 
4,4 
 
 
-3,0 
 
 
 
 
-6,6 
-10,1 
 
3,5 
-50,9 
-11,6 
-3,3 
4,9 
-3,4 
-3,4 
-3,9 
-2,6 
-17,9 
-31,2 
 
 
-20,0 
-21,2 
-7,0 
 
PQS biosynthesis and anthranilate metabolism:     
PA0997 
PA0998 
PA0999 
PA2579 
PA2080 
PA2081 
PA2511 
PA2512 
PA2513 
PA2514 
pqsB 
pqsC 
pqsD 
kynA 
kynU 
kynB 
antR 
antA 
antB 
antC 
Homologous to beta-keto-acyl-acyl-carrier protein syn.* 
Homologous to beta-keto-acyl-acyl-carrier protein syn.* 
3-oxoacyl-[acyl-carrier-protein] synthase III 
2,3-oxidoreductase (decyclizing) KynA 
kynureninase KynU 
kynurenine formamidase, KynB 
probable transcriptional regulator 
anthranilate dioxygenase large subunit 
anthranilate dioxygenase small subunit 
anthranilate dioxygenase reductase 
 2,3 
2,1 
2,0 
2,5 
2,1 
2,5 
4,8 
3,4 
5,3 
4,2 
 
 
 
 
-2,7 
-2,3 
 
 
 
 
 
 
 
 
 
 
3,8 
3,7 
5,9 
5,1 
       
       
Methionine auxotrophy - An adaptation strategy of Pseudomonas aeruginosa towards the cystic fibrosis 
lung 
 
 86 
Continued:      
Gene IDA Gene 
nameA 
FunctionA  
W4 / 
M4 
FC 
W12 / 
M12 
 
M12 / 
M4 
 
W12 / 
W4 
Phenazine biosynthesis:     
PA1901 
PA1902 
PA1903 
PA1904 
PA1905 
PA4209 
PA4210 
PA4211 
PA4217 
phzC2 
phzD2 
phzE2 
phzF2 
phzG2 
phzM 
phzA1 
phzB1 
phzS 
phenazine biosynthesis protein PhzC 
phenazine biosynthesis protein PhzD 
phenazine biosynthesis protein PhzE 
probable phenazine biosynthesis protein 
probable pyridoxamine 5'-phosphate oxidase 
probable phenazine-specific methyltransferase 
probable phenazine biosynthesis protein 
probable phenazine biosynthesis protein 
flavin-containing monooxygenase 
  5,0 
6,4 
14,2 
18,0 
21,8 
11,0 
28,4 
13,8 
22,7 
7,2 
5,9 
14,3 
16,5 
20,0 
13,4 
31,4 
23,3 
28,0 
Hydrogen cyanide biosynthesis:     
PA2193 
PA2194 
PA2195 
hcnA 
hcnB 
hcnC 
hydrogen cyanide synthase HcnA 
hydrogen cyanide synthase HcnB 
hydrogen cyanide synthase HcnC 
  14,9 
14,0 
9,9 
21,4 
10,3 
12,0 
       
PA3049 
PA1898 
rmf 
qscR 
ribosome modulation factor 
quorum-sensing control repressor 
3,4 
 
 
3,0 
3,5 
 
 
A Gene ID, gene name, function and PseudoCAP Function Class (PCFC) are according to the 
“Pseudomonas Genome Database” (Winsor et al., 2011). 
*Abbreviations: syn. (synthase) 
 
The expression pattern indicates that the PAO1 utilizes arginine very efficiently via the ADI and 
AST pathway genes after 4 h, whereas arginine must have still been present in the PAO1 
"metF culture after 12 h and was probably still utilized at this time point. This indicates a 
different anaerobic consumption of arginine by PAO1 and by PAO1 "metF.  
Both genes for the aerobic and microaerobic to anaerobic utilization of arginine were detected 
with the genes of the AST and ADI pathway expressed for both strains. The ArgR regulator and 
the presence of exogenous arginine regulate both pathways (Itoh, 1997; Park et al., 1997). 
Moreover, the arcDABC operon is induced by low oxygen tension and Anr the global regulator 
of the anaerobic gene expression (Gamper et al., 1991; Mercenier et al., 1980). Anr possesses 
an oxygen sensitive iron-sulphur cluster and directly induces genes required for arginine 
fermentation and cyanide biosynthesis (Zimmermann et al., 1991). Therefore, the oxygen 
concentration and the culture conditions were able to induce both pathways. Due to the 
absence of nitrate / nitrite the arc genes were not repressed by the nitrate response regulator 
NarXL (Benkert et al., 2008). 
The change of oxygen concentration during growth was also detected by the change of 
expression of cytochrome oxidases in both strains. The cox operon consisting of the genes 
coxBA, PA0107 and colll was downregulated after 12 h for both PAO1 and for PAO1 "metF, 
since the oxygen concentration in the cultures was very low (Fig. 23 C), this is in accordance 
with a previous study (Kawakami et al., 2010). The cox operon is described to encode for an 
aa3-type oxidase of low oxygen affinity and was shown to be induced by RpoS and repressed 
by RoxSR (Kawakami et al., 2010; Schuster et al., 2004).  
RoxSR is proposed to be regulated directly or indirectly by the redox status of the respiratory 
chain (Arai, 2011). Moreover, the cox operon is described to be regulated by starvation of 
carbon, nitrogen or iron (Arai, 2011; Kawakami et al., 2010). Interestingly, the expression of the 
cox operon was increased in the PAO1 after 4 h and 12 h compared to PAO1 "metF. This 
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indicates that either the oxygen concentration, the oxygen sensing or the underlying regulation 
pattern must have been either slightly increased or altered in PAO1 vs. PAO1 "metF culture at 
both time points. No significant change was visible in the measured oxygen concentration (Fig. 
23 C). It could be discussed if this is due to increased expression of the roxS gene in PAO1 
"metF compared to PAO1 after 12 h. Besides, the induction of the regulator RpoS in PAO1 
"metF could be altered.  
The cbb3-type 2 oxidase operon (PA1555-PA1557) was upregulated for both PAO1 and PAO1 
"metF after 12 h. After 12 h the induction in PAO1 "metF was much stronger than in PAO1, 
since the expression was downregulated for PAO1. The cbb3-type 2 oxidase is predicted to 
have a high affinity for oxygen and is expressed at low oxygen levels (Alvarez-Ortega and 
Harwood, 2007; Kawakami et al., 2010). The transcriptional profile suggested that PAO1 "metF 
was using the cbb3-type 2 oxidase operon preferably after 12 h. At this time point the oxygen 
concentrations inside each culture was depleted (Fig. 23 C). The cbb3-type 2 oxidase operon is 
positively regulated by Anr and RoxSR. This is in accordance with the previous observations. 
The gene cioA encoding for the cyanide insensitive bd-type oxidase (PA3930) was 
downregulated in PAO1 after 12 h and no change in expression was observed for PAO1 "metF. 
The cio oxidase operon is only induced if no other terminal oxidase of the heme-copper 
superfamily is able to function (Arai, 2011). The cio oxidase operon is positively regulated by 
RoxSR and activated to a small degree by RpoS but negatively regulated by Anr (Comolli and 
Donohue, 2004; Cooper et al., 2003; Kawakami et al., 2010). Interestingly, the cyanide 
biosynthesis operon hcnABC was upregulated in both PAO1 and PAO1 "metF after 12 h. In 
agreement, the cyanide biosynthesis is also regulated by Anr and is dependent on microaerobic 
conditions and the entry of stationary phase (Pessi and Haas, 2000; Williams et al., 2007). It 
was shown that the amino acids threonine and glycine stimulate cyanide production. 
Furthermore, cyanide biosynthesis is regulated cell density dependent by the RhlI/R quorum 
system and GacS/GacA (Reimmann et al., 1997). The question remains why there is no change 
of expression of cioA observed for PAO1 "metF as the induction of the cyanide biosynthesis is 
observed. The cioA expression might be influenced by an altered regulation of RhlI/R quorum 
system and GacS/GacA by the increased expression of quorum sensing molecules. The 
increased production was observed for both BHL and odDHL in PAO1 "metF after 24 h (3.2.5).  
A very strong induction of cbb3-type 2 oxidase operon in PAO1 "metF was observed after 12 h. 
This might be the solution for energy generation by PAO1 "metF to compensate for the 
unchanged cioA expression and might be stimulated by RoxS. No decrease in CFU was 
observed for neither PAO1 "metF nor PAO1. Therefore, the PAO1 "metF culture seems not to 
be inhibited by cyanide, if produced. But the actual cyanide production of PAO1 "metF cultures 
has to be determined. 
Interestingly, the genes nirE and hemN encoding for the proteins NirE and HemN, which are 
both SAM dependent enzymes, were upregulated in PAO1 "metF after 12 h. NirE is a SAM-
dependent uroporphyrinogen III methyltransferase, which catalyses the conversion of 
uroporphyrinogen III to precorrin-2 (Storbeck et al., 2009). HemN catalyses the essential 
conversion of coproporphyrinogen III to protoporphyrinogen IX during heme biosynthesis (Layer 
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et al., 2003). HemN is an iron-sulphur cluster containing protein belonging to the radical SAM 
protein family (Layer et al., 2003; Sofia et al., 2001). The promoter of hemN is recognized by 
both Anr and Dnr (Schreiber et al., 2007). 
Besides nirE, the genes nirD and nirN were also upregulated in PAO1 "metF after 12 h. NirD is 
a predicted transcriptional regulator, which also possesses enzymatic properties (Nicke, 2013; 
Walter, 2011). NirN probably catalyses together with NirF the last step of heme d1-biosynthesis 
and cofactor-insertion into NirS (Nicke, 2013). Normally, the nir operon is induced by the NO-
sensing regulator Dnr. The expression of nirS is moreover NarXL regulated. The observed 
transcriptional upregulation of the genes nirE and hemN seems to be specific for PAO1 "metF. 
One can discuss if the induction is due to either a higher demand for their reaction products or 
due to reduced availability of both proteins as functional enzymes with SAM as cofactor due to 
limitation of SAM caused by the unbalanced intracellular methionine level in PAO1 "metF. But 
in order to fully understand the underlying regulation it has to be further investigated. 
The universal stress protein gene uspK and the alcohol dehydrogenase adhA gene were both 
induced in PAO1 "metF also in comparison to PAO1 after 12 h. The gene uspK is highly 
induced in PAO1 "metF indicating the increased need for the protein. UspK is essential for 
surviving specific anaerobic energy stress conditions such as pyruvate fermentation and 
anaerobic stationary phase (Boes et al., 2008; Schreiber et al., 2006). Both genes were also 
observed upregulated in the study of Alvarez-Ortega and Harwood (2007) and under 
microaerobic conditions in SCFM (Palmer et al., 2007a). Moreover, the gene micA encoding for 
DNA mismatch repair was upregulated in PAO1 "metF vs. PAO1 after 4 h. It would be very 
interesting to obtain further inside views into the stress response of PAO1 "metF since it 
appeared to be altered. 
The PQS biosynthesis was increased in PAO1 after 12 h. The pqsBCD operon genes were at 
least 2-fold upregulated as well as the kynABU operon, which converts tryptophan to the 
precursor of PQS biosynthesis anthranilic acid (Farrow and Pesci, 2007). Oxygen is necessary 
for the last step of PQS biosynthesis by PqsH (Schertzer et al., 2010). The antRABC operon, 
which converts anthranilic acid to catechol, was also upregulated in PAO1 after 12 h. Both PQS 
synthesis and anthranilate degradation for energy production take place in PAO1. No increase 
or change of expression of PQS biosynthesis genes was observed for PAO1 "metF. The 
kynABU operon was downregulated in PAO1 "metF after 12 h, therefore the anthranilic acid 
pool is not refilled via tryptophan. 
No difference in expression of the genes encoding the phenazine pyocyanin biosynthesis e.g. 
the phzABCDEFG operon, phzM and phzS was observed for both strains. The observed 
reduction of pyocyanin production in PAO1 "metF is not due to transcriptional downregulation. 
In addition, pyocyanin can be used to maintain a stable redox equilibrium. Pyocyanin can 
oxidise NADH to NAD+ without the need for a catalysing enzyme during oxygen limitation in the 
culture as shown by a recent study (Dietrich et al., 2013). PAO1 "metF possesses probably an 
altered redox balance compared to PAO1. This is probably indicated by a 2-fold upregulation of 
the expression of RoxS is in PAO1 "metF after 12h, which also might be reflected in the strong 
induction of cbb3-type 2 oxidase operon. 
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Methionine and SAM metabolism genes are upregulated in Pseudomonas aeruginosa 
PAO1 !metF 
The majority of the genes differently regulated in PAO1 and PAO1 "metF were genes encoding 
for proteins of the methionine and SAM metabolism (Table 18). These proteins are involved in 
methionine synthesis or are necessary for the conversion to SAM. SAM is used for various 
reactions. It is the second most frequently used enzyme substrate after ATP (Fontecave et al., 
2004; Loenen, 2006). Approximately 95 % of SAM are used for methylation reactions (Griffith, 
1987). The remaining SAH after a methylation reaction is recycled via SahH (Fig. 17). The 
corresponding gene sahH was 5.5-fold upregulated in PAO1 "metF and downregulated in 
PAO1 after 4 h. The SahH protein is a very stable enzyme. The upregulation of the sahH gene 
indicates the necessity and the high demand for the recycling of SAM via SahH in PAO1 "metF. 
This might indicate an unbalanced SAM /SAH level in PAO1 "metF. 
The final step of methionine biosynthesis is the conversion of Hcy via either MetE or MetH to 
methionine. MetH is a cobalamine dependent and MetE a cobalamine independent methionine 
synthase. Under the investigated conditions in PAO1 "metF MetE was clearly the enzyme 
induced, since the metE gene was 168.3-fold and 59.5-fold upregulated, respectively. For metH 
only a 4.8-fold upregulation in PAO1 "metF after 4 h was observed. The gene metE shows the 
highest induction of all genes indicating the extraordinary need for methionine in PAO1 "metF. 
Both enzymes use the cofactor Me-THF or Me-THP as methyl-group donor, respectively. Me-
THF or Me-THP is generated by MetF from N5,N10-methylene-THF or N5,N10-methylene-THP. 
This pathway is blocked by the deletion of metF in PAO1 "metF. 
Methionine can be directly incorporated into biosynthesis or further converted via S-
adenosylmethionine synthetase MetK to SAM. The metK gene was also upregulated in PAO1 
"metF indicating the demand for SAM. The genes of the cobalamin and folate metabolism were 
identified upregulated in PAO1 "metF after 4 h. Cysteine metabolism genes were only 
upregulated in the PAO1 wt after 12 h.  
The genes of the cleavage system gcvT2H2P2, glyA1 hydroxy-methyltransferase and metE are 
described to be under positive quorum sensing control (Schuster et al., 2003; Wagner et al., 
2003).  
The need for methionine and SAM is also reflected by the upregulation of the transcriptional 
regulator gene metR in PAO1 "metF after 4 h and after 12 h. This is in accordance with E. coli, 
for which it is described that MetR is an activator of expression of the genes metE, metH, glyA 
and probably metF (Cowan et al., 1993; Maxon et al., 1989). Hcy acts as co-activator together 
with MetR for the expression of the genes metE and glyA or as co-repressor for metH 
expression (Plamann and Stauffer, 1989). In addition, MetR is regulated by MetJ in E. coli, 
which is regulating all methionine biosynthesis genes with exception of metH and metK 
according to the cellular SAM level (Greene, 1996). No MetJ homolog is annotated for 
P. aeruginosa so far and not much is known about the regulation of methionine and SAM 
metabolism genes in P. aeruginosa. 
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Table 18: Microarray analysis of selected methionine metabolism and SAM metabolism genes in 
PAO1 compared to PAO1 !metF in M9 0.5 % caseinate  
Differentially regulated genes of P. aeruginosa PAO1 compared to PAO1 "metF after 4 h and after 
12 h in M9 0.5 % caseinate under microaerobic to anaerobic conditions. Shown are the gene ID, 
gene name, function and the fold change (FC) of genes differently regulated of PAO1 wt 4 h vs. 
PAO1 "metF 4 h (W4 / M4), PAO1 wt 12 h vs. PAO1 "metF wt 12 h (W12 / M12), PAO1 "metF 12 
h vs PAO1 "metF 4 h (M12 / M4) and PAO1 wt 12 h vs PAO1 wt 4 h (W12 / W4).  
Gene IDA Gene 
nameA 
FunctionA  
W4 / 
M4 
FC 
W12 / 
M12 
 
M12 / 
M4 
 
W12 / 
W4 
PA0314 
PA0315 
PA0316 
PA0390 
PA0430 
PA0431 
PA0432 
PA0546 
PA0547 
PA0582 
PA0583 
PA1276 
PA1838 
PA1843 
PA1927 
 
PA2445 
PA2446 
PA3169 
PA3587 
PA3816 
PA3824 
PA4314 
PA4442 
PA4443 
PA4602 
PA5213 
PA5415 
 
 
serA 
metX 
metF 
 
sahH 
metK 
 
folB 
 
cobC 
cysI 
metH 
metE 
 
gcvP2 
gcvH2 
mtnA 
metR 
cysE 
queA 
purU1 
cysN 
cysD 
glyA3 
gcvP1 
glyA1 
L-cysteine transporter of ABC system FliY 
hypothetical protein 
D-3-phosphoglycerate dehydrogenase 
homoserine O-acetyltransferase 
5,10-methylenetetrahydrofolate reductase 
hypothetical protein 
S-adenosyl-L-homocysteine hydrolase 
methionine adenosyltransferase 
probable transcriptional regulator 
dihydroneopterin aldolase 
7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase 
cobalamin biosynthetic protein CobC 
sulfite reductase 
methionine synthase 
5-methyltetrahydropteroyltriglutamate-homocysteine S-
methyltransferase 
glycine cleavage system protein P2 
glycine cleavage system protein H2 
5-methylthioribose-1-phosphate isomerase MtnA 
transcriptional regulator MetR 
O-acetylserine synthase 
S-adenosylmethionine:t-Rna ribosyltransferase-isomerase 
formyltetrahydrofolate deformylase 
ATP sulphurylase GTP-binding subunit/APS kinase 
ATP sulphurylase small subunit 
serine hydroxymethyltransferase 
glycine cleavage system protein P1 
serine hydroxymethyltransferase 
2,4 
 
-15,5 
 
2,5 
-2,7 
-5,5 
-5,4 
-8,6 
-10,1 
-7,9 
-2,1 
 
-4,8 
-168,3 
 
 
 
 
-3,3 
 
 
 
 
 
-12,8 
2,4 
2,5 
 
2,5 
-4,2 
 
7,2 
 
 
-2,4 
-3,2 
 
 
 
 
 
-59,5 
 
 
 
 
-3,1 
 
 
 
 
 
-2,4 
 
 
-2,1 
-3,2 
-2,2 
-2,7 
 
 
 
 
 
-3,6 
-3,6 
 
 
-3,8 
-2,1 
 
 
 
 
 
 
 
-2,2 
 
 
-2,6 
 
 
-4,5 
-2,0 
 
 
3,2 
 
2,6 
2,0 
4,1 
 
 
2,3 
2,5 
 
 
 
2,3 
2,5 
2,2 
 
2,3 
2,1 
 
3,1 
3,5 
2,1 
-3,5 
-2,5 
A Gene ID, gene name, function and PseudoCAP Function Class (PCFC) are according to the 
“Pseudomonas Genome Database” (Winsor et al., 2011). 
 
For PA14 was shown that the deletion of metR abolished the ability to swarm (Yeung et al., 
2009). Moreover, they detected that metH and metF were downregulated in PA14 metR- 
mutant. They also observed a downregulation of virulence-associated genes under the tested 
swarming conditions. One can assume that part of the regulatory network for the regulation of 
methionine biosynthesis genes e.g. metH and metF is similar to E. coli. As mentioned several 
methionine and SAM biosynthesis genes are also quorum sensing regulated (Heurlier et al., 
2006; Schuster et al., 2003; Wagner et al., 2003). But since no MetJ regulator was identified for 
P. aeruginosa the regulatory network, especially concerning the regulation of virulence factors 
and in regard to quorum sensing regulation might be totally different. 
In addition, a recent study described the presence of a SAH dependent riboswitch in the mRNA 
of the sahH operon for Pseudomonas syringae (Wang et al., 2008). Wang et al. proposed that 
SAH binding activates the gene expression. 15 SAH RNA motifs were identified in the 
Pseudomonadales (Wang et al., 2008). Recently, a SAM-III box was identified in the 
5´untranslated region (5´ UTR) of metK in Enterococcus faecalis (Smith et al., 2010). The 
presence of SAH or SAM dependent riboswitches in the 5´UTR of sahH, metK and metH 
seemed possible from the results of !-galactosidase assays (4.2.10) for P. aeruginosa PAO1. 
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Sequence analysis (4.2.9) neither proved nor disproved this assumption nor did the here 
conducted microarray analysis. The regulatory network of P. aeruginosa methionine and SAM 
metabolism has to be further analysed to identify the underlying regulatory network and its 
regulators. 
Methionine metabolism - a connection point for iron metabolism in Pseudomonas 
aeruginosa   
A connection between iron and sulphur metabolism can be assumed. In this study several iron 
starvation genes were detected upregulated in PAO1 "metF after 12 h. The probable ECF 
sigma factor PA1300 and the probable membrane sensor PA1301 were upregulated in PAO1 
"metF, respectively (Table 19). 
Moreover, the genes encoding for the biosynthesis of the siderophores pyoverdine and 
pyochelin were upregulated. The regulator pvdS gene was downregulated in PAO1 "metF 
compared to PAO1 after 12 h. PvdS expression is described to be oxygen dependent (Vasil, 
2007), but after 12 h both cultures were oxygen depleted (Fig. 23 C). A previous study showed 
that CysB the central regulator of sulphur metabolism in P. aeruginosa is crucial for PvdS 
expression (Imperi et al., 2010). The cysB gene (PA1754) was found downregulated in the 
PAO1 after 12 h and was not detected in the PAO1 "metF (Appendix Table 34).  
Another well-known connection between iron and sulphur metabolism are the iron-sulphur 
clusters, which are essential prosthetic groups for electron transfer, gene regulation and 
environmental sensing. Therefore, assembly is carefully regulated to avoid toxicity of free iron 
and sulphide (Ayala-Castro et al., 2008). On the other hand energy is saved, when uptake and 
assembly are coregulated. One can discuss if an unbalanced methionine and SAM level might 
also influence indirectly iron metabolism and uptake.  
A previous study examined the influence of MetR on the virulence of Aspergillus fumigatus. 
They identified MetR as potential regulator of the sulphur assimilation, especially of inorganic 
sources (Amich et al., 2013). The A. fumigatus !metR strain was attenuated in virulence in two 
model systems, but could be complemented by methionine.  
A. fumigatus "metR strain showed an increased intracellular iron content, while showing the 
gene expression pattern of iron starvation (Amich et al., 2013). The intracellular iron content 
was even increased in the absence of methionine and even more iron was present chelated by 
ferricrocin in !metR with and without methionine supplementation. They observed an 
upregulation of iron uptake genes under sulphur starvation conditions. Furthermore, they 
detected a hypersensitivity of the A. fumigatus !metR towards iron. In the presence of high iron 
concentrations the A. fumigatus !metR was unable to grow. 
One can assume that iron sulphur homeostasis might also be affected in PAO1 "metF. The 
effect might not be as strong as in a A. fumigatus !metR mutant, as metF is not a transcriptional 
regulator but an enzyme of methionine and SAM metabolism. Furthermore, the regulatory 
network of regulator MetR in P. aeruginosa is probably different from A. fumigatus. 
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Table 19: Microarray analysis of selected iron regulated genes in PAO1 compared to PAO1 !metF 
in M9 0.5 % caseinate  
Differentially regulated genes of P. aeruginosa PAO1 compared to PAO1 "metF after 4 h and after 
12 h in M9 0.5 % caseinate under microaerobic to anaerobic conditions. Shown are the gene ID, 
gene name, function and the fold change (FC) of genes differently regulated of PAO1 wt 4 h vs. 
PAO1 "metF 4 h (W4 / M4), PAO1 wt 12 h vs. PAO1 "metF wt 12 h (W12 / M12), PAO1 "metF 12 
h vs PAO1 "metF 4 h (M12 / M4) and PAO1 wt 12 h vs PAO1 wt 4 h (W12 / W4).  
Gene IDA Gene 
nameA 
FunctionA  
W4 / 
M4 
FC 
W12 / 
M12 
 
M12 / 
M4 
 
W12 / 
W4 
Iron starvation:      
PA0346 
PA0471 
PA0472 
PA0672 
PA0707 
PA0929 
PA0930 
PA1134 
PA1300 
PA1301 
PA2033 
PA2034 
PA2385 
PA2386 
PA2388 
PA2391 
PA2392 
PA2393 
PA2394 
PA2395 
PA2396 
PA2397 
PA2398 
PA2399 
PA2400 
PA2402 
PA2404 
PA2405 
PA2406 
PA2407 
PA2408 
PA2411 
PA2412 
PA2413 
PA2424 
PA2425 
PA2426 
PA2427 
PA2451 
PA2467 
PA2468 
PA3285 
PA3397 
PA3407 
PA3530 
PA3786 
PA4220 
PA4221 
PA4222 
PA4223 
PA4224 
PA4225 
PA4226 
PA4227 
PA4228 
PA4229 
PA4230 
PA4231 
PA4236 
 
 
 
fiuI  
hemO 
toxR 
 
 
 
 
 
viuB 
 
pvdQ 
pvdA 
fpvR 
opmQ 
pvdP 
 
pvdN 
pvdO 
pvdF 
pvdE 
fpvA 
pvdD 
pvdJ 
 
 
 
 
 
 
 
 
pvdH 
pvdL 
pvdG 
pvdS 
 
 
foxR 
foxI 
 
fpr 
hasAp 
 
 
 
fptA 
 
 
pchG 
pchF 
pchE 
pchR 
pchD 
pchC 
pchB 
pchA 
katA 
 
hypothetical protein 
probable transmembrane sensor 
probable sigma-70 factor, ECF subfamily 
heme oxygenase 
transcriptional regulator ToxR 
two-component response regulator 
two-component sensor 
hypothetical protein 
probable sigma-70 factor, ECF subfamily 
probable transmembrane sensor 
hypothetical protein 
hypothetical protein 
3-oxo-C12-homoserine lactone acylase PvdQ 
L-ornithine N5-oxygenase 
FpvR 
probable outer membrane protein precursor 
PvdP 
probable dipeptidase precursor 
PvdN 
PvdO 
pyoverdine synthetase F 
pyoverdine biosynthesis protein PvdE 
ferripyoverdine receptor 
pyoverdine synthetase D 
PvdJ 
probable non-ribosomal peptide synthetase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable adhesion protein 
probable ATP-binding component of ABC transporter 
probable thioesterase 
conserved hypothetical protein 
L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase 
PvdL 
PvdG 
sigma factor PvdS 
hypothetical protein 
hypothetical protein 
Anti-sigma factor FoxR 
ECF sigma factor FoxI 
probable sigma-70 factor, ECF subfamily 
ferredoxin-NADP+ reductase 
heme acquisition protein HasAp 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
Fe(III)-pyochelin outer membrane receptor precursor 
probable ATP-binding component of ABC transporter 
probable ATP-binding component of ABC transporter 
pyochelin biosynthetic protein PchG 
pyochelin synthetase 
dihydroaeruginoic acid synthetase 
transcriptional regulator PchR 
pyochelin biosynthesis protein PchD 
pyochelin biosynthetic protein PchC 
salicylate biosynthesis protein PchB 
salicylate biosynthesis isochorismate synthase 
catalase 
 
  
 
 
 
 
 
 
 
-2,2 
-2,3 
 
-2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
-2,1 
-2,1 
 
2,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
 
2,6 
2,1 
2,6 
2,7 
2,7 
 
 
5,7 
11,8 
7,9 
2,9 
7,8 
18,8 
 
4,6 
10,5 
5,3 
7,2 
2,9 
9,1 
6,2 
2,0 
18,7 
15,5 
14,8 
13,5 
2,4 
2,3 
2,4 
2,2 
3,4 
21,1 
17,3 
14,4 
21,6 
8,9 
2,6 
23,9 
2,8 
3,7 
 
 
 
4,2 
2,2 
2,0 
7,3 
4,1 
6,4 
7,1 
8,5 
7,5 
6,4 
2,2 
4,4 
8,0 
5,6 
8,2 
 
 
 
 
3,5 
4,0 
3,0 
2,0 
2,2 
3,4 
8,4 
4,6 
2,2 
4,1 
18,8 
2,7 
4,3 
8,8 
6,0 
7,9 
3,1 
10,5 
6,9 
3,7 
12,9 
8,7 
9,1 
10,9 
2,9 
2,5 
2,4 
2,6 
3,0 
15,1 
17,9 
8,3 
11,4 
7,6 
7,6 
14,2 
 
2,9 
2,5 
2,3 
4,3 
2,3 
4,7 
 
6,9 
4,5 
5,1 
6,2 
7,5 
7,6 
6,5 
2,4 
4,1 
4,4 
4,3 
5,5 
-2,5 
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Continued:      
Gene IDA Gene 
nameA 
FunctionA  
W4 / 
M4 
FC 
W12 / 
M12 
 
M12 / 
M4 
 
W12 / 
W4 
PA4358 
PA4359 
PA4362 
PA4366 
PA4370 
PA4467 
PA4468 
PA4469 
PA4470 
PA4471 
PA4570 
PA4708 
PA4709 
PA4895 
PA4896 
PA5150 
 
 
 
 
sodB 
icmP 
 
sodM 
 
fumC1 
 
 
phuT 
 
 
 
 
probable ferrous iron transport protein  
conserved hypothetical protein 
hypothetical protein  
superoxide dismutase 
Insulin-cleaving metalloproteinase outer membrane pp.* 
hypothetical protein 
superoxide dismutase 
hypothetical protein 
fumarate hydratase 
hypothetical protein 
hypothetical protein 
Heme-transport protein, PhuT 
probable hemin degrading factor 
probable transmembrane sensor 
probable sigma-70 factor, ECF subfamily 
probable short-chain dehydrogenase 
 -4,4 
-3,1 
 
2,5 
2,0 
-3,5 
-2,5 
-3,1 
-2,8 
 
 
 
 
 
 
 
8,7 
5,8 
 
-3,6 
 
14,2 
6,3 
11,1 
13,4 
5,3 
11,9 
3,0 
3,1 
2,7 
2,2 
4,1 
 
2,1 
-3,2 
 
 
3,7 
2,5 
3,4 
4,6 
3,4 
5,4 
2,9 
3,6 
 
 
 
Regulated by PA4896B (all genes classified as “related to phage, transposon, or plasmid”):   
PA0614 
PA0615 
PA0616 
PA0617 
PA0618 
PA0619 
PA0620 
PA0621 
PA0622 
PA0623 
PA0624 
PA0625 
PA0626 
PA0627 
PA0628 
PA0629 
PA0630 
PA0631 
PA0633 
PA0634 
PA0635 
PA0636 
PA0637 
PA0638 
PA0639 
PA0640 
PA0641 
PA0644 
PA0645 
 
 Putative holin  
R-type pyocin, related to P2 phage  
R-type pyocin, related to P2 phage; tail spike  
R-type pyocin, related to P2 phage; baseplate  
R-type pyocin, related to P2 phage; baseplate/tail fibre  
R-type pyocin, related to P2 phage; tail formation  
R-type pyocin, related to P2 phage; tail fibre  
R-type pyocin, related to P2 phage; tail fibre assembly  
R-type pyocin, related to P2 phage; tail sheath  
R-type pyocin, related to P2 phage; tail tube  
R-type pyocin, related to P2 phage  
R-type pyocin, related to P2 phage; tail length det.* 
R-type pyocin, related to P2 phage; tail formation  
R-type pyocin, related to P2 phage; tail formation  
R-type pyocin, related to P2 phage; tail formation  
Related to phage, lytic enzyme  
Related to phage, lysis control  
Related to phage, lysis control  
F-type pyocin, related to l phage; major tail protein  
F-type pyocin, related to l phage  
F-type pyocin, related to l phage  
F-type pyocin, related to l phage; tail length determination 
F-type pyocin, related to l phage; tail formation  
F-type pyocin, related to l phage; tail formation  
PF-type pyocin, related to l phage; tail formation  
probable bacteriophage protein 
probable bacteriophage protein 
F-type pyocin, related to l phage 
F-type pyocin, related to l phage 
  
-2,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
 
 
 
 
3,5 
3,4 
3,5 
4,3 
4,3 
4,1 
3,3 
2,3 
4,8 
4,1 
4,8 
3,0 
2,7 
3,9 
3,0 
2,3 
3,3 
3,2 
3,1 
4,4 
3,6 
4,9 
4,4 
4,5 
3,9 
2,2 
2,0 
2,2 
2,4 
2,9 
2,5 
2,1 
2,4 
2,5 
2,1 
2,1 
 
2,4 
2,0 
 
2,0 
 
2,1 
2,2 
 
 
2,1 
 
2,1 
2,1 
3,2 
2,3 
2,9 
 
 
 
 
 
Predicted Fur regulation by (van Oeffelen et al., 2008):     
PA5504 
PA4296 
 
pprB 
D-methionine ABC transporter membrane protein 
two-component response regulator, PprB 
 
2,7 
  
-2,1 
2,1 
-5,6 
A Gene ID, gene name, function and PseudoCAP Function Class (PCFC) are according to the 
“Pseudomonas Genome Database” (Winsor et al., 2011). 
B Functions for genes regulated by PA4896 are annotated according to (Llamas et al., 2008) 
*Abbreviations: det. (determination); pp* (protein precursor) 
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3.3 Conclusions 
This study confirms the importance of methionine auxotrophy among the clinical P. aeruginosa 
CF strains. In total 13 different clone types among the 15 patients and the 30 methionine 
auxotrophic strains were identified.  
This study is the first to determine the genetic cause of methionine auxotrophy. 14 strains were 
complemented with the metF (PA0430) gene. PA0430 encodes for a 5,10-methylene 
tetrahydrofolate reductase. Moreover, two additional strains contained a mutation in metF gene 
and an additional mutation in the metH (PA1843) gene. The sequence analysis did not reveal a 
mutational hot spot within the metF gene. The growth of the remaining 14 non-complemented 
methionine auxotrophic strains was only complemented by methionine, which indicates that the 
mutation must be in the genes of the cofactor biosynthesis, metE and/or metH or a regulator. 
The metF mutation, itself does not seem to enhance the mutator frequency since PAO1 "metF 
did not show an increased mutator frequency compared to PAO1. This indicates that the 
methionine auxotrophy is selected independently of the mutator phenotype.  
An important characteristic of the PAO1 "metF strain and 30 methionine auxotrophic clinical 
isolates was the reduced to abolished pyocyanin production. The transcriptom of PAO1 "metF 
did not indicate any alterations in phenazine biosynthesis gene expression. Therefore, the 
reduction of pyocyanin biosynthesis must be a direct effect of the metF mutation.  
In general, methionine auxotrophic strains such as PAO1 "metF are dependent on external 
methionine, to refill their methionine pool and thereby refilling the SAM pool to be able to grow. 
On can discuss that decreased cellular methionine level together with decreased recycling of 
methionine most likely results in an imbalance of the intracellular SAM / SAH level, which is 
then influencing SAM dependent reactions such as e.g. pyocyanin biosynthesis or the 
transcription of the genes encoding for the iron-sulphur cluster containing radical SAM enzyme 
HemN and the SAM-dependent methylase NirE.  
Antipseudomonal treatments target actively growing cells, slower or non-growing cells have a 
survival advantage. One can suspect that this might be also be true for metF mutation 
especially in clinical P. aeruginosa CF strains. During methionine depletion a strain carrying a 
metF mutation would be unable to grow. Depending on the degree of methionine availability 
strains would produce wt amounts of pyoverdin and reduced amounts of pyocyanin or act as 
cheater during methionine depletion and use pyoverdin and pyocyanin produced by other 
strains. With sufficient methionine supplementation odDHL and BHL production was even 
increased in PAO1 "metF. Thereby, a metF mutant might stimulate other strains to produce 
public goods such as pyoverdin and pyocyanin. This overproduction was abolished in all clinical 
methionine auxotrophic strains investigated. Strains carrying a metF mutation might also be 
able to accumulate more iron - one of the essential goods during infection. But this hypothesis 
has to be verified by further investigations of the intracellular iron content of PAO1 "metF. 
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3.4 Material and Methods 
3.4.1 Isolation of Pseudomonas aeruginosa strains from the respiratory tract of cystic 
fibrosis patients 
The samples from the respiratory tract of the CF patients were taken during routine 
examinations. Strains were isolated as described (Hogardt et al., 2006). Strains were analysed 
for growth on minimal media and for growth on minimal media containing methionine. The 
strains were obtained from Michael Hogardt.  
For the further analysis of the methionine auxotrophic clinical P. aeruginosa strains M9 20 mM 
succinate minimal medium (Sambrook and Russell, 2001) was used containing 1 x M9- salts 
[47.7 mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 18.7 mM NH4Cl], 20 mM succinate, 2 mM 
MgSO4, 0.1 mM CaCl2, 1 x trace metals [0.148 mg/l ZnSO4 x 6 H2O, 0.100 mg/l MnCl2 x 4 H2O, 
0.236 mg/l CoSO4 x 7 H2O, 0.100 mg/l NiCl2 x 6 H2O, 0.020 mg/l CuCl2 x 2 H2O, 0.050 mg/l 
Na2MoO4 x 2 H2O, 1 #l/l 25 % HCl modified after (Schlegel, 2007) ] with and without 50 #M 
methionine (Sigma), respectively.  
Besides, the clinical P. aeruginosa strains were investigated for growth on M9 succinate with 
supplementation of 50 #M L-serine, L-homoserine, O-succinyl-L-homoserine, L-cysteine or Hcy 
(all obtained from Sigma), respectively. Hcy and vitamin B12 were used at 100 #M, as 
described previously (Barth et al., 1998). 
3.4.2 Bacterial strains and growth conditions 
All bacterial strains used in this study are shown in Table 20 and plasmids in Table 21. E. coli 
and P. aeruginosa strains were grown routinely in LB medium for standard molecular biology 
protocols. For P. aeruginosa the following concentrations of antibiotics were used: carbenicillin 
250 #g/ml, gentamicin 80 #g/ml and tetracycline 100 #g/ml. The E. coli strain DH10B was used 
as a host for cloning and ST18 for transfer of plasmids and cosmids to P. aeruginosa. The 
E. coli strain JM109, which was used for the biolumescence assay for the determination of AHL 
concentration, was incubated at 30°C. 
Cultures were inoculated at OD578 of 0.05 and shaken at 200 rpm at 37°C, if not indicated 
otherwise. For growth experiments in MHB an over night culture in LB medium was prepared. 
For growth experiments in M9 0.5% caseinate an over night culture in amino acid medium 
modified (AAMM) was prepared. AAMM (pH 6.9) contains 86 mM NaCl, 29 mM KCl, 20 mM 
Hepes, 15 #M DTPA, 1.75 mM CaCl2, 0.61 mM MgCl2, 0.271 mM MgSO4 and 2.55 mM 
Na2HPO4/ NaH2PO4 (pH 6.9) and 19 mM amino acids [1.8 mM alanine, 1.6 mM glutamate, 1.1 
mM isoleucine, 0.01 mM tryptophan, 1.6 mM leucine, 0.8 mM aspartate, 1.7 mM proline, 2.1 
mM lysine, 1.5 mM serine, 0.5 mM phenylalanine, 0.8 mM tyrosine, 1.1 mM valine, 1.1 mM 
threonine, 0.2 mM cysteine, 0.3 mM arginine, 1.2 mM glycine, 0.5 mM histidine (Sigma)]. The 
pH was adjusted with HCl and NaOH. For solid medium 15 g/l agar was added. Methionine was 
added in different concentrations depending on the experiment of 630 #M for simulated 
respiratory tract conditions or 100 #M or 200 #M. 
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3.4.3 Sequence analysis of the metF gene 
Colony PCR was performed using the respective primers. The PCR product was gel purified 
using gel purification Kit (Qiagen) according to the manufacturer´s instructions. The sequence 
was determined by GATC. The sequence was analysed using the program 4Peaks. 
3.4.4 Construction of Pseudomonas aeruginosa deletion strains 
To obtain unmarked gene deletion mutants the well-established strategies based on sacB 
counterselection and FLP recombinase excision (Hoang et al., 1998) were used. To achieve 
deletion of mtnP (PA3004) the pAW03 suicide plasmid, of metZ (PA3107) the pMR01 suicide 
plasmid, of metE (PA1927) the pFH06 suicide plasmid and of metH (PA1843) the pFH07 
suicide plasmid was constructed. 
For the construction of all plasmids the gentamycin resistance cassette of pPS858 was digested 
with the indicated enzymes (Table 22) and was cloned between two PCR fragments of the 
respective genes in the multiple cloning site of pEX18Ap, respectively. The two PCR fragments 
contained DNA homologous to upstream und downstream fragments of the above-mentioned 
genes, respectively, which should be deleted in the respective mutant strains. Primer sequence 
and vector details are shown in Table 22 and Table 21. 
The construction of PAO1 ΔsahH and PAO1 "metF are described elsewhere (Thoma, 2009). 
The gene deletion constructs were introduced into E. coli DH10B by transformation. Plasmids 
containing the correct insert were transferred via diparental mating using E. coli strain ST18 
(Thoma and Schobert, 2009) in P. aeruginosa PAO1. After successful gene deletion the 
gentamicin resistance cassette was removed from the genome using the pFLP2 plasmid to 
obtain unmarked gene deletion mutants (Hoang et al., 1998). The resulting deletion mutants 
were verified by PCR. Double or triple deletion mutants were obtained by repeating the 
described procedure for each gene to be deleted (Table 20). 
3.4.5 Construction of complementation vector and complementation of methionine 
auxotrophic Pseudomonas aeruginosa strains 
To identify if the methionine auxotrophy in the clinical CF isolates was caused by a mutation in 
the metF gene (PA0430) a in total 872 bp PCR product, was amplified and cloned into 
pUCP20T (pST10) (Thoma, 2009). Some strains were also complemented by pFH04 
(pUCP20T::metF::metH). Primer sequences and vector details are shown in Table 22 and Table 
21. The transfer of pST10 and pFH04 plasmid in P. aeruginosa and clinical isolates was carried 
out as described previously (Boes et al., 2008) modified by the use of ST18 (Thoma and 
Schobert, 2009).  
3.4.6 Motility assays - swimming, swarming and twitching motility  
Motility assays were performed as described, previously with minor modifications (O'Toole and 
Kolter, 1998; Yeung et al., 2009). Briefly, twitching motility was determined in 1% LB agar. 2 #l 
of the investigated strains were inoculated between the agar and the petri dish and incubated 
for 24 h at 37°C and for 48 h at 25°C. Swimming motility was investigated in 0.3 % LB agar. 2 #l 
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of the investigated strains were inoculated into the middle of the agar and incubated for 24 h at 
37°C. 
For the investigation of swarming motility a medium containing 0.5 % agar, 1 x M8- salts [47.7 
mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl], 0.4% glucose, 0.5 % casamino acids, 2 mM 
MgSO4 and 10 #M FeSO4 was used. 2 #l of the investigated strains were inoculated on the agar 
surface and incubated for 48 h at 37°C. Hazy zones around the inoculation were measured and 
the radius [mm] determined. 
3.4.7 AHL quorum sensing molecule formation 
For the determination of AHL molecule formation of the clinical isolates KI-AW01 to KI-AW28, 
CFCZ, PAO1 and PAO1 "metF the strains were grown over night in LB and inoculated to OD578 
0.05 in 10 ml Mueller-Hinton broth (MHB; Fluka). Cultures were shaken at 200 rpm at 37°C. 
After 24 h OD578 was measured.  
For the investigation of quorum sensing molecule formation of methionine metabolism deletion 
strains, the strains were grown over night in AAMM and inoculated to OD578 0.05 in 10 ml M9 
0.5% caseinate. Cultures were shaken at 200 rpm at 37°C. After 24 h OD578 was measured. 
Samples were prepared as described previously with minor modification of reduced sample size 
of 100 #l and incubation at 17°C for 18 h (Diggle et al., 2002).  
The E. coli JM109 strains harbouring the plasmids pSB1075 or pSB406 were used for 
bioluminescence assay in order to determine odDHL or BHL concentration, respectively. The 
assay was performed as described, previously (Winson et al., 1998). Briefly, 2 #l acidified and 
diluted sample or reference BHL (Fluka) or odDHL (Sigma) were mixed with 200 #l E. coli 
culture in a 96 well luminescence plate (Greiner) and sealed with sealing film Breath-easy 
(Roth) for gas exchange and shaken at 600 rpm (Varioskan Flash, Thermo Scientific) at 30°C 
for 2 h, during incubation OD578 and bioluminescence was measured. 
AHL concentrations were calculated according to the respective calibration curves determined 
for each measurement. odDHL was diluted in DSMO and BHL was diluted in MilliQ water. End 
concentrations of 0.63 nM to 80 nM odDHL and of 15.25 nM to 3.9 #M BHL in 200 #l were used 
for calibration. 
3.4.8 Mutator phenotype 
To investigate the frequency of mutator phenotype among the clinical CF isolates the strains 
cultures were inoculated at OD578 of 0.05 in 10 ml MHB and shaken at 200 rpm at 37°C for 24 h. 
CFU was determined on LB agar and mutator frequency was determined on LB rifampicin 
100 #g / ml (RA-100). Mutator frequency was calculated CFU RA-100 resistant bacteria vs. LB 
CFU.  We modified the terms defined by Ciofu et al. (2010). All strains with a mutator frequency 
' 1.5 x 10-7 were classified as strong mutators. Strains with lower mutator frequency of < 1.5 x 
10-7 to ' 1.5 x 10-8 were described as weak mutators. A mutator frequency of < 1.5 x 10-8 similar 
to the P. aeruginosa PAO1 was considered as non-mutator. P. aeruginosa PAO1 "mutS was 
used as positive control (Hogardt et al., 2006). 
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3.4.9 Virulence factor production - pyocyanin and pyoverdin 
For virulence factor production experiments, P. aeruginosa PAO1 and several methionine 
metabolism deletion mutants were grown in M9 minimal medium 0.5% caseinate (Sambrook 
and Russell, 2001) containing 1 x M9- salts [47.7 mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 
18.7 mM NH4Cl], 0.5% caseinate, 2 mM MgSO4, 0.1 mM CaCl2, 1 x trace metals [0.148 mg/l 
ZnSO4 x 6 H2O, 0.100 mg/l MnCl2 x 4 H2O, 0.236 mg/l CoSO4 x 7 H2O, 0.100 mg/l NiCl2 x 6 
H2O, 0.020 mg/l CuCl2 x 2 H2O, 0.050 mg/l Na2MoO4 x 2 H2O, 1 #l/l 25 % HCl modified after 
(Schlegel, 2007) ], respectively. Cultures were inoculated at OD578 of 0.05 in 10 ml medium and 
shaken at 200 rpm at 37°C, if not indicated otherwise. 
OD578 was determined after 24 h and 1 ml supernatant was sterilised by filtration. Pyocyanin 
and pyoverdin was extracted as described, previously. Pyocyanin was determined at OD695 and 
pyoverdin fluorescence was excited at 405 nm and emission was determined as relative 
fluorescence F460. As negative control for the pyocyanin production P. aeruginosa PA14 "phz 
was used. The results of at least three independent experiments are shown.  
3.4.10 Transcriptome analysis in M9 0.5% caseinate and measurement of oxygen 
concentration 
PAO1 and PAO1 "metF were cultivated in 250 ml M9 0.5% caseinate in 300 ml shaking flaks 
without baffles at 37°C and 200 rpm. The over night culture was prepared in AAMM with 630 
#M methionine. We used Fibox 3 LCD-trace (PreSens) together with the autoclavable oxygen 
sensor spot SP-PSt3 (PreSens), which was permanently attached inside the shaking flask for 
oxygen concentration measurement [#mol/l]. Data were exported with OxyView - LCDTRACE-
V2.04 10/2009 (PreSens). OD578 was measured using a photometer Ultrospec (Amersham 
Biosciences). 
3.4.11 RNA isolation, RNA enrichment and cDNA amplification 
For RNA isolation 25 ml of bacterial culture were harvested at the respective time points after 
4 h and 12 h. The sample was incubated with 15 ml RNAprotect® Bacteria Reagent (Qiagen) 
according to the manufacturer’s instructions. Samples were stored at - 80°C. RNA was isolated 
using RNeasy® Mini Kit (Qiagen). The RNA isolation was performed as described previously 
with minor modifications (Bielecki et al., 2011). Bacteria were lysed using 400 #l TE buffer 
containing 1 mg/ml lysozyme with periodic vortexing every 2 min for 15 sec for 10 min. 700 #l 
RLT puffer containing 1% !-mercaptoethanol were added. Afterwards samples were centrifuged 
at maximal speed (14.100 x g) for 2 min. The same amount of ethanol was added to the 
samples. The samples were loaded to a spin column, washed with RW1 buffer afterwards DNA 
was digested using RNase-free DNase I. RNA was eluted in 50 #l and 30 #l of RNase-free 
water. Eluted RNA was treated a second time with DNase I to ensure that all traces of genomic 
DNA were removed. The isolated RNA was stored at – 80°C. The yield of the isolated RNA was 
measured by light absorption at 260 nm using a Nanodrop ND-1000-UV/VIS (Peqlab). Integrity 
and purity was checked by 2100 BioAnalyzer (Agilent Technologies). 
P. aeruginosa GeneChip from Affymetrix requires 7,5 - 10 #g of RNA per microarray. Bacterial 
RNA amplification was used. This was performed using the MessageAmp Bacteria Kit® 
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(Ambion). The first step was to treat the total enriched bacterial RNA with a polyadenylation 
polymerase to produce polyA tails. The single stranded cDNA was produced using reverse 
transcriptase and oligo dT primers. Afterwards a second strain cDNA was produced, and the 
double stranded cDNA served as a template for in vitro transcription using T7 RNA polymerase 
and T7 oligonucleotides. During the in vitro transcription reaction the modified nucleotides 
biotin-11-CTP (PerkinElmer Life Sciences) and biotin-16-UTP (Roche Applied Science) were 
used. As a result antisense biotinylated RNA ready to use for GeneChip® hybridization was 
obtained. 
3.4.12 Microarray hybridisation  
Amplified RNA is commonly used for eukaryotic microarrays, but the original procedure for 
P. aeruginosa Gene-Chip® (Affymetrix) was for single stranded terminally labelled cDNA. As 
described previously, no difference in results for microarray analysis were observed for the 
standard procedure (without amplification) RNA procession or amplified RNA (Francois et al., 
2007). The hybridization and washing steps were performed in the Affymetrix Array facility at 
Helmholtz Centre for Infection Research (HZI) Braunschweig (Dr. Robert Geffers). Since the 
RNA had been amplified, some changes were introduced to the original Affymetrix protocol, 
such as that the RNA was fragmented using 5 x fragmentation buffer instead of DNase I 
treatment. Hybridisation was performed as described previously (Bielecki et al., 2011). 
3.4.13 Microarray data analysis 
Raw microarray data were pre-processed with the Bioconductor software framework 
(Gentleman et al., 2004). Expression values were calculated as described, previously (Trunk et 
al., 2010). Robust Multichip Average (RMA) method using quantile normalization, background 
corrected PM intensities and median polish as summarization method were applied (Bolstad et 
al., 2003; Irizarry et al., 2003a; Irizarry et al., 2003b). 
In addition, the pdes were computed for the following pairwise comparison of experimental 
conditions: PAO1 wt after 4 h versus PAO1 wt after 12 h, PAO1 "metF after 4 h versus PAO1 
"metF after 12 h, PAO1 wt after 4 h versus PAO1 "metF after 4 h and PAO1 wt after 12 h 
versus PAO1 "metF after 12 h. For this purpose, the pre-processed expression data were 
analysed by a regularized t-test based on a Bayesian statistical framework using the CyberT 
algorithm (Baldi and Long, 2001; Hatfield et al., 2003). The R package bayesreg, which 
implements the CyberT algorithm, was used for computing the posterior probabilities of 
differential expression (free download under http://cybert.microarray.ics.uci.edu/). The mean 
gene expression levels of the replicate experiments were ranked in ascending order, a sliding 
window of 101 genes was used and a confidence value of 10 was chosen as weight. More 
information on the use of this regularized t-test in the context of determining differentially 
expressed genes of prokaryotic DNA microarray expression data is published elsewhere (Hung 
et al., 2002). A combination of information from expression ratios and pdes allowed to identify 
the genes with the highest relative changes in expression values and the highest probabilities of 
differential expression at the same time. 
  
Methionine auxotrophy - An adaptation strategy of Pseudomonas aeruginosa towards the cystic fibrosis 
lung 
 
 100 
Table 20: Bacterial strains  
Bacterial strains  Genotype / description Reference 
P. aeruginosa:   
PAO1 Wild type (Dunn and Holloway, 1971) 
PAO1 "mutS PAO1 "mutS (PA3620) (Hogardt et al., 2006) 
ST30 PAO1 "metF (PA0430) (Thoma, 2009) 
ST26 PAO1 ΔsahH (PA0432) (Thoma, 2009) 
AW07 PAO1 ΔmtnP (PA3004) This study 
AW12 PAO1 ΔsahH ΔmtnP (PA0432, PA3004) This study 
AW18 PAO1 ΔmetZ (PA3107) This study 
FH01 PAO1 +metH (PA1843) This study, Frederike Haack 
FH03 PAO1 +metE (PA1927) This study, Frederike Haack 
FH05 PAO1 +metE +metH (PA1927, PA1843) This study, Frederike Haack 
FH08 PAO1 +metE +metF +metH (PA1927, PA0430, PA1843) This study, Frederike Haack 
AW20 PAO1 pUCP20T  This study 
AW21 PAO1 "metF pST10 This study 
PA14 "phz PA14 "phzA1-G1 "phzA2-G2 (Dietrich et al., 2006) 
Clinical cystic fibrosis isolates:  
CFCZ Clinical cystic fibrosis isolate from patient A, Medizinische 
Hochschule Hannover (MHH) 
(Bielecki et al., 2013) 
CF-1 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
CF-2 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
CF-3 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
CF-4 Clinical cystic fibrosis isolate from patient B (Bielecki et al., 2013) 
KI-AW 1 Clinical cystic fibrosis isolate from patient 1 Michael Hogardt 
KI-AW 2 Clinical cystic fibrosis isolate from patient 2 Michael Hogardt 
KI-AW 3 Clinical cystic fibrosis isolate from patient 2 Michael Hogardt 
KI-AW 4 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 5 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 6 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 7 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 8 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 9 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 10 Clinical cystic fibrosis isolate from patient 4 Michael Hogardt 
KI-AW 11 Clinical cystic fibrosis isolate from patient 4 Michael Hogardt 
KI-AW 12 Clinical cystic fibrosis isolate from patient 5 Michael Hogardt 
KI-AW 13 Clinical cystic fibrosis isolate from patient 5 Michael Hogardt 
KI-AW 14 Clinical cystic fibrosis isolate from patient 6 Michael Hogardt 
KI-AW 15 Clinical cystic fibrosis isolate from patient 6 Michael Hogardt 
KI-AW 16 Clinical cystic fibrosis isolate from patient 7 Michael Hogardt 
KI-AW 17 Clinical cystic fibrosis isolate from patient 8 Michael Hogardt 
KI-AW 18 Clinical cystic fibrosis isolate from patient 8 Michael Hogardt 
KI-AW 19 Clinical cystic fibrosis isolate from patient 8 Michael Hogardt 
KI-AW 20 Clinical cystic fibrosis isolate from patient 9 Michael Hogardt 
KI-AW 21 Clinical cystic fibrosis isolate from patient 3 Michael Hogardt 
KI-AW 22 Clinical cystic fibrosis isolate from patient 10 Michael Hogardt 
KI-AW 23 Clinical cystic fibrosis isolate from patient 8 Michael Hogardt 
KI-AW 24 Clinical cystic fibrosis isolate from patient 8 Michael Hogardt 
KI-AW 25 Clinical cystic fibrosis isolate from patient 11 Michael Hogardt 
KI-AW 26 Clinical cystic fibrosis isolate from patient 6 Michael Hogardt 
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Continued:   
Bacterial strains  Genotype / description Reference 
KI-AW 27 
KI-AW 28 
Clinical cystic fibrosis isolate from patient 6 
Clinical cystic fibrosis isolate from patient 12 
Michael Hogardt 
65 Clinical cystic fibrosis isolate from patient C Gerd Döring, Tübingen  
BT72 Clinical cystic fibrosis isolate from patient D  MHH 
E. coli:   
DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) "80dlacZΔM15 ΔlacX74 
deoR recA1 endA1 araD139 Δ(ara, leu) 7697 galU galK #- rpsL 
nupG 
GibcoBRL 
(Invitrogen) 
ST18 S17 (pir ΔhemA (Thoma and Schobert, 2009) 
JM109 recA1 endA1 gyrA96 thi hsdR17 supE44 relA1 !(lac-proAB) 
mcrA [FP traD36 proAB lacI lacZ !M15] with pSB1075 (for 
odDHL detection) or with pSB406 (for BHL detection) 
(Yanisch-Perron et al., 1985) 
(Winson et al., 1998) 
Table 21: Plasmids 
Plasmid Description Reference 
pEX18AP Apr, oriT+ sacB+; gene replacement vector with MCS of pUC18 (Hoang et al., 1998) 
pPS858 Apr, Gmr, source of gentamicin cassette (Hoang et al., 1998) 
pFLP2 Apr, source of FLP recombinase (Hoang et al., 1998) 
pUCP20T Cbr, mobilizable E. coli - P. aeruginosa shuttle vector  (Schweizer, 1996) 
pST06 Apr Gmr; pEX18Ap with 593 bp upstream sahH, Gmr-gfp fragment from 
pPS858 SacI digested, and 473 bp downstream of the coding region of 
sahH between KpnI and XbaI 
(Thoma, 2009) 
pST09 Apr Gmr; pEX18Ap with upstream metF and downstream of the coding 
region of metF between KpnI and XbaI, Gmr-gfp fragment from 
pPS858 SacI digested  
(Thoma, 2009) 
pST10 pUC20T containing a 872 bp SacI- HindIII fragment of metF (PA0430), 
Carbr, pUC20T::metF 
(Thoma, 2009) 
pMR01 Apr Gmr; pEX18Ap with 751 bp upstream metZ, Gmr-gfp fragment from 
pPS858 BamHI digested, and 524 bp downstream of the coding region 
of metZ between KpnI and XbaI 
This study, Matthias. 
Rottmann(Rottmann, 
2011)(Rottmann, 
2011)(Rottmann, 
2011)(Rottmann, 
2011)(Rottmann, 
2011)(Rottmann, 
2011)(Rottmann, 2011)  
pAW03 Apr Gmr; pEX18Ap with 752 bp upstream mtnP, Gmr-gfp fragment from 
pPS858 BamHI digested, and 522 bp downstream of the coding region 
of mtnP between KpnI and XbaI 
This study 
pFH04 pUC20T containing a 1048 bp EcoRI- XbaI fragment of metF (PA0430) 
and a 3840 bp XbaI HindIII fragment of metH (PA1843), Carbr, 
pUC20T::metF::metH 
This study, Frederike 
Haack 
pFH06 Apr Gmr; pEX18Ap with 809 bp upstream metE, Gmr-gfp fragment from 
pPS858 BamHI digested, and 613 bp downstream of the coding region 
of metE between SacI and XbaI 
This study, Frederike 
Haack 
pFH07 Apr Gmr; pEX18Ap with 460 bp upstream metH, Gmr-gfp fragment from 
pPS858 BamHI digested, and 837 bp downstream of the coding region 
of metH between SacI and XbaI 
This study, Frederike 
Haack 
pSB1075 Apr, ColE1 ori, fusion of lasRI::luxCDABE, pUC18 plasmid backbone (Winson et al., 1998) 
pSB406 Apr, ColE1 ori, fusion of rhlRI::luxCDABE, pUC18 plasmid backbone (Winson et al., 1998) 
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Table 22: Primer (restriction sites are underlined) 
Primer Primer sequence (5’ - 3’) Restriction 
site  
Construct 
pST09 metF:   
metFP1 GGGGTACCGCCGATCACTACAACCAG KpnI upstream fragment  
metFP2 GAGCTCCGCGCCTCTTCTTGTTGATT SacI upstream fragment 
metFP3 GAGCTCTGGCGATCTGGAAGAATCTC SacI downstream fragment 
metFP4 GCTCTAGACGATGACGCCGGAGTTGA XbaI downstream fragment 
pST06 sahH:   
sahHP1 GGAGTACCACCAGGGCGCTGCACATC KpnI upstream fragment  
sahHP2 CGAGCTCTGACAGCGCTCATGCGTAA SacI upstream fragment 
sahHP3 CGAGCTCCGGACACCTATCGCTACTA SacI downstream fragment 
sahHP4 GCTCTAGATGGCTGCAGGTTGGTGAT XbaI downstream fragment 
pMR01 metZ:   
oAW208 GGGGTACCTCGTTGTCGGCAAGCACTA KpnI upstream fragment  
oAW207 CGGGATCCGCCATCCTCAGCATGAGTT BamHI upstream fragment 
oAW152 CGGGATCCGCCGCTCTCCCCTTTGTCA BamHI downstream fragment 
oAW153 GCTCTAGACCAGGCGGCGCGGAAGAAA XbaI downstream fragment 
pAW03 mtnP:   
oAW154 GGGGTACCGCCTATGCGCTTGTTCCGT KpnI upstream fragment 
oAW155 CGGGATCCGGCGTTGCACGATGGCATT BamHI upstream fragment 
oAW162 CGGGATCCCTCCCTCAATCAATCAG BamHI downstream fragment 
oAW163 GCTCTAGAAGCATTTTCCCGGTCAC XbaI downstream fragment 
pFH06 metE:   
oFH01 CCGAGCTCGCGGGCTACTCGGAAATCTA SacI upstream fragment 
oFH02 CGGATCCCGTGGGTGTTCCTCCAGTCG BamHI upstream fragment 
oFH03 CGGGATCCCGGGGCCTGGTGAGCGGAA BamHI downstream fragment 
oFH04 GCTCTAGAGCCATCGCGACGCGGACTT XbaI downstream fragment 
pFH07 metH:   
oFH05 CCGAGCTCGCGCTGTATCGGCAGAAGTA SacI upstream fragment 
oFH06 CGGGATCCCGATGGACCTGGCGTCAGT BamHI upstream fragment 
oFH07 CGGGATCCCGCGAACCTTGGCTACGAT BamHI downstream fragment 
oFH08 CGTCTAGAGCCAGGGCATCAAGAACCT XbaI downstream fragment 
pST10:    
forward CGAGCTCAGCACTACCGCCAGTACTA SacI pUC20T::metF 
reverse CCCAAGCTTTCGTGGATCGCGTGAGA HindIII pUC20T::metF 
pFH04 metF::metH:   
oFH13 GGAATTCCGAGCACTACCGCCAGTACT EcoRI Forward primer metF 
oFH15 GCTCTAGAGCGATGCTTGCGTGAGTTG XbaI Reverse primer metF 
oFH17 GCTCTAGACGAAGCCCCGGCCTTTGTT XbaI Forward primer metH 
oFH18 CCCAAGCTTGGGCTTGCGCGGCTTTTC Hind III Reverse primer metH 
pAW08:    
oAW194 GGAATTCCATATGATGGTCGCGTCCAA NdeI pET-14b::metF 
oAW195 CCGCTCGAGTCAGCGTGGCAGCTGGAG XhoI pET-14b::metF 
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Supplemental Material: 
 
Fig. 24: Growth of methionine metabolism P. aeruginosa PAO1 deletion mutants in M9 20 mM 
succinate with 50 "M methionine supplementation 
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4 Ribavirin against Pseudomonas aeruginosa 
4.1 Introduction 
The need for new antibiotic substances and new antibiotic targets is undeniable especially in 
the time of rising bacterial antibiotic resistance. Antibiotics target life processes such as cell-wall 
biosynthesis and cell envelope, protein biosynthesis and ribosomes, RNA and DNA replication 
and the folate metabolism (Walsh, 2003).  
Multidrug resistant opportunistic pathogens such as the Gram-negative bacterium 
Pseudomonas aeruginosa, become more and more threating human pathogens, as it 
possesses intrinsic drug resistance (Hancock, 1998; Stover et al., 2000). P. aeruginosa is 
known to cause nosocomial infections especially in immunocompromised patients. Acute and 
persistent infections are frequently caused by P. aeruginosa in the lungs of cystic fibrosis (CF) 
patients. 
CF is a hereditary disease caused by a mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene (Hauser et al., 2011; Lyczak et al., 2002).  
Once a chronic P. aeruginosa infection is established, the infection is nearly impossible to cure 
and often associated with the decline of lung function (Hauser et al., 2011). But, how does 
P. aeruginosa achieve this state of resistance? Besides its intrinsic resistance, further changes 
of phenotype are observed, as P. aeruginosa colonizes the nutrient rich mucus in the lungs of 
CF patients. This special environment leads to the known phenotypes of mucoidy and the 
formation of microcolony and biofilm (Boucher et al., 1997; Govan and Deretic, 1996; Lam et al., 
1980). Bacteria prevent phagocytosis and the diffusion of antibiotics is hindered (Lewis, 2001; 
Xu et al., 2000). Nutrient availability also has a direct influence on bacterial metabolism and 
thereby influences growth and virulence factor production (Palmer et al., 2005). Oxygen 
limitation in the microaerobic to anaerobic environment of the CF lung further reduces antibiotic 
effectiveness and also leads to phenotype changes (Alvarez-Ortega and Harwood, 2007; 
Worlitzsch et al., 2002).  
Since resistance against commonly used CF antibiotics such as tobramycin and ciprofloxacin is 
increasing, new effective substances and new targets are necessary (Amini et al., 2011; 
Brazas et al., 2007; Wu et al., 1999). This study reports about both, a new antibiotic target and 
about an already known viral drug effective against P. aeruginosa.  
Ribavirin (1-!-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is as a purine analogue. It is 
structurally very similar to adenosine (Ado), e.g. inter alia the product of the hydrolysis of S-
adenosylhomocysteine (SAH) into homocysteine (Hcy) and Ado (Fig. 25A.&B.). Ribavirin is an 
approved drug against DNA and RNA viruses, e.g. for hepatitis C treatment in combination with 
interferon (Davis et al., 1998). Recently ribavirin’s impact on Trypanosmoma cruzi´s (Tc) S-
adenosylhomocysteine hydrolase SAHH was successfully tested (Cai et al., 2010; Cai et al., 
2007). Ribavirin resulted in total inhibition of the enzyme in an in vitro assay. Kruszewska et al. 
(2002) tested ribavirin successfully in their study looking for antimicrobial activity in non-
antibiotic drugs. In addition Kruszewska et al. could show an effect against P. aeruginosa. 
The potential drug target S-adenosylhomocysteine hydrolase (SahH, EC 3.3.1.1) has been 
identified in one of the essential metabolic pathways the activated methyl circle (AMC), exactly 
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in the recycling of S-adenosylmethionine (SAM) (Fig. 25). SAM is the second most frequently 
used enzyme substrate after ATP (Fontecave et al., 2004; Loenen, 2006). The majority of 
estimated 95 % of SAM is used for methylation reactions (Griffith, 1987). Methylation is one of 
the most ubiquitous chemical reactions in cellular metabolism (Stepkowski et al., 2005). The 
product of these reactions SAH is a potent inhibitor of transmethylation reactions. SAH is 
effectively converted to Hcy and Ado by SahH. SahH is a very important enzyme in the 
metabolism since methylation of macromolecules and small molecules is dependent on the 
SAM / SAH equilibrium.  
Recently the intracellular SAM and SAH level for the Escherichia coli wild type (wt) strain 
MG1665 (OD600 of 1.62 ± 0.16) was identified with a ratio of 300:1 with 0.4 mM and 1.3 #M, 
respectively (Halliday et al., 2010). In contrast to P. aeruginosa, E. coli and several other 
bacteria use a two-step mechanism instead, to convert SAH to Hcy. First S-ribosyl-
homocysteine (SRH) and adenine are generated by Pfs a 5,-methylthioadenosine/S-
adenosylhomocysteine nucleosidase. In a second step SRH is converted by LuxS a S-
ribosylhomocysteine lyase to Hcy and 4,5-dihydroxy-2,3-pentanedione (DPD), which 
spontaneously forms autoinducer-2 a quorum sensing molecule (Halliday et al., 2010; Parveen 
and Cornell, 2011; Winzer et al., 2002). 
Approximately 2-5 % of cellular SAM is used for decarboxylation reactions e.g. for the 
production of polyamines, quorum sensing molecules synthesis such as N-acylhomoserine 
lactones (AHLs) or as source of 5´deoxyadenosyl radicals. 5´deoxyadenosyl radicals are used 
for the production of vitamins e.g. biotin and lipoate. (Griffith, 1987; Parveen and Cornell, 2011). 
These reactions yield 5´-methylthioadenosine (MTA) or 5´deoxyadenosine (5´dAdo), 
respectively. 
Sun et al. investigated 138 bacterial species. 60 of the investigated species contained a SAH 
hydrolase, whereas 51 possessed MTA/SAH nucleosidase. Few bacteria carry both enzymes, 
while symbionts and intracellular pathogens lack both and are therefore probably dependent on 
their hosts (Sun et al., 2004; Winzer et al., 2002).  
P. aeruginosa is one of the few bacteria, which possess a SAH hydrolase as well as a MTA 
phosphorylase (MtnP, EC 2.4.2.28) for recycling of SAH and MTA, and probably for 5´dAdo 
(Challand et al., 2010; Challand et al., 2009; Choi-Rhee and Cronan, 2005). The narrow 
substrate specificity of both enzymes for the recycling of either SAH or MTA seems to be an 
advantage for survival of P. aeruginosa under the varying environmental conditions (Stepkowski 
et al., 2005). This makes SahH an excellent drug target. 
So far SahH is described as a homo tetrameric enzyme (Tanaka et al., 2004). It contains tightly 
bound NAD+ as cofactor. The structures of human, rat, mouse and of the malaria parasite 
Plasmodium falciparum SAHH are available (Ishihara et al., 2010; Tanaka et al., 2004; Turner 
et al., 2000; Yamada et al., 2005). The crystal structures for the bacterial SahHs of 
Mycobacterium tuberculosis and Corynebacterium glutamicum were determined (Lozada-
Ramirez et al., 2008; Reddy et al., 2008). Structure dependent drug design is possible for these 
SAH hydrolases. 
Other regulating factors seem to have an important impact on AMC genes and might be 
potentially targeted by drugs. Riboswitches are mRNA structures that regulate gene expression 
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(Blount and Breaker, 2006). For several bacterial species SAM and SAH dependent 
riboswitches were shown or were predicted in the mRNAs of the genes involved in the AMC. 
For Pseudomonas syringae a SAH dependent riboswitch in the mRNA of the sahH operon was 
described (Wang et al., 2008). Wang et al. proposed that SAH binding activates gene 
expression. 15 SAH RNA motifs were identified in the Pseudomonadales (Wang et al., 2008). 
Recently, a SAM-III box was identified in the 5´untranslated region (5´ UTR) of metK in 
Enterococcus faecalis (Smith et al., 2010). 
So far it is predicted and partly verified for some organisms that the genes of S-
adenosylhomocysteine hydrolase (sahH), cobalamin-dependent methionine synthase (metH) 
and methylenetetrahydrofolate reductase (metF) are possessing a possible SAH element in the 
5´ UTR (Wang et al., 2008; Weinberg et al., 2007). 
Here, the possibility of ribavirin usage against P. aeruginosa PAO1 was examined. SahH as 
potential drug target in P. aeruginosa and the mode of action of ribavirin was investigated. The 
influence of SahH and MtnP on bacterial phenotype was examined. The presence of SahH in 
minimal medium, under simulated respiratory conditions and in CF sputum samples was 
determined. The impact of ribavirin on P. aeruginosa PAO1 was determined under simulated 
respiratory tract conditions. In addition, the presence of riboswitches in the 5´ UTR of AMC 
genes in P. aeruginosa was investigated. SahH was recombinantly produced and the impact of 
the inhibitor ribavirin on enzyme level was analysed in vitro. 
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Fig. 25: Activated methylcycle (AMC) and SAM recycling in Pseudomonas aeruginosa 
(A) Methionine and ATP are converted by S-adenosylmethionine synthetase MetK into SAM, 
phosphate and diphosphate. SAM is used for various metabolic reactions in the cell. If SAM is used 
for methylation the remaining SAH is hydrolysed by SahH into Ado and Hcy. Hcy can be generated 
out of O-succinyl-homoserine by MetZ. Hcy can be converted by either cobalamin-independent 
methionine synthase MetE or cobalamin-dependent methionine synthase MetH back into 
methionine. Both enzymes use the cofactor methyl-tetrahydrofolate (Me-THF) as methyl group 
donor. If SAM is used for other reactions e.g. by AHL synthase or as source of an amino propyl 
group for the generation of spermidine these reactions yield MTA. MTA is recycled by 5´-
methylthioadenosine phosphorylase MtnP and by several other enzymes to methionine. Adapted 
from (Fontecave et al., 2004; Heurlier et al., 2006; Parveen and Cornell, 2011; Sekowska et al., 
2004) 
(B) Ribavirin (1-!-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is as purine analogue structurally 
very similar to Ado. 
____________________________________________________________________________ 
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4.2 Results & Discussion 
4.2.1 High ribavirin concentrations lead to decreased growth in Pseudomonas 
aeruginosa PAO1. 
Kruszewska et al. (2002) described the antimicrobial activity of ribavirin against P. aeruginosa. 
To analyse if the antimicrobial activity of ribavirin has also a partial effect on P. aeruginosa 
PAO1 growth, the growth of PAO1 in the presence of different ribavirin concentrations was 
investigated (Fig. 26). Concentrations of 1 - 10 #g/ml ribavirin did not affect P. aeruginosa PAO1 
growth. 50 #g/ml ribavirin led to decreased growth of PAO1 up to 7 h. The incubation with 100 
#g/ml resulted in even further decrease of growth. Only half of the optical density at 578 nm 
(OD578) of the wild type (wt) was reached after 11 h. 250 #g/ml and 500 #g/ml led to growth 
inhibition and even reduction of OD578 in the latter case. 
 
 
Fig. 26: Growth of P. aeruginosa PAO1 in the presence of different ribavirin concentrations 
P. aeruginosa PAO1 was grown in M9 succinate 50 #M methionine supplementation with varying 
ribavirin concentrations while OD578 was measured. PAO1 control, grown without ribavirin (black 
circle, solid line), grew like PAO1 1 #g/ml ribavirin (grey diamond, dashed line) and PAO1 10 #g/ml 
ribavirin (grey triangle, dashed line). Supplementation of 50 #g/ml ribavirin (open circle, dashed 
line) led to decreased growth of PAO1 during the first 7 h. 100 #g/ml ribavirin (grey square, dashed 
!"!#$
!"#$
#$
!$ %$ &$ '$ ($ #!$ #%$
!
" #
$%
&
'()&*+,&
!$)*+,-$./012/./3$ #$)*+,-$./012/./3$ #!$)*+,-$./012/./3$
4!$)*+,-$./012/./3$ #!!$)*+,-$./012/./3$ %4!$)*+,-$./012/./3$
4!!$)*+,-$./012/./3$
Ribavirin against Pseudomonas aeruginosa 
 
 109 
line) further decreased growth. 250 #g/ml ribavirin (grey circle, dashed line) and PAO1 500 #g/ml 
ribavirin (light grey diamond, dashed line) led to growth inhibition. 
____________________________________________________________________________ 
Ribavirin showed effects on P. aeruginosa PAO1 growth in concentrations ' 50 #g/ml. Drastic 
growth effects were observed for ribavirin concentrations > 100 #g/ml. Since Cai et al. (2007) 
described the successful inhibition of T. cruzi SAHH by ribavirin, we constructed a PAO1 "sahH 
deletion mutant. In order to investigate, if the deletion of sahH led to similar growth as it can be 
observed for PAO1 wt with ribavirin supplementation (Fig. 26). This would be the case, if sahH 
was the main target of ribavirin in the cell. And if SahH is a target, MtnP could also be a 
possible target, since both enzymes are involved in the recycling of either SAH or MTA 
respectively as part of AMC. Therefore, a PAO1 "mtnP deletion mutant was constructed and 
investigated. 
An effect of ribavirin on transcription and translation was observed by Gupta et al. (2012) in 
mononuclear blood cells of HCV patients treated with Peg-interferon $ and ribavirin. A similar 
effect of ribavirin on P. aeruginosa transcription and translation was also observed in our study 
especially on the AMC genes. 
4.2.2 Pseudomonas aeruginosa PAO1 #sahH shows drastically decreased growth.  
The first step to analyse the influence of the genes sahH (PA0432) and mtnP (PA3004) was to 
investigate the growth phenotypes of P. aeruginosa PAO1 ΔsahH, PAO1 ΔmtnP and PAO1 
ΔsahH ΔmtnP. The methionine metabolism mutant PAO1 ΔmetZ was examined. 
The majority of SAM is used for methylation reactions of various molecules (Griffith, 1987) and 
therefore yields SAH. But since SAH is probably recycled by SahH in P. aeruginosa, an 
influence on phenotype in a PAO1 ΔsahH strain was expected.  
P. aeruginosa PAO1 wt and AMC metabolism deletion strains were cultivated in M9 minimal 
medium, with 50 #M methionine supplementation, respectively. PAO1 wt showed no difference 
when grown in the presence or absence of methionine (Fig. 27). But PAO1 ΔsahH showed 
decreased growth even in the presence of methionine compared to wt. Nearly no growth at all 
was observed when grown without methionine supplementation (Fig. 27A), which was also 
detected for the methionine auxotrophic PAO1 ΔmetZ strain (Fig. 27D). But in contrast to PAO1 
ΔsahH, PAO1 ΔmetZ showed wt like growth when supplemented with methionine. The growth 
defect of PAO1"sahH was similar to the growth defect of PAO1 wt in the presence of 50 #g/ml 
ribavirin (Fig. 27A), when both strains were grown with 50 #M methionine supplementation. 
No growth phenotype was observed for PAO1 ΔmtnP (Fig. 27C) in M9 with or without 
methionine, respectively. A PAO1 ΔsahH ΔmtnP mutant strain showed the same growth 
phenotype as the PAO1 ΔsahH. The mtnP deletion seems not to increase the impact.  
The decreased growth of PAO1 ΔsahH showed clearly the importance of SahH as recycling 
enzyme for SAH into Hcy and Ado. Growth, though decreased, of PAO1 ΔsahH was still 
possible in the presence of methionine. Methionine taken up, was possibly able to replenish the 
methionine pool and thereby refilling the SAM pool of the cell. Since methionine formation out of 
Hcy might be impaired in a PAO1 ΔsahH mutant strain and as Hcy level might be low whereas 
the SAH level might be high. Furthermore, the cellular SAM level might be low. Probably the 
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high SAH level were leading to inhibition of methylase reactions. All this might have contributed 
to the decreased growth observed for PAO1 ΔsahH in the presence of methionine. Without 
external methionine, the SAM pool might be to low, and the SAH pool to high to allow 
methylations, which are necessary for growth.  
The deletion of mtnP showed no such effects. This might be because only a minor part of SAM 
is recycled via MtnP. In addition no further decrease in growth was visible in a PAO1 ΔsahH 
ΔmtnP double deletion strain. It was assumed that MtnP is not capable of recycling SAH 
instead of MTA. The enzymes seem to have a narrow substrate specificity as supposed by 
Stepkowski et al. (2005). Furthermore, it was concluded that the deletion of SahH leads to 
methionine auxotrophy, as previously described for Rhodobacter capsulatus (Sganga et al., 
1992), or very impaired methionine synthesis.  
Since SAH hydrolases are very important enzymes in bacteria and influence growth drastically, 
it is definitely a potential drug target also in P. aeruginosa. Since inhibition of SahH should result 
in the same decreased growth or growth arrest as revealed by the deletion. Moreover, 50 #g/ml 
ribavirin led to a similar growth phenotype of PAO1 wt as the deletion sahH caused. This 
observation indicates that SahH might be a possible target of ribavirin in the cell. Moreover, it 
was confirmed that MtnP is not targeted by ribavirin, since the deletion of mtnP resulted in no 
growth effect. 
A. B. 
 
C.      D. 
 
Fig. 27: Growth curves of P. aeruginosa PAO1 wt, PAO1 #sahH, PAO1 #sahH #mtnP, PAO1 #mtnP 
and PAO1 #metZ in M9 succinate  
P. aeruginosa PAO1 and mutant strains were grown in M9 succinate with (closed symbols, solid 
line) and without (open symbols, dashed line) 50 #M methionine supplementation. Furthermore, 
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PAO1 wt was grown in the presence of 50 #g/ml ribavirin with methionine supplementation (open 
symbol with black strip, solid line) 
(A) PAO1 was grown with 50 #M methionine (black circle, solid line), without methionine (open 
circle, dashed line) and in the presence of 50 #g/ml ribavirin with methionine supplementation 
(open symbol with black strip, solid line). PAO1 +sahH was grown with 50#M methionine (grey 
square) and without methionine (open square, dashed line). No difference in growth in correlation 
with methionine was visible for the wt. In contrast, nearly no growth was observed for PAO1 +sahH 
without methionine supplementation. The critical growth conditions are also reflected by the high 
standard derivation for this condition. Even in the presence of methionine, growth of PAO1 +sahH 
was impaired compared to the wild type (wt) till stationary phase is reached. A similar growth 
pattern as for PAO1 "sahH can be observed for PAO1 wt incubated with 50 #g/ml ribavirin, both in 
the presence of 50 #M methionine. 
(B) PAO1 was grown with 50 #M methionine (black circle, solid line) and without methionine (open 
circle, dashed line) and PAO1 +sahH +mtnP was grown with 50 #M methionine (grey diamond) 
and without methionine (open diamond, dashed line). The same growth pattern as for PAO1 "sahH 
was observed, there is no further addition due to deletion of mtnP. 
(C) PAO1 was grown with 50 #M methionine (black circle, solid line) and without methionine (open 
circle, dashed line) and PAO1 +mtnP was grown with 50 #M methionine (grey x) and without 
methionine (grey x, dashed line). PAO1 "mtnP showed wt like growth behaviour. 
(D) PAO1 was grown with 50 #M methionine (black circle, solid line) and without methionine (open 
circle, dashed line) and PAO1 +metZ was grown with 50 #M methionine (grey triangle) and without 
methionine (open triangle, dashed line). PAO1 +metZ showed wt like growth behaviour when 
grown in the presence of methionine and no growth without methionine supplementation.  
Experiments were performed in dublicates. The standard deviation is shown. 
____________________________________________________________________________ 
4.2.3 SahH is detectable in Pseudomonas aeruginosa culture samples and also 
present in high amounts under simulated respiratory tract conditions. 
In order to analyse if the SahH protein is detectable in CF sputum samples and in P. aeruginosa 
culture, Western blot analysis using a polyclonal anti-P. aeruginosa (Pa) SahH antibody purified 
from rabbit serum was used. The SahH was detected in P. aeruginosa PAO1 culture after 5 h of 
aerobic cultivation in M9 minimal medium (Fig. 28B). With a high specificity only SahH was 
detected and not the recombinant P. aeruginosa MtnP (Guan et al., 2011), which is also 
involved in SAM recycling by converting MTA as MTA nucleosidase (Parveen and Cornell, 
2011). Both enzymes share 10 % identity on amino acid level. 
SahH seems to be an important factor under simulated respiratory tract conditions. In the 
proteome of P. aeruginosa PAO1 high amounts of SahH were identified by mass spectrometry, 
when grown as biofilm on ASM under anaerobic conditions (Thoma, 2009). 
But no SahH was detectable in Western blot analysis of CF-sputum samples. Though all 
samples contained high amounts of protein as is visible in the SDS-PAGE (Fig. 28C), since the 
detection is very sensitive, neither bacterial SahH was detected, nor cross detection of human 
SAHH took place. This might be because the CF patients were not colonised at the point of 
sampling or the samples did not contain sufficient amounts of P. aeruginosa. No CFU control 
was possible since samples were frozen at -80°C and no additional analysis was performed.  
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To further verify that only Pa SahH was detected, blood samples were analysed since human 
SAHH can be isolated from human serum and erythrocytes (Arredondo-Vega et al., 1989; 
Hershfield et al., 1979). As expected no human SAHH was detected in the erythrocyte, serum 
or monocyte fraction (Fig. 28D), even though the percent identity of Pa SahH and Homo 
sapiens (Hs) SAHH is 57 % (Fig. 29). 
 
A.   B.   C.      D. 
  
 
Fig. 28: Production and purification of recombinant SahH from P. aeruginosa (Pa) and detection of 
Pa SahH in CF-sputum samples and specificity testing of anti-Pa SahH antibody against SAHH in 
human blood sample 
(A) SDS-PAGE analysis of the production and purification of SahH. Lane M, marker proteins with 
Mr indicated; lane 1, proteins within cell-free extract of E. coli BL21 (DE3) carrying pET14b::sahH 
after induction with isopropyl !-D-1-thiogalactopyranoside (IPTG); lane 2, recombinant His-SahH 
after chromatography on Ni SepharoseTM 6 Fast Flow ; lane 3, SahH after thrombin cleavage. 
(B) SDS-PAGE analysis and Western blot of P. aeruginosa PAO1 and PAO1 +sahH culture after 
growth of 5 h in M9 succinate. Lane M, marker proteins with Mr indicated; lane 1, recombinant Pa 
His-SahH; lane 2, recombinant Pa His-MtnP; lane 3, proteins of PAO1 culture; lane 4, proteins of 
PAO1 +sahH culture. 
Western blot analysis of the SahH production in the supernatant of PAO1 and PAO1 +sahH was 
detected by anti-Pa SahH antibody. 
(C) SDS-PAGE analysis of 13 different CF-sputum samples. Lane M, marker proteins with Mr 
indicated; lane 1, proteins of CF-sputum sample 132; lane 2, proteins of CF-sputum sample 177; 
lane 3, proteins of CF-sputum sample 025; lane 4, proteins of CF-sputum sample 154; lane 5, 
proteins of CF-sputum sample 090; lane 6, proteins of CF-sputum sample 153; lane 7, proteins of 
CF-sputum sample 369; lane 8, proteins of CF-sputum sample 373; lane 9, proteins of CF-sputum 
sample 091; lane 10, proteins of CF-sputum sample 089; lane 11, proteins of CF-sputum sample 
372; lane 12, proteins of CF-sputum sample 368; lane 13, proteins of CF-sputum sample 148; lane 
14, recombinant Pa His-SahH. 
Underneath a Western blot of the SDS-PAGE is shown using a polyclonal anti-Pa SahH rabbit 
antibody and an alkaline phosphatase conjugated goat anti-rabbit secondary antibody. Lane 1-13, 
CF-sputum samples; Lane 14, recombinant Pa His-SahH. SahH was not detected in the CF-
sputum samples. 
(D) SDS-PAGE and Western blot analysis of human blood samples fractions. The specificity of the 
SahH antibody was tested against different blood components and detected by anti-Pa SahH 
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antibody. Lane M, marker proteins with Mr indicated; lane 1, proteins of erythrocyte fraction; lane 2, 
proteins of the serum faction; lane 3, proteins of monocyte fraction.  
____________________________________________________________________________ 
4.2.4 SAH hydrolases are a highly conserved among bacteria and eukaryotes.  
The alignment of amino acid sequences of different SAH hydrolases performed by ClustalW2 
was used to determine the percent identity (Larkin et al., 2007). Several SAH hydrolases 
already crystallised or investigated as potential drug targets were compared (Fig. 29). The 
sequences of Hs SAHH, Rattus norvegicus (Rn) SAHH, Trypanosaoma cruzi (Tc) SAHH, 
Mycobacterium tuberculosis (Mt) SahH, Corynebacterium glutamicum (Cg) SahH, Plasmodium 
falciparum (Pf) SAHH and Pa SahH were used (Cai et al., 2010; Cai et al., 2007; Ishihara et al., 
2010; Lozada-Ramirez et al., 2008; Reddy et al., 2008; Tanaka et al., 2004; Turner et al., 2000; 
Yamada et al., 2005) . 
The highest level of percent identity was found for the eukaryotic hydrolases Hs SAHH with Rn 
SAHH with 96 %. The second highest percentage of identity was detected for Hs SAHH with Tc 
SAHH with 73 %. Furthermore Mt SahH and Cg SahH showed the highest percent of identity for 
bacterial SahHs with 75 %. The percent identity of Pa SahH aligned with the other hydrolases 
ranged from 58 % with Rn SAHH and 57 % with Hs SAHH to 50 % with Cg SahH. The 12 amino 
acids between AA 270 - 282 in the Pa SahH were not found in other here investigated 
hydrolases and for AA 353 – 360 applies the same (Fig. 29). Stepkowski et al. (2005) obtained 
similar results in their alignment of bacterial SahHs. They also showed that only Synechococcus 
sp. PCC 7002 contains the same 12 amino acids (Pa SahH AA 270 – 282) in its sequence. This 
clearly shows that SAH hydrolases are highly conserved enzymes and very important for the 
hydrolysis of SAH into Hcy and Ado. 57 % percent identity on amino acid level of Hs SAHH and 
Pa SahH shows a high degree of conservation, but leaves also amino acid differences. Thereby 
potentially leading to structural differences, catalytical differences and differences in substrate 
specificity. Cai et al. (2007) showed that even though the SAHH sequences of Hs and Tc are 
highly similar with 73% percent identity, the inactivation of Tc SaHH by the nucleoside analogue 
ribavirin is 5 fold faster than the inactivation of the human enzyme. 
 
H.sapiens           --------------MSDKLPYKVADIGLAAWGRKALDIAENEMPGLMRMRERYSASKPLK 46 
R.norvegicus        --------------MADKLPYKVADIGLAAWGRKALDIAENEMPGLMRMREMYSASKPLK 46 
T.cruzi             --------------MTD---YKVRDISLAEWGRKAIEIAENEMPGLMELRREYSQSKPLK 43 
M.tuberculosis      MTGNLVTKNSLTPDVRNGIDFKIADLSLADFGRKELRIAEHEMPGLMSLRREYAEVQPLK 60 
C.glutamicum        ------------------MDFKVADLSLAEAGRHQIRLAEYEMPGLMQLRKEFADEQPLK 42 
P.falciparum        ---------------MVENKSKVKDISLAPFGKMQMEISENEMPGLMRIREEYGKDQPLK 45 
P.aeruginosa        --------MSAVMTPAGFTDYKVADITLAAWGRRELIIAESEMPALMGLRRKYAGQQPLK 52 
                                         *: *: **  *:  : ::* ***.** :*. :.  :*** 
 
H.sapiens           GARIAGCLHMTVETAVLIETLVTLGAEVQWSSCNIFSTQDHAAAAIAKA---------GI 97 
R.norvegicus        GARIAGCLHMTVETAVLIETLVALGAEVRWSSCNIFSTQDHAAAAIAKA---------GI 97 
T.cruzi             GAKIAGCLHMTVQTAVLIETLIQLGAEVRWSSCNIFSTQDNAAAAIAKR---------GI 94 
M.tuberculosis      GARISGSLHMTVQTAVLIETLTALGAEVRWASCNIFSTQDHAAAAVVVGPHGTPDEPKGV 120 
C.glutamicum        GARIAGSIHMTVQTAVLIETLTALGAEVRWASCNIFSTQDEAAAAIVVG-SGTVEEPAGV 101 
P.falciparum        NAKITGCLHMTVECALLIETLQKLGAQIRWCSCNIYSTADYAAAAVSTL--------ENV 97 
P.aeruginosa        GAKILGCIHMTIQTGVLIETLVALGAEVRWSSCNIFSTQDQAAAAIAAA---------GI 103 
                    .*:* *.:***:: .:*****  ***:::*.****:** * ****:            .: 
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H.sapiens           PVYAWKGETDEEYLWCIEQTLY-FK--DGPLNMILDDGGDLTNLIHT------------- 141 
R.norvegicus        PVFAWKGETDEEYLWCIEQTLH-FK--DGPLNMILDDGGDLTNLIHT------------- 141 
T.cruzi             PVFAWKGETEEEYQWCIEQTLKGFSG-DGFPNMILDDGGDLTNHVLD------------- 140 
M.tuberculosis      PVFAWKGETLEEYWWAAEQMLTWPD-PDKPANMILDDGGDATMLVLRGMQYEKAG----V 175 
C.glutamicum        PVFAWKGESLEEYWWCINQIFSWG---DELPNMILDDGGDATMAVIRGREYEQAG----L 154 
P.falciparum        TVFAWKNETLEEYWWCVESALTWGDGDDNGPDMIVDDGGDATLLVHKGVEYEKLYEEKNI 157 
P.aeruginosa        PVFAWKGETEEEYEWCIEQTILKDG-QPWDANMVLDDGGDLTEILHK------------- 149 
                    .*:***.*: *** *. :. :          :*::***** *  :                
 
H.sapiens           ----------------------------KYPQLLPGIRGISEETTTGVHNLYKMMANGIL 173 
R.norvegicus        ----------------------------KHPQLLSGIRGISEETTTGVHNLYKMMANGIL 173 
T.cruzi             ----------------------------HCPHLVDKIYGISEETTTGVKNLYKRLQRGKL 172 
M.tuberculosis      VPPAEEDDPAEWKVFLNLLRTRFETDKDKWTKIAESVKGVTEETTTGVLRLYQFAAAGDL 235 
C.glutamicum        VPPAEANDSDEYIAFLGMLREVLAAEPGKWGKIAEAVKGVTEETTTGVHRLYHFAEEGVL 214 
P.falciparum        LPDPEKAKNEEERCFLTLLKNSILKNPKKWTNIAKKIIGVSEETTTGVLRLKKMDKQNEL 217 
P.aeruginosa        ----------------------------KYPQMLERIHGITEETTTGVHRLLDMLKNGTL 181 
                                                :  ::   : *::******* .* .    . * 
 
H.sapiens           KVPAINVNDSVTKSKFDNLYGCRESLIDGIKRATDVMIAGKVAVVAGYGDVGKGCAQALR 233 
R.norvegicus        KVPAINVNDSVTKSKFDNLYGCRESLIDGIKRATDVMIAGKVAVVAGYGDVGKGCAQALR 233 
T.cruzi             PIPAINVNDSVTKSKFDNLYGCRESLVDGIKRATDVMIAGKTACVCGYGDVGKGCAAALR 232 
M.tuberculosis      AFPAINVNDSVTKSKFDNKYGTRHSLIDGINRGTDALIGGKKVLICGYGDVGKGCAEAMK 295 
C.glutamicum        PFPAMNVNDAVTKSKFDNKYGTRHSLIDGINRATDMLMGGKNVLVCGYGDVGKGCAEAFD 274 
P.falciparum        LFTAINVNDAVTKQKYDNVYGCRHSLPDGLMRATDFLISGKIVVICGYGDVGKGCASSMK 277 
P.aeruginosa        KVPAINVNDSVTKSKNDNKYGCRHSLNDAIKRGTDHLLSGKQALVIGYGDVGKGSSQSLR 241 
                     ..*:****:***.* ** ** *.** *.: *.** ::.** . : ********.: ::  
 
H.sapiens           GFGARVIITEIDPINALQAAMEGYEVTT-------------MDEACQ-EGNIFVTTTGCI 279 
R.norvegicus        GFGARVIITEIDPINALQAAMEGYEVTT-------------MDEACK-EGNIFVTTTGCV 279 
T.cruzi             AFGARVVVTEVDPINALQAAMEGYQVLL-------------VEDIVE-QAHIFVTTTGND 278 
M.tuberculosis      GQGARVSVTEIDPINALQAMMEGFDVVT-------------VEEAIG-DADIVVTATGNK 341 
C.glutamicum        GQGARVKVTEADPINALQALMDGYSVVT-------------VDEAIE-DADIVITATGNK 320 
P.falciparum        GLGARVYITEIDPICAIQAVMEGFNVVT-------------LDEIVD-KGDFFITCTGNV 323 
P.aeruginosa        QEGMIVKVAEVDPICAMQACMDGFEVVSPYKNGINDGTEASIDAALLGKIDLIVTTTGNV 301 
                      *  * ::* *** *:** *:*:.*               ::     . .:.:* **   
 
H.sapiens           DIILGRHFEQMKDDAIVCNIGHFDVEIDVKW-LNENAVEKVNIKPQVDRYRLK------- 331 
R.norvegicus        DIILGRHFEQMKDDAIVCNIGHFDVEIDVKW-LNENAVEKVNIKPQVDRYLLK------- 331 
T.cruzi             DIITAEHFPRMQDDAIVCNIGHFDTEIQVSW-LKANAKERVEVKPQVDRYTMH------- 330 
M.tuberculosis      DIIMLEHIKAMKDHAILGNIGHFDNEIDMAG-LERSGATRVNVKPQVDLWTFGD------ 394 
C.glutamicum        DIISFEQMLKMKDHALLGNIGHFDNEIDMHSLLHRDDVTRTTIKPQVDEFTFS------- 373 
P.falciparum        DVIKLEHLLKMKNNAVVGNIGHFDDEIQVNELFNYKGIHIENVKPQVDRITLP------- 376 
P.aeruginosa        NVCDANMLKALKKRAVVCNIGHFDNEIDTAF--MRKNWAWEEVKPQVHKIHRTGKDGFDA 359 
                    ::   . :  ::. *:: ****** **:       .      :****.             
 
H.sapiens           -NGRRIILLAEGRLVNLGCAMGHPSFVMSNSFTNQVMAQIELWTHPD--KYPVG------ 382 
R.norvegicus        -NGHRIILLAEGRLVNLGCAMGHPSFVMSNSFTNQVMAQIELWTHPD--KYPVG------ 382 
T.cruzi             -NGRHIILLAEGRLVNLGCASGHPSFVMSNSFSNQVLAQIELWTQRESGKYPRGEKA--Q 387 
M.tuberculosis      -TGRSIIVLSEGRLLNLGNATGHPSFVMSNSFANQTIAQIELWTKNDE--YDNE------ 445 
C.glutamicum        -TGRSIIVLSEGRLLNLGNATGHPSFVMSNSFADQTIAQIELFQNEGQ--YENE------ 424 
P.falciparum        -NGNKIIVLARGRLLNLGCATGHPAFVMSFSFCNQTFAQLDLWQNKDTNKYENK------ 429 
P.aeruginosa        HNDDYLILLAEGRLVNLGNATGHPSRIMDGSFANQVLAQIHLFEQKYADLPAAEKAKRLS 419 
                     ..  :*:*:.***:*** * ***: :*. ** :*.:**:.*: :                
 
H.sapiens           VHFLPKKLDEAVAEAHLGKLNVKLTKLTEKQAQYLGMSCDGPFKPDHYRY 432 
R.norvegicus        VHFLPKKLDEAVAEAHLGKLNVKLTKLTEKQAQYLGMPINGPFKPDHYRY 432 
T.cruzi             VYFLPKKLDEKVAALHLGKLGAKLTKLTARQADYINCPVDGPFKPDHYRY 437 
M.tuberculosis      VYRLPKHLDEKVARIHVEALGGHLTKLTKEQAEYLGVDVEGPYKPDHYRY 495 
C.glutamicum        VYRLPKVLDEKVARIHVEALGGQLTELTKEQAEYIGVDVAGPFKPEHYRY 474 
P.falciparum        VYLLPKHLDEKVALYHLKKLNASLTELDDNQCQFLGVNKSGPFKSNEYRY 479 
P.aeruginosa        VEVLPKKLDEEVALEMVKGFGGVVTQLTPKQAEYIGVSVEGPFKPDTYRY 469 
                    *  *** *** **   :  :.  :*:*  .*.:::.    **:*.: *** 
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Fig. 29: Alignment of bacterial and eukaryotic SAH hydrolases with Pa SahH 
Amino acid sequence alignment of H. sapiens (Hs) SAHH (432 AA), R. norvegicus (Rn) SAHH (432 
AA), T. cruzi (Tc) SAHH (437 AA), M. tuberculosis (Mt) SahH (495AA), C. glutamicum (Cg) SahH 
(474 AA), P. falciparum (Pf) SAHH (479 AA) and P. aeruginosa (Pa) SahH (469 AA) using 
ClustalW2 (Larkin et al., 2007). The percent identity of Pa SahH and Hs SAHH is 57 %, Pa SahH 
and Rn SAHH is 58 %, of Pa SahH and Tc SAHH is 56 %, of Pa SahH and Mt SahH is 51 %, of Pa 
SahH and Cg SahH is 50 % and of Pa SahH and Pf SAHH is 54 %, respectively. The UniProtKB 
accession numbers of the hydrolases are for Hs SAHH (P23526), Rn SAHH (P10760), Tc SAHH 
(Q7YUF0) Mt SahH (A5U7S2), Cg SahH (Q8NSC4), Pf SAHH (P50250) and Pa SahH (Q9I685) as 
indicated. Amino acids only present in the Pa sequence in this alignment are marked in bold letters. 
____________________________________________________________________________ 
4.2.5 Deletion of sahH leads to impaired growth under simulated respiratory tract 
conditions. 
As already mentioned SahH is present under simulated CF respiratory tract conditions in high 
amounts (Thoma, 2009). Furthermore, PAO1 ΔsahH also showed a decreased growth rate in 
biofilms on polyvinyl filter on ASM (Sriramulu et al., 2005) under anaerobic conditions CF 
compared to the wt even with sufficient amounts of methionine (Thoma, 2009), similar to growth 
behaviour in M9 with methionine supplementation.  
4.2.6 Inhibition of SahH under simulated respiratory tract conditions by the nucleoside 
analogue ribavirin.  
Since SahH was also very important under simulated CF conditions, the potential already 
approved drug ribavirin was tested. Ribavirin is as a purine analogue structurally very similar to 
Ado, the product of the hydrolysis of SAH into Hcy and Ado (Fig. 25A & B). Ribavirin licensed 
against DNA and RNA viruses e.g. for hepatitis C treatment in combination with interferon 
(Davis et al., 1998). 
Treatment of stationary phase biofilm with 2 mg/ml ribavirin for 12 h (Thoma, 2009) led to a 
drastically reduced survival rate of P. aeruginosa PAO1 wt with only 30 % survival in the biofilm 
model under simulated respiratory tract conditions. Ribavirin seems to be a promising drug to 
decrease P. aeruginosa PAO1 survival even in biofilms under simulated CF conditions. 
4.2.7 Does slow growth of PAO1 !sahH lead to altered antibiotic resistance? 
Some might argue that the impaired growth leads to altered antibiotic resistance in PAO1 
"sahH. Slow growth often results in an altered resistance, since commonly used antibiotics 
target life processes and if metabolic processes, e.g. cell wall biosynthesis in the case of !-
lactams, are slowed down the antibiotics are not as effective. Two studies using transposon 
libraries found for the PA14 sahH (PA14_05620) transposon mutant and the PAO1 sahH 
(PA0432) orthologous transposon mutant altered antibiotic resistance. One study using Vitek 2 
for semiautomatic susceptibility testing observed an altered resistance against the 
fluoroquinolone levofloxacin of 3 fold change in the MIC (in Log2) compared to the Pa14 wt. 
Whereas the growth rate was determined with 0.45 compared with 1.0 for the wt (Dotsch et al., 
2009). Moreover, they remarked that no mutant exhibited serious growth alterations. No 
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alteration for tobramycin resistance was detected. But on the other hand the study performed by 
Schurek et al. (2007) classified the sahH gene in the class of tobramycin resistance genes. 
PA14 sahH (PA14_05620) transposon mutant was described as general growth defect mutant 
causing defective growth in LB broth (Schurek et al., 2008).  
Independently from the results, these high-throughput studies identified sahH as an important 
factor. But most antibiotic resistance studies are performed under laboratory conditions, which 
do not simulate the conditions in the natural environment or the host. This leads to different 
results concerning MIC and resistance in general. Therefore, a closer look on transcription and 
translation in PAO1 "sahH was taken to exclude that only growth is the factor for altered 
resistance or effectiveness of drugs. 
4.2.8 Differences in transcription and translation of AMC genes in PAO1 !sahH 
compared to PAO1 wt. 
The influence of a sahH deletion on transcription and translation was investigated using 
transcriptional and translational lacZ reporter gene fusions. The regulation of AMC genes was of 
especial interest. Therefore, bacteria were grown as described in Material and Methods. 
Bacteria were harvested when reaching a similar OD578 of 0.300 ± 0.05. That was the case after 
4 h for PAO1 and after 6 h for PAO1 "sahH. 
Interestingly, the transcription of sahH operon and metK operon was 5.5-fold and 3.7-fold 
induced compared to the PAO1 wt, respectively. This progress was observed for translation 
with 9.8-fold and 10.3-fold for the sahH operon and the metK operon, respectively (Table 23 
and Fig. 30). This means that the probably high SAH level, which was already determined on 
molecule level for E. coli pfs and luxS mutants (Halliday et al., 2010), probably influences the 
transcription of both operons positively. Furthermore, the translation of metK was even further 
increased. This strongly supports the assumption of possible ribozyme regulation in the 5´UTR 
of metK and sahH. The high level of SAH or the low level of SAM might lead to expression of 
sahH operon and metK operon, respectively. Direct ligand binding might lead to a stabilisation 
of secondary and tertiary structures, and thereby might make the Shine-Dalgarno (SD) 
sequence accessible for the ribosome and the initiation of translation possible (Wang et al., 
2008). 
The transcription level of the two methionine synthases genes of P. aeruginosa metH and metE 
was 1.3-fold and 1.8-fold induced (Table 23). MetH is a cobalamin dependent and the encoded 
MetE is a cobalamin independent methionine synthase. 3.6-fold induced is metH translation but 
in contrast is metE translation - 14.0-fold decreased compared to PAO1 wt. The PAO1 "sahH 
mutant seems to use MetH to a higher degree, as the expression of metH is clearly 
upregulated. This might be because of a potential SAH riboswitch in the 5´UTR of the metH 
operon. Binding of SAH or absence of SAM might make the SD sequence accessible for 
translation. 
The presence of SAH or SAM dependent riboswitches in the 5´UTR of sahH, metK and metH 
seems possible from the results of !-galactosidase assays.  
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Table 23: Fold change of transcription and translation in PAO1 !sahH compared to the samples of 
PAO1 wt [MU / MU]  
 PAO1 "sahH 
 Transcriptional fusion 
(mini-CTX-lacZ) 
Translational fusion 
(pME6013) 
P sahH 5.5 ± 0.1   9.8 ± 0.1 
P metK 3.7 ± 0.3 10.3 ± 0.2 
P metH 1.3 ± 0.1   3.6 ± 0.1 
PmetE 1.8 ± 0.1 -14.0 ± 0.8 
 
 
Fig. 30: Influence of the deletion of sahH on transcription and translation in PAO1 !sahH compared 
to PAO1 wt 
Fold change of transcription (mini-CTX-lacZ, grey bars) and translation (pME6013, white bars) of 
the genes sahH, metK and metH was determined in PAO1 +sahH. The fold change was compared 
to PAO1 wt. 
The standard deviation of two representative experiments is shown. The value of the empty control 
vectors mini-CTX-lacZ and pME6013, performed for each condition tested, was subtracted. 
____________________________________________________________________________ 
4.2.9 A potential SAH riboswitch in the 5´untranslated region of sahH gene.  
For the 5´untranslated region (5´UTR) of sahH gene of P. syringae a SAH riboswitch was 
described (Wang et al., 2008). Therefore, an alignment of 150 bp upstream of start codon of 
sahH gene of P. syringae pv. phaseolicola 1448A (PSPPH_0451), P. syringae pv. tomato str. 
DC3000 (PSPTO_5068) and P. aeruginosa PAO1 (PA0432) was performed. The percentage of 
sequence identity was 94 % for P. syringae pv. phaseolicola 1448A and P. syringae pv. tomato 
str. DC3000 (Fig. 31A). Furthermore, revealed the comparison of PAO1 sahH sequence to 
P. syringae sahH a high level of conservation of bases and base pairing in the stem loops 
proposed for P. syringae sahH by Wang et al. (2008). The proposed loop regions of P. syringae 
do not contain the poly U in P. aeruginosa. This can also be observed in the high percentage of 
identity in the alignment of PAO1 sahH of 71 % for P. syringae pv. phaseolicola 1448A and 67 
% for P. syringae pv. tomato str. DC3000 (Fig. 31A). The sequence alignment is showing the 
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high level of conservation and therefore makes the presence of a SAH dependent riboswitch in 
the 5´UTR very likely. 
 
A. 
PSPPH_0451 P. syringae      3´GUA-ACUCUCAGAGGUAAGGUAUUUUUACGCUUACCCGCGGCAAC-ACGC 48 
PSPTO_5068 P. syringae      3´GUA-ACUCUCAGAGGUAAGGUAUUUUUACGCUUACCCGCGGCAAC-ACGC 48 
PA0432     P. aeruginosa    3´GUACGCAUUGAGAGGUAAGCAACA--GACGCUUACCCGCGGCAACCACGC 48 
                             ***  *  * *********  *     ****************** **** 
 
PSPPH_0451 P. syringae       AAAUUCCAAACGGCCAGCUCCUAGCAGGACCGUUUGUUGCGGGGUAGGCU 98 
PSPTO_5068 P. syringae       AAAUUCCGAACGGCCGACAC-UAGUUGGACUGUUUGUUGCGGGGUAGGCU 97 
PA0432     P. aeruginosa     AACUGUC---UGGCCG-CUC-CGGCCGGACU-CUCGC-GCGAGGCAAGCU 91 
                             ** *  *    ****  * *   *  ****   * *  *** ** * *** 
 
PSPPH_0451 P. syringae       CGGACUGUCCC-UUUUGGACGACGUCGCGGGGAGCCUGUCCACCGCCCUU 147 
PSPTO_5068 P. syringae       CGGACUGUCCC-AUUUGGACGACGUCGCGGGGAGCCUGUCCACCGCCCUU 146 
PA0432     P. aeruginosa     CGGACUGUCCGGAUCCGGACGACGUCGCGGGGAGCUUGCCUUCCGCCCUC 141 
                             **********   *  ******************* ** *  *******  
 
PSPPH_0451 P. syringae       GCCAUA------ 5´ 153 
PSPTO_5068 P. syringae       GCCAUAG----- 5´ 153 
PA0432     P. aeruginosa     GCUGGGCUUCCC 5´ 153 
                             **           
B. 
metK P. aeruginosa      3´GUAGUUAGCCAAGGAUGUAAUGGCCACCCACUCCGC----CGAAA-GCCUACGU-----A 50 
metH P. aeruginosa      3´GUACCUA-CCUGGACCGCAGUCACCCGCCUUUCCACUUUUCGUAUUGUUUCCGUCCCCGA 59 
sahH P.aeruginosa       3´GUACGCA--UUGAGAGGUAAGCAACAGACGCUUACC----CGCGGCAACCACGC-----A 49 
                          ***   *         * *     *   *  *   *    **         **      * 
 
metK P. aeruginosa       GGGACCG--CUUCAC-GGCCUGG-ACCUAGACCUUCGGUAACGC------AUUUGGUUAC 100 
metH P. aeruginosa       AAGGCCGGCCCCCACCAGCCUGGUACUUAAA------GUAA---------GUUCAACUUC 104 
sahH P. aeruginosa       ACUGUCUGGCCGCUCCGGCCGGACUCUCGCGCG--AGGCAAGCUCGGACUGUCCGGAUCC 107 
                              *   *  * *  *** *   *           * **          *     * * 
 
metK P. aeruginosa       AUUUCU----GAGAGCGGCCCGCACUC---GGGACGCCGCAGCCGGGUGACCCGGUCCAG 5´ 153 
metH P. aeruginosa       CUACAA----GUAAGCGCCCGGCCUUUUUAGGGAC--CGCGGCAAAACAGC---GUCA-- 5´ 153 
sahH P. aeruginosa       GGACGACGUCGCGGGGAGCUUGCCUUC-------CGCCCUCGCUGGGCUUC----CC--- 5´ 153 
                                   *   *   *  **  *        *  *   **       *     *    
Fig. 31: Alignment of potential riboswitches in the 5´UTR of the mRNA of sahH and AMC genes 
(A) Alignment of 150 bp upstream of start codon of the sahH gene of P. syringae pv. phaseolicola 
1448A (PSPPH_0451), P. syringae pv. tomato str. DC3000 (PSPTO_5068) and P. aeruginosa 
PAO1 (PA0432) using Clustal W. For P. syringae a SAH dependent riboswitch was predicted 
by Wang et al. (2008).  
(B) Alignment of 150 bp upstream of start codon of P. aeruginosa PAO1 metK, metH and sahH 
gene. Start codon and SD-sequence are marked.  
____________________________________________________________________________ 
 
The percentage of identity of the upstream regions of metK, metH and sahH was compared 
because the !-galactosidase assays indicated the possibility of riboswitches activated by high 
SAH levels or low SAM levels. The percent identity is 50 % for the alignment of sahH and metK 
(Fig. 31B). For sahH and metH it is 41 % and for metH and metK it is 53 %. Since riboswitches 
share certain conservation on sequence level, but more importantly in secondary structure, no 
conclusion can be drawn from these results, because sequence identity is not highly conserved. 
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On the other hand, it is not clear, if the 150 bp upstream of metK and metH really contain the 
riboswitch, nor if the riboswitches all belong to the same class. 
4.2.10 Downregulation of transcription and translation of AMC genes due to ribavirin. 
Several other studies investigated the influence of potential SahH inhibitors on enzyme level. 
The influence on transcriptional and translational level using lacZ reporter gene fusions of the 
AMC genes was also investigated. PAO1 and PAO1 ΔsahH were grown in the presence of 50 
#g/ml ribavirin, respectively. 50 #g/ml ribavirin led to growth of the PAO1 wt like PAO1 ΔsahH 
mutant in M9 supplemented with methionine (Fig. 27A).  
It was assumed that if ribavirin leads to inhibition of sahH in PAO1 wt, the same pattern of 
transcription and translation must be observed, as it is seen in PAO1 "sahH, since transcription 
and translation seem to be strongly influenced by the elevated SAH level and lower SAM level. 
The fold change of the ribavirin treated PAO1 wt and PAO1 "sahH was compared to the 
untreated PAO1 wt or the untreated PAO1 "sahH, respectively. 
But in contrast, it was observed that the fold change of transcription and translation was 
decreased for all investigated AMC genes in PAO1 treated with ribavirin (Table 24 and Fig. 
32A). The strongest reduction in transcription was observed for metH in the wt with - 7.9-fold 
downregulation. The transcription of the genes sahH and metK was - 2.3-fold downregulated in 
the wt. Furthermore, the translation of metK and sahH was downregulated with - 3.5-fold and  
- 3.3-fold in wt, respectively. Downregulation of transcription and translation was also detected 
in PAO1 "sahH. The transcription of metK was with - 4.4-fold strongly downregulated in 
PAO1 "sahH. Moreover, the translation of metH was strongly decreased with - 8.9-fold in PAO1 
"sahH. The translation of all other AMC genes in wt and PAO1 "sahH was approximately - 1.5 
± 0.3 -fold decreased. 
Transcription and translation of the investigated AMC genes were always higher in PAO1 
"sahH under all conditions (Table 25 and Fig. 32B). Only transcription of metH had the same 
level for wt and PAO1 "sahH. This higher level of transcription and translation can also be seen 
for the treatment with ribavirin for PAO1 "sahH. Here, was also metH the exception, but the 
translation was lower than in the wt even with ribavirin treatment (Fig. 32B). Translation of sahH 
was also very low in PAO1 (Fig. 32B). Furthermore, transcription and translation were always 
lower for the ribavirin treated strain compared to the untreated strain. 
 
Table 24: Fold change of transcription and translation of AMC genes of PAO1 and of PAO1 !sahH 
in the presence of 50 "g/ml ribavirin compared to the untreated samples of PAO1 and PAO1 !sahH 
[MU / MU] 
 Transcriptional fusion (mini-CTX-
lacZ) with ribavirin 
Translational fusion (pME6013) 
with ribavirin 
 PAO1 PAO1 "sahH PAO1 PAO1 "sahH 
P sahH -2.3 ± 0.3 -1.5 ± 0.3 -6.2 ± 0.2 -1.8 ± 0.1 
P metK -2.3 ± 0.1 -4.4 ± 0.1 -3.5 ± 0.2 -1.2 ± 0.2 
P metH -7.9 ± 0.3 -1.3 ± 0.0 -1.5 ± 0.3 -8.9 ± 0.1 
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Table 25: Transcription and translation of AMC genes of PAO1 and of PAO1 !sahH in the presence 
and absence of 50 "g/ml ribavirin in Miller Units [MU] 
  
Miller Units [MU] 
PAO1 PAO1  
with ribavirin 
PAO1 "sahH PAO1 "sahH 
with ribavirin 
Tr
an
sc
rip
tio
n 
         
mini-CTX-lacZ::sahH 3111 ± 964 1353 ± 949 16924 ± 68 11560 ± 153 
mini-CTX-lacZ::metK 5062 ±1464 2232 ± 207 18667 ±1689 4242 ±3456 
mini-CTX-lacZ::metH 916 ± 553 115 ± 304 1032 ± 71 779 ± 345 
Tr
an
sl
at
io
n 
         
pME6013::sahH 4 ± 3 0.6 ± 0.5 23 ± 17 13 ± 2 
pME6013::metK 210 ± 65 60 ± 6 2167 ± 54 1860 ± 475 
pME6013::metH 337 ± 145 222 ± 10 1203 ± 502 135 ± 9 
 
From these results was concluded that the major target of ribavirin in P. aeruginosa is not 
SahH. Ribavirin might have a more general effect on the bacterial cell. It might interact as a 
purine analogue in general with the transcription and translation machinery, as also the 
transcription and translation of the control vectors was reduced (data not shown). Suppression 
of ribosomal protein synthesis and protein translation factors was also observed in mononuclear 
blood cells of HCV patients treated with Peg-interferon $ and ribavirin (Gupta et al., 2012). 
Furthermore, the downregulation of transcription and translation of AMC genes was also 
detected in PAO1 "sahH (Table 24 and Fig. 32B). 
A. 
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B. 
 
Fig. 32: Influence of 50 "g/ml ribavirin on transcription and translation in PAO1 wt and PAO1 !sahH  
(A) Fold change of transcription (mini-CTX-lacZ) and translation (pME6013) of sahH, metK, and 
metH in PAO1 and PAO1 +sahH treated with 50 #g/ml ribavirin. The fold change is compared 
for PAO1 ribavirin to the untreated PAO1 wt and for PAO1 +sahH ribavirin to the untreated 
PAO1 +sahH. PAO1 fold change of transcription (grey bars), PAO1 fold change of translation 
(light grey bars) and PAO1 +sahH fold change of transcription (white bars) and PAO1 +sahH 
fold change of translation (black bars) are depicted. 
The value of the empty control vectors mini-CTX-lacZ and pME6013, performed for each 
condition tested, was subtracted.  
Experiments were performed independently three times. The standard deviation is indicated.  
(B) !-Galactosidase activity in Miller Units [MU] of sahH, metK and metH in PAO1 and PAO1 
+sahH treated with and without 50 #g/ml ribavirin. PAO1 (grey bars), PAO1 with 50 #g/ml 
ribavirin (light grey bars) and PAO1 +sahH (white bars) and PAO1 +sahH incubated with 50 
#g/ml ribavirin (black bars) are exhibited, respectively.  
The standard deviation of two representative experiments is shown. The value of the empty 
control vectors mini-CTX-lacZ and pME6013, performed for each condition tested, was 
subtracted. 
____________________________________________________________________________ 
4.2.11 Influence of ribavirin on SahH in vitro. 
To investigate Pa SahH also on enzyme level, SahH was recombinantly produced and purified 
as N-terminal hexahistidine-tagged (His-tagged) protein with a theoretical molecular weight of 
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53.7 kDa (489 AA). The native SahH contains 469 amino acids (AA) and a theoretical molecular 
mass of 51.4 kDa (Fig. 28A). 
To examine the effect of ribavirin in vitro, a SahH enzyme assay was applied to investigating the 
hydrolytic reaction. SAH is converted by SahH into Ado and Hcy. Therefore, SahH was 
incubated in a time-dependent manner as described previously by Cai et al. (2007) with and 
without 100 #M ribavirin. The rate of Hcy formation was connected with TNB2- formation out of 
DNTB. Hcy and DNTB reacted to TNB2-, which was detected at 412 nm. The reaction was 
driven by the deamination of Ado to inosine by the Ado deaminase. 
 
A.      B. 
 
Fig. 33: Inhibition of SahH activity by 100 "M ribavirin time-dependent  
Time-dependent loss of total and relative enzyme activity of Pa SahH. SahH was incubated with 
and without 100 #M ribavirin, respectively. The relative enzyme activity was calculated. The 
enzyme activity was measured in the hydrolytic direction. 
(A) SahH was incubated time-dependent in phosphate buffer pH 7.2 and enzyme activity was 
measured in the presence of 100 #M ribavirin.  
(B) Relative enzyme activity [%] of SahH incubated with 100 #M ribavirin was calculated by 
comparing SahH treated with 100 #M ribavirin with untreated SahH. 
Experiments were performed independently two times. The standard deviation from the two 
representative experiments is shown. 
____________________________________________________________________________ 
Prolonged incubation of SahH with ribavirin up to 120 min led to continuous reduction of 
enzyme activity (Fig. 33A). The first reduction of relative enzyme activity to 72 % was relatively 
fast after only 10 min of incubation with ribavirin (Fig. 33B). After 120 min ribavirin resulted in 
37 % less relative activity. The relative enzyme activity was reduced to 63 %.  
For the Tc SAHH a higher level of inhibition was observed when incubated with 100 #M ribavirin 
after 120 min only 10 % activity remained. Whereas Hs SAHH still possessed around 70 % 
remaining activity (Cai et al., 2007). Pa SahH seems to be very similar in the inhibition potential 
by ribavirin to Hs SAHH with still 63 % relative activity.  
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Perhaps other nucleoside analogues will inhibit Pa SahH more effectively than ribavirin. 
Nonetheless crystal structure of Pa SahH would be a very helpful tool to design new drugs that 
especially target the unique structures of Pa SahH. 
4.3 Conclusions 
This study confirms that ribavirin definitely shows antimicrobial activity against P. aeruginosa 
PAO1. High concentrations of ribavirin > 250 #g/ml during cultivation led to growth inhibition. 
Furthermore, incubation of mature P. aeruginosa PAO1 biofilm with 2 mg/ml ribavirin for 12 h 
under simulated respiratory tract conditions led to a survival rate of only 30 %. This means that 
ribavirin is effective under anaerobic CF conditions. Since the growth curves of PAO1 "sahH 
and PAO1 wt incubated with 50 #g/ml ribavirin were very similar and SahH was indicated as 
ribavirin target in T. cruzi, it was assumed that SahH could be a major target of ribavirin in 
P. aeruginosa. 
No typical altered gene expression in PAO1 treated with ribavirin as in PAO1 "sahH was 
observed. In contrast, a totally unexpected downregulation of transcription and translation in 
both PAO1 and PAO1 "sahH treated with ribavirin was detected. Interestingly, ribavirin is very 
successful against PAO1 biofilm but the exact mode of action remains to be discovered. 
This clearly shows that SahH is not the main target of ribavirin in P. aeruginosa. However, it 
was shown that the enzyme SahH is definitely a bottleneck enzyme in the essential part of 
bacterial metabolism and therefore a powerful drug target candidate. This is supported by the 
fact that a deletion of sahH has drastic effects on bacterial growth. Bacterial metabolism might 
be unbalanced because of the unbalanced intracellular SAH/SAM level. Thereby causing an 
altered transcription and translation of AMC genes and probably other genes. This different 
regulation seems to be an attempt of bacterial metabolism to antagonize the imbalances.  
On the other hand, methionine auxotrophy was observed in P. aeruginosa PAO1 "sahH in 
methionine free medium. Since Hcy cannot be generated out of SAH by SahH in a PAO1 
"sahH mutant. Therefore, the methionine pool cannot be refilled by the formation of methionine 
out of Hcy and Me-THF as cofactor by the enzymes MetE and MetH (Fig. 25A). This indicates, 
as previously described by Wang, et al. (2008), that the loss of Hcy pool is not compensated by 
increased de novo synthesis e.g. by MetZ pathway, but instead methionine is taken up from the 
medium to replenish the AMC. If the methionine pool is refilled, slow growth in a PAO1 "sahH 
mutant is still possible. Interestingly, a PAO1 "sahH "mtnP double mutant did not show an 
increased reduction of growth under the tested conditions. This indicates that there might still be 
other mechanisms of SAM and MTA recycling in P. aeruginosa to be discovered. SahH was 
detected by Western blot and proteome analysis in high amounts in minimal medium as well as 
in ASM under simulated respiratory tract conditions.  
Sequence comparison revealed that the percent identity of human SAHH and Pa SahH is highly 
conserved with 57 %. But furthermore, two unique sequence areas were detected for Pa SahH. 
Moreover, sequence comparison of the 5´UTR region of sahH revealed a potential SAH 
dependent riboswitch, which seems to positively regulate transcription and translation of the 
sahH operon. This riboswitch might also be a potential target for newly designed drugs against 
P. aeruginosa. 
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The high inhibition rate of Tc SAHH by ribavirin could not be confirmed for Pa SahH. Pa SahH 
showed only 28 % reduced relative enzyme activity after short term incubation of 10 min and 
even long term incubation with 100 #M ribavirin only resulted in 63 % relative enzyme activity. 
This clearly shows that SahH is not the main target of ribavirin in P. aeruginosa.  
The next step is to crystallize the Pa SahH to make the structural differences to the Hs SAHH 
obvious. Then Pa SahH structure dependent inhibitor design is possible in order to find new 
antibiotics against a powerful drug target. Ribavirin on the other hand is effective against 
P. aeruginosa PAO1 under CF conditions and as already approved drug ready for 
administration. 
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4.4 Material and Methods 
4.4.1 Bacterial strains and growth conditions 
All bacterial strains used in this study are shown Table 26 and plasmids in Table 27. E. coli and 
P. aeruginosa strains were grown routinely in LB medium for standard molecular biology 
protocols. For P. aeruginosa the following concentrations of antibiotics were used: carbenicillin 
250 #g/ml, gentamicin 80 #g/ml, and tetracycline 100 #g/ml. For growth experiments ribavirin 
was added to the medium to achieve the concentrations of 1 #g/ml up to 500 #g/ml. 
The E. coli strain DH10B was used as a host for cloning and E. coli strain BL21 (DE3) was used 
for protein production. 
For growth experiments, P. aeruginosa was grown in M9 minimal medium (Sambrook and 
Russell, 2001) containing 1 x M9- salts [47.7 mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 18.7 
mM NH4Cl], 20 mM succinate, 2 mM MgSO4, 0.1 mM CaCl2, 1 x trace metals [0.148 mg/l ZnSO4 
x 6 H2O, 0.100 mg/l MnCl2 x 4 H2O, 0.236 mg/l CoSO4 x 7 H2O, 0.100 mg/l NiCl2 x 6 H2O, 0.020 
mg/l CuCl2 x 2 H2O, 0.050 mg/l Na2MoO4 x 2 H2O, 1 #l/l 25 % HCl modified after (Schlegel, 
2007) ] and 50 #M methionine, respectively. Cultures were inoculated at OD578 of 0.05 and 
shaken at 200 rpm at 37°C, if not indicated otherwise. 
The results of at least two independent experiments are shown. Standard derivation is shown 
as error bars. 
4.4.2 Construction of Pseudomonas aeruginosa deletion strains 
To obtain unmarked gene deletion mutants the well-established strategies based on sacB 
counterselection and FLP recombinase excision (Hoang et al., 1998) were used. To achieve 
deletion of mtnP (PA3004) the pAW03 suicide plasmid was constructed and in case of metZ 
(PA3107) pMR01. 
For the construction of both plasmids the gentamycin resistance cassette of pPS858 was 
digested by BamHI and was cloned between two PCR fragments of mtnP and metZ in the 
multiple cloning site of pEX18Ap, respectively. The two PCR fragments contained DNA 
homologous to upstream und downstream fragments of mtnP and metZ genes respectively, 
which were deleted in the respective mutant strains. Primer sequence and vector details are 
shown in Table 27 and Supplemental Table 28.  
The construction of PAO1 ΔsahH is described elsewhere (Thoma, 2009). The gene deletion 
constructs were introduced into E. coli DH10B by transformation. Plasmids containing the 
correct insert were transferred via diparental mating using E. coli strain ST18 (Thoma and 
Schobert, 2009) in P. aeruginosa PAO1. After successful gene deletion the gentamicin 
resistance cassette was removed from the genome using the pFLP2 plasmid to obtain 
unmarked gene deletion mutants (Hoang et al., 1998). The resulting mutants were verified by 
PCR. 
4.4.3 Construction of transcriptional and translational promoter-lacZ reporter gene 
fusions 
Chromosomal transcriptional promoter-lacZ reporter gene fusions were constructed using the 
mini-CTX-lacZ vector (Becher and Schweizer, 2000) and translational lacZ reporter gene 
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fusions were constructed using the pME6013 (Schnider-Keel et al., 2000) to analyse the 
presence and activity of putative riboswitches (Wang et al., 2008). To analyse the putative sahH 
(PA0432) promoter region, a 500 bp fragment upstream of the translational start and 159 bp of 
the coding region, a in total 659 bp PCR product, was amplified. Primer sequences and vector 
details are shown in Table 27 and Supplemental Table 28. The other constructs were generated 
likewise. Transfer of promoter-lacZ fusions harbouring plasmids in P. aeruginosa was carried 
out as described previously (Boes et al., 2008) modified by use of ST18 (Thoma and Schobert, 
2009). Constructed plasmids were transferred into P. aeruginosa PAO1 wt and PAO1 "sahH 
strain. In these strains parts of the mini-CTX-lacZ vector containing the tetracycline resistance 
cassette (Tcr) were not deleted. For the transfer of pME6013 constructs electroporation 
(settings: 25 #F, 200 Ω, 2.5 kV on a electroporator 2510 (Eppendorf)) was used as described 
previously (Choi et al., 2006). 
4.4.4 $-Galactosidase assay of transcriptional and translational promoter-lacZ reporter 
gene fusions 
!-Galactosidase assays were performed as outlined before in detail (Boes et al., 2008; 
Eschbach et al., 2004), and activity was reported in Miller units (Miller, 1992). 
To analyse the activation and presence of riboswitches and the impact of ribavirin the AMC 
promoter constructs were incubated under aerobic conditions. Bacteria were grown in M9 
minimal medium supplemented with 50 #M methionine and 50 #g/ml ribavirin (204 #M), 
respectively. Cultures were grown in 1.5 ml medium in wells of a 24 well plate (Thermo Fisher 
Scientific) and sealed with sealing film Breath-easy (Roth) for gas exchange and shaken at 300 
rpm (Thermo Shaker PST-60 HL-4, Lab4You) at 37°C. OD578 was measured using Varioskan 
Flash (Thermo Scientific) and a conventional photometer Ultrospec (Amersham Biosciences). 
Bacteria were harvested when reaching a similar OD578 of 0.300 ± 0.05.  
4.4.5 Construction of expression vector pET14b::sahH 
The sahH expression vector was constructed using the sahH gene from P. aeruginosa PAO1. 
For PCR amplification primers oAW192 and oAW193 were used (for details see Supplemental 
Table 28) and cloned in the multiple cloning site (MCS) of pET14b (Novagen) between NdeI 
and BamHI restriction sites.  
4.4.6 Recombinant SahH production and purification  
For protein production BL21 (DE3) containing the pET14b::sahH plasmid was cultivated at 37°C 
in 500 ml LB medium supplemented with 100 #g/ml carbenicillin until an OD578 of 0.6. Then 
protein production was induced by addition of 50 #M isopropyl !-D-1-thiogalactopyranoside 
(IPTG). The cells were further cultivated for 18 h at 17°C. The cells were harvested by 
centrifugation and stored at -20°C. 
All protein purification steps were performed at 4°C. Harvested E. coli cells were resuspended 
in buffer A [50 mM Tris-HCl (pH 7.5), 300 mM NaCl] containing 15 mM imidazole and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and disrupted by two French press passages at 1000 
p.s.i. (68947.57 hPa) and afterwards centrifuged for 60 min at 175 000 g. The supernatant was 
applied to 1.5 ml of Ni SepharoseTM 6 Fast Flow (GE Healthcare) equilibrated with buffer A. 
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After extensive washing with buffer A, His-SahH was eluted with buffer A containing 300 mM 
imidazole. NAP-25 column (GE Healthcare) was used for buffer exchange. 
N-terminal His tag was removed with thrombin using the Thrombin Cleavage Capture Kit 
(Novagen) according to the manufacturer’s instructions. Cleaved SahH was separated from His-
SahH by 1 ml of equilibrated Ni SepharoseTM 6 Fast Flow. The protein concentration of the flow 
through was routinely determined with Bradford reagent (Sigma-Aldrich), using BSA as 
standard. The purified SahH protein was stored at -20°C in buffer A with 10% glycerol.  
4.4.7 SahH detection via Western blot analysis 
Protein samples were separated in 12 % SDS-PAGE gel and stained with Coomassie blue. 
Western blot analyses were performed using standard protocols (Sambrook and Russell, 2001). 
Briefly, protein samples of purified SahH, P. aeruginosa culture supernatant, CF- Sputum 
samples (Supplemental Table 29) and blood samples were separated by SDS-PAGE and 
electro-blotted onto a polyvinylidene fluoride (PVDF) membrane (Schleicher & Schuell) using 
Towbin buffer (Towbin et al., 1979). The membranes were then incubated for 60 min at room 
temperature in blocking solution (TBS [50 mM Tris-HCl, 150 mM NaCl] containing 3% BSA), 
after intensive washing with TBS-T containing 0.1% Tween 20, followed by an 1 h incubation 
with polyclonal rabbit antibody against P. aeruginosa SahH (Davids biotechnology). The 
membrane was incubated for 1 h with 1:5000 alkaline phosphatase conjugated goat anti-rabbit 
IgG polyclonal secondary antibody (Thermo Scientific). Immune complexes were visualised by 
the conversion of 5-brom-4-chlor-3-indoxyl phosphate (BCIP) (Merck) in the presence of nitro 
blue tetrazolium (NBT) (Merck) and oxygen into 5,5'-dibromo-4,4'-dichloro indigo. 
Anti-Pa SahH polyclonal rabbit antibodies were produced by Davids biotechnology. The 
antibodies were isolated from rabbit sera using 1.5 ml protein A & G resin (2:1 mixture) 
(GenScript). Briefly, rabbit serum was diluted in buffer B [150 mM NaCl, 20 mM Na2HPO4, pH 
8.0] and bound to the resin. Antibodies were eluted and neutralized according to the 
manufacturer`s instructions. Protein concentration was determined as described above. 
Antibodies were stored at - 20°C until required and used at a concentration of 0.1 µg/ml. 
4.4.8 SahH activity assay 
In vitro SahH activity assay was performed as previously described (Cai et al., 2007; Yuan et 
al., 1996). The SahH reaction in the hydrolytic direction was investigated. SAH is converted into 
Ado and Hcy with the modification that experiments were conducted at 37°C with 0.11 #M His-
SahH in a final volume of 1 ml. Furthermore no NAD+ was added to the reaction. The 
generation of the yellow 5-thio-2-nitrobenzoate TNB2- (extinction coefficient: 13 600 M-1 * cm-1) 
from 5,5'-dithiobis-(2-nitrobenzoic acid) DTNB (Fluka) during the reaction was monitored using a 
V-550 UV/Vis spectrophotometer (Jasco) at 412 nm and 37 °C. For the inhibition experiment 
SahH was incubated with 0 #M and 100 #M ribavirin (Sigma), and samples were taken after 0, 
5, 10, 30, 75 and 120 min. 1 U of adenosine deaminase (Sigma-Aldrich) was added directly 
before the addition of the substrate solution containing S-adenosylhomocysteine (Sigma) and 
DTNB in 50 mM phosphate buffer pH 7.2. 
Ribavirin against Pseudomonas aeruginosa 
 
 128 
4.5 Supplemental information  
4.5.1 Blood purification  
Briefly, blood sample was taken and mixed with heparin. Afterwards the blood sample was 
diluted 1:1 with 1 x PBS pH 7.5. A ficoll paqueTM Plus (GE Healthcare) and histopaque 1119 
(Sigma) gradient was used to separate erythrocytes, monocytes and serum. 
4.5.2 Cystic fibrosis-sputum samples 
CF-sputum samples were a generous gift of Michael Hogardt, Munich. Samples were stored at -
80°C.  
Table 26: Bacterial Strains  
Bacterial strains  Genotype Reference 
P. aeruginosa:   
PAO1 Wild type (Dunn and Holloway, 1971) 
ST26 PAO1 ΔsahH (PA0432) (Thoma, 2009) 
AW07 PAO1 ΔmtnP (PA3004) This study 
AW12 PAO1 ΔsahH ΔmtnP (PA0432, PA3004) This study 
AW18 PAO1 ΔmetZ (PA3107) This study 
AW28 PAO1 pME6013, Tcr This study 
AW29 PAO1 pAW10, Tcr This study 
AW31 PAO1 pAW12, Tcr This study 
AW32 PAO1 pAW13, Tcr This study 
AW36 PAO1 attB::(lacZ), Tcr .PAO1 containing promoterless lacZ 
from mini-CTX-lacZ 
This study 
AW37 PAO1 attB::(PmetK-lacZ), Tcr  This study 
AW39 PAO1 attB::(PmetH-lacZ), Tcr This study 
AW40 PAO1 attB::(PsahH-lacZ), Tcr This study 
AW78 PAO1 ΔsahH pME6013, Tcr This study 
AW79 PAO1 ΔsahH pAW10, Tcr This study 
AW81 PAO1 ΔsahH pAW12, Tcr This study 
AW82 PAO1 ΔsahH pAW13, Tcr This study 
AW85 PAO1 ΔsahH attB::(lacZ), Tcr This study 
AW86 PAO1 ΔsahH attB::(PmetK-lacZ), Tcr This study 
AW88 PAO1 ΔsahH attB::(PmetH-lacZ), Tcr This study 
AW89 PAO1 ΔsahH attB::(PsahH-lacZ), Tcr This study 
E. coli:   
DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) "80dlacZΔM15 ΔlacX74 
deoR recA1 endA1 araD139 Δ(ara, leu) 7697 galU galK #- rpsL 
nupG 
GibcoBRL 
(Invitrogen) 
ST18 S17 (pir ΔhemA (Thoma and Schobert, 2009) 
BL21 (DE3)  F- ompT hsdSB(rB- mB-) gal dcm (DE3)  Novagen 
 
  
Ribavirin against Pseudomonas aeruginosa 
 
 129 
Supplemental Material: 
Table 27: Plasmids 
Plasmid Genotype Reference 
pEX18AP Apr, oriT+ sacB+; gene replacement vector with MCS of pUC18 (Hoang et al., 1998) 
pPS858 Apr, Gmr, source of gentamicin cassette (Hoang et al., 1998) 
pFLP2 Apr, source of FLP recombinase (Hoang et al., 1998) 
pST06 Apr Gmr; pEX18Ap with 593 bp upstream sahH, Gmr-gfp fragment from 
pPS858 SacI digested, and 473 bp downstream of the coding region of 
sahH between KpnI and XbaI 
(Thoma, 2009) 
pMR01 Apr Gmr; pEX18Ap with 751 bp upstream metZ, Gmr-gfp fragment from 
pPS858 BamHI digested, and 524 bp downstream of the coding region 
of metZ between KpnI and XbaI 
This study 
pAW03 Apr Gmr; pEX18Ap with 752 bp upstream mtnP, Gmr-gfp fragment from 
pPS858 BamHI digested, and 522 bp downstream of the coding region 
of mtnP between KpnI and XbaI 
This study 
pET14b Apr, N-terminal His Tag ®, thrombin site, T7 promoter, T7 terminator, 
pBR322 origin 
Novagen 
pAW04 Apr, pET14b with 1416 bp of the coding region of sahH between NdeI 
and BamHI and N-terminal His Tag 
This study 
pME6013 Cloning vector for construction of translational lacZ fusions; Tcr (Schnider-Keel et al., 
2000) 
mini-CTX- lacZ self-proficient integration vector for construction of transcriptional lacZ 
fusions; Tcr 
(Becher and Schweizer, 
2000) 
pAW10 pME6013 containing a 659 bp EcoRI-PstI fragment, encoding 500 bp 
upstream of the metK translational start and 159 bp of the coding 
region, Tcr; pME6013::metK 
This study 
pAW12 pME6013 containing a 650 bp EcoRI-PstI fragment, encoding 500 bp 
upstream of the metH translational start and 150 bp of coding region, 
Tcr; pME6013::metH 
This study 
pAW13 pME6013 containing a 659 bp EcoRI- EcoRI fragment, encoding 500 
bp upstream of the sahH translational start and 159 bp of and coding 
region, Tcr, orientation was confirmed via PCR; pME6013::sahH 
This study 
pAW17 mini-CTX-lacZ containing a 659 bp EcoRI-PstI fragment, encoding 500 
bp upstream of the metK translational start and 159 bp of the coding 
region, Tcr ;mini-CTX- lacZ::metK 
This study 
pAW19 mini-CTX-lacZ containing a 650 bp EcoRI-PstI fragment , encoding 
500 bp upstream of the metH translational start and 150 bp of coding 
region, Tcr; mini-CTX- lacZ::metH 
This study 
pAW20 mini-CTX-lacZ containing a 659 bp EcoRI- EcoRI fragment, encoding 
500 bp upstream of the sahH translational start and 159 bp of and 
coding region, Tcr, orientation was confirmed via PCR; mini-CTX- 
lacZ::sahH 
This study 
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Table 28: Primer (restriction sites are underlined) 
Primer Primer sequence (5’ - 3’) Restriction site  Construct 
pST06 sahH:   
sahHP1 GGAGTACCACCAGGGCGCTGCACATC KpnI upstream fragment  
sahHP2 CGAGCTCTGACAGCGCTCATGCGTAA SacI upstream fragment 
sahHP3 CGAGCTCCGGACACCTATCGCTACTA SacI downstream fragment 
sahHP4 GCTCTAGATGGCTGCAGGTTGGTGAT XbaI downstream fragment 
pMR01 metZ:   
oAW208 GGGGTACCTCGTTGTCGGCAAGCACTA KpnI upstream fragment  
oAW207 CGGGATCCGCCATCCTCAGCATGAGTT BamHI upstream fragment 
oAW152 CGGGATCCGCCGCTCTCCCCTTTGTCA BamHI downstream fragment 
oAW153 GCTCTAGACCAGGCGGCGCGGAAGAAA XbaI downstream fragment 
pAW03 mtnP:   
oAW154 GGGGTACCGCCTATGCGCTTGTTCCGT KpnI upstream fragment 
oAW155 CGGGATCCGGCGTTGCACGATGGCATT BamHI upstream fragment 
oAW162 CGGGATCCCTCCCTCAATCAATCAG BamHI downstream fragment 
oAW163 GCTCTAGAAGCATTTTCCCGGTCAC XbaI downstream fragment 
pAW04:    
oAW192 GGAATTCCATATGATGAGCGCTGTCAT NdeI pET-14b::sahH 
oAW193 CGCGGATCCTTAGTAGCGATAGGTGTC BamHI pET-14b::sahH 
lacZ constructs:   
AW233 CGGAATTCCGATGCCGAGGTCGTACC EcoRI PmetK 
AW234 TGCACTGCAGTGATTCAGTCGCAGCGAGTC PstI PmetK 
AW237 CGGAATTCTCGCCGGCCTGAAGGGCC EcoRI PmetH 
AW238 TGCACTGCAGTGCATGCCGCCATCGAGGAT PstI PmetH 
oAW243 CGGAATTCCAGGGATAGCCATTGGCTGGC EcoRI PsahH 
oAW244 CGGAATTCGCCTTTCAGCGGCTGCTG EcoRI PsahH 
 
Table 29: CF-sputum samples (from Michael Hogardt, Munich) 
Lane SDS-PAGE Number Patient code Date (Day/month/year) 
1 132 BM_000 132 15/04/11 
2 177 CM_000 177 25/05/11 
3 025 CM_000 025 21/01/11 
4 154 CM_000 154 11/05/11 
5 090 BM_000 090 17/03/11 
6 153 CM_000 153 11/05/11 
7 369 C10_000 369 09/12/10 
8 373 B10_000 373 15/11/10 
9 091 BM_000 091 17/03/11 
10 089 BM_000 089 17/03/11 
11 372 C10_000 372 15/12/10 
12 368 C10_000 368 09/12/10 
13 148 CM_000 148 05/09/11 
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5 Outlook  
The development of ASM-Chelex allows further interesting investigations. Little modifications 
have to be implemented such as increased phosphate addition to overcome the phosphate 
limitation, induced by Chelex to get closer to ex vivo conditions. Moreover, the incubation times 
of the P. aeruginosa strains have to be optimized to reach an state of metabolic inactivity close 
to the ex vivo conditions. It would be also important to search for further iron chelators, with a 
high affinity for iron and reduced ability to chelate other substances, which is not metabolized by 
P. aeruginosa. 
Furthermore, different characteristic P. aeruginosa isolates from different CF patients should be 
analysed in ASM-Chelex. This would allow the determination of the more general answers of 
P. aeruginosa towards the CF environment. Moreover, strain specific answers could also be 
elucidated and the underlying adaptation strategies of the respective strains could be identified. 
In general, it is of great importance to obtain more ex vivo transcriptome data and compare 
them to in vitro ASM-Chelex data. Furthermore, ASM-Chelex is suitable for the analysis of new 
antibiotic targets and new antibiotic substances. Evolutionary adaptations could be analysed in 
this model system. Interactions between different P. aeruginosa strains and with other 
colonizing pathogens could be further investigated and new insights into the pathogenesis could 
be derived. 
 
In order to prove the increased iron scavenger ability and the resulting increased intracellular 
iron content of P. aeruginosa mutant strain PAO1 "metF certain experiments need to be 
conducted. The intracellular iron concentration of PAO1 "metF should be determined. The rate 
of iron-sulphur cluster proteins should be investigated. It would be interesting to analyse the 
growth of PAO1 "metF in the presence of high iron concentrations with and without sufficient 
methionine supplementation. 
 
For further investigations of P. aeruginosa SahH as antibiotic target crystallization would be the 
next step to determine structural differences compared to the human SAHH. This would allow 
structure dependent inhibitor design and new functional inhibitors could be determined.  
The mode of action of ribavirin against P. aeruginosa should be further investigated. 
  
References 
 
 133 
6 References  
Ahmed, A. (1973). "Mechanism of repression of methionine biosynthesis in Escherichia 
coli. I. The role of methionine, s-adenosylmethionine, and methionyl-transfer 
ribonucleic acid in repression." Mol Gen Genet 123(4): 299-324. 
Akerlund, T., K. Nordstrom and R. Bernander (1995). "Analysis of cell size and DNA 
content in exponentially growing and stationary-phase batch cultures of Escherichia 
coli." J Bacteriol 177(23): 6791-6797. 
Alm, R. A., J. P. Hallinan, A. A. Watson and J. S. Mattick (1996). "Fimbrial biogenesis 
genes of Pseudomonas aeruginosa: pilW and pilX increase the similarity of type 4 
fimbriae to the GSP protein-secretion systems and pilY1 encodes a gonococcal PilC 
homologue." Mol Microbiol 22(1): 161-173. 
Alvarez-Ortega, C. and C. S. Harwood (2007). "Responses of Pseudomonas 
aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic 
respiration." Mol Microbiol 65(1): 153-165. 
Amich, J., L. Schafferer, H. Haas and S. Krappmann (2013). "Regulation of sulphur 
assimilation is essential for virulence and affects iron homeostasis of the human-
pathogenic mould Aspergillus fumigatus." PLoS Pathog 9(8): e1003573. 
Amiel, E., R. R. Lovewell, G. A. O'Toole, D. A. Hogan and B. Berwin (2010). 
"Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming 
motility and is independent of flagellum expression." Infect Immun 78(7): 2937-2945. 
Amini, S., A. K. Hottes, L. E. Smith and S. Tavazoie (2011). "Fitness landscape of 
antibiotic tolerance in Pseudomonas aeruginosa biofilms." PLoS Pathog 7(10): 
e1002298. 
Arai, H. (2011). "Regulation and function of versatile aerobic and anaerobic respiratory 
metabolism in Pseudomonas aeruginosa." Front Microbiol 2. 
Arai, H., Y. Igarashi and T. Kodama (1995). "The structural genes for nitric oxide 
reductase from Pseudomonas aeruginosa." Biochim Biophys Acta 1261(2): 279-284. 
Arredondo-Vega, F. X., J. A. Charlton, Y. H. Edwards, D. A. Hopkinson and D. B. 
Whitehouse (1989). "Isozyme and DNA analysis of human S-adenosyl-L-homocysteine 
hydrolase (AHCY)." Ann Hum Genet 53(Pt 2): 157-167. 
Ayala-Castro, C., A. Saini and F. W. Outten (2008). "Fe-S cluster assembly pathways 
in bacteria." Microbiol Mol Biol Rev 72(1): 110-125, table of contents. 
Baldi, P. and A. D. Long (2001). "A Bayesian framework for the analysis of microarray 
expression data: regularized t -test and statistical inferences of gene changes." 
Bioinformatics 17(6): 509-519. 
Balloy, V., A. Verma, S. Kuravi, M. Si-Tahar, M. Chignard and R. Ramphal (2007). 
"The role of flagellin versus motility in acute lung disease caused by Pseudomonas 
aeruginosa." J Infect Dis 196(2): 289-296. 
Bandyopadhaya, A., M. Kesarwani, Y. A. Que, J. He, K. Padfield, R. Tompkins and L. 
G. Rahme (2012). "The quorum sensing volatile molecule 2-amino acetophenon 
modulates host immune responses in a manner that promotes life with unwanted 
guests." PLoS Pathog 8(11): e1003024. 
References 
 
 134 
Barth, A. L. and T. L. Pitt (1995). "Auxotrophic variants of Pseudomonas aeruginosa 
are selected from prototrophic wild-type strains in respiratory infections in patients with 
cystic fibrosis." J Clin Microbiol 33(1): 37-40. 
Barth, A. L. and T. L. Pitt (1996). "The high amino-acid content of sputum from cystic 
fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa." J Med 
Microbiol 45(2): 110-119. 
Barth, A. L., N. Woodford and T. L. Pitt (1998). "Complementation of methionine 
auxotrophs of Pseudomonas aeruginosa from cystic fibrosis." Curr Microbiol 36(4): 
190-195. 
Becher, A. and H. P. Schweizer (2000). "Integration-proficient Pseudomonas 
aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene 
fusions." Biotechniques 29(5): 948-950, 952. 
Becker, K. A., H. Grassme, Y. Zhang and E. Gulbins (2010). "Ceramide in 
Pseudomonas aeruginosa infections and cystic fibrosis." Cell Physiol Biochem 26(1): 
57-66. 
Behrends, V., T. M. Ebbels, H. D. Williams and J. G. Bundy (2009). "Time-resolved 
metabolic footprinting for nonlinear modeling of bacterial substrate utilization." Appl 
Environ Microbiol 75(8): 2453-2463. 
Benkert, B., N. Quack, K. Schreiber, L. Jaensch, D. Jahn and M. Schobert (2008). 
"Nitrate-responsive NarX-NarL represses arginine-mediated induction of the 
Pseudomonas aeruginosa arginine fermentation arcDABC operon." Microbiology 
154(Pt 10): 3053-3060. 
Bielecki, P. (2008). Towards Understanding Pseudomonas aeruginosa Infection 
through Global Expression Profiling: From Models to Real Infection Settings and 
Proposed Prevention Strategies 
. PhD thesis, TU Braunschweig. 
Bielecki, P., J. Glik, M. Kawecki and V. A. Martins dos Santos (2008). "Towards 
understanding Pseudomonas aeruginosa burn wound infections by profiling gene 
expression." Biotechnol Lett 30(5): 777-790. 
Bielecki, P., U. Komor, A. Bielecka, M. Musken, J. Puchalka, M. W. Pletz, M. Ballmann, 
V. A. Martins dos Santos, S. Weiss and S. Haussler (2013). "Ex vivo transcriptional 
profiling reveals a common set of genes important for the adaptation of Pseudomonas 
aeruginosa to chronically infected host sites." Environ Microbiol 15(2): 570-587. 
Bielecki, P., J. Puchalka, M. L. Wos-Oxley, H. Loessner, J. Glik, M. Kawecki, M. 
Nowak, B. Tummler, S. Weiss and V. A. dos Santos (2011). "In-vivo expression 
profiling of Pseudomonas aeruginosa infections reveals niche-specific and strain-
independent transcriptional programs." PLoS One 6(9): e24235. 
Bleves, S., V. Viarre, R. Salacha, G. P. Michel, A. Filloux and R. Voulhoux (2010). 
"Protein secretion systems in Pseudomonas aeruginosa: A wealth of pathogenic 
weapons." Int J Med Microbiol 300(8): 534-543. 
Blount, K. F. and R. R. Breaker (2006). "Riboswitches as antibacterial drug targets." 
Nat Biotechnol 24(12): 1558-1564. 
Boes, N., K. Schreiber and M. Schobert (2008). "SpoT-triggered stringent response 
controls usp gene expression in Pseudomonas aeruginosa." J Bacteriol 190(21): 7189-
7199. 
References 
 
 135 
Bolstad, B. M., R. A. Irizarry, M. Astrand and T. P. Speed (2003). "A comparison of 
normalization methods for high density oligonucleotide array data based on variance 
and bias." Bioinformatics 19(2): 185-193. 
Bonfield, T. L., M. W. Konstan and M. Berger (1999). "Altered respiratory epithelial cell 
cytokine production in cystic fibrosis." J Allergy Clin Immunol 104(1): 72-78. 
Boucher, J. C., H. Yu, M. H. Mudd and V. Deretic (1997). "Mucoid Pseudomonas 
aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and 
analysis of clearance in a mouse model of respiratory infection." Infect Immun 65(9): 
3838-3846. 
Boucher, R. C. (2007). "Airway surface dehydration in cystic fibrosis: pathogenesis and 
therapy." Annu Rev Med 58: 157-170. 
Bragonzi, A., M. Paroni, A. Nonis, N. Cramer, S. Montanari, J. Rejman, C. Di Serio, G. 
Doring and B. Tummler (2009). "Pseudomonas aeruginosa microevolution during cystic 
fibrosis lung infection establishes clones with adapted virulence." Am J Respir Crit 
Care Med 180(2): 138-145. 
Brandel, J., N. Humbert, M. Elhabiri, I. J. Schalk, G. L. Mislin and A. M. Albrecht-Gary 
(2012). "Pyochelin, a siderophore of Pseudomonas aeruginosa: physicochemical 
characterization of the iron(III), copper(II) and zinc(II) complexes." Dalton Trans 41(9): 
2820-2834. 
Braun, V. and H. Killmann (1999). "Bacterial solutions to the iron-supply problem." 
Trends Biochem Sci 24(3): 104-109. 
Brazas, M. D., E. B. Breidenstein, J. Overhage and R. E. Hancock (2007). "Role of lon, 
an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to 
ciprofloxacin." Antimicrob Agents Chemother 51(12): 4276-4283. 
Bredenbruch, F., M. Nimtz, V. Wray, M. Morr, R. Muller and S. Haussler (2005). 
"Biosynthetic pathway of Pseudomonas aeruginosa 4-hydroxy-2-alkylquinolines." J 
Bacteriol 187(11): 3630-3635. 
Brichta, D. M., K. N. Azad, P. Ralli and G. A. O'Donovan (2004). "Pseudomonas 
aeruginosa dihydroorotases: a tale of three pyrCs." Arch Microbiol 182(1): 7-17. 
Britigan, B. E., M. B. Hayek, B. N. Doebbeling and R. B. Fick, Jr. (1993). "Transferrin 
and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected 
lungs of patients with cystic fibrosis." Infect Immun 61(12): 5049-5055. 
Bundy, B. M., A. L. Campbell and E. L. Neidle (1998). "Similarities between the 
antABC-encoded anthranilate dioxygenase and the benABC-encoded benzoate 
dioxygenase of Acinetobacter sp. strain ADP1." J Bacteriol 180(17): 4466-4474. 
Byrd, M. S., I. Sadovskaya, E. Vinogradov, H. Lu, A. B. Sprinkle, S. H. Richardson, L. 
Ma, B. Ralston, M. R. Parsek, E. M. Anderson, J. S. Lam and D. J. Wozniak (2009). 
"Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl 
exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in 
Psl and LPS production." Mol Microbiol 73(4): 622-638. 
Cai, S., J. Fang, Q. S. Li, R. T. Borchardt, K. Kuczera, C. R. Middaugh and R. L. 
Schowen (2010). "Comparative kinetics of cofactor association and dissociation for the 
human and trypanosomal S-adenosylhomocysteine hydrolases. 3. Role of lysyl and 
tyrosyl residues of the C-terminal extension." Biochemistry 49(38): 8434-8441. 
References 
 
 136 
Cai, S., Q. S. Li, R. T. Borchardt, K. Kuczera and R. L. Schowen (2007). "The antiviral 
drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from 
Trypanosoma cruzi." Bioorg Med Chem 15(23): 7281-7287. 
Challand, M. R., F. T. Martins and P. L. Roach (2010). "Catalytic activity of the 
anaerobic tyrosine lyase required for thiamine biosynthesis in Escherichia coli." J Biol 
Chem 285(8): 5240-5248. 
Challand, M. R., T. Ziegert, P. Douglas, R. J. Wood, M. Kriek, N. M. Shaw and P. L. 
Roach (2009). "Product inhibition in the radical S-adenosylmethionine family." FEBS 
Lett 583(8): 1358-1362. 
Choi, K. H., A. Kumar and H. P. Schweizer (2006). "A 10-min method for preparation of 
highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment 
transfer between chromosomes and plasmid transformation." J Microbiol Methods 
64(3): 391-397. 
Choi-Rhee, E. and J. E. Cronan (2005). "A nucleosidase required for in vivo function of 
the S-adenosyl-L-methionine radical enzyme, biotin synthase." Chem Biol 12(5): 589-
593. 
Chugani, S. and E. P. Greenberg (2007). "The influence of human respiratory epithelia 
on Pseudomonas aeruginosa gene expression." Microb Pathog 42(1): 29-35. 
Chugani, S. and E. P. Greenberg (2010). "LuxR homolog-independent gene regulation 
by acyl-homoserine lactones in Pseudomonas aeruginosa." Proc Natl Acad Sci U S A 
107(23): 10673-10678. 
Ciofu, O., V. Fussing, N. Bagge, C. Koch and N. Hoiby (2001). "Characterization of 
paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic 
fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting." J 
Antimicrob Chemother 48(3): 391-396. 
Ciofu, O., L. F. Mandsberg, T. Bjarnsholt, T. Wassermann and N. Hoiby (2010). 
"Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of 
patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic 
backgrounds emerge in mucA and/or lasR mutants." Microbiology 156(Pt 4): 1108-
1119. 
Ciofu, O., B. Riis, T. Pressler, H. E. Poulsen and N. Hoiby (2005). "Occurrence of 
hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with 
the oxidative stress caused by chronic lung inflammation." Antimicrob Agents 
Chemother 49(6): 2276-2282. 
Collier, D. N., L. Anderson, S. L. McKnight, T. L. Noah, M. Knowles, R. Boucher, U. 
Schwab, P. Gilligan and E. C. Pesci (2002). "A bacterial cell to cell signal in the lungs 
of cystic fibrosis patients." FEMS Microbiol Lett 215(1): 41-46. 
Colombo, C., D. Costantini, A. Rocchi, L. Cariani, M. L. Garlaschi, S. Tirelli, G. Calori, 
E. Copreni and M. Conese (2005). "Cytokine levels in sputum of cystic fibrosis patients 
before and after antibiotic therapy." Pediatr Pulmonol 40(1): 15-21. 
Comolli, J. C. and T. J. Donohue (2004). "Differences in two Pseudomonas aeruginosa 
cbb3 cytochrome oxidases." Mol Microbiol 51(4): 1193-1203. 
Cooper, M., G. R. Tavankar and H. D. Williams (2003). "Regulation of expression of 
the cyanide-insensitive terminal oxidase in Pseudomonas aeruginosa." Microbiology 
149(5): 1275-1284. 
References 
 
 137 
Cornelis, P., S. Matthijs and L. Van Oeffelen (2009). "Iron uptake regulation in 
Pseudomonas aeruginosa." Biometals 22(1): 15-22. 
Costerton, J. W., P. S. Stewart and E. P. Greenberg (1999). "Bacterial biofilms: a 
common cause of persistent infections." Science 284(5418): 1318-1322. 
Cowan, J. M., M. L. Urbanowski, M. Talmi and G. V. Stauffer (1993). "Regulation of the 
Salmonella typhimurium metF gene by the MetR protein." J Bacteriol 175(18): 5862-
5866. 
Cox, C. D. and J. Parker (1979). "Use of 2-aminoacetophenone production in 
identification of Pseudomonas aeruginosa." J Clin Microbiol 9(4): 479-484. 
Csonka, L. N. and A. D. Hanson (1991). "Prokaryotic osmoregulation: genetics and 
physiology." Annu Rev Microbiol 45: 569-606. 
D'Argenio, D. A., M. Wu, L. R. Hoffman, H. D. Kulasekara, E. Deziel, E. E. Smith, H. 
Nguyen, R. K. Ernst, T. J. Larson Freeman, D. H. Spencer, M. Brittnacher, H. S. 
Hayden, S. Selgrade, M. Klausen, D. R. Goodlett, J. L. Burns, B. W. Ramsey and S. I. 
Miller (2007). "Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted 
to the airways of cystic fibrosis patients." Mol Microbiol 64(2): 512-533. 
Darling, K. E., A. Dewar and T. J. Evans (2004). "Role of the cystic fibrosis 
transmembrane conductance regulator in internalization of Pseudomonas aeruginosa 
by polarized respiratory epithelial cells." Cell Microbiol 6(6): 521-533. 
Dasgupta, N., E. P. Ferrell, K. J. Kanack, S. E. West and R. Ramphal (2002). "fleQ, the 
gene encoding the major flagellar regulator of Pseudomonas aeruginosa, is sigma70 
dependent and is downregulated by Vfr, a homolog of Escherichia coli cyclic AMP 
receptor protein." J Bacteriol 184(19): 5240-5250. 
Davies, K. J., D. Lloyd and L. Boddy (1989). "The effect of oxygen on denitrification in 
Paracoccus denitrificans and Pseudomonas aeruginosa." J Gen Microbiol 135(9): 
2445-2451. 
Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. 
Shiffman, S. Zeuzem, A. Craxi, M. H. Ling and J. Albrecht (1998). "Interferon alfa-2b 
alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. 
International Hepatitis Interventional Therapy Group." N Engl J Med 339(21): 1493-
1499. 
Dekimpe, V. and E. Deziel (2009). "Revisiting the quorum-sensing hierarchy in 
Pseudomonas aeruginosa: the transcriptional regulator RhlR regulates LasR-specific 
factors." Microbiology 155(Pt 3): 712-723. 
Di, A., M. E. Brown, L. V. Deriy, C. Li, F. L. Szeto, Y. Chen, P. Huang, J. Tong, A. P. 
Naren, V. Bindokas, H. C. Palfrey and D. J. Nelson (2006). "CFTR regulates 
phagosome acidification in macrophages and alters bactericidal activity." Nat Cell Biol 
8(9): 933-944. 
Dickschat, J. S. (2010). "Quorum sensing and bacterial biofilms." Nat Prod Rep 27(3): 
343-369. 
Dietrich, L. E., C. Okegbe, A. Price-Whelan, H. Sakhtah, R. C. Hunter and D. K. 
Newman (2013). "Bacterial community morphogenesis is intimately linked to the 
intracellular redox state." J Bacteriol 195(7): 1371-1380. 
References 
 
 138 
Dietrich, L. E., A. Price-Whelan, A. Petersen, M. Whiteley and D. K. Newman (2006). 
"The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network 
of Pseudomonas aeruginosa." Mol Microbiol 61(5): 1308-1321. 
Diggle, S. P., A. S. Griffin, G. S. Campbell and S. A. West (2007a). "Cooperation and 
conflict in quorum-sensing bacterial populations." Nature 450(7168): 411-414. 
Diggle, S. P., S. Matthijs, V. J. Wright, M. P. Fletcher, S. R. Chhabra, I. L. Lamont, X. 
Kong, R. C. Hider, P. Cornelis, M. Camara and P. Williams (2007b). "The 
Pseudomonas aeruginosa 4-quinolone signal molecules HHQ and PQS play 
multifunctional roles in quorum sensing and iron entrapment." Chem Biol 14(1): 87-96. 
Diggle, S. P., K. Winzer, A. Lazdunski, P. Williams and M. Camara (2002). "Advancing 
the quorum in Pseudomonas aeruginosa: MvaT and the regulation of N-
acylhomoserine lactone production and virulence gene expression." J Bacteriol 
184(10): 2576-2586. 
Doring, G. (1999). "Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor 
deficiency and cystic fibrosis." Pediatr Pulmonol 28(5): 363-375. 
Doring, G. and E. Gulbins (2009). "Cystic fibrosis and innate immunity: how chloride 
channel mutations provoke lung disease." Cell Microbiol 11(2): 208-216. 
Dotsch, A., T. Becker, C. Pommerenke, Z. Magnowska, L. Jansch and S. Haussler 
(2009). "Genomewide identification of genetic determinants of antimicrobial drug 
resistance in Pseudomonas aeruginosa." Antimicrob Agents Chemother 53(6): 2522-
2531. 
Dunn, N. W. and B. W. Holloway (1971). "Pleiotrophy of p-fluorophenylalanine-resistant 
and antibiotic hypersensitive mutants of Pseudomonas aeruginosa." Genet Res 18(2): 
185-197. 
Eschbach, M., K. Schreiber, K. Trunk, J. Buer, D. Jahn and M. Schobert (2004). "Long-
term anaerobic survival of the opportunistic pathogen Pseudomonas aeruginosa via 
pyruvate fermentation." J Bacteriol 186(14): 4596-4604. 
Farrow, J. M., 3rd and E. C. Pesci (2007). "Two distinct pathways supply anthranilate 
as a precursor of the Pseudomonas quinolone signal." J Bacteriol 189(9): 3425-3433. 
Federle, M. J. and B. L. Bassler (2003). "Interspecies communication in bacteria." J 
Clin Invest 112(9): 1291-1299. 
Folkesson, A., L. Jelsbak, L. Yang, H. K. Johansen, O. Ciofu, N. Hoiby and S. Molin 
(2012). "Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an 
evolutionary perspective." Nat Rev Microbiol 10(12): 841-851. 
Fontecave, M., M. Atta and E. Mulliez (2004). "S-adenosylmethionine: nothing goes to 
waste." Trends Biochem Sci 29(5): 243-249. 
Foundation, C. F. (2013). 2012 annual data report Cystic Fibrosis Foundation patient 
registry C. F. Foundation. Bethesda, Maryland, Cystic Fibrosis Foundation. 
Francois, P., C. Garzoni, M. Bento and J. Schrenzel (2007). "Comparison of 
amplification methods for transcriptomic analyses of low abundance prokaryotic RNA 
sources." J Microbiol Methods 68(2): 385-391. 
References 
 
 139 
Galimand, M., M. Gamper, A. Zimmermann and D. Haas (1991). "Positive FNR-like 
control of anaerobic arginine degradation and nitrate respiration in Pseudomonas 
aeruginosa." J Bacteriol 173(5): 1598-1606. 
Gallagher, L. A., S. L. McKnight, M. S. Kuznetsova, E. C. Pesci and C. Manoil (2002). 
"Functions required for extracellular quinolone signaling by Pseudomonas aeruginosa." 
J Bacteriol 184(23): 6472-6480. 
Gamper, M., A. Zimmermann and D. Haas (1991). "Anaerobic regulation of 
transcription initiation in the arcDABC operon of Pseudomonas aeruginosa." J Bacteriol 
173(15): 4742-4750. 
Gentleman, R. C., V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, 
L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry, F. 
Leisch, C. Li, M. Maechler, A. J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, 
J. Y. Yang and J. Zhang (2004). "Bioconductor: open software development for 
computational biology and bioinformatics." Genome Biol 5(10): R80. 
Giltner, C. L., M. Habash and L. L. Burrows (2010). "Pseudomonas aeruginosa minor 
pilins are incorporated into type IV pili." J Mol Biol 398(3): 444-461. 
Govan, J. R. and V. Deretic (1996). "Microbial pathogenesis in cystic fibrosis: mucoid 
Pseudomonas aeruginosa and Burkholderia cepacia." Microbiol Rev 60(3): 539-574. 
Govan, J. R. and J. W. Nelson (1993). "Microbiology of cystic fibrosis lung infections: 
themes and issues." J R Soc Med 86 Suppl 20: 11-18. 
Grasemann, H., I. Ioannidis, R. P. Tomkiewicz, H. de Groot, B. K. Rubin and F. Ratjen 
(1998). "Nitric oxide metabolites in cystic fibrosis lung disease." Arch Dis Child 78(1): 
49-53. 
Greene, R. C. (1996). Biosynthesis of methionine. Escherichia coli and 
Salmonella. Cellular and molecular biology. F. C. Neidhardt. Washington, D.C, ASM 
Press: 542-560. 
Griffith, O. W. (1987). "Mammalian sulfur amino acid metabolism: an overview." 
Methods Enzymol 143: 366-376. 
Groisman, E. A., E. Chiao, C. J. Lipps and F. Heffron (1989). "Salmonella typhimurium 
phoP virulence gene is a transcriptional regulator." Proc Natl Acad Sci U S A 86(18): 
7077-7081. 
Guan, R., M. C. Ho, S. C. Almo and V. L. Schramm (2011). "Methylthioinosine 
phosphorylase from Pseudomonas aeruginosa. Structure and annotation of a novel 
enzyme in quorum sensing." Biochemistry 50(7): 1247-1254. 
Guenther, B. D., C. A. Sheppard, P. Tran, R. Rozen, R. G. Matthews and M. L. Ludwig 
(1999). "The structure and properties of methylenetetrahydrofolate reductase from 
Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia." Nat 
Struct Biol 6(4): 359-365. 
Gupta, R., S. Kim and M. W. Taylor (2012). "Suppression of ribosomal protein 
synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV 
patients blood mononuclear cells (PBMC)." J Transl Med 10: 54. 
Hall, L. M. and S. K. Henderson-Begg (2006). "Hypermutable bacteria isolated from 
humans--a critical analysis." Microbiology 152(Pt 9): 2505-2514. 
References 
 
 140 
Halliday, N. M., K. R. Hardie, P. Williams, K. Winzer and D. A. Barrett (2010). 
"Quantitative liquid chromatography-tandem mass spectrometry profiling of activated 
methyl cycle metabolites involved in LuxS-dependent quorum sensing in Escherichia 
coli." Anal Biochem 403(1-2): 20-29. 
Hampton, M. B., A. J. Kettle and C. C. Winterbourn (1998). "Inside the neutrophil 
phagosome: oxidants, myeloperoxidase, and bacterial killing." Blood 92(9): 3007-3017. 
Hancock, R. E. (1998). "Resistance mechanisms in Pseudomonas aeruginosa and 
other nonfermentative gram-negative bacteria." Clin Infect Dis 27 Suppl 1: S93-99. 
Hancock, R. E., C. Egli, R. Benz and R. J. Siehnel (1992). "Overexpression in 
Escherichia coli and functional analysis of a novel PPi-selective porin, oprO, from 
Pseudomonas aeruginosa." J Bacteriol 174(2): 471-476. 
Hancock, R. E., L. M. Mutharia, L. Chan, R. P. Darveau, D. P. Speert and G. B. Pier 
(1983). "Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of 
serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains." 
Infect Immun 42(1): 170-177. 
Harbitz, O., A. O. Jenssen and O. Smidsrod (1984). "Lysozyme and lactoferrin in 
sputum from patients with chronic obstructive lung disease." Eur J Respir Dis 65(7): 
512-520. 
Hassett, D. J. (1996). "Anaerobic production of alginate by Pseudomonas aeruginosa: 
alginate restricts diffusion of oxygen." J Bacteriol 178(24): 7322-7325. 
Hassett, D. J., M. D. Sutton, M. J. Schurr, A. B. Herr, C. C. Caldwell and J. O. Matu 
(2009). "Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic 
fibrosis airways." Trends Microbiol 17(3): 130-138. 
Hatfield, G. W., S. P. Hung and P. Baldi (2003). "Differential analysis of DNA 
microarray gene expression data." Mol Microbiol 47(4): 871-877. 
Hauser, A. R. (2009). "The type III secretion system of Pseudomonas aeruginosa: 
infection by injection." Nat Rev Microbiol 7(9): 654-665. 
Hauser, A. R., M. Jain, M. Bar-Meir and S. A. McColley (2011). "Clinical significance of 
microbial infection and adaptation in cystic fibrosis." Clin Microbiol Rev 24(1): 29-70. 
Haussler, S. and T. Becker (2008). "The pseudomonas quinolone signal (PQS) 
balances life and death in Pseudomonas aeruginosa populations." PLoS Pathog 4(9): 
e1000166. 
Hentzer, M. and M. Givskov (2003). "Pharmacological inhibition of quorum sensing for 
the treatment of chronic bacterial infections." J Clin Invest 112(9): 1300-1307. 
Hershfield, M. S., N. M. Kredich, D. R. Ownby, H. Ownby and R. Buckley (1979). "In 
vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-
deoxyadenosine in adenosine deaminase-deficient patients." J Clin Invest 63(4): 807-
811. 
Heurlier, K., V. Denervaud and D. Haas (2006). "Impact of quorum sensing on fitness 
of Pseudomonas aeruginosa." Int J Med Microbiol 296(2-3): 93-102. 
Hoang, T. T., R. R. Karkhoff-Schweizer, A. J. Kutchma and H. P. Schweizer (1998). "A 
broad-host-range Flp-FRT recombination system for site-specific excision of 
References 
 
 141 
chromosomally-located DNA sequences: application for isolation of unmarked 
Pseudomonas aeruginosa mutants." Gene 212(1): 77-86. 
Hoffman, L. R., A. R. Richardson, L. S. Houston, H. D. Kulasekara, W. Martens-
Habbena, M. Klausen, J. L. Burns, D. A. Stahl, D. J. Hassett, F. C. Fang and S. I. Miller 
(2010). "Nutrient availability as a mechanism for selection of antibiotic tolerant 
Pseudomonas aeruginosa within the CF airway." PLoS Pathog 6(1): e1000712. 
Hogardt, M. and J. Heesemann (2013). "Microevolution of Pseudomonas aeruginosa to 
a chronic pathogen of the cystic fibrosis lung." Curr Top Microbiol Immunol 358: 91-
118. 
Hogardt, M., C. Hoboth, S. Schmoldt, C. Henke, L. Bader and J. Heesemann (2007). 
"Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during 
chronic pulmonary infection in patients with cystic fibrosis." J Infect Dis 195(1): 70-80. 
Hogardt, M., S. Schubert, K. Adler, M. Gotzfried and J. Heesemann (2006). "Sequence 
variability and functional analysis of MutS of hypermutable Pseudomonas aeruginosa 
cystic fibrosis isolates." Int J Med Microbiol 296(4-5): 313-320. 
Hueck, C. J. (1998). "Type III protein secretion systems in bacterial pathogens of 
animals and plants." Microbiol Mol Biol Rev 62(2): 379-433. 
Hung, S. P., P. Baldi and G. W. Hatfield (2002). "Global gene expression profiling in 
Escherichia coli K12. The effects of leucine-responsive regulatory protein." J Biol Chem 
277(43): 40309-40323. 
Iglewski, B. H. and D. Kabat (1975). "NAD-dependent inhibition of protein synthesis by 
Pseudomonas aeruginosa toxin." Proc Natl Acad Sci U S A 72(6): 2284-2288. 
Imperi, F., F. Tiburzi, G. M. Fimia and P. Visca (2010). "Transcriptional control of the 
pvdS iron starvation sigma factor gene by the master regulator of sulfur metabolism 
CysB in Pseudomonas aeruginosa." Environ Microbiol 12(6): 1630-1642. 
Irizarry, R. A., B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs and T. P. Speed (2003a). 
"Summaries of Affymetrix GeneChip probe level data." Nucleic Acids Res 31(4): e15. 
Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf and 
T. P. Speed (2003b). "Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data." Biostatistics 4(2): 249-264. 
Ishihara, M., Y. Kusakabe, T. Ohsumichi, N. Tanaka, M. Nakanishi, Y. Kitade and K. T. 
Nakamura (2010). "Crystallization of mouse S-adenosyl-L-homocysteine hydrolase." 
Acta Crystallogr Sect F Struct Biol Cryst Commun 66(Pt 3): 313-315. 
Itoh, Y. (1997). "Cloning and characterization of the aru genes encoding enzymes of 
the catabolic arginine succinyltransferase pathway in Pseudomonas aeruginosa." J 
Bacteriol 179(23): 7280-7290. 
Jaffe, A. and A. Bush (2001). "Cystic fibrosis: review of the decade." Monaldi Arch 
Chest Dis 56(3): 240-247. 
Juhas, M., L. Wiehlmann, B. Huber, D. Jordan, J. Lauber, P. Salunkhe, A. S. Limpert, 
F. von Gotz, I. Steinmetz, L. Eberl and B. Tummler (2004). "Global regulation of 
quorum sensing and virulence by VqsR in Pseudomonas aeruginosa." Microbiology 
150(Pt 4): 831-841. 
References 
 
 142 
Kawakami, T., M. Kuroki, M. Ishii, Y. Igarashi and H. Arai (2010). "Differential 
expression of multiple terminal oxidases for aerobic respiration in Pseudomonas 
aeruginosa." Environ Microbiol 12(6): 1399-1412. 
Kerem, B., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, 
M. Buchwald and L. C. Tsui (1989). "Identification of the cystic fibrosis gene: genetic 
analysis." Science 245(4922): 1073-1080. 
Kim, S. and T. P. West (1991). "Pyrimidine catabolism in Pseudomonas aeruginosa." 
FEMS Microbiol Lett 61(2-3): 175-179. 
Kiratisin, P., K. D. Tucker and L. Passador (2002). "LasR, a transcriptional activator of 
Pseudomonas aeruginosa virulence genes, functions as a multimer." J Bacteriol 
184(17): 4912-4919. 
Klausen, M., A. Heydorn, P. Ragas, L. Lambertsen, A. Aaes-Jorgensen, S. Molin and 
T. Tolker-Nielsen (2003). "Biofilm formation by Pseudomonas aeruginosa wild type, 
flagella and type IV pili mutants." Mol Microbiol 48(6): 1511-1524. 
Klein, J., S. Leupold, R. Munch, C. Pommerenke, T. Johl, U. Karst, L. Jansch, D. Jahn 
and I. Retter (2008). "ProdoNet: identification and visualization of prokaryotic gene 
regulatory and metabolic networks." Nucleic Acids Res 36(Web Server issue): W460-
464. 
Kleinstreuer, C., Z. Zhang and J. F. Donohue (2008). "Targeted drug-aerosol delivery 
in the human respiratory system." Annu Rev Biomed Eng 10: 195-220. 
Konstan, M. W., K. A. Hilliard, T. M. Norvell and M. Berger (1994). "Bronchoalveolar 
lavage findings in cystic fibrosis patients with stable, clinically mild lung disease 
suggest ongoing infection and inflammation." Am J Respir Crit Care Med 150(2): 448-
454. 
Kromer, J. O., M. Fritz, E. Heinzle and C. Wittmann (2005). "In vivo quantification of 
intracellular amino acids and intermediates of the methionine pathway in 
Corynebacterium glutamicum." Anal Biochem 340(1): 171-173. 
Kulasekara, B. R., H. D. Kulasekara, M. C. Wolfgang, L. Stevens, D. W. Frank and S. 
Lory (2006). "Acquisition and evolution of the exoU locus in Pseudomonas 
aeruginosa." J Bacteriol 188(11): 4037-4050. 
Lam, J., R. Chan, K. Lam and J. W. Costerton (1980). "Production of mucoid 
microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis." 
Infect Immun 28(2): 546-556. 
Larkin, M. A., G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, H. 
McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J. D. Thompson, T. J. Gibson 
and D. G. Higgins (2007). "Clustal W and Clustal X version 2.0." Bioinformatics 23(21): 
2947-2948. 
Lau, G. W., D. J. Hassett, H. Ran and F. Kong (2004). "The role of pyocyanin in 
Pseudomonas aeruginosa infection." Trends Mol Med 10(12): 599-606. 
Layer, G., J. Moser, D. W. Heinz, D. Jahn and W. D. Schubert (2003). "Crystal 
structure of coproporphyrinogen III oxidase reveals cofactor geometry of Radical SAM 
enzymes." EMBO J 22(23): 6214-6224. 
Lewis, K. (2001). "Riddle of biofilm resistance." Antimicrob Agents Chemother 45(4): 
999-1007. 
References 
 
 143 
Linnane, S. J., V. M. Keatings, C. M. Costello, J. B. Moynihan, C. M. O'Connor, M. X. 
Fitzgerald and P. McLoughlin (1998). "Total sputum nitrate plus nitrite is raised during 
acute pulmonary infection in cystic fibrosis." Am J Respir Crit Care Med 158(1): 207-
212. 
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method." Methods 25(4): 
402-408. 
Llamas, M. A., M. J. Mooij, M. Sparrius, C. M. Vandenbroucke-Grauls, C. Ratledge and 
W. Bitter (2008). "Characterization of five novel Pseudomonas aeruginosa cell-surface 
signalling systems." Mol Microbiol 67(2): 458-472. 
Loenen, W. A. (2006). "S-adenosylmethionine: jack of all trades and master of 
everything?" Biochem Soc Trans 34(Pt 2): 330-333. 
Lory, S., M. Merighi and M. Hyodo (2009). "Multiple activities of c-di-GMP in 
Pseudomonas aeruginosa." Nucleic Acids Symp Ser (Oxf)(53): 51-52. 
Lozada-Ramirez, J. D., I. Martinez-Martinez, A. Sanchez-Ferrer and F. Garcia-
Carmona (2008). "S-adenosylhomocysteine hydrolase from Corynebacterium 
glutamicum: cloning, overexpression, purification, and biochemical characterization." J 
Mol Microbiol Biotechnol 15(4): 277-286. 
Lu, C. D., H. Winteler, A. Abdelal and D. Haas (1999). "The ArgR regulatory protein, a 
helper to the anaerobic regulator ANR during transcriptional activation of the arcD 
promoter in Pseudomonas aeruginosa." J Bacteriol 181(8): 2459-2464. 
Lu, C. D., Z. Yang and W. Li (2004). "Transcriptome analysis of the ArgR regulon in 
Pseudomonas aeruginosa." J Bacteriol 186(12): 3855-3861. 
Luzar, M. A. and T. C. Montie (1985). "Avirulence and altered physiological properties 
of cystic fibrosis strains of Pseudomonas aeruginosa." Infect Immun 50(2): 572-576. 
Lyczak, J. B., C. L. Cannon and G. B. Pier (2002). "Lung infections associated with 
cystic fibrosis." Clin Microbiol Rev 15(2): 194-222. 
Mahenthiralingam, E., M. E. Campbell and D. P. Speert (1994). "Nonmotility and 
phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized 
patients with cystic fibrosis." Infect Immun 62(2): 596-605. 
Mashburn, L. M., A. M. Jett, D. R. Akins and M. Whiteley (2005). "Staphylococcus 
aureus serves as an iron source for Pseudomonas aeruginosa during in vivo 
coculture." J Bacteriol 187(2): 554-566. 
Mashburn, L. M. and M. Whiteley (2005). "Membrane vesicles traffic signals and 
facilitate group activities in a prokaryote." Nature 437(7057): 422-425. 
Mashburn-Warren, L., J. Howe, K. Brandenburg and M. Whiteley (2009). "Structural 
requirements of the Pseudomonas quinolone signal for membrane vesicle stimulation." 
J Bacteriol 191(10): 3411-3414. 
Mathee, K., O. Ciofu, C. Sternberg, P. W. Lindum, J. I. Campbell, P. Jensen, A. H. 
Johnsen, M. Givskov, D. E. Ohman, S. Molin, N. Hoiby and A. Kharazmi (1999). 
"Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism 
for virulence activation in the cystic fibrosis lung." Microbiology 145 ( Pt 6): 1349-1357. 
References 
 
 144 
Matsui, H., M. W. Verghese, M. Kesimer, U. E. Schwab, S. H. Randell, J. K. Sheehan, 
B. R. Grubb and R. C. Boucher (2005). "Reduced three-dimensional motility in 
dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway 
epithelial surfaces." J Immunol 175(2): 1090-1099. 
Matsui, H., V. E. Wagner, D. B. Hill, U. E. Schwab, T. D. Rogers, B. Button, R. M. 
Taylor, 2nd, R. Superfine, M. Rubinstein, B. H. Iglewski and R. C. Boucher (2006). "A 
physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas 
aeruginosa biofilms." Proc Natl Acad Sci U S A 103(48): 18131-18136. 
Mattick, J. S. (2002). "Type IV pili and twitching motility." Annu Rev Microbiol 56: 289-
314. 
Maxon, M. E., B. Redfield, X. Y. Cai, R. Shoeman, K. Fujita, W. Fisher, G. Stauffer, H. 
Weissbach and N. Brot (1989). "Regulation of methionine synthesis in Escherichia coli: 
effect of the MetR protein on the expression of the metE and metR genes." 
Proceedings of the National Academy of Sciences 86(1): 85-89. 
McKenney, D., K. L. Pouliot, Y. Wang, V. Murthy, M. Ulrich, G. Doring, J. C. Lee, D. A. 
Goldmann and G. B. Pier (1999). "Broadly protective vaccine for Staphylococcus 
aureus based on an in vivo-expressed antigen." Science 284(5419): 1523-1527. 
Medina, G., K. Juarez, R. Diaz and G. Soberon-Chavez (2003). "Transcriptional 
regulation of Pseudomonas aeruginosa rhlR, encoding a quorum-sensing regulatory 
protein." Microbiology 149(Pt 11): 3073-3081. 
Mena, A., E. E. Smith, J. L. Burns, D. P. Speert, S. M. Moskowitz, J. L. Perez and A. 
Oliver (2008). "Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic 
fibrosis patients is catalyzed by hypermutation." J Bacteriol 190(24): 7910-7917. 
Mercenier, A., J. P. Simon, C. Vander Wauven, D. Haas and V. Stalon (1980). 
"Regulation of enzyme synthesis in the arginine deiminase pathway of Pseudomonas 
aeruginosa." J Bacteriol 144(1): 159-163. 
Meyer, J. M. (2000). "Pyoverdines: pigments, siderophores and potential taxonomic 
markers of fluorescent Pseudomonas species." Arch Microbiol 174(3): 135-142. 
Meyer, J. M., A. Neely, A. Stintzi, C. Georges and I. A. Holder (1996). "Pyoverdin is 
essential for virulence of Pseudomonas aeruginosa." Infect Immun 64(2): 518-523. 
Michel-Briand, Y. and C. Baysse (2002). "The pyocins of Pseudomonas aeruginosa." 
Biochimie 84(5-6): 499-510. 
Miller, J. M. (1992). A short course in bacterial genetics: a laboratory manual and 
handbook for Escherichia coli and related bacteria. Cold Spring Harbor, NY, Cold 
Spring Harbor Laboratory Press. 
Miller, R. A. and B. E. Britigan (1997). "Role of oxidants in microbial pathophysiology." 
Clin Microbiol Rev 10(1): 1-18. 
Miller, V. L. (2002). "Connections between transcriptional regulation and type III 
secretion?" Curr Opin Microbiol 5(2): 211-215. 
Moreau-Marquis, S., B. A. Stanton and G. A. O'Toole (2008). "Pseudomonas 
aeruginosa biofilm formation in the cystic fibrosis airway." Pulm Pharmacol Ther 21(4): 
595-599. 
References 
 
 145 
Nicke, T. (2013). Untersuchung zur Maturation der Cytochrom cd1 Nitritreduktase NirS 
aus Pseudomonas aeruginosa PAO1. PhD thesis, TU Braunschweig. 
O'Sullivan, B. P. and S. D. Freedman (2009). "Cystic fibrosis." Lancet 373(9678): 1891-
1904. 
O'Sullivan, B. P. and A. D. Michelson (2006). "The inflammatory role of platelets in 
cystic fibrosis." Am J Respir Crit Care Med 173(5): 483-490. 
O'Toole, G. A. and R. Kolter (1998). "Flagellar and twitching motility are necessary for 
Pseudomonas aeruginosa biofilm development." Mol Microbiol 30(2): 295-304. 
Ochs, M. M., C. D. Lu, R. E. Hancock and A. T. Abdelal (1999). "Amino acid-mediated 
induction of the basic amino acid-specific outer membrane porin OprD from 
Pseudomonas aeruginosa." J Bacteriol 181(17): 5426-5432. 
Ochsner, U. A., P. J. Wilderman, A. I. Vasil and M. L. Vasil (2002). "GeneChip 
expression analysis of the iron starvation response in Pseudomonas aeruginosa: 
identification of novel pyoverdine biosynthesis genes." Mol Microbiol 45(5): 1277-1287. 
Ogierman, M. and V. Braun (2003). "Interactions between the outer membrane ferric 
citrate transporter FecA and TonB: studies of the FecA TonB box." J Bacteriol 185(6): 
1870-1885. 
Oglesby, A. G., J. M. Farrow, 3rd, J. H. Lee, A. P. Tomaras, E. P. Greenberg, E. C. 
Pesci and M. L. Vasil (2008). "The influence of iron on Pseudomonas aeruginosa 
physiology: a regulatory link between iron and quorum sensing." J Biol Chem 283(23): 
15558-15567. 
Oliver, A., R. Canton, P. Campo, F. Baquero and J. Blazquez (2000). "High frequency 
of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection." Science 
288(5469): 1251-1254. 
Olson, J. C. and D. E. Ohman (1992). "Efficient production and processing of elastase 
and LasA by Pseudomonas aeruginosa require zinc and calcium ions." J Bacteriol 
174(12): 4140-4147. 
Palleroni, N. J. (1992). Introduction to the family of Pseudomonadaceae. Procaryotes: 
3071–3085. 
Palma, M., S. Worgall and L. E. Quadri (2003). "Transcriptome analysis of the 
Pseudomonas aeruginosa response to iron." Arch Microbiol 180(5): 374-379. 
Palmer, K. L., L. M. Aye and M. Whiteley (2007a). "Nutritional cues control 
Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum." J Bacteriol 
189(22): 8079-8087. 
Palmer, K. L., S. A. Brown and M. Whiteley (2007b). "Membrane-bound nitrate 
reductase is required for anaerobic growth in cystic fibrosis sputum." J Bacteriol 
189(12): 4449-4455. 
Palmer, K. L., L. M. Mashburn, P. K. Singh and M. Whiteley (2005). "Cystic fibrosis 
sputum supports growth and cues key aspects of Pseudomonas aeruginosa 
physiology." J Bacteriol 187(15): 5267-5277. 
Park, S. M., C. D. Lu and A. T. Abdelal (1997). "Cloning and characterization of argR, a 
gene that participates in regulation of arginine biosynthesis and catabolism in 
Pseudomonas aeruginosa PAO1." J Bacteriol 179(17): 5300-5308. 
References 
 
 146 
Parsons, J. F., B. T. Greenhagen, K. Shi, K. Calabrese, H. Robinson and J. E. Ladner 
(2007). "Structural and functional analysis of the pyocyanin biosynthetic protein PhzM 
from Pseudomonas aeruginosa." Biochemistry 46(7): 1821-1828. 
Parveen, N. and K. A. Cornell (2011). "Methylthioadenosine/S-adenosylhomocysteine 
nucleosidase, a critical enzyme for bacterial metabolism." Mol Microbiol 79(1): 7-20. 
Pessi, G. and D. Haas (2000). "Transcriptional control of the hydrogen cyanide 
biosynthetic genes hcnABC by the anaerobic regulator ANR and the quorum-sensing 
regulators LasR and RhlR in Pseudomonas aeruginosa." J Bacteriol 182(24): 6940-
6949. 
Philippot, L. and O. Hojberg (1999). "Dissimilatory nitrate reductases in bacteria." 
Biochim Biophys Acta 1446(1-2): 1-23. 
Pier, G. B. (2000). "Role of the cystic fibrosis transmembrane conductance regulator in 
innate immunity to Pseudomonas aeruginosa infections." Proc Natl Acad Sci U S A 
97(16): 8822-8828. 
Pirnay, J. P., D. De Vos, C. Cochez, F. Bilocq, A. Vanderkelen, M. Zizi, B. Ghysels and 
P. Cornelis (2002). "Pseudomonas aeruginosa displays an epidemic population 
structure." Environ Microbiol 4(12): 898-911. 
Pirnay, J. P., S. Matthijs, H. Colak, P. Chablain, F. Bilocq, J. Van Eldere, D. De Vos, M. 
Zizi, L. Triest and P. Cornelis (2005). "Global Pseudomonas aeruginosa biodiversity as 
reflected in a Belgian river." Environ Microbiol 7(7): 969-980. 
Plamann, M. D. and G. V. Stauffer (1989). "Regulation of the Escherichia coli glyA 
gene by the metR gene product and homocysteine." J Bacteriol 171(9): 4958-4962. 
Potvin, E., F. Sanschagrin and R. C. Levesque (2008). "Sigma factors in Pseudomonas 
aeruginosa." FEMS Microbiol Rev 32(1): 38-55. 
Ratjen, F. and G. Doring (2003). "Cystic fibrosis." Lancet 361(9358): 681-689. 
Ratjen, F., C. M. Hartog, K. Paul, J. Wermelt and J. Braun (2002). "Matrix 
metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by 
treatment with dornase alpha." Thorax 57(11): 930-934. 
Reddy, M. C., G. Kuppan, N. D. Shetty, J. L. Owen, T. R. Ioerger and J. C. Sacchettini 
(2008). "Crystal structures of Mycobacterium tuberculosis S-adenosyl-L-homocysteine 
hydrolase in ternary complex with substrate and inhibitors." Protein Sci 17(12): 2134-
2144. 
Reimmann, C., M. Beyeler, A. Latifi, H. Winteler, M. Foglino, A. Lazdunski and D. Haas 
(1997). "The global activator GacA of Pseudomonas aeruginosa PAO positively 
controls the production of the autoinducer N-butyryl-homoserine lactone and the 
formation of the virulence factors pyocyanin, cyanide, and lipase." Mol Microbiol 24(2): 
309-319. 
Rietsch, A., M. C. Wolfgang and J. J. Mekalanos (2004). "Effect of metabolic imbalance 
on expression of type III secretion genes in Pseudomonas aeruginosa." Infect Immun 
72(3): 1383-1390. 
Riordan, J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. 
Zielenski, S. Lok, N. Plavsic, J. L. Chou and et al. (1989). "Identification of the cystic 
fibrosis gene: cloning and characterization of complementary DNA." Science 
245(4922): 1066-1073. 
References 
 
 147 
Robinson, C. V., M. R. Elkins, K. M. Bialkowski, D. J. Thornton and M. A. Kertesz 
(2012). "Desulfurization of mucin by Pseudomonas aeruginosa: influence of sulfate in 
the lungs of cystic fibrosis patients." J Med Microbiol 61(Pt 12): 1644-1653. 
Rogan, M. P., P. Geraghty, C. M. Greene, S. J. O'Neill, C. C. Taggart and N. G. 
McElvaney (2006). "Antimicrobial proteins and polypeptides in pulmonary innate 
defence." Respir Res 7: 29. 
Rogan, M. P., C. C. Taggart, C. M. Greene, P. G. Murphy, S. J. O'Neill and N. G. 
McElvaney (2004). "Loss of microbicidal activity and increased formation of biofilm due 
to decreased lactoferrin activity in patients with cystic fibrosis." J Infect Dis 190(7): 
1245-1253. 
Rommens, J. M., M. C. Iannuzzi, B. Kerem, M. L. Drumm, G. Melmer, M. Dean, R. 
Rozmahel, J. L. Cole, D. Kennedy, N. Hidaka and et al. (1989). "Identification of the 
cystic fibrosis gene: chromosome walking and jumping." Science 245(4922): 1059-
1065. 
Roomans, G. M. (2003). "Pharmacological approaches to correcting the ion transport 
defect in cystic fibrosis." Am J Respir Med 2(5): 413-431. 
Rottmann, M. C. (2011). Charakterisierung methioninauxotropher Stämme von 
Pseudomonas aeruginosa Bachelor thesis, TU Braunschweig. 
Rottner, M., C. Kunzelmann, M. Mergey, J. M. Freyssinet and M. C. Martinez (2007). 
"Exaggerated apoptosis and NF-kappaB activation in pancreatic and tracheal cystic 
fibrosis cells." FASEB J 21(11): 2939-2948. 
Sambrook, J. and D. Russell (2001). Molecular Cloning: a Laboratory Manual. Cold 
Spring Harbor, NY, Cold Spring Harbor Laboratory Press. 
Sandoz, K. M., S. M. Mitzimberg and M. Schuster (2007). "Social cheating in 
Pseudomonas aeruginosa quorum sensing." Proc Natl Acad Sci U S A 104(40): 15876-
15881. 
Schalk, I. J. and L. Guillon (2012). "Pyoverdine biosynthesis and secretion in 
Pseudomonas aeruginosa: implications for metal homeostasis." Environ Microbiol. 
Schertzer, J. W., M. L. Boulette and M. Whiteley (2009). "More than a signal: non-
signaling properties of quorum sensing molecules." Trends Microbiol 17(5): 189-195. 
Schertzer, J. W., S. A. Brown and M. Whiteley (2010). "Oxygen levels rapidly modulate 
Pseudomonas aeruginosa social behaviours via substrate limitation of PqsH." Mol 
Microbiol 77(6): 1527-1538. 
Schlegel, H. G. (2007). Allgemeine Mikrobiologie. Stuttgart, New York Georg Thieme 
Verlag. 
Schmidt, K. D., B. Tummler and U. Romling (1996). "Comparative genome mapping of 
Pseudomonas aeruginosa PAO with P. aeruginosa C, which belongs to a major clone 
in cystic fibrosis patients and aquatic habitats." J Bacteriol 178(1): 85-93. 
Schnider-Keel, U., A. Seematter, M. Maurhofer, C. Blumer, B. Duffy, C. Gigot-
Bonnefoy, C. Reimmann, R. Notz, G. Defago, D. Haas and C. Keel (2000). 
"Autoinduction of 2,4-diacetylphloroglucinol biosynthesis in the biocontrol agent 
Pseudomonas fluorescens CHA0 and repression by the bacterial metabolites salicylate 
and pyoluteorin." J Bacteriol 182(5): 1215-1225. 
References 
 
 148 
Schobert, M. and H. Görisch (1999). "Cytochrome c550 is an essential component of 
the quinoprotein ethanol oxidation system in Pseudomonas aeruginosa: cloning and 
sequencing of the genes encoding cytochrome c550 and an adjacent acetaldehyde 
dehydrogenase." Microbiology 145 ( Pt 2): 471-481. 
Schreiber, K., N. Boes, M. Eschbach, L. Jaensch, J. Wehland, T. Bjarnsholt, M. 
Givskov, M. Hentzer and M. Schobert (2006). "Anaerobic survival of Pseudomonas 
aeruginosa by pyruvate fermentation requires an Usp-type stress protein." J Bacteriol 
188(2): 659-668. 
Schreiber, K., R. Krieger, B. Benkert, M. Eschbach, H. Arai, M. Schobert and D. Jahn 
(2007). "The anaerobic regulatory network required for Pseudomonas aeruginosa 
nitrate respiration." J Bacteriol 189(11): 4310-4314. 
Schurek, K. N., A. K. Marr, P. K. Taylor, I. Wiegand, L. Semenec, B. K. Khaira and R. 
E. Hancock (2008). "Novel genetic determinants of low-level aminoglycoside resistance 
in Pseudomonas aeruginosa." Antimicrob Agents Chemother 52(12): 4213-4219. 
Schuster, M., A. C. Hawkins, C. S. Harwood and E. P. Greenberg (2004). "The 
Pseudomonas aeruginosa RpoS regulon and its relationship to quorum sensing." Mol 
Microbiol 51(4): 973-985. 
Schuster, M., C. P. Lostroh, T. Ogi and E. P. Greenberg (2003). "Identification, timing, 
and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a 
transcriptome analysis." J Bacteriol 185(7): 2066-2079. 
Schwarzmann, S. and J. R. Boring (1971). "Antiphagocytic Effect of Slime from a 
Mucoid Strain of Pseudomonas aeruginosa." Infect Immun 3(6): 762-767. 
Schweizer, H. P., T. R. Klassen, and T. Hoang (1996). Improved methods for gene 
analysis and expression in Pseudomonas. Molecular biology of pseudomonads. K. F. 
Edited by T. Nakazawa, D. Haas & S. Silver. Washington, DC, American Society for 
Microbiology. 
Seed, P. C., L. Passador and B. H. Iglewski (1995). "Activation of the Pseudomonas 
aeruginosa lasI gene by LasR and the Pseudomonas autoinducer PAI: an 
autoinduction regulatory hierarchy." J Bacteriol 177(3): 654-659. 
Sekowska, A., V. Denervaud, H. Ashida, K. Michoud, D. Haas, A. Yokota and A. 
Danchin (2004). "Bacterial variations on the methionine salvage pathway." BMC 
Microbiol 4: 9. 
Sganga, M. W., R. R. Aksamit, G. L. Cantoni and C. E. Bauer (1992). "Mutational and 
nucleotide sequence analysis of S-adenosyl-L-homocysteine hydrolase from 
Rhodobacter capsulatus." Proc Natl Acad Sci U S A 89(14): 6328-6332. 
Sharma, V., C. E. Noriega and J. J. Rowe (2006). "Involvement of NarK1 and NarK2 
proteins in transport of nitrate and nitrite in the denitrifying bacterium Pseudomonas 
aeruginosa PAO1." Appl Environ Microbiol 72(1): 695-701. 
Sheppard, C. A., E. E. Trimmer and R. G. Matthews (1999). "Purification and 
properties of NADH-dependent 5, 10-methylenetetrahydrofolate reductase (MetF) from 
Escherichia coli." J Bacteriol 181(3): 718-725. 
Shrout, J. D., D. L. Chopp, C. L. Just, M. Hentzer, M. Givskov and M. R. Parsek (2006). 
"The impact of quorum sensing and swarming motility on Pseudomonas aeruginosa 
biofilm formation is nutritionally conditional." Mol Microbiol 62(5): 1264-1277. 
References 
 
 149 
Siehnel, R. J., C. Egli and R. E. Hancock (1992). "Polyphosphate-selective porin OprO 
of Pseudomonas aeruginosa: expression, purification and sequence." Mol Microbiol 
6(16): 2319-2326. 
Singh, P. K., M. R. Parsek, E. P. Greenberg and M. J. Welsh (2002). "A component of 
innate immunity prevents bacterial biofilm development." Nature 417(6888): 552-555. 
Smith, A. M., R. T. Fuchs, F. J. Grundy and T. M. Henkin (2010). "The SAM-responsive 
S(MK) box is a reversible riboswitch." Mol Microbiol 78(6): 1393-1402. 
Smith, E. E., D. G. Buckley, Z. Wu, C. Saenphimmachak, L. R. Hoffman, D. A. 
D'Argenio, S. I. Miller, B. W. Ramsey, D. P. Speert, S. M. Moskowitz, J. L. Burns, R. 
Kaul and M. V. Olson (2006). "Genetic adaptation by Pseudomonas aeruginosa to the 
airways of cystic fibrosis patients." Proc Natl Acad Sci U S A 103(22): 8487-8492. 
Smith, R. S., E. R. Fedyk, T. A. Springer, N. Mukaida, B. H. Iglewski and R. P. Phipps 
(2001). "IL-8 production in human lung fibroblasts and epithelial cells activated by the 
Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally 
regulated by NF-kappa B and activator protein-2." J Immunol 167(1): 366-374. 
Sofia, H. J., G. Chen, B. G. Hetzler, J. F. Reyes-Spindola and N. E. Miller (2001). 
"Radical SAM, a novel protein superfamily linking unresolved steps in familiar 
biosynthetic pathways with radical mechanisms: functional characterization using new 
analysis and information visualization methods." Nucleic Acids Res 29(5): 1097-1106. 
Son, M. S., W. J. Matthews, Jr., Y. Kang, D. T. Nguyen and T. T. Hoang (2007). "In 
vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the 
lungs of cystic fibrosis patients." Infect Immun 75(11): 5313-5324. 
Sousa, S. A., M. Ulrich, A. Bragonzi, M. Burke, D. Worlitzsch, J. H. Leitao, C. Meisner, 
L. Eberl, I. Sa-Correia and G. Doring (2007). "Virulence of Burkholderia cepacia 
complex strains in gp91phox-/- mice." Cell Microbiol 9(12): 2817-2825. 
Sriramulu, D. D., H. Lunsdorf, J. S. Lam and U. Romling (2005). "Microcolony 
formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis 
lung." J Med Microbiol 54(Pt 7): 667-676. 
Stepkowski, T., K. Brzezinski, A. B. Legocki, M. Jaskolski and G. Bena (2005). 
"Bayesian phylogenetic analysis reveals two-domain topology of S-
adenosylhomocysteine hydrolase protein sequences." Mol Phylogenet Evol 34(1): 15-
28. 
Storbeck, S., J. Walther, J. Muller, V. Parmar, H. M. Schiebel, D. Kemken, T. Dulcks, 
M. J. Warren and G. Layer (2009). "The Pseudomonas aeruginosa nirE gene encodes 
the S-adenosyl-L-methionine-dependent uroporphyrinogen III methyltransferase 
required for heme d(1) biosynthesis." FEBS J 276(20): 5973-5982. 
Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. 
S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. 
Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. 
Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. 
Reizer, M. H. Saier, R. E. Hancock, S. Lory and M. V. Olson (2000). "Complete 
genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen." 
Nature 406(6799): 959-964. 
Stutts, M. J., M. R. Knowles, J. T. Gatzy and R. C. Boucher (1986). "Oxygen 
consumption and ouabain binding sites in cystic fibrosis nasal epithelium." Pediatr Res 
20(12): 1316-1320. 
References 
 
 150 
Suh, S. J., L. Silo-Suh, D. E. Woods, D. J. Hassett, S. E. West and D. E. Ohman 
(1999). "Effect of rpoS mutation on the stress response and expression of virulence 
factors in Pseudomonas aeruginosa." J Bacteriol 181(13): 3890-3897. 
Sun, J., R. Daniel, I. Wagner-Dobler and A. P. Zeng (2004). "Is autoinducer-2 a 
universal signal for interspecies communication: a comparative genomic and 
phylogenetic analysis of the synthesis and signal transduction pathways." BMC Evol 
Biol 4: 36. 
Tamber, S. and R. E. Hancock (2003). "On the mechanism of solute uptake in 
Pseudomonas." Front Biosci 8: s472-483. 
Tanaka, N., M. Nakanishi, Y. Kusakabe, K. Shiraiwa, S. Yabe, Y. Ito, Y. Kitade and K. 
T. Nakamura (2004). "Crystal structure of S-adenosyl-L-homocysteine hydrolase from 
the human malaria parasite Plasmodium falciparum." J Mol Biol 343(4): 1007-1017. 
Taylor, R. F., M. E. Hodson and T. L. Pitt (1992). "Auxotrophy of Pseudomonas 
aeruginosa in cystic fibrosis." FEMS Microbiol Lett 71(3): 243-246. 
Teichgräber, V., M. Ulrich, N. Endlich, J. Riethmuller, B. Wilker, C. C. De Oliveira-
Munding, A. M. van Heeckeren, M. L. Barr, G. von Kurthy, K. W. Schmid, M. Weller, B. 
Tummler, F. Lang, H. Grassme, G. Doring and E. Gulbins (2008). "Ceramide 
accumulation mediates inflammation, cell death and infection susceptibility in cystic 
fibrosis." Nat Med 14(4): 382-391. 
Thoma, S. (2009). Metabolismus und Antibiotikaresistenz von Pseudomonas 
aeruginosa unter simulierten Respirationstraktbedingungen. PhD thesis, TU 
Braunschweig. 
Thoma, S. and M. Schobert (2009). "An improved Escherichia coli donor strain for 
diparental mating." FEMS Microbiol Lett 294(2): 127-132. 
Thomas, S. R., A. Ray, M. E. Hodson and T. L. Pitt (2000). "Increased sputum amino 
acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic 
fibrosis lung disease." Thorax 55(9): 795-797. 
Tingpej, P., L. Smith, B. Rose, H. Zhu, T. Conibear, K. Al Nassafi, J. Manos, M. Elkins, 
P. Bye, M. Willcox, S. Bell, C. Wainwright and C. Harbour (2007). "Phenotypic 
characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated 
from lungs of adults with cystic fibrosis." J Clin Microbiol 45(6): 1697-1704. 
Towbin, H., T. Staehelin and J. Gordon (1979). "Electrophoretic transfer of proteins 
from polyacrylamide gels to nitrocellulose sheets: procedure and some applications." 
Proc Natl Acad Sci U S A 76(9): 4350-4354. 
Tralau, T., S. Vuilleumier, C. Thibault, B. J. Campbell, C. A. Hart and M. A. Kertesz 
(2007). "Transcriptomic analysis of the sulfate starvation response of Pseudomonas 
aeruginosa." J Bacteriol 189(19): 6743-6750. 
Trunk, K., B. Benkert, N. Quack, R. Munch, M. Scheer, J. Garbe, L. Jansch, M. Trost, 
J. Wehland, J. Buer, M. Jahn, M. Schobert and D. Jahn (2010). "Anaerobic adaptation 
in Pseudomonas aeruginosa: definition of the Anr and Dnr regulons." Environ Microbiol 
12(6): 1719-1733. 
Tunney, M. M., T. R. Field, T. F. Moriarty, S. Patrick, G. Doering, M. S. Muhlebach, M. 
C. Wolfgang, R. Boucher, D. F. Gilpin, A. McDowell and J. S. Elborn (2008). "Detection 
of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis." Am 
J Respir Crit Care Med 177(9): 995-1001. 
References 
 
 151 
Turner, M. A., X. Yang, D. Yin, K. Kuczera, R. T. Borchardt and P. L. Howell (2000). 
"Structure and function of S-adenosylhomocysteine hydrolase." Cell Biochem Biophys 
33(2): 101-125. 
Ueda, A. and T. K. Wood (2009). "Connecting quorum sensing, c-di-GMP, pel 
polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine 
phosphatase TpbA (PA3885)." PLoS Pathog 5(6): e1000483. 
Untergasser, A., H. Nijveen, X. Rao, T. Bisseling, R. Geurts and J. A. Leunissen 
(2007). "Primer3Plus, an enhanced web interface to Primer3." Nucleic Acids Res 
35(Web Server issue): W71-74. 
van Oeffelen, L., P. Cornelis, W. Van Delm, F. De Ridder, B. De Moor and Y. Moreau 
(2008). "Detecting cis-regulatory binding sites for cooperatively binding proteins." 
Nucleic Acids Res 36(8): e46. 
Vander Wauven, C., A. Pierard, M. Kley-Raymann and D. Haas (1984). "Pseudomonas 
aeruginosa mutants affected in anaerobic growth on arginine: evidence for a four-gene 
cluster encoding the arginine deiminase pathway." J Bacteriol 160(3): 928-934. 
Vasil, M. L. (2007). "How we learnt about iron acquisition in Pseudomonas aeruginosa: 
a series of very fortunate events." Biometals 20(3-4): 587-601. 
Vasil, M. L. and U. A. Ochsner (1999). "The response of Pseudomonas aeruginosa to 
iron: genetics, biochemistry and virulence." Mol Microbiol 34(3): 399-413. 
Venturi, V. (2006). "Regulation of quorum sensing in Pseudomonas." FEMS Microbiol 
Rev 30(2): 274-291. 
Verkman, A. S., Y. Song and J. R. Thiagarajah (2003). "Role of airway surface liquid 
and submucosal glands in cystic fibrosis lung disease." Am J Physiol Cell Physiol 
284(1): C2-15. 
von Gotz, F., S. Haussler, D. Jordan, S. S. Saravanamuthu, D. Wehmhoner, A. 
Strussmann, J. Lauber, I. Attree, J. Buer, B. Tummler and I. Steinmetz (2004). 
"Expression analysis of a highly adherent and cytotoxic small colony variant of 
Pseudomonas aeruginosa isolated from a lung of a patient with cystic fibrosis." J 
Bacteriol 186(12): 3837-3847. 
Wagner, V. E., D. Bushnell, L. Passador, A. I. Brooks and B. H. Iglewski (2003). 
"Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of 
growth phase and environment." J Bacteriol 185(7): 2080-2095. 
Walsh, C. (2003). "Where will new antibiotics come from?" Nat Rev Microbiol 1(1): 65-
70. 
Walter, H. (2011). Biosynthese des Isobakteriochlorins Häm d1: Charakterisierung der 
Proteine 
NirJ und NirDLGH aus Pseudomonas aeruginosa. PhD thesis, TU Braunschweig. 
Wang, J. X., E. R. Lee, D. R. Morales, J. Lim and R. R. Breaker (2008). "Riboswitches 
that sense S-adenosylhomocysteine and activate genes involved in coenzyme 
recycling." Mol Cell 29(6): 691-702. 
Weinberg, Z., J. E. Barrick, Z. Yao, A. Roth, J. N. Kim, J. Gore, J. X. Wang, E. R. Lee, 
K. F. Block, N. Sudarsan, S. Neph, M. Tompa, W. L. Ruzzo and R. R. Breaker (2007). 
"Identification of 22 candidate structured RNAs in bacteria using the CMfinder 
comparative genomics pipeline." Nucleic Acids Res 35(14): 4809-4819. 
References 
 
 152 
Whitchurch, C. B., T. Tolker-Nielsen, P. C. Ragas and J. S. Mattick (2002). 
"Extracellular DNA required for bacterial biofilm formation." Science 295(5559): 1487. 
Wiegand, I., A. K. Marr, E. B. Breidenstein, K. N. Schurek, P. Taylor and R. E. Hancock 
(2008). "Mutator genes giving rise to decreased antibiotic susceptibility in 
Pseudomonas aeruginosa." Antimicrob Agents Chemother 52(10): 3810-3813. 
Wiehlmann, L., G. Wagner, N. Cramer, B. Siebert, P. Gudowius, G. Morales, T. Kohler, 
C. van Delden, C. Weinel, P. Slickers and B. Tummler (2007). "Population structure of 
Pseudomonas aeruginosa." Proc Natl Acad Sci U S A 104(19): 8101-8106. 
Wilder, C. N., S. P. Diggle and M. Schuster (2011). "Cooperation and cheating in 
Pseudomonas aeruginosa: the roles of the las, rhl and pqs quorum-sensing systems." 
ISME J 5(8): 1332-1343. 
Williams, H. D., J. E. Zlosnik and B. Ryall (2007). "Oxygen, cyanide and energy 
generation in the cystic fibrosis pathogen Pseudomonas aeruginosa." Adv Microb 
Physiol 52: 1-71. 
Williams, P. and M. Camara (2009). "Quorum sensing and environmental adaptation in 
Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal 
molecules." Curr Opin Microbiol 12(2): 182-191. 
Winson, M. K., S. Swift, L. Fish, J. P. Throup, F. Jorgensen, S. R. Chhabra, B. W. 
Bycroft, P. Williams and G. S. Stewart (1998). "Construction and analysis of 
luxCDABE-based plasmid sensors for investigating N-acyl homoserine lactone-
mediated quorum sensing." FEMS Microbiol Lett 163(2): 185-192. 
Winsor, G. L., D. K. Lam, L. Fleming, R. Lo, M. D. Whiteside, N. Y. Yu, R. E. Hancock 
and F. S. Brinkman (2011). "Pseudomonas Genome Database: improved comparative 
analysis and population genomics capability for Pseudomonas genomes." Nucleic 
Acids Res 39(Database issue): D596-600. 
Winzer, K., K. R. Hardie, N. Burgess, N. Doherty, D. Kirke, M. T. Holden, R. Linforth, K. 
A. Cornell, A. J. Taylor, P. J. Hill and P. Williams (2002). "LuxS: its role in central 
metabolism and the in vitro synthesis of 4-hydroxy-5-methyl-3(2H)-furanone." 
Microbiology 148(Pt 4): 909-922. 
Wolfgang, M. C., V. T. Lee, M. E. Gilmore and S. Lory (2003). "Coordinate regulation of 
bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway." 
Dev Cell 4(2): 253-263. 
Worlitzsch, D., R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K. C. Meyer, P. Birrer, G. 
Bellon, J. Berger, T. Weiss, K. Botzenhart, J. R. Yankaskas, S. Randell, R. C. Boucher 
and G. Doring (2002). "Effects of reduced mucus oxygen concentration in airway 
Pseudomonas infections of cystic fibrosis patients." J Clin Invest 109(3): 317-325. 
Wu, R. S., K. H. Lam, J. M. Lee and T. C. Lau (2007). "Removal of phosphate from 
water by a highly selective La(III)-chelex resin." Chemosphere 69(2): 289-294. 
Wu, W. and S. Jin (2005). "PtrB of Pseudomonas aeruginosa suppresses the type III 
secretion system under the stress of DNA damage." J Bacteriol 187(17): 6058-6068. 
Wu, Y. L., E. M. Scott, A. L. Po and V. N. Tariq (1999). "Development of resistance and 
cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic 
concentrations." APMIS 107(6): 585-592. 
References 
 
 153 
Xu, K. D., G. A. McFeters and P. S. Stewart (2000). "Biofilm resistance to antimicrobial 
agents." Microbiology 146 ( Pt 3): 547-549. 
Yahr, T. L., L. M. Mende-Mueller, M. B. Friese and D. W. Frank (1997). "Identification 
of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon." J 
Bacteriol 179(22): 7165-7168. 
Yamada, T., Y. Takata, J. Komoto, T. Gomi, H. Ogawa, M. Fujioka and F. Takusagawa 
(2005). "Catalytic mechanism of S-adenosylhomocysteine hydrolase: roles of His 54, 
Asp130, Glu155, Lys185, and Aspl89." Int J Biochem Cell Biol 37(11): 2417-2435. 
Yang, W., K. Li, Y. Bai, R. Zhou, W. Zhou and M. Bartlam (2010). "Expression, 
purification, crystallization and preliminary crystallographic analysis of PA3885 (TpbA) 
from Pseudomonas aeruginosa PAO1." Acta Crystallogr Sect F Struct Biol Cryst 
Commun 66(Pt 11): 1473-1476. 
Yanisch-Perron, C., J. Vieira and J. Messing (1985). "Improved M13 phage cloning 
vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors." 
Gene 33(1): 103-119. 
Yeung, A. T., E. C. Torfs, F. Jamshidi, M. Bains, I. Wiegand, R. E. Hancock and J. 
Overhage (2009). "Swarming of Pseudomonas aeruginosa is controlled by a broad 
spectrum of transcriptional regulators, including MetR." J Bacteriol 191(18): 5592-5602. 
Yoon, S. S., R. F. Hennigan, G. M. Hilliard, U. A. Ochsner, K. Parvatiyar, M. C. 
Kamani, H. L. Allen, T. R. DeKievit, P. R. Gardner, U. Schwab, J. J. Rowe, B. H. 
Iglewski, T. R. McDermott, R. P. Mason, D. J. Wozniak, R. E. Hancock, M. R. Parsek, 
T. L. Noah, R. C. Boucher and D. J. Hassett (2002). "Pseudomonas aeruginosa 
anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis." Dev Cell 
3(4): 593-603. 
Yuan, C. S., D. B. Ault-Riche and R. T. Borchardt (1996). "Chemical modification and 
site-directed mutagenesis of cysteine residues in human placental S-
adenosylhomocysteine hydrolase." J Biol Chem 271(45): 28009-28016. 
Zaborin, A., K. Romanowski, S. Gerdes, C. Holbrook, F. Lepine, J. Long, V. Poroyko, 
S. P. Diggle, A. Wilke, K. Righetti, I. Morozova, T. Babrowski, D. C. Liu, O. Zaborina 
and J. C. Alverdy (2009). "Red death in Caenorhabditis elegans caused by 
Pseudomonas aeruginosa PAO1." Proc Natl Acad Sci U S A 106(15): 6327-6332. 
Zannoni, D. (1989). "The respiratory chains of pathogenic pseudomonads." Biochim 
Biophys Acta 975(3): 299-316. 
Zhao, D. and A. K. Sengupta (1998). "Ultimate removal of phosphate from wastewater 
using a new class of polymeric ion exchangers." Water Research 32(5): 1613-1625. 
Zimmermann, A., C. Reimmann, M. Galimand and D. Haas (1991). "Anaerobic growth 
and cyanide synthesis of Pseudomonas aeruginosa depend on anr, a regulatory gene 
homologous with fnr of Escherichia coli." Mol Microbiol 5(6): 1483-1490. 
Zumft, W. G. (1997). "Cell biology and molecular basis of denitrification." Microbiol Mol 
Biol Rev 61(4): 533-616. 
 
 
  
Appendix 
 
 154 
7 Appendix  
7.1 List of figures 
Fig. 1: Clearance of bacteria from the airways of healthy individuals and cystic fibrosis patients 
(adapted from Doring and Gulbins, 2009 and Worlitzsch et al., 2002) .............................. 12!
Fig. 2: Quorum sensing and regulatory network of P. aeruginosa (from Venturi, 2006) ............ 16!
Fig. 3: Phenotypic adaptation of Pseudomonas aeruginosa during acute and chronic cystic 
fibrosis infection ................................................................................................................. 18!
Fig. 4: Methionine metabolism and SAM recycling in Pseudomonas aeruginosa ...................... 21!
Fig. 5: Chemical structure of ribavirin, adenosine and S-adenosylhomocysteine ...................... 23!
Fig. 6: Functional classification of genes differentially regulated during growth in ASM compared 
to ex vivo sputum samples of the the clinical Pseudomonas aeruginosa strains CFCZ and 
CF1 - 4 ............................................................................................................................... 28!
Fig. 7: Fold difference in gene expression of Pseudomonas aeruginosa iron limitation marker 
genes in differently supplemented artificial sputum media ................................................ 30!
Fig. 8: Scatter plots and correlation values between the growth conditions of ex vivo, ASM and 
ASM-Chelex of the clinical Pseudomonas aeruginosa strains CFCZ and CF1 - 4 ............ 31!
Fig. 9: Functional classification of genes differentially regulated during growth in ASM-Chelex 
compared to ex vivo sputum samples of the clinical Pseudomonas aeruginosa strains 
CFCZ and CF1 - 4 ............................................................................................................. 32!
Fig. 10: Functional classification of genes differentially regulated during growth in ASM-Chelex 
compared to growth in ASM the clinical Pseudomonas aeruginosa strains CFCZ and CF1 - 
4 ......................................................................................................................................... 33!
Fig. 11: Direct and indirect control of TonB-dependent genes by Fur modified from 
Cornelis et al. (2009) ......................................................................................................... 34!
Fig. 12: Predicted Fur regulation of genes involved in iron uptake and storage modified from 
Cornelis  et al. (2009) ........................................................................................................ 35!
Fig. 13: Schematic overview of PQS synthesis and anthranilate degradation (modified after 
(Bundy et al., 1998; Farrow and Pesci, 2007) ................................................................... 41!
Fig. 14: Schematic depiction of denitrification and arginine fermentation pathways in P. 
aeruginosa ......................................................................................................................... 45!
Fig. 15: Amino acid concentrations during growth of P. aeruginosa PAO1 in amino acid medium 
(AAM) ................................................................................................................................. 50!
Fig. 16: Model of genes regulated in CF1-4 and CFCZ under ex vivo conditions, in ASM and 
ASM-Chelex ....................................................................................................................... 55!
Fig. 17: Methionine metabolism and SAM recycling in Pseudomonas aeruginosa .................... 66!
Fig. 18: Isolation of methionine auxotrophic clinical Pseudomonas aeruginosa cystic fibrosis 
isolates and identification of the mutation causing methionine auxotrophy ....................... 67!
Fig. 19: Distribution of clone and clone type of methionine auxotrophic P. aeruginosa cystic 
fibrosis isolates .................................................................................................................. 69!
Fig. 20: Clonal complex structures of 240 P. aeruginosa strains (adapted from Wiehlmann et al. 
(2007)) ............................................................................................................................... 70!
Appendix 
 
 155 
Fig. 21: Production of virulence factors and quorum sensing molecules by the methionine 
metabolism P. aeruginosa deletion strains ........................................................................ 80!
Fig. 22: Pyocyanin synthesis (adapted from Lau et al., 2004) ................................................... 81!
Fig. 23: Transcriptome analysis for PAO1 wt and PAO1 "metF in M9 0.5 % caseinate under 
microaerobic to anaerobic conditions ................................................................................ 83!
Fig. 24: Growth of methionine metabolism P. aeruginosa PAO1 deletion mutants in M9 20 mM 
succinate with 50 #M methionine supplementation ......................................................... 103!
Fig. 25: Activated methylcycle (AMC) and SAM recycling in Pseudomonas aeruginosa ......... 107!
Fig. 26: Growth of P. aeruginosa PAO1 in the presence of different ribavirin concentrations . 108!
Fig. 27: Growth curves of P. aeruginosa PAO1 wt, PAO1 +sahH, PAO1 +sahH +mtnP, PAO1 
+mtnP and PAO1 +metZ in M9 succinate ....................................................................... 110!
Fig. 28: Production and purification of recombinant SahH from P. aeruginosa (Pa) and detection 
of Pa SahH in CF-sputum samples and specificity testing of anti-Pa SahH antibody against 
SAHH in human blood sample ......................................................................................... 112!
Fig. 29: Alignment of bacterial and eukaryotic SAH hydrolases with Pa SahH ........................ 115!
Fig. 30: Influence of the deletion of sahH on transcription and translation in PAO1 "sahH 
compared to PAO1 wt ...................................................................................................... 117!
Fig. 31: Alignment of potential riboswitches in the 5´UTR of the mRNA of sahH and AMC genes
 ......................................................................................................................................... 118!
Fig. 32: Influence of 50 #g/ml ribavirin on transcription and translation in PAO1 wt and PAO1 
"sahH .............................................................................................................................. 121!
Fig. 33: Inhibition of SahH activity by 100 #M ribavirin time-dependent .................................. 122!
 
  
Appendix 
 
 156 
 
7.2 List of tables 
Table 1: Fold change of gene expression of selected iron regulated transcriptional regulators in 
ASM compared to ex vivo sputum samples ....................................................................... 28!
Table 2: Fold change of gene expression of selected iron regulated genes chosen for further 
investigation by qRT-PCR to establish iron limitation in modified ASM ............................. 29!
Table 3: Fold change of gene expression of selected* iron regulated genes in ASM, ASM-
Chelex and ex vivo sputum samples ................................................................................. 37!
Table 4: Fold change of gene expression of selected PQS biosynthesis, anthranilate 
metabolism and sigma factor genes in ASM, ASM-Chelex and ex vivo sputum samples . 40!
Table 5: Fold change of gene expression of selected sulphur, molybedenum, zinc and 
phosphate regulated genes in ASM, ASM-Chelex and ex vivo sputum samples .............. 42!
Table 6: Fold change of gene expression of selected energy metabolism genes in ASM, ASM-
Chelex and ex vivo sputum samples ................................................................................. 44!
Table 7: Fold change of gene expression of gene expression of selected metabolism genes in 
ASM, ASM-Chelex and ex vivo sputum samples .............................................................. 47!
Table 8: Fold change of gene expression of selected motility genes in ASM, ASM-Chelex and 
ex vivo sputum samples .................................................................................................... 52!
Table 9: Fold change of gene expression of selected virulence associated genes in ASM, ASM-
Chelex and ex vivo sputum samples ................................................................................. 53!
Table 10: Pseudomonas aeruginosa strains .............................................................................. 63!
Table 11: Primers used for detection of transcript levels of Pseudomonas aeruginosa PAO1 iron 
starvation genes pvdA, pvdF, pvdS, fpvA, fptA and pchG during qRT-PCR ..................... 63!
Table 12: Single-nucleotide polymorphism analysis of clinical P. aeruginosa cystic fibrosis 
isolates ............................................................................................................................... 69!
Table 13: Summary of positive phenotypic characteristics according to phenotype .................. 71!
Table 14: Summary of phenotypic characterisation of methionine auxotrophic clinical 
P. aeruginosa CF isolates sorted according to patient and mutator phenotype ................ 73!
Table 15: Summary of sequence analysis of mutations in the metF gene (PA0340) on 
nucleotide level of clinical methionine auxotrophic P. aeruginosa CF isolates .................. 76!
Table 16: Summary of sequence deviations in the MetF protein (PA0340) on amino acid level of 
clinical methionine auxotrophic P. aeruginosa CF isolates ................................................ 77!
Table 17: Microarray analysis of selected genes in PAO1 compared to PAO1 "metF in M9 0.5 
% caseinate ....................................................................................................................... 85!
Table 18: Microarray analysis of selected methionine metabolism and SAM metabolism genes 
in PAO1 compared to PAO1 "metF in M9 0.5 % caseinate .............................................. 90!
Table 19: Microarray analysis of selected iron regulated genes in PAO1 compared to PAO1 
"metF in M9 0.5 % caseinate ............................................................................................ 92!
Table 20: Bacterial strains ........................................................................................................ 100!
Table 21: Plasmids ................................................................................................................... 101!
Table 22: Primer (restriction sites are underlined) ................................................................... 102!
Appendix 
 
 157 
Table 23: Fold change of transcription and translation in PAO1 !sahH compared to the samples 
of PAO1 wt [MU / MU] ..................................................................................................... 117!
Table 24: Fold change of transcription and translation of AMC genes of PAO1 and of PAO1 
"sahH in the presence of 50 #g/ml ribavirin compared to the untreated samples of PAO1 
and PAO1 "sahH [MU / MU] ........................................................................................... 119!
Table 25: Transcription and translation of AMC genes of PAO1 and of PAO1 "sahH in the 
presence and absence of 50 #g/ml ribavirin in Miller Units [MU] ..................................... 120!
Table 26: Bacterial Strains ....................................................................................................... 128!
Table 27: Plasmids ................................................................................................................... 129!
Table 28: Primer (restriction sites are underlined) ................................................................... 130!
Table 29: CF-sputum samples (from Michael Hogardt, Munich) .............................................. 130!
Table 30: Microarray analysis of iron regulated genes in ASM and ASM-Chelex compared to ex 
vivo patients’ samples and comparison of both media .................................................... 158!
Table 31: Summary of phenotypic characterisation of methionine auxotrophic clinical 
P. aeruginosa CF isolates ................................................................................................ 168!
Table 32: Mutations in metF (PA0430) nucleotide sequence (detailed single base exchange) 170!
Table 33: Amino acid exchanges in MetF (PA0430) protein sequence resulting from nucleotide 
sequence (detailed amino acid  exchange) ..................................................................... 172!
Table 34: Microarray analysis of regulated genes in PAO1 "metF compared to PAO1 in M9 0.5 
% caseinate after growth for 4 h and 12 h ....................................................................... 174!
 
  
Appendix 
 
 158 
 
7.3 Appendix A 
Table 30: Microarray analysis of iron regulated genes in ASM and ASM-Chelex compared to ex vivo 
patients’ samples and comparison of both media 
Differentially regulated genes (pfp < 0.05) of the clinical Pseudomonas aeruginosa strains CFCZ 
and CF1 - 4 grown in ASM (A) and ASM-Chelex (ACh) in comparison with ex vivo (EV) sputum 
samples. Shown are the gene ID, gene name, function and the fold change (FC) of genes 
differently regulated genes in artificial sputum medium ASM (A) compared to ex vivo (A / EV), ASM-
Chelex compared to ex vivo (ACh / EV) and ASM-Chelex compared to ASM (ACh / A). 
Gene IDa Gene 
namea 
Functiona PCFCa,b  
A / EV 
FC 
ACh / 
EV 
 
ACh / 
A 
1996806- 
1997509 
1997509- 
1996806 
3112877- 
3112150 
517462- 
518083 
630527- 
629884 
PA0044 
PA0062 
PA0070 
PA0075 
PA0083 
PA0084 
PA0085 
PA0105 
PA0106 
PA0107 
PA0108 
PA0110 
PA0111 
PA0113 
PA0131 
PA0132 
PA0140 
PA0150 
PA0161 
PA0177 
PA0179 
PA0200 
PA0201 
PA0226 
PA0227 
PA0228 
PA0229 
PA0230 
PA0231 
PA0232 
PA0269 
PA0283 
PA0284 
PA0316 
PA0320 
PA0327 
PA0365 
PA0382 
PA0430 
PA0439 
PA0440 
PA0441 
PA0444 
PA0447 
PA0459 
PA0461 
PA0465 
PA0466 
PA0472 
 
 
 
 
 
 
 
 
 
 
exoT 
 
 
pppA 
 
 
hcp1 
coxB 
coxA 
 
coIII 
 
 
 
 
 
ahpF 
 
 
 
 
 
 
 
 
pcaF 
pcaT 
pcaB 
pcaD 
pcaC 
 
sbp 
 
serA 
 
 
 
micA 
metF 
 
 
dht 
 
gcdH 
 
 
creD 
 
fiuR  
unknown function 
 
unknown function 
 
unknown function 
 
unknown function 
 
unknown function 
 
exoenzyme T 
hypothetical protein 
hypothetical protein 
PppA 
conserved hypothetical protein 
conserved hypothetical protein 
Hcp1 
cytochrome c oxidase, subunit II 
cytochrome c oxidase, subunit I 
conserved hypothetical protein 
cytochrome c oxidase, subunit III 
hypothetical protein 
hypothetical protein 
probable cytochrome c oxidase assembly factor 
hypothetical protein 
beta-alanine--pyruvate transaminase 
alkyl hydroperoxide reductase subunit F 
probable transmembrane sensor 
hypothetical protein 
probable purine-binding C protein 
probable two-component response regulator 
hypothetical protein 
hypothetical protein 
probable CoA transferase, subunit A 
probable CoA transferase, subunit B 
beta-ketoadipyl CoA thiolase PcaF 
dicarboxylic acid transporter PcaT 
3-carboxy-cis,cis-muconate cycloisomerase 
beta-ketoadipate enol-lactone hydrolase 
gamma-carboxymuconolactone decarboxylase 
conserved hypothetical protein 
sulfate-binding protein precursor 
hypothetical protein 
D-3-phosphoglycerate dehydrogenase 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
DNA mismatch repair protein MicA 
5,10-methylenetetrahydrofolate reductase 
probable oxidoreductase 
probable oxidoreductase 
dihydropyrimidinase 
N-carbamoyl-beta-alanine amidohydrolase 
glutaryl-CoA dehydrogenase 
probable ClpA/B protease ATP binding subunit 
conserved hypothetical protein 
inner membrane protein CreD 
hypothetical protein 
probable sigma-70 factor, ECF subfamily 
UGS  
 
UGS  
 
UGS  
 
UGS  
 
UGS  
 
SF 
HUU 
MP 
PE ; PSE 
HUU 
HUU 
SF 
EM 
EM 
EM 
EM 
HUU 
HUU 
EM 
HUU 
ABM 
AP 
MP ; TR 
HUU 
AP ; C 
C ; AP ; TCR 
HUU 
HUU 
CC 
CC 
FPM ; CC 
MP ; TSM 
CC 
CC 
CC 
HUU 
TSM 
HUU 
ABM 
HUU 
HUU 
MP 
DRR 
ABM ; CIM 
PE 
PE 
NM 
NM 
FPM ; ABM ; 
CC 
TPD 
HUU 
MP 
HUU 
6,5 
 
9,4 
 
 
 
3,9 
 
5,0 
 
-13,5 
 
 
 
 
 
 
23,3 
35,7 
25,0 
43,7 
7,3 
17,6 
9,9 
4,6 
5,4 
-14,6 
-7,9 
6,9 
 
11,3 
4,1 
-4,9 
95,1 
53,3 
55,6 
5,6 
6,6 
10,6 
31,1 
 
 
 
-6,3 
-16,7 
 
 
 
 
27,3 
5,2 
8,6 
22,3 
 
4,3 
5,8 
-76,3 
-29,5 
-9,0 
8,6 
 
8,7 
 
5,3 
 
 
 
7,8 
 
-13,2 
 
 
 
 
 
 
26,2 
42,8 
33,2 
48,5 
8,6 
19,5 
9,5 
 
5,0 
-13,9 
-9,0 
 
 
 
 
-5,0 
 
 
 
 
 
 
 
3,2 
-6,0 
-5,8 
-15,2 
 
 
4,8 
-4,7 
-5,5 
5,5 
 
 
6,5 
7,1 
6,7 
5,2 
-76,3 
-29,6 
 
 
 
 
 
5,6 
 
 
 
 
 
 
4,0 
-5,1 
-3,4 
-6,6 
-4,1 
-7,0 
 
 
 
 
 
 
 
 
 
 
 
-5,6 
-3,7 
 
 
 
-64,1 
-42,6 
-54,9 
-5,4 
-6,5 
-10,2 
-19,6 
 
 
 
 
25,2 
6,0 
 
 
 
-5,0 
 
 
-3,4 
3,6 
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PA0484 
PA0505 
PA0524 
PA0546 
PA0547 
PA0576 
PA0577 
PA0578 
PA0588 
PA0612 
PA0613 
PA0614 
PA0622 
PA0623 
PA0624 
PA0627 
PA0631 
PA0633 
PA0634 
PA0635 
PA0636 
PA0637 
PA0638 
PA0639 
PA0647 
PA0648 
PA0656 
PA0672 
PA0674 
PA0730 
PA0737 
PA0738 
PA0745 
PA0746 
PA0767 
PA0781 
PA0782 
PA0795 
PA0802 
PA0805 
PA0807 
PA0808 
PA0848 
PA0849 
PA0850 
PA0865 
PA0866 
PA0867 
PA0870 
PA0871 
PA0872 
PA0876 
PA0887 
PA0908 
PA0910 
PA0911 
PA0921 
PA0929 
PA0930 
PA0959 
PA0996 
PA0997 
PA0998 
PA0999 
PA1000 
PA1001 
PA1002 
PA1041 
PA1077 
PA1078 
PA1079 
PA1080 
PA1081 
PA1082 
PA1083 
PA1084 
PA1134 
PA1135 
 
 
norB 
metK 
 
rpoD 
dnaG 
 
 
ptrB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hemO 
vreA 
 
 
 
 
 
lepA 
 
putA 
prpC 
 
 
 
 
 
trxB2 
 
hpd 
aroP2 
mliC 
phhC 
phhB 
phhA 
 
acsA 
 
 
 
 
 
 
 
pqsA 
pqsB 
pqsC 
pqsD 
pqsE 
phnA 
phnB 
 
flgB 
flgC 
flgD 
flgE 
flgF 
flgG 
flgH 
flgI 
 
 
conserved hypothetical protein 
hypothetical protein 
nitric-oxide reductase subunit B 
methionine adenosyltransferase 
probable transcriptional regulator 
sigma factor RpoD 
DNA primase 
conserved hypothetical protein 
conserved hypothetical protein 
repressor, PtrB 
hypothetical protein 
hypothetical protein 
probable bacteriophage protein 
probable bacteriophage protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable bacteriophage protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
probable HIT family protein 
heme oxygenase 
VreA 
probable transferase 
hypothetical protein 
conserved hypothetical protein 
probable enoyl-CoA hydratase/isomerase 
probable acyl-CoA dehydrogenase 
GTP-binding protein LepA 
hypothetical protein 
proline dehydrogenase PutA 
citrate synthase 2 
hypothetical protein 
hypothetical protein 
AmpDh3 
hypothetical protein 
probable alkyl hydroperoxide reductase 
thioredoxin reductase 2 
hypothetical protein 
4-hydroxyphenylpyruvate dioxygenase 
aromatic amino acid transport protein AroP2 
membrane-bound lysozyme inhibitor of c-type l 
aromatic amino acid aminotransferase 
pterin-4-alpha-carbinolamine dehydratase 
phenylalanine-4-hydroxylase 
probable transcriptional regulator 
acetyl-coenzyme A synthetase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
two-component response regulator 
two-component sensor 
hypothetical protein 
probable coenzyme A ligase 
Homologous to beta-keto-acyl-acyl-carrier p.s.+ 
Homologous to beta-keto-acyl-acyl-carrier p.s.+ 
3-oxoacyl-[acyl-carrier-protein] synthase III 
Quinolone signal response protein 
anthranilate synthase component I 
anthranilate synthase component II 
probable o.m. protein precursor 
flagellar basal-body rod protein FlgB 
flagellar basal-body rod protein FlgC 
flagellar basal-body rod protein FlgD 
flagellar hook protein FlgE 
flagellar basal-body rod protein FlgF 
flagellar basal-body rod protein FlgG 
flagellar L-ring protein precursor FlgH 
flagellar P-ring protein precursor FlgI 
Predicted thiol-disulphide oxidoreductase 
conserved hypothetical protein 
TR 
HUU 
HUU 
EM 
ABM ; CIM 
TR 
TR 
DRR 
HUU 
HUU 
TR 
HUU 
HUU 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
PE 
BC 
TR 
PE 
HUU 
MP 
PE 
PE 
TPD ; PSE 
HUU 
ABM 
CIM ; CC 
MP 
HUU 
ARS 
HUU 
AP ; PE 
NM 
HUU 
ABM 
TSM 
HUU ; AP 
ABM 
ABM 
ABM 
TR 
CC ; CIM 
HUU 
HUU 
HUU 
MP 
TSM ; TCR 
TSM ; TCR 
HUU 
BC 
BC 
BC 
BC 
BC 
AP 
ABM ; AP 
MP ; TSM 
CLC ; MA 
CLC ; MA 
CLC ; MA 
CLC ; MA 
CLC ; MA 
CLC ; MA 
CLC ; MA 
CLC ; MA 
HUU 
HUU 
5,3 
7,9 
-6,9 
-8,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8,9 
-133,3 
-21,4 
 
-8,3 
-8,4 
4,8 
 
 
-14,9 
-6,1 
6,4 
-6,1 
-7,5 
 
 
-11,7 
-8,4 
4,8 
13,7 
6,4 
 
 
4,5 
 
6,2 
15,0 
 
 
 
22,3 
-22,6 
-8,1 
 
5,3 
 
 
4,1 
 
 
 
9,6 
 
-5,9 
-4,8 
-7,4 
-6,9 
 
 
 
 
24,9 
5,8 
 
-6,9 
-8,8 
-4,9 
-4,9 
-4,5 
-7,7 
5,2 
 
 
14,4 
6,2 
7,6 
10,6 
7,1 
5,7 
5,5 
11,4 
29,2 
6,4 
6,2 
6,2 
6,0 
7,2 
18,2 
11,1 
-48,5 
 
 
 
 
7,0 
6,0 
-4,9 
 
 
6,6 
 
 
13,2 
7,4 
-5,7 
-6,9 
7,7 
29,3 
21,6 
5,0 
5,8 
12,8 
9,8 
7,8 
7,3 
13,5 
21,4 
13,7 
30,8 
 
 
4,9 
34,3 
30,6 
39,0 
34,7 
23,5 
34,1 
26,7 
11,3 
-6,8 
-20,2 
-11,7 
-35,6 
-8,2 
-7,5 
-5,2 
-6,7 
5,1 
73,2 
 
 
 
 
 
 
 
 
 
8,7 
6,6 
6,8 
 
8,2 
7,3 
7,6 
5,7 
5,2 
8,7 
22,6 
5,3 
5,4 
 
5,6 
4,0 
19,3 
 
 
8,7 
4,8 
5,7 
4,3 
 
 
 
5,0 
 
 
 
 
17,7 
7,0 
 
 
 
 
 
 
 
 
 
 
 
6,9 
11,9 
7,5 
 
10,0 
 
 
6,4 
14,7 
13,1 
8,4 
12,9 
19,5 
10,9 
 
 
-3,4 
 
-4,8 
 
 
 
 
6,2 
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PA1137 
PA1159 
PA1172 
PA1173 
PA1174 
PA1175 
PA1176 
PA1177 
PA1178 
PA1179 
PA1180 
PA1183 
PA1190 
PA1193 
PA1198 
PA1283 
PA1300 
PA1301 
PA1302 
PA1327 
PA1337 
PA1338 
PA1339 
PA1340 
PA1341 
PA1342 
PA1348 
PA1404 
PA1441 
PA1471 
PA1540 
PA1542 
PA1555 
PA1556 
PA1557 
PA1571 
PA1591 
PA1606 
PA1608 
PA1617 
PA1688 
PA1698 
PA1699 
PA1700 
PA1701 
PA1702 
PA1706 
PA1707 
PA1708 
PA1710 
PA1711 
PA1712 
PA1713 
PA1714 
PA1715 
PA1716 
PA1717 
PA1718 
PA1722 
PA1728 
PA1789 
PA1842 
PA1843 
PA1911 
PA1912 
PA1921 
PA1922 
PA1924 
PA1925 
PA1927 
PA1985 
PA1999 
PA2000 
PA2004 
PA2008 
PA2024 
PA2026 
PA2027 
 
 
napC 
napB 
napA 
napD 
napF 
napE 
oprH 
phoP 
phoQ 
dctA 
 
 
 
 
 
 
 
 
ansB 
ggt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
popN 
 
 
 
 
pcrV 
pcrH 
popB 
exsC 
exsE 
exsB 
exsA 
exsD 
pscB 
pscC 
pscD 
pscE 
pscI 
 
 
 
metH 
femR 
femI 
 
 
 
 
metE 
pqqA 
dhcA 
dhcB 
 
fahA 
 
 
 
probable oxidoreductase 
probable cold-shock protein 
cytochrome c-type protein NapC 
cytochrome c-type protein NapB precursor 
periplasmic nitrate reductase protein NapA 
NapD protein of periplasmic nitrate reductase 
ferredoxin protein NapF 
periplasmic nitrate reductase protein NapE 
PhoP/Q, low Mg2+ inducible o.m. prot. H1 prc. 
two-component response regulator PhoP 
two-component sensor PhoQ 
C4-dicarboxylate transport protein 
conserved hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable transcriptional regulator 
probable sigma-70 factor, ECF subfamily 
probable transmembrane sensor 
probable heme utilization protein precursor 
probable protease 
glutaminase-asparaginase 
gamma-glutamyltranspeptidase precursor 
amino acid ABC transporter ATP binding protein 
amino acid ABC transporter membrane protein 
amino acid ABC transporter membrane protein 
probable binding protein component of ABC  
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable cytochrome c 
probable cytochrome c oxidase subunit 
probable cytochrome oxidase subunit (cbb3-typ.) 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable Chemotaxis transducer 
probable AMP-binding enzyme 
hypothetical protein 
Type III secretion o.m. protein PopN precursor 
conserved hypothetical protein in type III secr. 
conserved hypothetical protein in type III secr.  
conserved hypothetical protein in type III secr. 
conserved hypothetical protein in type III secr. 
type III secr. protein PcrV 
regulatory protein PcrH 
translocator protein PopB 
exoenzyme S synthesis protein C precursor. 
ExsE 
exoenzyme S synthesis protein B 
transcriptional regulator ExsA 
ExsD 
type III export apparatus protein 
Type III secr. o.m. protein PscC precursor 
type III export protein PscD 
type III export protein PscE 
type III export protein PscI 
hypothetical protein 
hypothetical protein 
hypothetical protein 
methionine synthase 
sigma factor regulator, FemR 
ECF sigma factor, FemI 
hypothetical protein 
probable TonB-dependent receptor 
hypothetical protein 
hypothetical protein 
cobalamin-independent methionine synthase 
pyrroloquinoline quinone biosynthesis protein 
dehydrocarnitine CoA transferase, subunit A 
dehydrocarnitine CoA transferase, subunit B 
conserved hypothetical protein 
fumarylacetoacetase 
probable ring-cleaving dioxygenase 
conserved hypothetical protein 
hypothetical protein 
PE 
TR ; AP 
EM 
EM 
EM 
EM 
EM 
EM 
MP ; AP  
TR ; TCR 
TCR 
TSM 
MP 
HUU 
HUU 
TR 
TR 
MP ; TR 
MP ; TSM 
PE 
ABM 
ABM ; AP  
TSM 
TSM 
MP ; TSM 
TSM 
HUU 
HUU 
HUU 
HUU 
MP 
HUU 
EM 
EM 
EM 
HUU 
MP 
HUU 
AP ; C 
PE 
HUU 
MP ; PSE 
PSE 
PSE 
PSE 
PSE 
PSE 
SF ; PSE 
PSE 
TPD ; PSE 
HUU ; TR  
TPD ; PSE 
PSE ; TR 
HUU 
PSE 
PSE 
PSE 
PSE 
PSE 
HUU 
HUU 
HUU 
ABM 
MP ; TR 
TR 
HUU 
TSM 
HUU 
HUU 
ABM 
BC 
ABM ; CC 
ABM ; CC 
MP 
CC 
PE 
MP 
HUU 
5,1 
 
5,6 
6,9 
28,3 
8,0 
15,0 
26,8 
 
 
 
-6,8 
 
 
5,9 
4,2 
-42,2 
-14,5 
-5,6 
 
8,9 
5,5 
6,7 
10,6 
9,5 
12,1 
4,7 
 
-7,6 
 
-16,5 
3,9 
  
 
4,2 
 
 
 
-5,1 
4,2 
 
 
-7,5 
-9,0 
-9,5 
-18,9 
-9,3 
-9,0 
-15,7 
-4,6 
-8,5 
-16,3 
-5,6 
-9,4 
-16,2 
-12,7 
-7,6 
-12,6 
-7,2 
 
4,8 
 
 
-7,4 
-11,1 
 
-8,8 
-7,0 
-10,5 
-13,4 
 
 
 
 
 
8,2 
 
203,5 
 
5,6 
 
5,0 
16,0 
4,9 
12,3 
35,0 
5,6 
7,6 
9,4 
 
6,1 
-6,2 
7,2 
9,6 
-37,5 
-12,0 
-5,6 
6,4 
7,0 
 
4,7 
9,4 
7,6 
9,5 
6,6 
9,1 
-14,6 
 
-8,7 
12,8 
12,4 
8,5 
10,6 
5,3 
-6,9 
36,7 
-5,1 
5,6 
-8,4 
-4,5 
-7,5 
-10,3 
-9,5 
-18,5 
-9,4 
-10,8 
-16,1 
-6,2 
-19,2 
-20,3 
-5,3 
-12,7 
-16,2 
-14,7 
-8,1 
-12,6 
-7,2 
6,6 
5,2 
-4,9 
-6,0 
-5,1 
-7,7 
 
 
 
 
-13,7 
26,8 
8,8 
7,3 
 
5,0 
13,6 
 
 
-3,6 
 
 
 
 
 
 
 
 
 
 
5,9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6,7 
 
 
5,9 
5,9 
 
 
 
37,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11,6 
15,6 
7,3 
15,7 
 
17,8 
6,4 
4,8 
4,3 
 
 
-4,0 
-200,0 
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PA2033 
PA2034 
PA2110 
PA2111 
PA2112 
PA2114 
PA2116 
PA2134 
PA2143 
PA2146 
PA2159 
PA2166 
PA2170 
PA2171 
PA2172 
PA2173 
PA2174 
PA2182 
PA2190 
PA2231 
PA2232 
PA2247 
PA2248 
PA2249 
PA2317 
PA2318 
PA2321 
PA2331 
PA2364 
PA2365 
PA2375 
PA2378 
PA2379 
PA2381 
PA2382 
PA2384 
PA2385 
PA2386 
PA2393 
PA2394 
PA2395 
PA2396 
PA2397 
PA2398 
PA2399 
PA2400 
PA2402 
PA2403 
PA2404 
PA2405 
PA2406 
PA2407 
PA2408 
PA2409 
PA2411 
PA2412 
PA2413 
PA2424 
PA2426 
PA2427 
PA2428 
PA2433 
PA2442 
PA2444 
PA2444 
PA2445 
PA2446 
PA2467 
PA2468 
PA2476 
PA2478 
PA2501 
PA2504 
PA2507 
PA2508 
PA2509 
PA2511 
PA2512 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pslA 
pslB 
bkdA1 
bkdA2 
bkdB 
 
 
 
 
 
 
 
 
 
 
lldA 
 
pvdQ 
pvdA 
 
pvdN 
pvdO 
pvdF 
pvdE 
fpvA 
pvdD 
pvdJ 
 
 
 
 
 
 
 
 
 
 
pvdH 
pvdL 
pvdS 
 
 
 
gcvT2 
glyA2 
glyA2 
gcvP2 
gcvH2 
foxR 
foxI 
dsbG 
 
 
 
catA 
catC 
catB 
 
antA 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable major facilitator superfamily transporter 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
PslA 
PslB 
2-oxoisovalerate dehydrogenase (alpha subunit) 
2-oxoisovalerate dehydrogenase (beta subunit) 
branched-chain alpha-keto acid dehydrogenase  
probable oxidoreductase 
hypothetical protein 
gluconokinase 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable aldehyde dehydrogenase 
probable oxidoreductase 
hypothetical protein 
L-lactate dehydrogenase 
hypothetical protein 
3-oxo-C12-homoserine lactone acylase PvdQ 
L-ornithine N5-oxygenase 
probable dipeptidase precursor 
PvdN 
PvdO 
pyoverdine synthetase F 
pyoverdine biosynthesis protein PvdE 
ferripyoverdine receptor 
pyoverdine synthetase D 
PvdJ 
probable non-ribosomal peptide synthetase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable adhesion protein 
probable ATP-binding component of ABC transp. 
probable permease of ABC transporter 
probable thioesterase 
conserved hypothetical protein 
PvdH 
PvdL 
sigma factor PvdS 
hypothetical protein 
hypothetical protein 
hypothetical protein 
glycine cleavage system protein T2 
serine hydroxymethyltransferase 
serine hydroxymethyltransferase 
glycine cleavage system protein P2 
glycine cleavage system protein H2 
Anti-sigma factor FoxR 
ECF sigma factor FoxI 
thiol:disulphide interchange protein DsbG 
probable thiol:disulphide interchange protein 
hypothetical protein 
hypothetical protein 
catechol 1,2-dioxygenase 
muconolactone delta-isomerase 
muconate cycloisomerase I 
probable transcriptional regulator 
anthranilate dioxygenase large subunit 
HUU 
HUU 
HUU 
HUU 
HUU 
MP ; TSM 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
CLC 
CLC 
ABM 
ABM 
ABM 
PE 
HUU 
EM ; CC 
MP 
HUU 
HUU 
MP 
PE 
PE 
HUU 
EM 
HUU 
AP 
AP 
CIM 
AP 
AP 
SF ; AP 
MP ; AP  
TSM 
SF ; AP 
AP 
PE 
MP 
MP 
HUU 
HUU 
MA 
TSM 
MP ; TSM 
AP ; PE 
HUU 
AP 
AP 
TR 
HUU 
HUU 
HUU 
CIM ; ABM 
ABM 
ABM 
CIM ; ABM 
ABM 
MP ; TR 
TR 
TPD ; CHP 
MP ; PE 
MP 
HUU 
CC 
CC 
CC 
TR 
CC 
-16,4 
-26,8 
 
 
 
 
 
 
6,3 
19,5 
 
21,9 
5,9 
 
 
6,9 
 
5,9 
 
4,1 
3,8 
 
 
 
9,6 
15,1 
-6,2 
 
5,7 
7,7 
 
4,9 
 
6,7 
 
-17,8 
-11,4 
-62,5 
-9,2 
-20,4 
-6,6 
-18,8 
-17,8 
-101,0 
-13,1 
-8,6 
-13,3 
-9,2 
-12,1 
-22,1 
-13,5 
-28,2 
-6,3 
-10,5 
-20,0 
-29,0 
-6,2 
-7,9 
-71,9 
 
 
18,7 
 
 
 
 
 
-15,5 
-7,9 
 
 
13,1 
 
182,0 
159,8 
55,1 
21,8 
102,5 
-12,5 
-24,3 
7,7 
14,0 
13,2 
12,7 
16,1 
16,3 
11,0 
37,3 
5,2 
28,9 
8,8 
10,4 
7,0 
23,9 
7,9 
9,0 
13,3 
 
 
12,7 
8,2 
10,0 
 
 
-6,6 
-5,7 
 
 
8,0 
4,7 
5,4 
34,6 
-5,0 
-15,4 
-11,4 
-62,5 
-9,2 
-20,7 
-6,6 
-24,9 
-17,8 
-80,0 
-14,0 
-8,5 
-13,4 
-5,8 
-10,3 
-13,1 
-13,4 
-28,5 
-6,8 
-7,3 
-20,0 
-25,9 
-6,0 
-7,9 
-37,6 
 
45,3 
39,8 
 
5,8 
 
 
 
-8,6 
-4,9 
 
 
7,6 
6,5 
 
 
 
 
 
 
 
8,6 
14,6 
13,3 
14,7 
46,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-8,2 
-4,2 
 
 
 
-4,1 
 
 
 
5,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5,2 
44,9 
 
4,9 
 
27,8 
23,1 
16,2 
 
 
4,3 
4,8 
 
 
-103,1 
-56,8 
-51,5 
-14,1 
-80,0 
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PA2513 
PA2514 
PA2519 
PA2552 
PA2555 
PA2573 
PA2618 
PA2622 
PA2624 
PA2635 
PA2657 
PA2658 
PA2659 
PA2662 
PA2679 
PA2682 
PA2686 
PA2740 
PA2746 
PA2747 
PA2762 
PA2779 
PA2803 
PA2804 
PA2840 
PA2850 
PA2881 
PA2906 
PA2911 
PA2912 
PA2913 
PA2914 
PA2915 
PA2937 
PA3000 
PA3038 
PA3040 
PA3049 
PA3080 
PA3118 
PA3119 
PA3119 
PA3120 
PA3120 
PA3121 
PA3123 
PA3129 
PA3174 
PA3183 
PA3205 
PA3205 
PA3216 
PA3219 
PA3231 
PA3232 
PA3234 
PA3235 
PA3236 
PA3237 
PA3278 
PA3280 
PA3281 
PA3282 
PA3283 
PA3284 
PA3308 
PA3347 
PA3362 
PA3363 
PA3365 
PA3366 
PA3368 
PA3369 
PA3371 
PA3382 
PA3383 
PA3384 
PA3397 
antB 
antC 
xylS 
 
 
 
 
cspD 
idh 
 
 
 
 
idh 
 
 
pfeR 
pheS  
 
 
 
 
 
 
 
ohr 
 
 
 
 
 
 
 
 
aroP1 
 
 
rmf 
 
leuB 
 
 
leuD 
leuD 
leuC 
 
 
 
zwf 
 
 
 
 
 
 
gltX 
 
 
 
 
oprO 
 
 
 
 
hepA 
 
 
amiR 
 
amiE 
 
 
 
phnE 
 
phnC 
fpr 
anthranilate dioxygenase small subunit 
anthranilate dioxygenase reductase 
transcriptional regulator XylS 
probable acyl-CoA dehydrogenase 
probable AMP-binding enzyme 
probable C transducer 
hypothetical protein 
cold-shock protein CspD 
isocitrate dehydrogenase 
hypothetical protein 
probable two-component response regulator 
hypothetical protein 
hypothetical protein 
isocitrate dehydrogenase 
hypothetical protein 
conserved hypothetical protein 
two-component response regulator PfeR 
phenylalanyl-tRNA synthetase, alpha-subunit 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable ATP-dependent RNA helicase 
organic hydroperoxide resistance protein 
probable two-component response regulator 
probable oxidoreductase 
probable TonB-dependent receptor 
probable ATP-binding component of ABC transp. 
hypothetical protein 
probable permease of ABC transporter 
hypothetical protein 
hypothetical protein 
aromatic amino acid transport protein AroP1 
probable porin 
conserved hypothetical protein 
ribosome modulation factor 
hypothetical protein 
3-isopropylmalate dehydrogenase 
conserved hypothetical protein 
conserved hypothetical protein 
3-isopropylmalate dehydratase small subunit 
3-isopropylmalate dehydratase small subunit 
3-isopropylmalate dehydratase large subunit 
conserved hypothetical protein 
conserved hypothetical protein 
probable transcriptional regulator 
glucose-6-phosphate 1-dehydrogenase 
hypothetical protein 
hypothetical protein 
probable aspartate-semialdehyde dehydrogenase 
hypothetical protein 
probable aldolase 
probable hydrolase 
glutamyl-tRNA synthetase 
probable transcriptional regulator 
probable secretion protein 
hypothetical protein 
hypothetical protein 
Pyrophosphate-specific o.m. porin OprO prec. 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
RNA helicase HepA 
hypothetical protein 
hypothetical protein 
aliphatic amidase regulator 
probable chaperone 
aliphatic amidase 
probable acetyltransferase 
hypothetical protein 
hypothetical protein 
phosphonate transport protein PhnE 
binding protein component of ABC phosphonate t. 
ATP-binding component of ABC phosphonate t. 
ferredoxin--NADP+ reductase 
CC 
CC 
TR 
PE 
PE 
AP ; C 
TPD 
TR ; AP 
EM 
HUU 
TR ; TCR 
HUU 
HUU 
EM 
HUU 
PE 
TR ; TCR 
TPD 
MP 
HUU 
HUU 
HUU 
HUU 
HUU 
TRD 
AP 
TR ; TCR 
PE 
MP ; TSM 
TSM 
TSM 
MP ; TSM 
HUU 
HUU 
TSM 
TSM 
HUU 
TPD 
HUU 
ABM 
HUU 
HUU 
ABM 
ABM 
ABM 
HUU 
HUU 
TR 
EM ; CC 
HUU 
HUU 
ABM 
HUU 
CIM ; CC 
PE 
TPD 
TR 
TSM 
HUU 
MP 
TSM 
MP 
HUU 
HUU 
HUU 
TRD 
HUU 
MP 
CC ; TR 
CHP 
CC 
PE 
MP 
HUU 
MP ; TSM 
TSM 
TSM 
BC ; EM 
241,7 
83,5 
5,3 
 
 
 
5,2 
10,0 
 
 
 
 
 
-5,1 
6,2 
22,2 
-5,1 
 
8,3 
12,6 
11,7 
4,6 
12,7 
10,5 
-15,4 
-11,1 
5,4 
 
-19,0 
-13,8 
-10,6 
-10,4 
12,5 
12,5 
 
17,6 
 
10,0 
5,8 
4,9 
5,6 
 
13,3 
 
12,1 
4,8 
 
 
 
 
 
10,4 
 
6,2 
4,9 
37,9 
79,1 
6,1 
-13,9 
6,1 
-5,5 
-59,9 
-72,5 
-66,7 
-29,8 
 
 
6,1 
5,4 
7,3 
8,9 
 
11,6 
5,6 
 
 
 
-6,9 
 
 
 
4,9 
 
4,9 
5,9 
11,2 
-5,1 
6,6 
 
 
5,0 
 
 
 
-5,1 
-5,7 
24,0 
8,4 
7,7 
8,5 
12,1 
10,5 
-25,4 
-11,1 
 
-5,5 
-19,6 
-12,0 
-12,8 
-8,0 
11,1 
20,9 
-5,8 
8,5 
5,2 
12,6 
 
 
 
 
 
 
 
4,9 
-4,7 
 
-5,2 
17,2 
 
13,3 
14,0 
9,2 
 
12,4 
26,8 
 
-13,9 
5,7 
21,7 
-18,3 
-14,6 
-13,2 
-7,1 
-4,6 
5,3 
 
 
-7,3 
 
6,2 
9,8 
4,8 
9,3 
51,3 
9,7 
-10,0 
-65,8 
-80,0 
-4,2 
 
5,7 
 
 
 
 
5,4 
4,8 
9,0 
8,5 
 
 
-15,2 
 
 
 
 
 
 
 
 
 
 
4,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
-4,3 
 
-9,7 
 
-10,5 
 
 
6,2 
 
 
6,0 
 
13,5 
 
 
 
 
 
 
 
 
 
 
5,0 
 
 
 
 
 
 
 
5,5 
 
 
9,6 
51,3 
9,7 
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PA3399 
PA3407 
PA3408 
PA3415 
PA3416 
 
PA3417 
 
PA3418 
PA3431 
PA3432 
PA3441 
PA3445 
PA3446 
PA3450 
PA3451 
PA3465 
PA3496 
PA3530 
PA3531 
PA3568 
PA3569 
PA3570 
PA3572 
PA3575 
PA3578 
PA3586 
PA3598 
PA3600 
PA3601 
PA3615 
PA3622 
PA3628 
PA3629 
PA3638 
PA3656 
PA3662 
PA3684 
PA3688 
PA3700 
PA3723 
PA3731 
PA3741 
PA3742 
PA3743 
PA3768 
PA3786 
PA3792 
PA3795 
PA3810 
PA3814 
PA3823 
PA3824 
PA3841 
PA3842 
PA3843 
PA3848 
PA3871 
PA3873 
PA3874 
PA3876 
PA3877 
PA3885 
PA3899 
PA3910 
PA3915 
PA3922 
PA3931 
PA3933 
PA3957 
PA3967 
PA3986 
PA4003 
PA4010 
PA4063 
PA4064 
PA4065 
PA4066 
 
hasAp 
hasR 
 
 
 
 
 
ldh 
 
 
 
 
 
 
 
 
 
bfd  
bfrB 
 
mmsB 
mmsA 
 
 
 
 
 
 
 
 
rpoS 
 
adhC 
 
rpsB 
 
 
 
prfB 
 
 
 
rplS 
trmD 
 
 
leuA 
 
hscA 
iscS 
tgt 
queA 
exoS 
 
 
 
 
narJ 
narH 
narK2 
narK1 
tpbA 
 
 
moaB1 
 
 
 
 
 
 
pbpA 
 
 
 
 
 
hypothetical protein 
heme acquisition protein HasAp 
Haem uptake o.m. receptor HasR precursor 
probable dihydrolipoamide acetyltransferase 
probable pyruvate dehydrogenase E1 component, 
beta chain 
probable pyruvate dehydrogenase E1 component, 
alpha subunit 
leucine dehydrogenase 
conserved hypothetical protein 
hypothetical protein 
probable molybdopterin-binding protein 
conserved hypothetical protein 
conserved hypothetical protein 
probable antioxidant protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
bacterioferritin-associated ferredoxin 
bacterioferritin 
probable acetyl-coa synthetase 
3-hydroxyisobutyrate dehydrogenase 
methylmalonate-semialdehyde dehydrogenase 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable hydrolase 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
sigma factor RpoS 
probable esterase 
alcohol dehydrogenase class III 
conserved hypothetical protein 
30S ribosomal protein S2 
hypothetical protein 
hypothetical protein 
hypothetical protein 
peptide chain release factor 2 
probable FMN oxidoreductase 
conserved hypothetical protein 
hypothetical protein 
50S ribosomal protein L19 
tRNA (guanine-N1)-methyltransferase 
probable metallo-oxidoreductase 
hypothetical protein 
2-isopropylmalate synthase 
probable oxidoreductase 
heat shock protein HscA 
L-cysteine desulphurase  
queuine tRNA-ribosyltransferase 
SAM:trna ribosyltransferase-isomerase 
exoenzyme S 
probable chaperone 
hypothetical protein 
hypothetical protein 
probable peptidyl-prolyl cis-trans isomerase 
respiratory nitrate reductase delta chain 
respiratory nitrate reductase beta chain 
nitrite extrusion protein 2 
nitrite extrusion protein 1 
protein tyrosine phosphatase TpbA 
probable sigma-70 factor, ECF subfamily 
hypothetical protein 
molybdopterin biosynthetic protein B1 
conserved hypothetical protein 
conserved hypothetical protein 
probable choline transporter 
probable short-chain dehydrogenase 
hypothetical protein 
hypothetical protein 
penicillin-binding protein 2 
hypothetical protein 
hypothetical protein 
probable ATP-binding component of ABC trans. 
hypothetical protein 
hypothetical protein 
HUU 
TSM 
TSM 
EM 
EM 
 
EM 
 
ABM 
MP 
MP 
TSM 
HUU 
HUU 
AP 
HUU 
MP 
HUU 
HUU 
TSM ; AP 
PE 
CC 
ABM ; CC 
HUU 
MP 
HUU 
PE 
HUU 
TPD 
TPD 
HUU 
TR 
PE 
CIM 
HUU 
TPD 
HUU 
HUU 
HUU 
TPD 
PE 
HUU 
HUU 
TPD 
TRD 
PE 
HUU 
ABM 
PE 
CHP 
ABM ; BC 
TRD ; TPD 
TPD 
SF 
SF ; CHP 
HUU 
HUU 
TPD ; CHP 
EM 
EM 
MP ; TSM 
MP ; TSM 
MA ; TPD 
TR 
HUU 
BC 
HUU 
HUU 
MP ; TSM 
PE 
HUU 
HUU 
CLC 
HUU 
HUU 
TSM 
MP 
HUU 
4,5 
-250,0 
-7,0 
12,0 
8,2 
 
5,8 
 
10,4 
-95,2 
-65,8 
-5,1 
-6,0 
-7,9 
-8,8 
 
5,9 
 
 
8,4 
8,8 
8,9 
3,9 
3,8 
7,8 
 
-5,6 
-17,2 
-161,3 
-54,9 
3,8 
4,6 
4,7 
5,8 
 
 
16,7 
4,5 
8,0 
 
15,4 
 
-23,6 
 
 
-5,4 
5,3 
29,7 
 
 
 
 
 
-7,7 
-13,9 
-8,6 
3,9 
-6,7 
-8,0 
-7,8 
-12,6 
-13,3 
-5,7 
-20,7 
 
-15,3 
7,8 
 
-5,2 
 
 
 
-6,5 
 
-45,0 
-21,3 
-10,0 
-8,5 
 
-227,3 
-7,0 
16,7 
9,3 
 
9,4 
 
16,4 
-105,3 
-61,7 
 
-6,0 
-8,9 
-11,5 
8,8 
5,1 
14,0 
 
 
8,3 
15,6 
4,7 
6,8 
13,0 
 
 
-10,8 
 
 
 
9,8 
 
 
-5,0 
-6,7 
12,4 
4,9 
9,3 
-6,1 
25,1 
 
-36,2 
-6,7 
-5,2 
 
 
 
4,7 
-5,0 
-5,8 
-4,8 
-7,1 
-10,7 
-14,3 
-8,6 
 
-7,0 
-8,4 
-7,8 
-11,7 
-14,0 
-7,0 
-16,7 
12,7 
-15,4 
6,8 
-6,3 
-8,6 
5,9 
-5,8 
6,0 
-6,4 
8,0 
 
-4,8 
-5,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10,2 
-4,3 
 
 
 
 
 
5,1 
4,9 
 
57,3 
29,0 
 
 
 
 
 
 
 
 
 
 
 
-3,7 
 
 
 
 
 
-20,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12,7 
 
 
 
 
 
 
 
 
 
21,5 
4,4 
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PA4073 
PA4091 
PA4092 
PA4107 
PA4110 
PA4111 
PA4121 
PA4122 
PA4123 
 
PA4124 
PA4125 
PA4126 
PA4127 
PA4128 
PA4170 
PA4181 
PA4182 
PA4198 
PA4218 
PA4219 
PA4220 
PA4221 
PA4222 
PA4223 
PA4224 
PA4225 
PA4226 
PA4227 
PA4228 
PA4229 
PA4230 
PA4231 
PA4237 
PA4247 
PA4250 
PA4251 
PA4271 
PA4290 
PA4296 
PA4350 
PA4351 
PA4352 
PA4357 
PA4358 
PA4359 
PA4364 
PA4365 
PA4370 
 
PA4373 
PA4432 
PA4433 
PA4467 
PA4468 
PA4469 
PA4470 
PA4471 
PA4480 
PA4507 
PA4515 
PA4537 
PA4550 
 
PA4551 
PA4552 
PA4553 
PA4554 
PA4555 
PA4556 
PA4557 
PA4570 
PA4573 
PA4577 
PA4587 
PA4602 
PA4606 
PA4607 
 
hpaA 
hpaC 
 
ampC 
 
 
 
hpcC 
 
hpcB 
hpcD 
 
hpcG 
 
 
 
 
 
 
 
 
fptA 
 
 
pchG 
pchF 
pchE 
pchR 
pchD 
pchC 
pchB 
pchA 
rplQ 
rplR 
rpsN 
rplE 
rplL 
 
pprB 
 
 
 
 
 
 
 
 
icmP 
 
 
rpsI 
rplM 
 
sodM 
 
fumC1 
 
mreC 
 
piuC 
 
murA 
 
 
pilW 
pilX 
 
 
 
lytB 
 
 
 
ccpR 
glyA3 
 
 
probable aldehyde dehydrogenase 
4-hydroxyphenylacetate 3-monooxygenase l. ch. 
4-hydroxyphenylacetate 3-monooxygenase s. ch. 
hypothetical protein 
beta-lactamase precursor 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
5-carboxy-2-hydroxymuconate semialdehyde 
dehydrogenase 
homoprotocatechuate 2,3-dioxygenase 
5-carboxymethyl-2-hydroxymuconate isomerase 
probable major facilitator superfam transporter 
2-oxo-hept-3-ene-1,7-dioate hydratase 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable AMP-binding enzyme 
probable transporter 
hypothetical protein 
hypothetical protein 
Fe(III)-pyochelin o.m. receptor precursor 
probable ATP-binding component of ABC trans. 
probable ATP-binding component of ABC trans. 
pyochelin biosynthetic protein PchG 
pyochelin synthetase 
dihydroaeruginoic acid synthetase 
transcriptional regulator PchR 
pyochelin biosynthesis protein PchD 
pyochelin biosynthetic protein PchC 
salicylate biosynthesis protein PchB 
salicylate biosynthesis isochorismate synthase 
50S ribosomal protein L17 
50S ribosomal protein L18 
30S ribosomal protein S14 
50S ribosomal protein L5 
50S ribosomal protein L7 / L12 
probable Chemotaxis transducer 
two-component response regulator, PprB 
conserved hypothetical protein 
probable acyltransferase 
conserved hypothetical protein 
conserved hypothetical protein 
probable ferrous iron transport protein 
conserved hypothetical protein 
hypothetical protein 
probable transporter 
Insulin-cleaving metalloproteinase o.m. protein 
precursor 
hypothetical protein 
30S ribosomal protein S9 
50S ribosomal protein L13 
hypothetical protein 
superoxide dismutase 
hypothetical protein 
fumarate hydratase 
hypothetical protein 
rod shape-determining protein MreC 
hypothetical protein 
Uncharacterized iron-regulated protein 
hypothetical protein 
UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 
conserved hypothetical protein 
type 4 fimbrial biogenesis protein PilW 
type 4 fimbrial biogenesis protein PilX 
conserved hypothetical protein 
probable permease of ABC transporter 
probable ATP-binding component of ABC trans. 
LytB protein 
HUU; weak similarity to IclR repressor family 
hypothetical protein 
hypothetical protein 
cytochrome c551 peroxidase precursor 
serine hydroxymethyltransferase 
conserved hypothetical protein 
hypothetical protein 
PE 
CC 
CC 
HUU 
AP 
HUU 
HUU 
HUU 
CC 
 
CC 
CC 
MP ; CC  
CC 
PE 
HUU 
HUU 
HUU 
PE 
MP ; TSM 
MP 
HUU 
TSM 
TSM 
MP ; TSM 
TSM ; MP 
SF ; TSM 
SF ; TSM 
TR 
SF ; TSM 
SF ; TSM 
SF ; TSM 
SF ; TSM 
TPD 
TPD 
TPD 
TPD 
TPD 
AP ; C 
TR ; TCR  
HUU 
FPM 
HUU 
HUU 
MP ; TSM 
HUU 
HUU 
MP ; TSM 
 
MP 
HUU 
TPD 
TPD 
MP 
AP 
HUU 
EM 
HUU 
CLC  
MP 
HUU 
HUU 
CLC 
 
HUU 
MA 
MA 
HUU 
MP ; TSM 
TSM 
AP 
HUU 
HUU 
HUU 
EM 
ABM 
AP 
HUU 
4,1 
24,0 
24,6 
 
-48,3 
-64,5 
10,6 
8,3 
27,2 
 
11,4 
9,3 
4,1 
5,2 
4,9 
 
10,2 
18,2 
5,6 
-60,2 
-48,8 
-263,2 
-41,7 
-4,8 
-23,4 
-76,3 
-19,2 
-47,8 
 
-27,9 
-45,7 
-38,8 
-18,4 
-5,5 
 
 
 
 
10,2 
15,7 
 
 
4,2 
-23,4 
-63,3 
-9,6 
15,8 
10,9 
-6,1 
 
-8,2 
 
 
-38,2 
-20,2 
-14,1 
-42,4 
-6,1 
 
31,2 
-6,8 
 
 
 
 
 
 
 
 
 
-5,6 
-43,3 
 
 
7,1 
-5,4 
3,9 
12,3 
 
10,6 
20,2 
-4,6 
-33,7 
-72,5 
 
 
9,9 
 
 
 
 
 
 
 
 
 
 
-5,4 
-10,7 
-5,0 
-5,2 
 
 
 
-4,4 
 
-13,9 
 
-7,7 
 
-11,3 
-5,4 
-4,9 
-6,2 
-5,1 
-4,6 
 
-4,6 
65,4 
31,4 
 
-5,1 
-5,4 
 
 
 
 
 
-4,9 
-5,8 
-4,5 
-31,4 
-15,6 
-10,7 
-24,7 
-6,1 
-4,8 
9,8 
-5,4 
5,2 
7,2 
 
 
5,7 
5,3 
 
 
 
-6,5 
-5,1 
4,9 
5,0 
6,3 
-12,3 
 
15,7 
 
 
 
 
 
 
 
 
 
 
 
-5,0 
 
 
 
6,2 
-11,8 
-16,3 
-4,5 
11,1 
4,6 
52,1 
8,0 
 
5,8 
18,0 
4,3 
11,9 
5,1 
6,5 
5,9 
9,9 
 
 
 
 
 
 
 
 
 
65,6 
31,4 
 
4,6 
11,6 
5,1 
-13,9 
-8,8 
 
 
 
 
 
 
 
 
 
 
 
 
 
5,4 
 
5,7 
4,4 
5,1 
4,7 
3,6 
3,7 
 
8,4 
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PA4608 
PA4611 
PA4630 
PA4635 
PA4661 
PA4670 
PA4671 
PA4672 
PA4673 
PA4691 
PA4692 
PA4695 
PA4696 
PA4702 
PA4703 
PA4706 
PA4707 
PA4708 
PA4709 
PA4710 
 
PA4733 
PA4739 
PA4740 
PA4742 
PA4743 
PA4744 
PA4776 
 
PA4787 
PA4803 
PA4810 
 
PA4811 
 
PA4812 
PA4832 
PA4834 
PA4835 
PA4836 
PA4837 
PA4838 
PA4880 
PA4884 
PA4895 
PA4896 
PA4915 
PA4925 
PA4932 
PA4933 
PA4934 
PA4935 
PA5106 
PA5116 
PA5117 
PA5118 
PA5153 
 
PA5155 
 
PA5167 
PA5168 
PA5169 
PA5173 
PA5196 
PA5202 
PA5217 
PA5233 
PA5288 
PA5315 
PA5348 
PA5351 
PA5359 
PA5360 
PA5365 
PA5366 
 
PA5367 
 
 
 
 
pagL 
prs 
 
 
 
 
 
ilvH 
ilvI 
 
 
 
 
phuT 
 
phuR 
 
acsB 
 
pnp 
truB 
rbfA 
infB 
pmrA 
 
 
 
fdnI 
 
fdnH 
 
fdnG 
 
 
 
 
 
 
 
 
 
 
 
 
rplI 
 
rpsR 
rpsF 
 
 
typA 
thiI 
 
 
 
 
 
 
 
arcC 
 
 
 
 
glnK 
rpmG 
 
rubA1 
 
phoB 
phoU 
pstB 
 
pstA 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
Lipid A 3-O-deacylase 
ribose-phosphate pyrophosphokinase 
probable ribosomal protein L25 
peptidyl-tRNA hydrolase 
conserved hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
acetolactate synthase isozyme III small subunit 
acetolactate synthase large subunit 
hypothetical protein 
hypothetical protein 
probable ATP-binding component of ABC trans. 
probable permease of ABC transporter 
Heme-transport protein, PhuT 
probable hemin degrading factor 
Haem/Haemoglobin uptake o.m. receptor PhuR 
precursor 
acetyl-coenzyme A synthetase 
conserved hypothetical protein 
polyribonucleotide nucleotidyltransferase 
tRNA pseudouridine 55 synthase 
ribosome-binding factor A 
translation initiation factor IF-2 
PmrA: two-component regulator system response 
regulator PmrA 
probable transcriptional regulator 
hypothetical protein 
nitrate-inducible formate dehydrogenase, gamma 
subunit 
nitrate-inducible formate dehydrogenase, beta 
subunit 
formate dehydrogenase-O, major subunit 
probable short-chain dehydrogenase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable o.m. protein precursor 
hypothetical protein 
probable bacterioferritin 
hypothetical protein 
probable transmembrane sensor 
probable sigma-70 factor, ECF subfamily 
probable Chemotaxis transducer 
conserved hypothetical protein 
50S ribosomal protein L9 
hypothetical protein 
30S ribosomal protein S18 
30S ribosomal protein S6 
conserved hypothetical protein 
probable transcriptional regulator 
regulatory protein TypA 
thiazole biosynthesis protein ThiI 
amino acid (lysine/arginine/ornithine/histidine/ 
octopine) ABC transporter periplasmic binding pr. 
amino acid (lysine/arginine/ornithine/histidine/ 
octopine) ABC transporter membrane protein 
probable c4-dicarboxylate-binding protein 
probable dicarboxylate transporter 
probable C4-dicarboxylate transporter 
carbamate kinase 
hypothetical protein 
hypothetical protein 
probable binding protein component of ABC iron . 
hypothetical protein 
nitrogen regulatory protein P-II 2 
50S ribosomal protein L33 
probable DNA-binding protein 
Rubredoxin 1 
hypothetical protein 
two-component response regulator PhoB 
phosphate uptake regulatory protein PhoU 
ATP-binding component of ABC phosphate 
transporter 
membrane protein component of ABC phosphate 
HUU 
HUU 
HUU 
HUU 
HUU 
CC ; NM 
AP ; TPD 
TPD 
HUU 
HUU 
HUU 
BC ; ABM 
BC ; ABM 
HUU 
HUU 
TSM 
MP ; TSM 
TSM 
PE 
TSM 
 
CC ; CIM 
HUU 
TRD 
TPD ; TRD 
TPD ; AP 
TP 
TCR 
 
TR 
HUU 
EM 
 
EM 
 
EM 
PE 
MP 
HUU ; MP 
HUU 
MP ; TSM 
HUU 
CIM 
HUU 
MP ; TR 
TR 
AP ; C 
HUU 
TPD 
MP 
TPD 
TPD 
HUU 
TR 
AP 
BC 
TSM 
 
MP ; TSM 
 
MP ; TSM 
MP ; TSM 
MP ; TSM 
ABM 
HUU 
HUU 
TSM 
HUU 
CIM 
TPD 
DRR 
CC 
HUU 
TR ; TCR 
MP ; TR 
MP ; TSM 
 
MP ; TSM 
6,1 
10,7 
10,9 
 
 
 
 
 
-6,1 
-9,0 
-10,8 
 
4,4 
6,0 
8,1 
-5,6 
-6,7 
-7,2 
-7,4 
-9,7 
 
6,0 
4,6 
 
 
-8,5 
 
 
 
7,3 
 
12,9 
 
20,4 
 
28,6 
-9,1 
-15,0 
-36,9 
-27,9 
-43,7 
-26,8 
7,1 
-10,2 
-6,0 
-21,5 
6,3 
7,1 
-6,0 
-4,5 
 
 
 
 
-6,9 
 
3,8 
 
 
 
 
 
4,8 
-4,6 
 
 
-5,8 
4,2 
4,6 
 
9,3 
 
 
 
 
 
 
 
9,5 
13,3 
7,5 
 
7,0 
-5,4 
-6,0 
-7,7 
-11,5 
 
 
 
 
7,3 
8,8 
-7,1 
-9,1 
-8,1 
-15,7 
-25,8 
 
9,2 
 
-6,0 
-6,1 
-17,6 
-6,2 
-6,9 
 
8,2 
9,2 
10,0 
 
17,1 
 
19,7 
-7,7 
 
-9,2 
-5,2 
-6,1 
-5,1 
7,2 
-10,2 
-6,0 
-19,0 
6,7 
6,1 
-9,5 
 
-4,8 
-4,7 
6,4 
9,7 
-9,5 
-11,7 
6,3 
 
9,6 
 
8,3 
6,5 
16,8 
 
5,8 
-5,0 
 
 
 
-8,9 
15,9 
4,9 
6,3 
38,4 
7,3 
15,4 
 
12,6 
 
 
 
5,6 
4,1 
 
 
 
 
 
 
-4,0 
-6,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4,5 
 
 
 
 
 
 
 
 
5,4 
7,2 
5,2 
 
 
 
 
 
 
 
 
 
 
 
4,3 
 
 
 
 
 
 
 
 
 
 
 
 
5,1 
 
 
 
 
 
 
41,4 
14,2 
33,5 
 
16,7 
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PA5368 
 
PA5369 
 
PA5372 
PA5373 
PA5374 
PA5380 
PA5396 
PA5410 
PA5415 
PA5424 
PA5429 
PA5436 
 
PA5445 
PA5470 
PA5481 
PA5482 
PA5500 
PA5503 
PA5504 
PA5531 
PA5532 
PA5534 
PA5535 
PA5536 
PA5538 
PA5539 
PA5540 
PA5541 
PA5546 
Pae_flgK 
M57501cd 
tRNA-Cys 
tRNA-Pro 
tRNA-Val 
tRNA-Ser 
tRNA-Pro 
tRNA-Asn 
tRNA-Arg 
 
tRNA-Leu 
 
tRNA-Thr 
tRNA-Tyr 
tRNA-Met 
tRNA-Met 
tRNA-Phe 
 
pstC 
 
pstS 
 
betA 
betB 
betI 
gbdR 
 
gbcA 
glyA1 
 
aspA 
 
 
 
 
 
 
znuC 
 
 
tonB 
 
 
 
 
amiA 
 
 
pyrQ 
 
 
flaA 
 
 
 
 
 
 
 
 
 
 
 
 
 
transporter 
membrane protein component of ABC phosphate 
transporter 
phosphate ABC transporter, periplasmic 
phosphate-binding protein, PstS 
choline dehydrogenase 
betaine aldehyde dehydrogenase 
transcriptional regulator BetI 
GbdR 
hypothetical protein 
GbcA 
serine hydroxymethyltransferase 
conserved hypothetical protein 
aspartate ammonia-lyase 
probable biotin carboxylase subunit of a 
transcarboxylase 
probable coenzyme A transferase 
probable peptide chain release factor 
hypothetical protein 
hypothetical protein 
zinc transport protein ZnuC 
probable ATP-binding component of ABC trans. 
D-methionine ABC transporter membrane protein 
TonB protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
N-acetylmuramoyl-L-alanine amidase 
hypothetical protein 
hypothetical protein 
dihydroorotase 
conserved hypothetical protein 
 
Pseudomonas aeruginosa flagellin (flaA) gene 
PA2581.1 
PA2736.1/PA3031.1/ PA4541.2 
PA2775.1/PA3094.3/PA3262.2 
PA2852.1/PA0905.1/ PA1013.1/PA2603.1 
PA3031.1 
PA3139.1/PA4541.3 
PA3368.1/PA4581.1/PA0905.2/PA0905.3/ 
PA1796.1/ PA0263.1 
PA3824.1 /PA4937.1/ PA4937.2/ PA1796.3/ 
PA2570.1/ PA4746.2 
PA4277.1/PA4524.1/ PA5160.1  
PA4277.3 
PA4673.1 
PA4746.1/PA4673.1/ PA0574.1/PA0922.1 
PA5149.1 
 
MP ; TSM 
 
TSM 
 
ABM ; AP 
ABM ; AP 
TR 
TR 
HUU 
ABM 
ABM 
MP 
ABM 
CIM 
 
PE 
TPD 
HUU 
MP 
TSM 
TSM 
MP ; TSM 
TSM 
HUU 
HUU 
HUU 
HUU 
CLC 
HUU 
HUU 
NM 
PE 
MA 
MA 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
 
NR 
 
NR 
NR 
NR 
NR 
NR 
 
 
 
 
 
-6,8 
-10,3 
-9,5 
4,9 
8,1 
8,3 
 
 
 
3,9 
 
9,9 
-5,0 
10,9 
11,4 
-6,5 
 
 
-5,5 
-19,8 
-14,4 
-54,6 
-46,7 
-18,2 
-24,3 
-51,5 
-47,2 
 
 
13,6 
24,7 
6,1 
4,2 
212,9 
 
 
 
 
23,2 
 
 
 
 
 
7,3 
 
7,4 
 
16,5 
 
-12,4 
-25,4 
-33,0 
 
 
 
4,8 
4,9 
4,9 
 
 
-5,1 
-4,9 
 
8,3 
 
-5,0 
-5,8 
 
-5,6 
-5,2 
 
 
 
 
-5,1 
-5,5 
4,8 
-6,2 
5,7 
327,9 
27,9 
 
416,9 
 
5,3 
7,8 
 
59,4 
 
46,5 
5,1 
 
27,9 
53,6 
 
7,4 
 
22,3 
 
 
 
 
 
 
 
4,3 
 
13,3 
 
 
 
 
 
 
 
 
 
6,2 
 
 
16,6 
13,8 
8,7 
5,5 
10,2 
8,6 
 
 
 
13,3 
 
 
 
4,6 
 
 
 
 
 
12,3 
4,2 
25,5 
 
7,4 
 
a Gene ID, gene name, function and PCFC are according to the “Pseudomonas Genome Database” 
(Winsor et al., 2011). 
b Abbreviations used for PseudoCAP Function Class (PCFC) are as following Adaptation, 
Protection (AP); Amino acid biosynthesis and metabolism (ABM); Antibiotic resistance and 
susceptibility (ARS); Biosynthesis of cofactors, prosthetic groups and carriers (BC);Carbon 
compound catabolism (CC); Cell wall, LPS, capsule (CLC); Central intermediary metabolism(CIM); 
Chaperones & heat shock proteins (CHP); Chemotaxis (C); DNA replication, recombination, 
modification and repair (DRR); Energy metabolism (EM); Fatty acid and phospholipid metabolism 
(FPM); Hypothetical, unclassified, unknown (HUU); Membrane proteins (MP); Motility & Attachment 
(MA); Non-coding RNA gene (NR); Nucleotide biosynthesis and metabolism (NM); Protein 
secretion/export apparatus (PSE); Putative enzymes (PE); Related to phage, transposon, or 
plasmid (RPT); Secreted Factors (toxins, enzymes, alginate) (SF); Transcriptional regulators (TR); 
Transcription, RNA processing and degradation (TRD); Translation, post-translational modification, 
degradation (TPD); Transport of small molecules (TSM); Two-component regulatory systems (TCR) 
and Unclassified genome space (UGS). 
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+ Other abbreviations used are protein synthase (p.s.), outer membrane (o.m.), precursor (prc.), 
secretion (secr.), transporter (trans.) 
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7.4 Appendix B 
 
Table 31: Summary of phenotypic characterisation of methionine auxotrophic clinical 
P. aeruginosa CF isolates 
Patient Colonizing 
strain 
CloneA Clone 
typeA 
Mutator 
pheno-
typeB* 
BHLC* 
[#M] / 
OD578n
m
 
odDHLD* 
[nM] / 
OD578nm 
Swimming
E * [mm] 
SwarmingF
* [mm] 
TwitchingG
* [mm] 
Patient 1 KI-AW 1 P 2C2A 1,09E-07 ± 
8,80E-08 
28,9 ± 
2,5 
26,0 ± 
2,0 
5,3 ± 0,6 6,0 ± 1,0 3,0 ± 1,0 
Patient 4 KI-AW 10 I F429 4,64E-07 ± 
5,58E-07 
18,3 ± 
5,9 
77,9 ± 
3,5 
14,7 ± 0,6 4,5 ± 0,5 2,2 ± 0,8 
Patient 7 KI-AW 16  3BAA 7,15E-07 ± 
4,26E-07 
15,3 ± 
7,1 
1,7 ± 0,9 3,3 ± 0,6 1,8 ± 0,3 8,7 ± 0,6 
Patient 8 KI-AW 23  441A 7,23E-07 ± 
2,44E-07 
23,2 ± 
12,1 
2,2 ± 0,3 4,7 ± 1,5 5,3 ± 2,1 5,3 ± 0,6 
Patient 9 KI-AW 20 M 6E12 2,80E-08 ± 
3,00E-08 
38,2 ± 
4,1 
70,8 ± 
4,4 
2,2 ± 0,3 3,0 ± 1,0 3,3 ± 0,6 
Patient 11 KI-AW 22  2D92 4,33E-08 ± 
3,65E-08 
18,0 ± 
6,4 
3,2 ± 0,2 21,0 ± 6,6 10,7 ± 0,6 8,3 ± 3,8 
Patient 13 KI-AW 25  6862 2,36E-08 ± 
1,76E-08 
48,3 ± 
13,1 
3,2 ± 1,6 1,7 ± 0,6 2,3 ± 0,6 3,3 ± 0,6 
Patient A CFCZ  E59A 3,16E-08 ± 
4,04E-08 
21,2 ± 
10,1 
2,2 ± 0,6 5,0 ± 1,0 2,7 ± 0,6 3,0 ± 1,0 
Patient 3 
 
KI-AW 4 P 6C2A 8,76E-08 ± 
1,25E-07 
13,1 ± 
10,0 
0,9 ± 0,4 7,0 ± 0,1 5,3 ± 0,6 3,0 ± 1,0 
KI-AW 5 P 6C2A 2,97E-08 ± 
2,67E-08 
13,1 ± 
7,4 
4,5 ± 3,5 13,7 ± 0,6 6,0 ± 1,0 3,2 ± 0,8 
KI-AW 7 P 6C2A 1,54E-08 ± 
1,05E-08 
27,9 ± 
13,8 
6,0 ± 2,5 12,0 ± 1,0 3,3 ± 0,6 2,8 ± 1,3 
KI-AW 8 P 6C2A 1,67E-08 ± 
1,08E-08 
26,2 ± 
16,8 
0,3 ± 0,4 13,7 ± 0,6 7,3 ± 1,5 3,3 ± 0,6 
KI-AW 9 P 6C2A 1,45E-07 ± 
2,08E-07 
7,1 ± 
2,0 
1,1 ± 1,0 11,0 ± 2,0 8,3 ± 1,5 3,3 ± 0,6 
KI-AW 21 P 6C2A 2,33E-08 ± 
2,88E-08 
28,0 ± 
20,1 
7,2 ± 4,4 12,7 ± 1,5 5,3 ± 0,6 3,7 ± 0,6 
KI-AW 6 P 6C2A 8,20E-06 ± 
9,05E-06 
20,9 ± 
9,2 
46,6 ± 
1,9 
3,0 ± 1,0 1,8 ± 0,3 3,2 ± 0,8 
Patient 2 
 
KI-AW 2 B E429 1,31E-06 
±1,00E-06 
5,7 ± 
5,0 
3,3 ± 3,9 4,3 ± 0,6 1,5 ± 0,5 8,3 ± 1,5 
KI-AW 3 B E429 1,57E-06 
±1,77E-06 
16,7 ± 
6,3 
4,4 ± 4,2 3,7 ± 0,6 0,5 ± 0,1 6,7 ± 1,5 
Patient 4 KI-AW 11 I F429 2,77E-06 
±4,53E-06 
32,3 ± 
3,2 
7,0 ± 2,3 13,0 ± 1,0 8,3 ± 0,6 1,7 ± 0,3 
Patient 5 KI-AW 12 I F429 1,92E-06 
±1,64E-06 
11,2 ± 
5,7 
1,9 ± 1,3 1,5 ± 0,5 3,3 ± 0,6 3,8 ± 0,3 
Patient 6 KI-AW 14 E 1BAE 2,67E-06 
±8,04E-07 
6,8 ± 
3,1 
3,7 ± 1,9 3,7 ± 0,6 6,3 ± 1,5 5,7 ± 1,2 
 KI-AW 15 E 1BAE 8,08E-06 
±1,13E-05 
10,3 ± 
6,7 
2,4 ± 2,0 3,3 ± 0,6 8,0 ± 2,0 4,7 ± 0,6 
 KI-AW 26 E 1BAE 5,09E-06 ± 
2,03E-06 
18,0 ± 
11,1 
2,3 ± 0,4 2,3 ± 1,2 4,3 ± 0,6 5,3 ± 0,6 
 KI-AW 27 E 1BAE 1,52E-06 ± 
4,87E-07 
12,9 ± 
8,6 
2,4 ± 0,5 4,0 ± 1,0 5,0 ± 1,0 4,7 ± 0,6 
Patient 8 
 
KI-AW 17  441A 1,67E-05 
±1,23E-05 
6,4 ± 
3,2 
2,5 ± 1,8 3,7 ± 1,5 5,3 ± 2,5 5,7 ± 0,6 
KI-AW 18  441A 3,71E-06 
±4,31E-06 
18,4 ± 
5,9 
1,9 ± 0,9 4,0 ± 1,0 4,0 ± 1,0 4,3 ± 0,6 
KI-AW 19  441A 1,83E-05 
±2,86E-05 
11,6 ± 
9,9 
0,3 ± 0,3 2,7 ± 0,6 1,8 ± 0,3 4,3 ± 0,6 
 KI-AW 24  441A 1,77E-06 
±1,46E-06 
20,0 ± 
7,1 
2,1 ± 0,2 1,7 ± 0,6 3,3 ± 0,6 4,3 ± 0,6 
Patient 12 KI-AW 28  2F82 2,61E-06 
±4,06E-06 
32,9 ± 
4,1 
2,2 ± 0,2 1,8 ± 1,3 2,3 ± 0,6 3,7 ± 0,6 
 PAO1 
+mutS 
  4,94E-006 
±2,76E-06 
ND ND ND ND ND 
 PAO1 
+metF 
  7,16E-08 ± 
1,03E-07 
45,1 ± 
9,9 
188,9 ± 
26,9 
24,7 ± 0,6 19,7 ± 6,0 6,3 ± 1,5 
 PAO1   1,54E-08 ± 
2,05E-09 
48,3 ± 
16,4 
147,3 ± 
3,9 
25,3 ± 1,5 19,7 ± 4,5 8,0 ± 1,0 
A Clone and clone type according to single-nucleotide polymorphisms (SNPs) at seven conserved 
loci and two multiallelic loci (Wiehlmann et al., 2007) 
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B Mutator phenotype was determined as CFU of rifampicin 100 #g/ml (RA-100) resistant bacteria 
vs. CFU. Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (bold 
black). Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak 
mutators (bold grey). Strains with mutator frequency of < 1.5 x 10-8 were classified as non-mutator. 
Experiments were performed by Matthias Rottmann (Rottmann, 2011) 
C BHL [#M] / OD578 was determined. Results above the average > 20 ± 8 are marked in bold letters. 
D odDHL [nM] / OD578 was determined. Results above the average > 10 ± 3 are marked in bold 
letters. 
E Swimming as the radius [mm] of the respective swimming halo was determined. Results above 
the average radius of > 6.5 ± 1 mm are marked in bold letters. 
F Swarming as the radius [mm] of the respective swarming halo was determined. Results above the 
average radius of > 4.5 ± 1 mm are marked in bold letters. 
G Twitching as the radius [mm] of the respective twitching halo was determined. Results above the 
average radius of > 4.5 ± 1 mm are marked in bold letters. 
* Results of at least three independent experiments are shown. The standard deviation of the mean 
is shown. 
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Table 32: Mutations in metF (PA0430) nucleotide sequence (detailed single base exchange) 
Patient Colonizing 
strainC 
Mutations unique 
for isolate 
481222A 
(P 25) 
481225 A  
(P 26) 
481229 A 
(P 33) 
481241 A 
(P 45) 
481312 A 
(P116) 
481386 A 
(P 190) 
Patient 1 KI-AW 1 481734 C>T 
482015 T>C 
     T>C 
Patient 2 KI-AW 2    T I* G>A  T>C 
 KI-AW 3 481987 no seq.*   T I* G>A  T>C 
Patient 3 KI-AW 4 481201 T>G 
481203 I* (34 bp) 
481205 G >A 
481206 G>A 
481196 T>A 
A >C T>C    T>C 
 KI-AW 5       T>C 
 KI-AW 6  A >C     T>C 
 KI-AW 7   T>C    T>C 
 KI-AW 8  A >C     T>C 
 KI-AW 9       T>C 
 KI-AW 21       T>C 
Patient 4 KI-AW 10 482010 T>C       
 KI-AW 11 482010 T>C       
Patient 5 KI-AW 12 481432 C >D*       
Patient 6 KI-AW 14        
 KI-AW 15  A >C T>C     
 KI-AW 26        
 KI-AW 27        
Patient 7 KI-AW 16 481356 G>A       
Patient 8 KI-AW 17      C> D*  
 KI-AW 18      C> D*  
 KI-AW 19 481225 G>T A >C T>C   C> D*  
 KI-AW 23      C> D*  
 KI-AW 24      C> D*  
Patient 9 KI-AW 20 481269 G>A 
481623 A I* 
      
Patient 
10 
KI-AW 22 481608 – 481617 
D* 
      
Patient 
11 
KI-AW 25 481436 T>C       
Patient 
12 
KI-AW 28 481659 C I* 
481667 C>T 
      
Patient A CFCZ        
Patient C 65 481525 G>A       
Patient D BT72 481807 T>A       
A Genomic position in P. aeruginosa PAO1 genome, and base position Pxxx in the metF gene (873 
bp) 
C Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (bold black). 
Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak mutators (bold 
grey). Strains with mutator frequency of < 1.5 x 10-8 were classified as non-mutator. 
I* insertion 
D* deletion 
no seq.* no sequence afterwards  
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Table 32: Continued mutations in metF (PA0430) nucleotide sequence (detailed single base 
exchange) 
Patient Colonizing 
strainC 
481416 A 
(P 220) 
481431 A 
(P 235) 
481454 A 
(P 258) 
481491 A 
(P 295) 
481500 A 
(P 304) 
481550 A 
– 
481562 
(P 354 - 
366) 
481648 A 
(P 452) 
482051 A 
(P 855) 
Patient 1 KI-AW 1  G>C     G>A  
Patient 2 KI-AW 2     C>T  G>A  
 KI-AW 3     C>T  G>A  
Patient 3 KI-AW 4    C>A C>T D* G>A  
 KI-AW 5    C>A C>T D* G>A  
 KI-AW 6    C>A C>T D* G>A  
 KI-AW 7    C>A C>T D* G>A  
 KI-AW 8    C>A C>T D* G>A  
 KI-AW 9    C>A C>T D* G>A  
 KI-AW 21    C>A C>T D* G>A  
Patient 4 KI-AW 10  G>C     G>A  
 KI-AW 11 G>A G>C     G>A  
Patient 5 KI-AW 12 G>A G>C     G>A  
Patient 6 KI-AW 14 G>A G>C C>A      
 KI-AW 15  G>C C>A      
 KI-AW 26  G>C C>A      
 KI-AW 27  G>C C>A      
Patient 7 KI-AW 16  G>C      A I* 
Patient 8 KI-AW 17        A I* 
 KI-AW 18         
 KI-AW 19         
 KI-AW 23         
 KI-AW 24         
Patient 9 KI-AW 20         
Patient 
10 
KI-AW 22         
Patient 
11 
KI-AW 25         
Patient 
12 
KI-AW 28         
Patient A CFCZ  G>C     G>A  
Patient C 65 G>A G>C     G>A  
Patient D BT72 G>A G>C     G>A  
A Genomic position in P. aeruginosa PAO1 genome, and base position Pxxx in the metF gene (873 
bp) 
C Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (bold black). 
Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak mutators (bold 
grey). Strains with mutator frequency of < 1.5 x 10-8 were classified as non-mutator. 
I* insertion 
D* deletion 
no seq.* no sequence afterwards  
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Table 33: Amino acid exchanges in MetF (PA0430) protein sequence resulting from nucleotide 
sequence (detailed amino acid  exchange) 
Patient Colonizing 
strainC 
Length of 
amino acid 
seq. [aa] 
Amino acid 
exchanges for 
each strain 
(unique to db* 
event) * 
Amino 
acid  
 
M9 
Amino acid  
 
 
G 28 
Amino 
acid 
 
L 62 
Amino 
acid 
 
S 86 
Patient 1 KI-AW 1 178 Q 179 SC*     
Patient 2 KI-AW 2 159 Q 11 H; FS* 
D 160 SC* 
    
 KI-AW 3 29 Q 11 H; FS* 
E 30 SC* 
    
Patient 3 KI-AW 4 40 V 2 G; FS* 
G 41 SC* 
    
 KI-AW 5 163      
 KI-AW 6 163  M 9 L    
 KI-AW 7 163  M 9 T    
 KI-AW 8 163  M 9 L    
 KI-AW 9 163      
 KI-AW 21 163      
Patient 4 KI-AW 10 290 Y 271 H     
 KI-AW 11 290 Y 271 H     
Patient 5 KI-AW 12 168 H 79 T;FS* 
S 81 P 
V 169 SC* 
    
Patient 6 KI-AW 14 85     S 86 SC* 
 KI-AW 15 85  M 9 P   S 86 SC* 
 KI-AW 26 85     S 86 SC* 
 KI-AW 27 85     S 86 SC* 
Patient 7 KI-AW 16 284 G 54 S 
N 285 SC* 
    
Patient 8 KI-AW 17 61   G 28 A; FS* L 62 SC*  
 KI-AW 18 61   G 28 A; FS* L 62 SC*  
 KI-AW 19 61 S 10 I M 9 P G 28 A; FS* L 62 SC*  
 KI-AW 23 61   G 28 A; FS* L 62 SC*  
 KI-AW 24 61   G 28 A; FS* L 62 SC*  
Patient 9 KI-AW 20 160 H 142 Q 
D 161 SC* 
    
Patient 
10 
KI-AW 22 164 G138 S; FS* 
V 165 SC* 
    
Patient 
11 
KI-AW 25 290 L 80 P     
Patient 
12 
KI-AW 28 156 Q 154 P 
A 155 G 
R 156 A 
S 157 SC* 
    
Patient A CFCZ 290      
Patient C 65 290 G 110 S     
Patient D BT72 290 V 203 E     
FS* frame shift after the indicated amino acid exchange 
SC* stop codon. Insertion of stop codon instead of amino acid is marked in bold letters. 
db* duplicate 
* Amino acid exchanges are unique and or in maximale in second strain occurring for clarity 
reasons not listed as as a single event in the table.  
C Strains with a mutator frequency ' 1.5 x 10-7 were classified as strong mutators (bold black). 
Strains with a mutator frequency < 1.5 x 10-7 to ' 1.5 x 10-8 were classified as weak mutators (bold 
grey). Strains with mutator frequency of < 1.5 x 10-8 were classified as non-mutator. 
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Table 33: Continued amino acid exchanges in MetF (PA0430) protein sequence resulting from 
nucleotide sequence (detailed amino acid exchange) 
Patient Colonizing 
strainC 
Length of 
amino acid 
seq. [aa] 
Amino acid  
 
 
M 118 
Amino acid  
 
 
F 164 
Patient 1 KI-AW 1 178   
Patient 2 KI-AW 2 159   
 KI-AW 3 29   
Patient 3 KI-AW 4 40   
 KI-AW 5 163 M 118 N; FS* F 164 SC* 
 KI-AW 6 163 M 118 N; FS* F 164 SC* 
 KI-AW 7 163 M 118 N; FS* F 164 SC* 
 KI-AW 8 163 M 118 N; FS* F 164 SC* 
 KI-AW 9 163 M 118 N; FS* F 164 SC* 
 KI-AW 21 163 M 118 N; FS* F 164 SC* 
Patient 4 KI-AW 10 290   
 KI-AW 11 290   
Patient 5 KI-AW 12 168   
Patient 6 KI-AW 14 85   
 KI-AW 15 85   
 KI-AW 26 85   
 KI-AW 27 85   
Patient 7 KI-AW 16 284   
Patient 8 KI-AW 17 61   
 KI-AW 18 61   
 KI-AW 19 61   
 KI-AW 23 61   
 KI-AW 24 61   
Patient 9 KI-AW 20 160   
Patient 
10 
KI-AW 22 164   
Patient 
11 
KI-AW 25 290   
Patient 
12 
KI-AW 28 156   
Patient A CFCZ 290   
Patient C 65 290   
Patient D BT72 290   
FS* frame shift after the indicated amino acid exchange 
SC* stop codon. Insertion of stop codon instead of amino acid is marked in bold letters. 
db* duplicate 
* Amino acid exchanges are unique and or in maximal occurring in a second strain, for clarity 
reasons these exchanges are not listed as a single event in the table.  
C Mutator phenotype in colonizing strains is shown in bold letters. 
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Table 34: Microarray analysis of regulated genes in PAO1 !metF compared to PAO1 in M9 0.5 % 
caseinate after growth for 4 h and 12 h  
Differentially regulated genes of P. aeruginosa PAO1 compared to PAO1 "metF after 4 h and after 
12 h in M9 0.5 % caseinate under microaerobic to anaerobic conditions. Shown are the gene ID, 
gene name, function and the fold change (FC) of genes differently regulated of PAO1 wt 4 h vs. 
PAO1 "metF 4 h (W4 / M4), PAO1 wt 12 h vs. PAO1 "metF wt 12 h (W12 / M12), PAO1 "metF 
12 h vs PAO1 "metF 4 h (M12 / M4) and PAO1 wt 12 h vs PAO1 wt 4 h (W12 / W4).  
Gene IDa Gene 
namea 
Functiona PCFCa,b  
W4/ 
M4 
FC 
W12/ 
M12 
 
M12/ 
M4 
 
W12/ 
W4 
1427453 
-1428080 
1996806 
-1997509 
2568929 
-2568284 
2722174 
-2721530 
3527428 
-3526677 
3649704 
-3648915 
4713098 
-4713795 
517462 - 
518083 
545644 - 
546334 
5563286 
-5563964 
629884 - 
630527 
721556 - 
727608 
991198 – 
991830 
PA0001 
PA0002 
PA0009 
PA0020 
PA0026 
PA0036 
PA0038 
PA0040 
PA0048 
PA0048 
PA0049 
PA0050 
PA0052 
PA0055 
PA0059 
PA0070 
PA0075 
PA0084 
PA0085 
PA0094 
PA0105 
PA0106 
PA0107 
PA0108 
PA0110 
PA0111 
PA0112 
PA0113 
PA0114 
PA0115 
PA0118 
PA0122 
PA0132 
PA0139 
PA0141 
PA0161 
PA0167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dnaA 
dnaN 
glyQ 
 
plcB 
trpB 
 
 
 
 
 
 
 
 
osmC 
 
pppA 
 
hcp1 
 
coxB 
coxA 
 
coIII 
 
 
 
 
senC 
 
 
 
 
ahpC 
 
 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
Unknown function 
 
chromosomal replication initiator protein DnaA 
DNA polymerase III, beta chain 
glycyl-tRNA synthetase alpha chain 
hypothetical protein 
phospholipase C,  PlcB 
tryptophan synthase beta chain 
hypothetical protein 
conserved hypothetical protein 
probable transcriptional regulator 
probable transcriptional regulator 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
osmotically inducible protein OsmC 
hypothetical protein 
PppA 
conserved hypothetical protein 
Hcp1 
hypothetical protein 
cytochrome c oxidase, subunit II 
cytochrome c oxidase, subunit I 
conserved hypothetical protein 
cytochrome c oxidase, subunit III 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable cytochrome c oxidase assembly fc.* 
SenC 
conserved hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
beta-alanine--pyruvate transaminase 
alkyl hydroperoxide reductase subunit C 
conserved hypothetical protein 
hypothetical protein 
probable transcriptional regulator 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
UGS 
 
DRR 
DRR 
ABM 
HUU 
SF 
ABM 
HUU 
HUU 
TR 
TR 
HUU 
HUU 
HUU 
HUU 
Ap 
MP 
PE ; PSE 
HUU 
SF 
HUU 
EM 
EM 
EM 
EM 
HUU 
HUU 
MP 
EM 
HUU 
HUU 
PE 
HUU 
ABM 
Ap 
HUU 
HUU 
TR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,4 
 
-2,0 
 
 
 
 
 
 
 
 
-2,3 
2,4 
 
2,5 
 
2,5 
 
2,3 
 
 
 
 
 
2,5 
3,3 
3,6 
3,1 
2,4 
2,9 
3,0 
3,5 
3,2 
-2,0 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
-2,1 
 
-2,2 
 
 
 
 
 
-2,3 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3,7 
 
2,4 
 
 
 
 
 
 
 
3,5 
3,7 
3,5 
2,2 
3,2 
2,4 
2,7 
 
 
 
 
 
 
-2,6 
 
 
3,7 
 
 
 
2,5 
 
4,4 
 
2,1 
 
3,0 
 
15,1 
 
 
 
2,3 
 
-2,0 
 
2,2 
 
 
 
 
 
-2,3 
-2,4 
-2,1 
-2,8 
 
-2,1 
 
 
 
-4,0 
-4,2 
 
 
-5,1 
 
-4,0 
-2,3 
-2,2 
-2,7 
-2,6 
-3,4 
-7,2 
-8,6 
-6,4 
-3,2 
-5,9 
-4,7 
-5,2 
-3,5 
 
-3,8 
9,3 
 
-2,7 
3,9 
5,1 
-2,5 
2,7 
 
-2,6 
 
 
 
 
 
 
 
 
 
11,5 
 
-2,0 
 
 
 
-2,3 
 
 
 
2,2 
 
 
 
 
 
 
 
-2,0 
 
-2,4 
 
 
-11,0 
-12,8 
 
-4,8 
-3,2 
-2,4 
-2,2 
 
 
 
 
-4,9 
-6,9 
-8,3 
-5,7 
-3,4 
-5,3 
-6,1 
-6,7 
-6,7 
 
-3,7 
5,5 
-3,2 
-2,1 
 
3,3 
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PA0169 
PA0170 
PA0171 
PA0172 
PA0173 
PA0174 
PA0175 
PA0176 
PA0177 
PA0178 
PA0179 
PA0180 
PA0200 
PA0201 
PA0208 
PA0209 
PA0210 
PA0211 
PA0212 
PA0213 
PA0214 
PA0215 
PA0216 
PA0250 
PA0256 
PA0263 
PA0265 
PA0266 
PA0274 
PA0276 
PA0284 
PA0296 
PA0297 
PA0298 
PA0299 
PA0300 
PA0301 
PA0302 
PA0303 
PA0311 
PA0314 
PA0315 
PA0316 
PA0323 
PA0326 
PA0328 
PA0328 
PA0329 
PA0341 
PA0346 
PA0349 
PA0353 
PA0363 
PA0364 
PA0365 
PA0366 
PA0376 
PA0380 
PA0382 
PA0384 
PA0385 
PA0388 
PA0390 
PA0409 
PA0430 
PA0431 
PA0432 
PA0433 
PA0446 
PA0447 
PA0449 
PA0456 
PA0459 
PA0460 
PA0462 
PA0467 
PA0468 
PA0471 
 
 
 
 
 
 
 
aer2 
 
 
 
 
 
 
mdcA 
 
mdcC 
mdcD 
mdcE 
 
 
 
 
 
 
hcpC 
gabD 
gabT 
 
 
 
spuI 
spuA 
spuB 
spuC 
spuD 
spuE 
spuF 
spuG 
 
 
 
serA 
 
 
 
 
 
lgt 
 
 
ilvD 
coaD 
 
 
 
rpoH 
 
micA 
 
 
 
metX 
pilH 
metF 
 
sahH 
 
 
gcdH 
 
 
 
 
 
 
 
 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable methylesterase 
conserved hypothetical protein 
probable Cprotein methyltransferase 
aerotaxis transducer Aer2 
probable purine-binding Cprotein 
probable two-component sensor 
probable two-component response regulator 
probable Ctransducer 
hypothetical protein 
hypothetical protein 
malonate decarboxylase alpha subunit 
conserved hypothetical protein 
malonate decarboxylase delta subunit 
malonate decarboxylase beta subunit 
malonate decarboxylase gamma subunit 
hypothetical protein 
probable acyl transferase 
malonate transporter MadL 
malonate transporter MadM 
conserved hypothetical protein 
hypothetical protein 
secreted protein Hcp 
succinate-semialdehyde dehydrogenase 
4-aminobutyrate aminotransferase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable glutamine synthetase 
probable glutamine amidotransferase 
probable glutamine synthetase 
putrescine aminotransferase 
polyamine transport protein 
polyamine transport protein 
polyamine transport protein PotG 
polyamine transport protein PotH 
hypothetical protein 
L-cysteine transporter of ABC system FliY 
hypothetical protein 
D-3-phosphoglycerate dehydrogenase 
probable binding protein com.* of ABC tr.* 
probable ATP-binding com.* of ABC tr.* 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
prolipoprotein diacylglyceryl transferase 
hypothetical protein 
hypothetical protein 
dihydroxy-acid dehydratase 
phosphopantetheine adenylyltransferase 
probable oxidoreductase 
hypothetical protein 
probable aldehyde dehydrogenase 
sigma factor RpoH 
conserved hypothetical protein 
DNA mismatch repair protein MicA 
hypothetical protein 
hypothetical protein 
hypothetical protein 
homoserine O-acetyltransferase 
twitching motility protein PilH 
5,10-methylenetetrahydrofolate reductase 
hypothetical protein 
S-adenosyl-L-homocysteine hydrolase 
hypothetical protein 
conserved hypothetical protein 
glutaryl-CoA dehydrogenase 
hypothetical protein 
probable cold-shock protein 
probable ClpA/B protease ATP binding sub.* 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable transmembrane sensor 
HUU 
HUU 
MA 
HUU 
Ap ;C 
HUU 
TR ; Ap  
Ap ;C 
Ap ;C 
C; Ap  
C; Ap 
Ap ;C 
HUU 
HUU 
CC 
PE 
CC 
CC 
CC 
CC 
CC 
MP 
MP  
HUU 
HUU 
SF 
CIM ; CC 
CIM ; CC 
HUU 
MP 
HUU 
PE 
ABM 
PE 
PE 
TSM 
TSM 
TSM 
MP; TSM 
HUU 
TSM 
HUU 
ABM 
TSM 
TSM 
HUU 
HUU 
HUU 
TPD 
HUU 
MP 
BC; ABM 
CIM 
PE 
MP 
PE 
TR 
HUU 
DRR 
HUU 
HUU 
HUU 
ABM 
TCR ; C 
ABM  
HUU 
ABM 
HUU 
HUU 
FPM; CC 
HUU 
TR ; Ap 
TPD 
HUU 
HUU 
HUU 
HUU 
TCR; TR 
 
 
 
-2,0 
2,7 
2,9 
3,3 
2,6 
2,1 
2,1 
2,7 
2,4 
 
 
 
 
 
 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
2,4 
2,0 
 
 
 
2,4 
 
-15,5 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
-2,2 
2,1 
 
 
 
 
2,5 
-2,7 
-5,5 
-2,1 
2,1 
 
 
 
 
2,3 
2,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3,3 
 
2,5 
 
2,3 
 
 
 
2,1 
 
2,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,5 
-4,2 
 
 
 
 
 
 
 
 
 
2,6 
 
 
 
 
2,1 
 
 
2,3 
 
 
 
7,2 
 
 
 
 
 
 
 
-2,5 
-2,2 
 
 
 
 
-2,0 
-2,9 
-2,5 
 
 
 
 
 
 
 
 
 
16,9 
2,1 
 
2,2 
 
 
2,4 
4,1 
2,4 
2,4 
2,2 
 
 
 
 
 
 
2,3 
 
-3,3 
-2,9 
-4,3 
-2,6 
-4,0 
-2,2 
-2,1 
-2,1 
-3,1 
-2,1 
-3,2 
-2,2 
 
 
-2,5 
 
 
-2,1 
2,6 
-2,2 
-2,1 
-3,1 
-2,2 
-2,0 
 
 
-2,2 
 
-2,0 
-2,6 
-2,1 
-2,7 
-2,3 
 
 
 
 
-2,4 
-2,9 
-2,9 
 
2,1 
 
 
 
 
2,1 
 
 
 
 
-3,6 
-3,3 
-4,1 
-3,7 
-2,9 
-2,9 
-3,8 
-3,6 
3,3 
 
2,6 
2,8 
3,7 
2,2 
3,5 
5,6 
4,5 
3,1 
3,1 
-2,4 
-2,4 
-2,6 
-2,2 
-2,3 
-3,0 
 
2,1 
-3,8 
-3,9 
-5,4 
-4,0 
-5,4 
-3,5 
-3,2 
-2,9 
-2,6 
-4,5 
-2,0 
 
-2,8 
-2,3 
 
-2,6 
-5,3 
 
 
-2,5 
 
 
-3,1 
-2,9 
-2,8 
2,2 
 
2,2 
-3,2 
 
 
 
 
3,2 
 
2,6 
 
-4,8 
-3,6 
-3,1 
2,0 
 
-2,7 
-4,3 
-2,2 
-2,1 
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PA0472 
PA0473 
PA0478 
PA0479 
PA0483 
PA0484 
PA0485 
PA0492 
PA0496 
PA0500 
PA0506 
PA0507 
PA0508 
PA0509 
PA0510 
PA0515 
PA0526 
PA0540 
PA0545 
PA0546 
PA0547 
PA0555 
PA0559 
PA0563 
PA0565 
PA0567 
PA0578 
PA0579 
PA0580 
PA0582 
PA0583 
PA0585 
PA0586 
PA0587 
PA0588 
PA0602 
PA0603 
PA0604 
PA0605 
PA0606 
PA0612 
PA0614 
PA0615 
PA0616 
PA0617 
PA0618 
PA0619 
PA0620 
PA0621 
PA0622 
PA0623 
PA0624 
PA0625 
PA0626 
PA0627 
PA0628 
PA0629 
PA0630 
PA0631 
PA0633 
PA0634 
PA0635 
PA0636 
PA0637 
PA0638 
PA0639 
PA0640 
PA0641 
PA0644 
PA0645 
PA0656 
PA0672 
PA0704 
PA0705 
PA0707 
PA0713 
PA0732 
PA0734 
 
 
 
 
 
 
 
 
 
bioB 
 
 
 
nirN 
 
 
 
 
 
metK 
 
fda 
 
 
 
 
 
rpsU 
gcp 
folB 
 
 
 
 
 
 
 
 
 
 
ptrB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hemO 
 
migA 
toxR 
 
 
 
probable sigma-70 factor, ECF subfamily 
probable glutathione S-transferase 
probable N-acetyltransferase 
probable transcriptional regulator 
probable acetyltransferase 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
biotin synthase 
probable acyl-CoA dehydrogenase 
probable acyl-CoA dehydrogenase 
probable acyl-CoA dehydrogenase 
probable c-type cytochrome 
probable uroporphyrin-III c-methyltransferase 
probable transcriptional regulator 
hypothetical protein 
hypothetical protein 
hypothetical protein 
methionine adenosyltransferase 
probable transcriptional regulator 
fructose-1,6-bisphosphate aldolase 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
30S ribosomal protein S21 
O-sialoglycoprotein endopeptidase 
dihydroneopterin aldolase 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
probable binding protein com.of ABC tr.* 
probable ATP-binding com.* of ABC tr.* 
probable binding protein com.*of ABC tr.* 
probable permease of ABC transporter 
probable permease of ABC tr.* 
repressor, PtrB 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable bacteriophage protein 
probable bacteriophage protein 
probable bacteriophage protein 
probable bacteriophage protein 
conserved hypothetical protein 
probable bacteriophage protein 
probable bacteriophage protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable bacteriophage protein 
conserved hypothetical protein 
probable bacteriophage protein 
probable bacteriophage protein 
hypothetical protein 
hypothetical protein 
probable HIT family protein 
heme oxygenase 
probable amidase 
alpha-1,6-rhamnosyltransferase MigA 
transcriptional regulator ToxR 
hypothetical protein 
hypothetical protein 
hypothetical protein 
TR 
PE 
PE 
TR 
PE 
HUU 
MP 
HUU 
HUU 
BC 
PE 
PE 
PE 
BC ; EM 
BC ; EM 
BC ; TR 
HUU 
HUU 
PE 
ABM 
TR 
CIM; CC 
HUU 
HUU 
HUU 
MP 
HUU 
TPD 
TPD 
BC 
BC 
HUU 
HUU 
HUU 
HUU 
TSM 
TSM 
TSM 
MP; TSM 
MP; TSM 
TR 
HUU 
HUU 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
RPT 
PE 
BC 
PE 
PE ; CLC 
TR 
HUU 
HUU 
HUU 
 
 
-2,1 
 
 
2,3 
 
 
 
 
 
 
-3,6 
 
 
 
 
 
 
-5,4 
-8,6 
 
 
 
 
 
 
-2,5 
 
-10,1 
-7,9 
3,6 
3,5 
3,3 
2,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,3 
 
 
 
 
 
2,0 
 
 
2,3 
 
 
 
 
 
 
 
 
 
 
 
-2,3 
-2,4 
-3,0 
-2,4 
 
 
-2,4 
-3,2 
 
 
 
 
 
3,3 
2,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
 
 
 
 
 
 
 
 
 
-6,2 
 
 
2,6 
-3,5 
 
 
 
 
-2,8 
 
 
2,2 
-3,2 
-4,2 
-4,9 
2,4 
2,4 
3,6 
4,4 
-3,0 
2,0 
 
 
-2,1 
 
-3,1 
-4,2 
 
-2,5 
-2,4 
 
-3,6 
-3,6 
 
-2,6 
 
-3,0 
-2,6 
-3,0 
-4,9 
 
-2,6 
3,8 
3,5 
3,4 
3,5 
4,3 
4,3 
4,1 
3,3 
2,3 
4,8 
4,1 
4,8 
3,0 
2,7 
3,9 
3,0 
2,3 
3,3 
3,2 
3,1 
4,4 
3,6 
4,9 
4,4 
4,5 
3,9 
2,2 
2,0 
2,2 
2,4 
 
2,7 
 
-2,2 
2,7 
3,4 
 
-2,2 
3,5 
 
 
-3,8 
-3,0 
-3,2 
-2,7 
-3,6 
-3,0 
 
-2,3 
-2,4 
 
 
 
 
2,4 
-3,2 
 
2,0 
4,1 
 
2,1 
 
-5,6 
-3,3 
2,4 
2,7 
2,0 
 
 
-4,4 
-11,5 
-7,3 
-10,8 
 
-2,3 
-4,2 
-2,2 
-2,3 
 
2,9 
2,5 
2,1 
2,4 
2,5 
2,1 
2,1 
 
2,4 
2,0 
 
2,0 
 
2,1 
2,2 
 
 
2,1 
 
2,1 
2,1 
3,2 
2,3 
2,9 
 
 
 
 
 
-4,7 
4,0 
-3,0 
 
3,0 
 
-2,8 
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PA0738 
PA0741 
PA0742 
PA0743 
PA0744 
PA0745 
PA0746 
PA0751 
PA0752 
PA0753 
PA0754 
PA0755 
PA0760 
PA0764 
PA0767 
PA0769 
PA0771 
PA0776 
PA0784 
PA0788 
PA0789 
PA0791 
PA0793 
PA0795 
PA0796 
 
PA0797 
PA0801 
PA0802 
PA0807 
PA0829 
PA0830 
PA0832 
PA0838 
PA0839 
PA0841 
PA0847 
PA0850 
PA0853 
PA0854 
PA0856 
PA0861 
PA0865 
PA0866 
PA0867 
PA0868 
PA0869 
PA0870 
PA0871 
PA0872 
PA0876 
PA0887 
PA0888 
PA0893 
PA0895 
PA0896 
PA0897 
PA0898 
PA0899 
PA0900 
PA0901 
PA0904 
PA0908 
PA0910 
PA0911 
PA0918 
PA0919 
PA0925 
PA0927 
PA0929 
PA0930 
PA0938 
PA0942 
PA0952 
PA0958 
 
PA0960 
PA0964 
 
 
 
 
 
 
 
 
 
 
 
opdH 
 
mucB 
lepA 
 
era 
 
 
 
 
 
 
prpC 
prpB 
 
 
 
 
ampD 
 
 
 
 
 
 
 
 
 
fumC 
 
 
hpd 
aroP2 
mliC 
 
pbpG 
phhC 
phhB 
phhA 
 
acsA 
aotJ 
argR 
aruC 
aruF 
aruG 
aruD 
aruB 
 
aruE 
lysC 
 
 
 
 
 
 
ldhA 
 
 
 
 
 
oprD 
 
 
pmpR 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable 3-hydroxyisobutyrate dehyd.* 
probable enoyl-CoA hydratase/isomerase 
probable enoyl-CoA hydratase/isomerase 
probable acyl-CoA dehydrogenase 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
cis-aconitate porin OpdH 
conserved hypothetical protein 
negative regulator for alginate biosynthesis  
GTP-binding protein LepA 
hypothetical protein 
GTP-binding protein Era 
hypothetical protein 
probable transcriptional regulator 
hypothetical protein 
probable amino acid permease 
probable transcriptional regulator 
hypothetical protein 
citrate synthase 2 
carboxyphosphonoenolpyruvate 
phosphonomutase 
probable transcriptional regulator 
hypothetical protein 
hypothetical protein 
AmpDh3 
probable hydrolase 
hypothetical protein 
conserved hypothetical protein 
probable glutathione peroxidase 
probable transcriptional regulator 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable oxidoreductase 
fumarate hydratase fumC2 
hypothetical protein 
hypothetical protein 
4-hydroxyphenylpyruvate dioxygenase 
aromatic amino acid transport protein AroP2 
m.-b.* lysozyme inhibitor of c-type lysozyme  
conserved hypothetical protein 
D-alanyl-D-alanine-endopeptidase 
aromatic amino acid aminotransferase 
pterin-4-alpha-carbinolamine dehydratase 
phenylalanine-4-hydroxylase 
probable transcriptional regulator 
acetyl-coenzyme A synthetase 
arginine/ornithine binding protein AotJ 
transcriptional regulator ArgR 
N-succinylglutamate 5-semialdehyde dehyd.* 
arginine/ornithine succinyltransferase AI sb.* 
arginine/ornithine succinyltransferase AII sb.* 
succinylglutamate 5-semialdehyde dehyd.* 
succinylarginine dihydrolase 
hypothetical protein 
succinylglutamate desuccinylase 
aspartate kinase alpha and beta chain 
hypothetical protein 
hypothetical protein 
hypothetical protein 
cytochrome b561 
hypothetical protein 
hypothetical protein 
D-lactate dehydrogenase (fermentative) 
two-component response regulator 
two-component sensor 
hypothetical protein 
probable transcriptional regulator 
hypothetical protein 
Basic amino acid, basic peptide and imipenem 
o.m.* porin OprD precursor 
hypothetical protein 
pqsR-mediated PQS regulator, PmpR 
MP 
HUU 
HUU 
CC 
PE 
PE 
PE 
MP 
MP 
MP 
HUU 
MP; TSM 
HUU 
TR ; CLC  
TPD  
HUU 
CD ; TPD 
HUU 
TR 
HUU 
MP; TSM 
TR 
HUU 
CIM ; CC 
FPM ;CC 
 
TR 
MP 
MP 
ARS 
PE 
HUU 
HUU 
PE 
TR 
HUU 
MA 
HUU 
PE 
EM ; CC 
HUU 
MA 
ABM 
TSM 
 Ap 
HUU 
CLC 
ABM 
ABM 
ABM 
TR 
CC ; CIM 
TSM 
ABM; TR 
ABM 
ABM 
ABM 
ABM 
ABM 
HUU 
ABM 
ABM 
HUU 
HUU 
HUU 
EM 
HUU 
HUU 
EM ; CC 
TSM  
TSM  
HUU 
TR 
HUU 
TSM 
 
HUU 
HUU 
 
 
2,2 
2,3 
 
2,0 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
3,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,2 
 
 
 
 
 
 
 
 
 
 
2,1 
2,0 
2,1 
 
 
 
 
 
 
2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
2,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,2 
 
2,6 
9,0 
3,0 
 
 
 
 
 
 
-5,4 
 
 
 
 
-2,1 
-2,0 
-2,2 
 
-2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,7 
 
 
 
 
 
 
-2,0 
-2,5 
-2,2 
-4,7 
-2,0 
 
 
-2,1 
 
-2,3 
 
 
 
 
 
2,1 
 
2,6 
 
2,3 
 
 
2,0 
-2,0 
-2,0 
-2,4 
 
-2,7 
-2,7 
 
-2,5 
 
 
-3,3 
 
6,2 
 
 
 
-2,1 
3,8 
2,8 
6,7 
-2,1 
3,5 
-2,2 
 
 
 
 
 
 
-2,0 
 
-2,2 
2,3 
2,3 
2,3 
 
 
-2,1 
 
 
 
 
2,0 
-3,4 
 
 
 
 
-2,9 
-2,1 
-2,8 
-2,6 
-2,1 
-2,4 
 
-3,0 
-5,0 
-3,8 
-9,6 
-3,9 
2,0 
-2,0 
 
-2,4 
 
-2,6 
-3,0 
-4,5 
2,3 
-2,5 
3,1 
2,8 
3,6 
 
4,1 
2,4 
3,5 
 
-2,0 
-2,7 
-3,2 
-2,4 
 
 
-2,2 
-2,7 
-3,3 
-2,1 
 
-2,4 
11,8 
7,3 
2,7 
2,0 
-3,2 
5,1 
4,0 
8,6 
 
 
-2,2 
-2,3 
-3,0 
-2,6 
-3,4 
-3,4 
-3,9 
-2,7 
-2,6 
 
 
 
 
-3,6 
-2,1 
 
-2,2 
2,0 
2,2 
2,8 
 
 
-2,5 
 
-2,1 
2,0 
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PA0976 
PA0979 
PA0989 
PA0997 
PA0998 
PA0999 
PA1000 
PA1001 
PA1002 
PA1009 
PA1027 
PA1033 
PA1039 
PA1041 
PA1050 
PA1057 
PA1058 
PA1061 
PA1064 
PA1071 
PA1074 
PA1077 
PA1078 
PA1079 
PA1080 
PA1081 
PA1082 
PA1083 
PA1086 
PA1087 
PA1089 
PA1090 
PA1092 
PA1093 
PA1096 
PA1099 
PA1116 
PA1119 
PA1123 
PA1130 
PA1131 
PA1134 
PA1135 
PA1157 
PA1166 
PA1167 
PA1172 
PA1173 
PA1174 
PA1175 
PA1176 
PA1177 
PA1190 
PA1196 
PA1202 
PA1208 
PA1216 
PA1217 
PA1218 
PA1219 
PA1220 
PA1221 
PA1245 
PA1246 
PA1247 
PA1249 
PA1250 
PA1274 
PA1276 
PA1288 
PA1289 
PA1297 
PA1300 
PA1301 
PA1320 
PA1325 
PA1337 
PA1338 
 
 
 
pqsB 
pqsC 
pqsD 
pqsE 
phnA 
phnB 
 
 
 
 
 
 
 
 
 
 
braF 
braC 
flgB 
flgC 
flgD 
flgE 
flgF 
flgG 
flgH 
flgK 
flgL 
 
 
fliC 
 
 
fleR 
 
 
 
rhlC 
 
 
 
 
 
 
napC 
napB 
napA 
napD 
napF 
napE 
 
 
 
 
 
 
 
 
 
 
 
aprD 
aprE 
aprA 
aprI 
 
cobC 
 
 
 
 
 
cyoD 
 
ansB 
ggt 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
Homolog. to beta-keto-acyl-acyl-carrier p.s.* 
Homolog. to beta-keto-acyl-acyl-carrier p.s.* 
3-oxoacyl-[acyl-carrier-protein] synthase III 
Quinolone signal response protein 
anthranilate synthase component I 
anthranilate synthase component II 
hypothetical protein 
probable aldehyde dehydrogenase 
probable glutathione S-transferase 
conserved hypothetical protein 
probable outer membrane protein precursor 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
branched-chain amino acid transport protein  
branched-chain amino acid transport protein  
flagellar basal-body rod protein FlgB 
flagellar basal-body rod protein FlgC 
flagellar b-b.* rod modification protein FlgD 
flagellar hook protein FlgE 
flagellar basal-body rod protein FlgF 
flagellar basal-body rod protein FlgG 
flagellar L-ring protein precursor FlgH 
flagellar hook-associated protein 1 FlgK 
flagellar hook-associated protein type 3 FlgL 
conserved hypothetical protein 
hypothetical protein 
flagellin type B 
hypothetical protein 
hypothetical protein 
two-component response regulator 
hypothetical protein 
probable outer membrane protein precursor 
hypothetical protein 
rhamnosyltransferase 2 
probable major facilitator superfamily tr.* 
hypothetical protein 
conserved hypothetical protein 
probable two-component response regulator 
hypothetical protein 
hypothetical protein 
cytochrome c-type protein NapC 
cytochrome c-type protein NapB precursor 
periplasmic nitrate reductase protein NapA 
NapD protein of periplasmic nitrate reductase 
ferredoxin protein NapF 
periplasmic nitrate reductase protein NapE 
conserved hypothetical protein 
probable transcriptional regulator 
probable hydrolase 
conserved hypothetical protein 
hypothetical protein 
probable 2-isopropylmalate synthase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
alkaline protease secretion protein AprD 
alkaline protease secretion protein AprE 
alkaline metalloproteinase precursor 
alkaline proteinase inhibitor AprI 
conserved hypothetical protein 
cobalamin biosynthetic protein CobC 
probable outer membrane protein precursor 
hypothetical protein 
probable metal transporter 
probable sigma-70 factor, ECF subfamily 
probable transmembrane sensor 
cytochrome o ubiquinol oxidase subunit IV 
conserved hypothetical protein 
glutaminase-asparaginase 
gamma-glutamyltranspeptidase precursor 
HUU 
RPT 
HUU 
BC 
BC 
BC 
BC 
Ap 
ABM ; Ap 
HUU 
PE 
PE 
HUU 
MP; TSM 
HUU 
MP 
MP 
PE 
HUU 
TSM 
TSM 
CLC; MA 
CLC; MA 
CLC; MA 
CLC; MA 
CLC; MA 
CLC; MA 
CLC; MA 
CLC; MA 
CLC; MA 
HUU 
HUU 
MA 
HUU 
HUU 
MA ; TR  
HUU 
MP 
HUU 
CLC; Ap 
MP; ARS  
HUU 
HUU 
TR ; TCR 
HUU 
HUU 
EM 
EM 
EM 
EM 
EM 
EM 
MP 
TR 
PE 
HUU 
HUU 
ABM 
HUU 
HUU 
HUU 
HUU 
MP 
SF ; PSE 
SF ; PSE 
SF 
SF 
HUU 
BC 
MP; TSM 
HUU 
MP; TSM 
TR 
MP ; TR 
EM 
HUU 
ABM 
ABM ; Ap  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
2,5 
 
 
 
2,9 
3,4 
3,0 
3,1 
2,3 
 
2,9 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
 
3,3 
 
 
 
 
 
2,7 
2,6 
 
 
 
2,3 
2,1 
2,0 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-5,9 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
2,5 
 
 
 
6,1 
3,0 
2,7 
2,0 
2,1 
2,2 
 
 
 
 
 
 
 
 
 
 
-2,2 
-2,3 
 
2,6 
 
 
 
2,2 
-2,2 
 
 
 
 
 
 
-2,6 
-2,4 
-2,4 
 
 
2,6 
 
 
-2,1 
-2,1 
 
-2,9 
-2,2 
 
 
-2,4 
 
-2,2 
 
 
 
 
 
-2,3 
 
 
 
 
 
8,0 
3,0 
4,5 
5,7 
 
 
 
-2,1 
 
 
-2,1 
-2,0 
-2,2 
 
 
2,0 
-3,7 
 
-6,6 
 
 
 
 
 
4,4 
2,7 
3,4 
2,5 
2,1 
 
 
-4,2 
-2,8 
 
11,8 
7,9 
2,9 
 
-2,9 
 
2,2 
 
 
 
 
 
2,4 
2,6 
2,1 
 
-2,8 
 
-2,3 
-3,4 
-2,3 
-2,0 
-2,6 
 
 
-2,1 
-3,7 
-2,4 
-3,2 
-2,7 
-3,5 
-2,1 
-2,9 
-2,0 
-2,8 
-2,8 
-2,1 
-2,1 
-2,8 
-2,5 
 
-2,3 
2,2 
-2,1 
 
3,9 
4,0 
3,4 
-4,0 
2,1 
-2,3 
-5,2 
-5,7 
-6,8 
-6,8 
-6,9 
-6,8 
-2,6 
 
 
-5,2 
-2,2 
-2,3 
 
 
 
 
 
3,5 
 
2,0 
 
2,3 
2,2 
2,3 
-3,3 
-7,9 
2,1 
8,4 
4,6 
 
3,0 
-5,8 
-3,2 
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PA1339 
PA1340 
PA1341 
PA1342 
PA1344 
PA1348 
PA1353 
PA1358 
PA1376 
PA1382 
PA1394 
PA1414 
PA1415 
PA1418 
PA1420 
PA1421 
PA1429 
PA1441 
PA1462 
PA1473 
PA1476 
PA1483 
PA1504 
PA1525 
PA1535 
PA1542 
PA1543 
PA1546 
PA1548 
PA1550 
PA1551 
PA1555 
PA1556 
PA1557 
PA1558 
PA1559 
PA1560 
PA1561 
PA1562 
PA1575 
PA1579 
PA1580 
PA1588 
PA1590 
PA1591 
PA1592 
PA1593 
PA1597 
PA1610 
PA1617 
PA1618 
PA1628 
PA1641 
PA1649 
PA1650 
PA1651 
PA1656 
PA1672 
PA1673 
PA1674 
PA1711 
PA1712 
PA1713 
PA1728 
PA1733 
PA1741 
PA1745 
PA1746 
PA1748 
PA1753 
PA1754 
PA1759 
PA1760 
PA1761 
PA1762 
PA1763 
PA1764 
PA1765 
 
 
 
 
 
 
 
 
aceK 
 
 
 
 
 
 
gbuA 
 
 
 
 
ccmB 
cycH 
 
alkB2 
 
 
apt 
hemN 
 
 
 
 
 
 
 
 
 
aer 
acnA 
 
 
gltA 
sucC 
braB 
 
 
 
 
fabA 
 
 
 
 
 
 
 
 
 
 
folE2 
exsE 
exsB 
exsA 
 
 
 
 
 
 
 
cysB 
 
 
 
 
 
 
 
amino acid ABC transporter ATP b.p.* 
amino acid ABC transporter m.p.* 
amino acid ABC transporter m.p.* 
probable b. p.* component of ABC transporter 
probable short-chain dehydrogenase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
isocitrate dehydrogenase kinase/phosphatase 
probable type II secretion system protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable sodium:solute symport protein 
hypothetical protein 
guanidinobutyrase 
probable cation-transporting P-type ATPase 
hypothetical protein 
probable plasmid partitioning protein 
hypothetical protein 
heme exporter protein CcmB 
cytochrome c-type biogenesis protein 
probable transcriptional regulator 
alkane-1-monooxygenase 2 
probable acyl-CoA dehydrogenase 
hypothetical protein 
adenine phosphoribosyltransferase 
O2-independent coproporphyrinogen III ox.* 
conserved hypothetical protein 
hypothetical protein 
probable ferredoxin 
probable cytochrome c 
probable cytochrome c oxidase subunit 
probable cytochr. oxidase sub.* (cbb3-type) 
hypothetical protein 
hypothetical protein 
hypothetical protein 
aerotaxis receptor Aer 
aconitate hydratase 1 
hypothetical protein 
hypothetical protein 
citrate synthase 
succinyl-CoA synthetase beta chain 
branched chain amino acid transporter 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
beta-hydroxydecanoyl-ACP dehydrase 
probable AMP-binding enzyme 
conserved hypothetical protein 
probable 3-hydroxyacyl-CoA dehydrogenase 
hypothetical protein 
probable short-chain dehydrogenase 
probable transporter 
probable transporter 
hypothetical protein 
hypothetical protein 
hypothetical protein 
GTP cyclohydrolase I precursor 
ExsE 
exoenzyme S synthesis protein B 
transcriptional regulator ExsA 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable enoyl-CoA hydratase/isomerase 
conserved hypothetical protein 
transcriptional regulator CysB 
probable transcriptional regulator 
probable transcriptional regulator 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
TSM 
TSM 
MP; TSM 
TSM 
PE 
HUU 
HUU 
HUU 
CIM 
PSE 
HUU 
HUU 
HUU 
TSM 
HUU 
ABM 
MP; TSM 
HUU 
CD 
HUU 
MP; TSM 
EM 
TR 
CC 
PE 
HUU 
NM 
BC 
HUU 
HUU 
EM 
EM 
EM 
EM 
HUU 
HUU 
HUU 
Ap ;C 
EM 
HUU 
HUU 
EM 
EM 
TSM 
MP 
HUU 
HUU 
HUU 
FPM 
PE 
HUU 
PE 
HUU 
PE 
MP; TSM 
MP; TSM 
HUU 
HUU 
HUU 
BC 
TR ; PSE 
TPD 
PSE; TR 
HUU 
HUU 
HUU 
HUU 
HUU 
PE 
HUU 
ABM; TR 
TR 
TR 
HUU 
HUU 
HUU 
HUU 
HUU 
 
2,5 
2,3 
2,3 
2,0 
2,5 
 
2,2 
 
 
-2,2 
 
2,2 
 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
 
 
2,0 
 
3,1 
 
 
 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
2,1 
 
 
 
 
-3,1 
 
 
 
 
-3,2 
 
 
 
 
 
2,6 
 
 
 
 
-2,8 
-2,3 
-3,5 
-2,6 
-8,3 
-6,7 
-6,4 
 
 
 
-2,4 
 
 
 
2,7 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,3 
 
-3,8 
2,2 
 
 
 
-2,1 
 
 
 
-8,8 
 
 
 
 
 
 
 
 
 
 
 
 
 
-6,2 
-2,2 
 
 
 
-2,1 
2,1 
-3,2 
5,0 
 
 
 
 
5,7 
 
 
 
 
2,2 
-2,7 
-2,1 
-2,2 
 
-2,1 
6,5 
2,4 
3,5 
2,7 
16,3 
13,9 
12,8 
2,1 
-3,6 
 
2,8 
 
 
-2,3 
-2,9 
-2,0 
2,4 
 
 
-2,1 
-2,2 
 
-7,3 
-7,9 
 
 
-2,7 
 
-2,4 
3,7 
2,3 
13,2 
-2,1 
2,6 
2,1 
2,0 
2,7 
 
 
-3,2 
27,3 
-4,3 
 
 
-2,4 
-2,6 
-8,0 
-3,9 
-6,7 
 
 
-3,3 
-3,8 
-3,4 
-8,0 
-5,1 
 
 
-2,9 
-2,0 
 
 
 
-2,2 
-2,2 
-2,3 
-2,3 
2,0 
-2,1 
-2,0 
-2,3 
2,1 
 
 
-4,0 
-3,6 
-2,1 
 
2,5 
 
 
 
2,3 
2,3 
2,3 
 
-3,4 
-2,1 
 
-2,0 
-2,4 
 
 
 
2,6 
2,7 
-2,8 
 
 
2,3 
-10,0 
-5,9 
-2,1 
-2,5 
 
-4,3 
 
 
 
3,8 
 
2,2 
 
 
 
-2,6 
2,2 
-9,4 
2,5 
 
-2,3 
-2,4 
-3,1 
-3,5 
-8,1 
-5,7 
-8,8 
-2,7 
-3,3 
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PA1773 
PA1774 
PA1776 
PA1784 
PA1788 
PA1800 
PA1806 
PA1807 
PA1811 
PA1812 
PA1818 
 
PA1828 
PA1829 
PA1830 
PA1831 
PA1837 
PA1838 
PA1842 
PA1843 
PA1852 
PA1853 
PA1860 
PA1869 
PA1871 
PA1874 
PA1875 
PA1880 
PA1881 
PA1887 
PA1888 
PA1891 
PA1892 
PA1893 
PA1894 
PA1895 
PA1896 
PA1897 
PA1898 
PA1901 
PA1902 
PA1903 
PA1904 
PA1905 
PA1914 
PA1927 
 
PA1930 
PA1941 
PA1943 
PA1944 
PA1946 
PA1947 
PA1951 
PA1965 
PA1967 
PA1971 
PA1975 
PA1977 
PA1978 
PA1979 
PA1980 
PA1983 
PA1984 
PA1985 
PA1986 
PA1987 
PA1988 
PA1989 
PA1999 
PA2000 
PA2001 
PA2002 
PA2003 
PA2004 
PA2006 
PA2007 
PA2008 
cmaX 
crfX 
sigX 
 
 
tig 
fabI 
 
 
mltD  
ldcA  
 
 
 
 
 
 
cysI 
 
metH 
 
 
 
 
lasA 
 
 
 
 
 
 
 
 
 
 
 
 
 
qscR 
phzC 
phzD 
phzE 
phzF2 
phzG 
 
metE 
 
 
 
 
 
rbsB 
rbsA 
 
 
 
braZ 
 
 
erbR 
eraS 
eraR 
exaB 
exaC 
pqqA 
pqqB 
pqqC 
pqqD 
pqqE 
dhcA 
dhcB 
atoB 
 
bdhA 
 
 
maiA 
fahA 
CmaX protein 
CrfX protein 
ECF sigma factor SigX 
hypothetical protein 
hypothetical protein 
trigger factor 
NADH-dependent enoyl-ACP reductase 
probable ATP-binding component of ABC tr.* 
probable solute-binding protein 
m.-b.* lytic murein transglycosylase D prc.* 
lysine-specific pyridoxal 5'-phosphate-
dependent carboxylase, LdcA 
probable short-chain dehydrogenase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
sulfite reductase 
hypothetical protein 
methionine synthase 
hypothetical protein 
probable transcriptional regulator 
hypothetical protein 
probable acyl carrier protein 
LasA protease precursor 
hypothetical protein 
probable outer membrane protein precursor 
probable oxidoreductase 
probable oxidoreductase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
quorum-sensing control repressor 
phenazine biosynthesis protein PhzC 
phenazine biosynthesis protein PhzD 
phenazine biosynthesis protein PhzE 
probable phenazine biosynthesis protein 
probable pyridoxamine 5'-phosphate oxidase 
conserved hypothetical protein 
5-methyltetrahydropteroyltriglutamate-
homocysteine S-methyltransferase 
probable Ctransducer 
hypothetical protein 
hypothetical protein 
hypothetical protein 
b.p.* component precursor of ABC ribose tr.* 
ribose transport protein RbsA 
hypothetical protein 
hypothetical protein 
hypothetical protein 
branched chain amino acid transporter BraZ 
hypothetical protein 
hypothetical protein 
response regulator ErbR 
sensor kinase, EraS 
response regulator EraR 
cytochrome c550 
NAD+ dependent aldehyde dehyd. ExaC 
pyrroloquinoline quinone bio. p.* A 
pyrroloquinoline quinone bio. p.*B 
pyrroloquinoline quinone bio. p.* C 
pyrroloquinoline quinone bio. p.*D 
pyrroloquinoline quinone bio. p.* E 
DhcA, dehydrocarnitine CoA transf., sub.* A 
DhcB, dehydrocarnitine CoA transf., sub.* B 
acetyl-CoA acetyltransferase 
conserved hypothetical protein 
3-hydroxybutyrate dehydrogenase 
conserved hypothetical protein 
probable major facilitator superfamily tr.* 
maleylacetoacetate isomerase 
fumarylacetoacetase 
MP 
HUU 
TR 
HUU 
HUU 
CD; CHP 
FPM 
TSM 
TSM 
ABM 
ABM 
 
PE 
PE 
HUU 
HUU 
HUU 
CIM 
HUU 
ABM 
HUU 
TR 
PE 
FPM 
SF; TPD 
ARS 
PSE 
PE 
PE 
HUU 
HUU 
MP 
HUU 
PE 
HUU 
MP 
HUU 
MP 
TR 
SF 
SF 
SF 
SF 
SF 
PE 
ABM 
 
Ap ;C 
HUU 
HUU 
HUU 
TSM 
TSM 
HUU 
HUU 
HUU 
TSM 
HUU 
MP 
TR 
TCR 
TR ; TCR 
EM ; CC 
PE 
BC 
BC 
BC 
BC 
BC 
ABM; CC 
ABM ;CC 
CIM  
MP 
CC 
MP 
MP; TSM 
CC 
CC 
 
 
 
2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-4,2 
-4,8 
 
 
2,2 
-2,3 
 
4,1 
2,7 
 
2,0 
4,7 
4,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,3 
-
168,3 
3,0 
 
 
 
 
 
2,3 
-2,1 
 
 
 
 
 
 
 
 
3,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3,0 
3,0 
 
 
 
 
 
 
-59,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,4 
 
 
2,9 
 
 
 
2,4 
2,2 
 
 
 
 
 
-2,1 
 
 
 
-5,8 
-3,5 
-3,5 
-2,1 
 
 
-2,5 
-3,8 
5,3 
 
 
7,4 
2,1 
 
 
 
 
 
 
2,9 
2,2 
2,3 
 
2,7 
3,4 
 
 
5,0 
6,4 
14,2 
18,0 
21,8 
 
 
-2,1 
 
-2,8 
 
 
 
 
 
 
-2,1 
-2,3 
-3,1 
 
-7,3 
-3,0 
-2,0 
-2,2 
-2,4 
-2,1 
-2,4 
 
-2,1 
 
32,6 
11,4 
6,9 
 
4,2 
4,0 
2,2 
22,0 
9,4 
-2,2 
2,0 
2,2 
-3,1 
2,1 
2,6 
-2,0 
-2,1 
 
 
-2,5 
 
-3,1 
-2,0 
 
 
2,5 
2,5 
2,2 
 
4,8 
2,4 
-3,2 
19,0 
2,2 
-4,2 
-2,0 
-3,3 
-2,9 
-8,0 
-7,6 
3,6 
3,2 
3,0 
2,5 
2,9 
3,7 
2,3 
 
7,2 
5,9 
14,3 
16,5 
20,0 
-2,5 
 
 
-4,4 
 
-2,2 
-3,2 
-2,5 
-2,1 
-4,8 
2,6 
-2,8 
 
-2,1 
-2,1 
-9,2 
-2,5 
-2,1 
 
-7,6 
-2,6 
-3,2 
-2,1 
-2,2 
-2,0 
29,3 
18,4 
11,3 
3,0 
2,8 
3,9 
7,0 
14,5 
8,2 
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PA2009 
PA2010 
PA2011 
PA2012 
 
PA2013 
PA2014 
PA2015 
PA2016 
PA2024 
PA2027 
PA2030 
PA2031 
PA2033 
PA2034 
PA2038 
PA2047 
PA2062 
PA2067 
PA2068 
PA2069 
PA2071 
PA2072 
PA2080 
PA2081 
PA2109 
PA2110 
PA2111 
PA2112 
PA2113 
PA2114 
PA2116 
PA2119 
PA2120 
PA2121 
PA2128 
PA2174 
PA2177 
PA2182 
PA2193 
PA2194 
PA2195 
PA2204 
PA2205 
PA2231 
PA2232 
PA2233 
PA2234 
PA2235 
PA2236 
PA2237 
PA2239 
PA2242 
PA2247 
PA2248 
PA2249 
PA2250 
PA2273 
PA2274 
PA2290 
PA2302 
PA2305 
PA2306 
PA2326 
PA2327 
PA2329 
PA2357 
PA2364 
PA2365 
PA2366 
PA2367 
PA2371 
PA2372 
PA2373 
PA2379 
PA2380 
PA2381 
PA2382 
hmgA 
 
liuE 
liuD 
 
liuC 
liuB 
liuA 
liuR 
 
 
 
 
 
 
 
 
 
 
 
 
fusA2 
 
kynU 
kynB 
 
 
 
 
opdO 
 
 
 
 
 
cupA 
 
 
 
hcnA 
hcnB 
hcnC 
 
 
pslA 
pslB 
pslC 
pslD 
pslE 
pslF 
pslG 
pslI 
pslL 
bkdA 
bkdA 
bkdB 
lpdV 
 
 
gcd 
 
 
 
 
 
 
msuE 
 
 
 
 
 
 
 
 
 
 
lldA 
homogentisate 1,2-dioxygenase 
probable transcriptional regulator 
3-hydroxy-3-methylglutaryl-CoA lyase 
methylcrotonyl-CoA carboxylase, alpha-subunit 
(biotin-containing) 
putative 3-methylglutaconyl-CoA hydratase 
methylcrotonyl-CoA carboxylase, beta-subunit 
putative isovaleryl-CoA dehydrogenase 
regulator of liu genes 
probable ring-cleaving dioxygenase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable transcriptional regulator 
probable pyridoxal-phosphate dep.* enzyme 
probable hydrolase 
probable major facilitator superfamily tr.* 
probable carbamoyl transferase 
elongation factor G 
conserved hypothetical protein 
kynureninase KynU 
kynurenine formamidase, KynB 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
pyroglutamate porin OpdO 
probable major facilitator superfamily tr.* 
conserved hypothetical protein 
alcohol dehydrogenase (Zn-dependent) 
hypothetical protein 
probable transcriptional regulator 
fimbrial subunit CupA1 
hypothetical protein 
probable sensor/response regulator hybrid 
hypothetical protein 
hydrogen cyanide synthase HcnA 
hydrogen cyanide synthase HcnB 
hydrogen cyanide synthase HcnC 
probable binding protein com. of ABC tr.* 
hypothetical protein 
PslA 
PslB 
PslC 
PslD 
PslE 
PslF 
PslG 
PslI 
hypothetical protein 
2-oxoisovalerate dehyd. (alpha subunit) 
2-oxoisovalerate dehyd. (beta subunit) 
branched-chain alpha-keto acid dehyd.  
lipoamide dehydrogenase-Val 
probable transcriptional regulator 
hypothetical protein 
glucose dehydrogenase 
probable non-ribosomal peptide synthetase 
probable non-ribosomal peptide synthetase 
conserved hypothetical protein 
hypothetical protein 
probable permease of ABC transporter 
probable ATP-binding component of ABC tr.* 
NADH-dependent FMN reductase MsuE 
hypothetical protein 
conserved hypothetical protein 
uricase PuuD 
hypothetical protein 
probable ClpA/B-type protease 
hypothetical protein 
conserved hypothetical protein 
probable oxidoreductase 
hypothetical protein 
hypothetical protein 
L-lactate dehydrogenase 
CC 
TR 
CC 
CC 
CC 
 
CC 
CC 
TR 
PE 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
TR 
PE 
PE 
MP; TSM 
PE 
TPD 
MP 
HUU 
ABM 
HUU 
HUU 
HUU 
HUU 
TSM; MP 
MP; TSM 
HUU 
PE 
HUU 
TR 
MA 
HUU 
TCR 
HUU 
CIM 
CIM 
CIM 
TSM 
HUU 
CLC 
CLC 
PE ; CLC 
CLC  
CLC 
CLC 
PE ; CLC 
PE ; CLC 
HUU 
ABM 
ABM 
ABM 
ABM; EM 
TR 
HUU 
CC ; EM 
PE 
PE 
MP 
PE 
MP; TSM 
TSM 
CC ; CIM 
HUU 
HUU 
HUU 
HUU 
TPD 
HUU 
HUU 
PE 
HUU 
HUU 
EM 
 
 
 
 
 
 
 
 
 
2,5 
 
 
 
 
 
 
 
 
 
 
 
2,7 
 
 
 
 
 
 
 
2,4 
2,2 
2,3 
 
 
 
3,2 
2,8 
 
2,6 
 
 
 
 
 
 
 
2,1 
2,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,6 
 
 
 
 
 
 
 
-2,1 
2,3 
2,0 
3,0 
 
-2,3 
 
 
 
 
 
 
 
 
-2,3 
2,1 
2,5 
 
 
 
 
 
 
 
-2,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,6 
 
 
10,2 
7,9 
5,4 
9,7 
 
4,3 
10,5 
11,7 
6,4 
 
9,7 
 
 
2,9 
7,8 
 
 
2,4 
2,5 
2,2 
3,3 
 
 
-2,7 
-2,3 
-4,6 
-10,5 
-12,1 
-16,5 
-6,6 
-10,1 
-6,2 
3,7 
 
 
 
 
 
 
14,9 
14,0 
9,9 
2,5 
-3,0 
 
 
 
 
 
 
 
 
 
3,3 
5,4 
6,3 
7,8 
2,4 
2,5 
 
2,5 
 
-2,3 
2,1 
2,2 
2,1 
-4,0 
-2,3 
 
 
 
 
 
 
 
3,9 
3,4 
2,4 
17,3 
3,8 
7,3 
7,6 
 
5,7 
10,6 
12,5 
12,1 
-3,6 
25,3 
 
 
2,2 
4,1 
2,7 
-2,0 
 
 
3,4 
4,0 
-4,3 
-4,5 
 
 
-10,3 
-19,4 
-27,9 
-32,8 
-17,9 
-31,2 
-16,2 
 
-2,2 
-2,5 
-2,6 
-3,0 
-2,1 
-2,8 
21,4 
10,3 
12,0 
 
 
-2,4 
-3,2 
-2,9 
-2,8 
-2,2 
-2,3 
-2,2 
-2,1 
-2,1 
5,8 
6,6 
8,9 
8,9 
2,1 
7,0 
-2,0 
2,2 
2,2 
 
 
 
 
-4,1 
-2,8 
-2,8 
-2,9 
-2,6 
-2,5 
-2,5 
-2,5 
2,2 
 
2,1 
2,0 
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PA2383 
PA2384 
PA2385 
PA2386 
PA2388 
PA2389 
PA2390 
PA2391 
PA2392 
PA2393 
PA2394 
PA2395 
PA2396 
PA2397 
PA2398 
PA2399 
PA2400 
PA2402 
PA2404 
PA2405 
PA2406 
PA2407 
PA2408 
PA2411 
PA2412 
PA2413 
 
PA2424 
PA2425 
PA2426 
PA2427 
PA2433 
PA2445 
PA2446 
PA2450 
PA2451 
PA2453 
PA2464 
PA2467 
PA2468 
PA2481 
PA2486 
PA2501 
PA2504 
PA2511 
PA2512 
PA2513 
PA2514 
PA2532 
PA2539 
PA2550 
PA2552 
PA2553 
PA2554 
PA2555 
PA2556 
PA2557 
PA2558 
PA2562 
PA2564 
PA2565 
PA2566 
PA2568 
PA2572 
PA2573 
PA2577 
PA2578 
PA2579 
 
PA2591 
PA2592 
PA2593 
PA2605 
PA2606 
PA2607 
PA2608 
PA2609 
PA2618 
 
 
pvdQ 
pvdA 
fpvR 
 
 
opmQ 
pvdP 
 
pvdN 
pvdO 
pvdF 
pvdE 
fpvA 
pvdD 
pvdJ 
 
 
 
 
 
 
 
 
pvdH 
 
pvdL 
pvdG 
pvdS 
 
 
gcvP2 
gcvH 
 
 
 
 
foxR 
foxI 
 
 
 
 
 
antA 
antB 
antC 
tpx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
kynA 
 
 
 
 
 
 
 
 
 
 
probable transcriptional regulator 
hypothetical protein 
3-oxo-C12-homoserine lactone acylase PvdQ 
L-ornithine N5-oxygenase 
FpvR 
conserved hypothetical protein 
probable ATP-binding/permease fusion ABC 
transporter 
probable o. m.* protein precursor PvdP 
probable dipeptidase precursor 
PvdN 
PvdO 
pyoverdine synthetase F 
pyoverdine biosynthesis protein PvdE 
ferripyoverdine receptor 
pyoverdine synthetase D 
PvdJ 
probable non-ribosomal peptide synthetase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable adhesion protein 
probable ATP-binding com.* of ABC tr.* 
probable thioesterase 
conserved hypothetical protein 
L-2,4-diaminobutyrate:2-ketoglutarate 4-
aminotransferase, PvdH 
PvdL 
PvdG 
sigma factor PvdS 
hypothetical protein 
hypothetical protein 
glycine cleavage system protein P2 
glycine cleavage system protein H2 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
Anti-sigma factor FoxR 
ECF sigma factor FoxI 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable transcriptional regulator 
anthranilate dioxygenase large subunit 
anthranilate dioxygenase small subunit 
anthranilate dioxygenase reductase 
thiol peroxidase 
conserved hypothetical protein 
probable acyl-CoA dehydrogenase 
probable acyl-CoA dehydrogenase 
probable acyl-CoA thiolase 
probable short-chain dehydrogenase 
probable AMP-binding enzyme 
probable transcriptional regulator 
probable AMP-binding enzyme 
probable transport protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable two-component response regulator 
probable Ctransducer 
probable transcriptional regulator 
probable acetyltransferase 
L-Tryptophan:oxygen 2,3-oxidoreductase KynA 
probable transcriptional regulator 
prob.*periplasmic spermidine/putrescine-b. p.* 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
initiation factor 
TR 
HUU 
Ap 
Ap 
MP ; TR  
HUU 
MP; TSM 
MP; TSM 
Ap 
CIM 
Ap 
Ap 
SF ; Ap 
MP ; Ap  
TSM 
SF ; Ap 
Ap 
PE 
MP 
HUU 
HUU 
MA 
TSM 
Ap ; PE 
HUU 
Ap 
 
Ap 
Ap 
TR 
HUU 
HUU 
CIM 
ABM 
HUU 
HUU 
HUU 
HUU 
MP ; TR 
TR 
HUU 
HUU 
MP 
HUU 
TR 
CC 
CC 
CC 
Ap 
MP 
PE 
PE 
PE 
PE 
PE 
TR 
FPM 
MP; TSM 
HUU 
HUU 
HUU 
HUU 
MP 
TR ; TCR 
Ap ;C 
TR 
PE 
PE 
 
TR 
TSM 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
TPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,2 
 
 
 
 
 
-2,1 
 
 
 
2,3 
 
2,2 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
2,5 
 
 
2,1 
 
2,1 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
-2,1 
 
-2,1 
 
2,2 
 
 
 
 
 
 
 
 
 
 
 
 
-2,5 
 
4,8 
3,4 
5,3 
4,2 
2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,5 
 
 
 
 
 
 
 
 
 
 
5,9 
6,8 
18,8 
 
4,6 
4,2 
3,7 
10,5 
5,3 
7,2 
2,9 
9,1 
6,2 
2,0 
18,7 
15,5 
14,8 
13,5 
2,4 
2,3 
2,4 
2,2 
3,4 
21,1 
17,3 
14,4 
 
21,6 
8,9 
2,6 
23,9 
 
 
 
 
2,8 
-2,3 
 
3,7 
 
 
 
3,0 
 
 
 
 
 
-2,3 
 
-2,1 
 
2,5 
2,7 
2,5 
2,1 
4,5 
 
 
6,4 
4,6 
7,3 
 
 
 
-2,2 
 
 
 
3,3 
3,5 
2,3 
 
 
 
 
 
 
4,9 
6,5 
18,8 
2,7 
4,3 
3,1 
2,8 
8,8 
6,0 
7,9 
3,1 
10,5 
6,9 
3,7 
12,9 
8,7 
9,1 
10,9 
2,9 
2,5 
2,4 
2,6 
3,0 
15,1 
17,9 
8,3 
 
11,4 
7,6 
7,6 
14,2 
-2,5 
2,3 
2,5 
2,2 
 
 
2,2 
2,9 
2,5 
-2,3 
-2,5 
 
-2,2 
3,8 
3,7 
5,9 
5,1 
 
2,3 
 
2,1 
2,7 
3,0 
3,5 
2,9 
7,4 
2,5 
-2,6 
3,3 
2,8 
2,6 
2,1 
-2,6 
-2,1 
-3,8 
-3,2 
 
 
2,1 
3,6 
3,1 
-2,1 
-2,0 
-2,4 
-2,5 
-2,6 
-2,7 
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PA2619 
PA2629 
PA2633 
PA2634 
PA2639 
PA2640 
PA2644 
PA2646 
PA2658 
PA2659 
PA2662 
PA2667 
PA2682 
PA2704 
PA2717 
PA2741 
PA2744 
PA2746 
PA2747 
PA2753 
PA2754 
PA2756 
PA2760 
PA2761 
PA2762 
PA2771 
PA2774 
PA2775 
PA2776 
PA2779 
PA2788 
PA2822 
PA2824 
PA2825 
PA2826 
PA2841 
PA2842 
PA2844 
PA2845 
PA2847 
PA2849 
PA2851 
PA2862 
PA2863 
PA2864 
PA2867 
PA2876 
PA2886 
PA2887 
PA2888 
PA2889 
PA2890 
PA2891 
PA2892 
PA2893 
PA2900 
PA2901 
PA2906 
PA2929 
PA2931 
PA2937 
PA2939 
PA2941 
PA2945 
PA2950 
PA2952 
PA2953 
PA2967 
PA2968 
PA2970 
PA2971 
PA2982 
PA2983 
PA2993 
PA2994 
PA2996 
PA3000 
PA3001 
infA 
purB 
 
aceA 
nuoD 
nuoE 
nuoI 
nuoK 
 
 
 
 
 
 
cpo 
rplT 
thrS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ospR 
 
 
 
 
 
 
 
efp 
lipA 
lipH 
 
 
pyrF 
atuA 
atuB 
atuC 
atuD 
atuE 
atuF 
atuG 
atuH 
 
 
 
 
cifR 
 
 
 
 
 
etfB 
 
fabG 
fabD 
rpmF 
 
 
 
 
nqrF 
nqrD 
aroP1 
 
adenylosuccinate lyase 
hypothetical protein 
isocitrate lyase AceA 
NADH dehydrogenase I chain C,D 
NADH dehydrogenase I chain E 
NADH Dehydrogenase I chain I 
NADH dehydrogenase I chain K 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
probable transcriptional regulator 
chloroperoxidase precursor 
50S ribosomal protein L20 
threonyl-tRNA synthetase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable outer membrane protein precursor 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable Ctransducer 
conserved hypothetical protein 
probable sensor/response regulator hybrid 
OspR 
probable glutathione peroxidase 
probable enoyl-CoA hydratase/isomerase 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable transcriptional regulator 
translation elongation factor P 
lactonizing lipase precursor 
lipase modulator protein 
conserved hypothetical protein 
probable Ctransducer 
orotidine 5'-phosphate decarboxylase 
citronellol catabolism 
putative dehydrogenase  
geranyl-CoA carboxylase, beta-subunit 
putative citronellyl-CoA dehydrogenase  
putative isohexenylglutaconyl-CoA hydratase 
geranyl-CoA carboxylase, alpha-subunit  
GCase, alpha-subunit (biotin-containing) 
putative very-long chain acyl-CoA synthetase 
probable outer membrane protein precursor 
hypothetical protein 
probable oxidoreductase 
hypothetical protein 
CifR 
hypothetical protein 
probable aminopeptidase 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
electron transfer flavoprotein beta-subunit 
e.* transfer fp*-ubiquinone oxidoreductase 
3-oxoacyl-[acyl-carrier-protein] reductase 
malonyl-CoA- transacylase 
50S ribosomal protein L32 
conserved hypothetical protein 
conserved hypothetical protein 
probable tolQ-type transport protein 
conserved hypothetical protein 
NADH:quinone oxidoreductase, subunit Nqr6 
NADH:uniquinone oxidoreductase sub.* Nqr4 
aromatic amino acid transport protein AroP1 
probable glyceraldehyde-3-phosphate dehyd.* 
transcriptional regulator PsrA 
TPD 
ABM; NM 
RPT 
PE 
EM 
EM 
EM 
EM 
HUU 
HUU 
MP 
HUU 
PE 
TR 
CIM 
TPD 
ABM 
MP 
HUU 
HUU 
HUU 
HUU 
TSM 
MP 
HUU 
HUU 
MP 
MP 
HUU 
HUU 
Ap ;C 
HUU 
TCR 
TR 
Ap 
PE 
HUU 
HUU 
HUU 
HUU 
TR 
TPD 
CC ; SF 
PSE; SF 
HUU 
Ap ;C 
NM 
HUU 
PE 
PE 
PE 
PE 
PE 
PE 
FPM 
MP; TSM 
HUU 
PE 
MP 
TR 
HUU 
SF 
HUU 
BC 
HUU 
EM 
EM 
FPM 
FPM 
TPD 
HUU 
HUU 
TSM 
HUU 
EM 
EM 
TSM 
PE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,2 
2,8 
 
-2,3 
 
 
2,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,2 
2,1 
2,9 
3,7 
2,5 
2,8 
4,1 
2,1 
 
 
-2,1 
-2,4 
 
 
2,5 
 
-2,0 
 
 
 
 
 
-2,0 
-2,4 
-2,1 
 
 
 
 
 
 
2,1 
2,0 
 
 
2,2 
2,0 
2,3 
2,0 
 
 
-2,2 
2,2 
4,2 
2,3 
 
 
 
 
 
 
-2,1 
-2,2 
2,2 
 
 
 
 
 
 
 
-2,6 
 
 
 
 
 
 
 
-4,7 
 
 
 
4,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3,0 
-2,6 
 
-2,1 
 
 
 
3,0 
 
 
-3,6 
 
 
-2,0 
2,9 
2,6 
2,4 
3,4 
2,4 
 
-2,1 
 
 
 
 
 
 
4,9 
 
 
 
-2,3 
 
 
2,2 
4,8 
2,0 
-2,3 
 
-50,9 
-3,1 
 
3,2 
 
-2,0 
 
 
 
 
 
-3,7 
 
 
 
 
 
2,1 
2,1 
 
 
 
 
-2,2 
-2,1 
6,2 
 
 
 
 
 
 
 
 
 
 
2,2 
2,2 
-2,2 
 
 
 
 
 
-2,3 
-2,6 
 
 
3,7 
-2,2 
-2,2 
2,4 
 
2,5 
 
 
 
 
 
 
-3,0 
-3,3 
2,4 
2,2 
-2,0 
-4,8 
 
2,1 
-2,5 
-3,0 
-3,1 
-2,4 
2,4 
 
 
 
-2,6 
2,7 
-20,0 
-3,8 
-2,1 
 
2,2 
-4,5 
-4,2 
-5,0 
-6,7 
-4,2 
-5,6 
-13,8 
-2,5 
2,1 
3,0 
2,3 
 
 
 
-4,4 
2,3 
2,1 
2,4 
 
 
3,3 
2,7 
2,8 
3,0 
2,3 
2,2 
2,2 
2,1 
2,1 
2,3 
2,1 
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PA3006 
PA3009 
PA3017 
PA3019 
PA3021 
PA3022 
PA3038 
PA3040 
PA3041 
PA3042 
PA3049 
PA3079 
PA3080 
PA3081 
PA3089 
PA3092 
PA3111 
PA3112 
PA3113 
PA3116 
PA3123 
PA3129 
PA3142 
PA3162 
PA3164 
PA3165 
PA3169 
PA3177 
PA3178 
PA3181 
PA3182 
PA3183 
PA3186 
PA3188 
PA3190 
PA3195 
PA3199 
PA3216 
PA3227 
PA3234 
PA3235 
PA3236 
PA3242 
PA3245 
PA3250 
PA3251 
PA3252 
PA3254 
PA3263 
PA3270 
PA3276 
PA3277 
PA3278 
PA3285 
PA3289 
PA3295 
PA3299 
PA3300 
PA3309 
PA3311 
PA3323 
PA3325 
PA3326 
PA3327 
PA3328 
PA3329 
PA3330 
PA3331 
PA3332 
PA3333 
PA3334 
PA3335 
PA3336 
PA3337 
PA3342 
PA3344 
PA3347 
PA3361 
psrA 
 
 
 
 
 
 
 
 
 
rmf 
 
 
 
 
fadH1 
folC 
accD 
trpF 
 
 
 
 
rpsA 
 
hisC2 
mtnA 
 
 
 
pgl 
zwf 
oprB 
 
 
gapA 
 
 
ppiA 
 
 
 
 
minE 
 
 
 
 
 
 
 
 
 
 
 
 
fadD1 
fadD2 
 
 
 
 
 
 
 
 
 
 
 
fabH2 
 
 
 
rfaD 
 
recQ 
 
lecB 
hypothetical protein 
conserved hypothetical protein 
probable ATP-binding component of ABC tr.* 
hypothetical protein 
hypothetical protein 
probable porin 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
ribosome modulation factor 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
2,4-dienoyl-CoA reductase FadH1 
folylpolyglutamate synthetase 
acetyl-CoA carboxylase beta subunit 
N-(5'phosphoribosyl)anthranilate isomerase 
probable aspartate-semialdehyde dehyd.* 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
30S ribosomal protein S1 
prephenate dehydrogenase 
histidinol-phosphate aminotransferase 
5-methylthioribose-1-phosphate isomerase  
hypothetical protein 
hypothetical protein 
2-keto-3-deoxy-6-phosphogluconate aldolase 
6-phosphogluconolactonase 
glucose-6-phosphate 1-dehydrogenase 
Glucose/carbohydrate outer membrane porin  
probable permease of ABC sugar transporter 
prob.* binding protein com.* of ABC sugar tr.* 
glyceraldehyde 3-phosphate dehydrogenase 
conserved hypothetical protein 
hypothetical protein 
peptidyl-prolyl cis-trans isomerase A 
probable sodium:solute symporter 
conserved hypothetical protein 
probable glycine betaine-binding protein 
precursor 
probable lauroyl acyltransferase 
hypothetical protein 
hypothetical protein 
probable permease of ABC transporter 
probable ATP-binding component of ABC tr.* 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
probable short-chain dehydrogenase 
hypothetical protein 
probable sigma-70 factor, ECF subfamily 
hypothetical protein 
probable HIT family protein 
long-chain-fatty-acid--CoA ligase 
long-chain-fatty-acid--CoA ligase 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
probable Clp-family ATP-dependent protease 
probable non-ribosomal peptide synthetase 
probable FAD-dependent monooxygenase 
hypothetical protein 
probable short chain dehydrogenase 
cytochrome P450 
conserved hypothetical protein 
3-oxoacyl-[acyl-carrier-protein] synthase III 
probable acyl carrier protein 
hypothetical protein 
probable major facilitator superfamily tr.* 
ADP-L-glycero-D-mannoheptose 6-epimerase 
hypothetical protein 
ATP-dependent DNA helicase RecQ 
hypothetical protein 
fucose-binding lectin PA-IIL 
hypothetical protein 
TR 
HUU 
HUU 
TSM 
HUU 
HUU 
TSM 
HUU 
MP 
HUU 
TPD 
MP 
HUU 
HUU 
HUU 
FPM 
BC 
FPM 
ABM 
ABM 
HUU 
HUU 
RPT 
TPD 
ABM 
ABM 
TPD 
HUU 
HUU 
CIM ; CC 
CIM 
EM ; CC 
TSM 
TSM 
TSM 
EM ; CC 
HUU 
MP 
TPD  
MP; TSM 
MP 
Ap ; TSM 
CLC 
CD 
HUU 
HUU 
MP; TSM 
TSM 
HUU 
HUU 
HUU 
PE 
MP 
TR 
HUU 
PE 
FPM 
FPM 
HUU 
MP 
HUU 
HUU 
TPD 
Ap 
PE 
HUU 
PE 
Ap ; CC 
HUU 
FPM 
FPM 
HUU 
MP; TSM 
CLC 
MP 
DRR 
HUU 
MA 
-2,3 
 
 
 
 
 
 
2,4 
2,0 
 
3,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,1 
3,6 
 
 
 
5,1 
 
2,1 
 
 
 
4,1 
 
 
3,2 
 
 
 
 
 
 
 
-2,6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
 
 
 
 
 
 
-3,4 
-4,4 
 
 
 
 
 
 
 
 
 
 
 
-2,5 
 
 
 
 
 
-4,9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3,0 
 
 
 
 
 
 
-2,3 
 
-3,4 
2,1 
 
 
 
 
3,5 
-6,4 
-9,7 
-3,9 
 
-2,7 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
-2,0 
 
-2,9 
 
2,9 
 
 
 
-2,1 
 
 
 
-2,5 
 
 
-3,1 
 
 
 
-2,3 
-3,2 
-2,0 
12,1 
 
 
 
6,6 
5,0 
5,0 
4,3 
9,8 
8,1 
6,7 
8,7 
14,6 
12,3 
8,9 
5,6 
 
 
 
33,1 
2,6 
2,3 
 
2,3 
-2,2 
 
-2,5 
-4,7 
-3,8 
-3,0 
 
-3,9 
-5,4 
-2,7 
-2,4 
-2,4 
2,7 
2,4 
2,3 
2,5 
-2,5 
3,0 
 
2,7 
2,0 
2,2 
2,2 
-2,1 
2,8 
-2,0 
-2,7 
-4,7 
-2,7 
-2,4 
-3,3 
-8,4 
 
-3,3 
-3,4 
-2,5 
-2,1 
-6,5 
2,2 
2,1 
-6,4 
-2,0 
-2,4 
-2,1 
 
2,2 
2,2 
-3,3 
 
2,3 
-3,1 
 
 
 
2,2 
-2,3 
-2,5 
-2,0 
5,6 
7,0 
5,4 
6,9 
8,3 
8,1 
9,6 
8,2 
14,7 
12,3 
7,4 
 
-2,3 
2,1 
-2,0 
61,2 
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PA3362 
PA3363 
PA3364 
PA3365 
PA3366 
PA3387 
PA3397 
PA3407 
PA3412 
PA3416 
PA3418 
PA3420 
PA3421 
PA3422 
PA3427 
PA3429 
PA3430 
PA3435 
PA3440 
PA3451 
PA3454 
PA3465 
PA3472 
PA3475 
PA3476 
PA3478 
PA3479 
PA3496 
PA3520 
PA3525 
PA3530 
PA3536 
PA3568 
PA3569 
PA3570 
PA3572 
PA3581 
PA3582 
PA3583 
PA3584 
PA3587 
PA3611 
PA3613 
PA3618 
PA3628 
PA3629 
PA3641 
PA3642 
PA3644 
PA3650 
 
PA3651 
PA3654 
PA3655 
PA3656 
PA3661 
PA3662 
PA3688 
PA3691 
PA3709 
PA3710 
PA3712 
PA3723 
PA3723 
PA3723 
PA3724 
PA3731 
PA3742 
PA3743 
PA3744 
PA3745 
PA3746 
PA3749 
PA3768 
PA3784 
PA3785 
PA3786 
PA3791 
 
amiR 
amiC 
 
amiE 
rhlG 
fpr 
hasA 
 
 
ldh 
 
 
 
 
 
 
 
 
 
 
 
 
pheC 
rhlI 
rhlB 
rhlA 
 
 
argG 
 
 
 
mms 
mms 
 
glpF 
glpK 
glpR 
glpD 
metR 
 
 
 
 
adhC 
 
rnhB 
lpxA 
dxr 
 
cdsA 
pyrH 
tsf 
rpsB 
 
 
 
 
 
 
 
 
 
 
lasB 
 
rplS 
trmD 
rimM 
rpsP 
ffh 
 
 
 
 
 
 
aliphatic amidase regulator 
aliphatic amidase expression-regulating p.* 
probable chaperone 
aliphatic amidase 
beta-ketoacyl reductase 
ferredoxin--NADP+ reductase 
heme acquisition protein HasAp 
hypothetical protein 
probable pyruvate dehydrogenase E1 com.* 
leucine dehydrogenase 
probable transcriptional regulator 
conserved hypothetical protein 
hypothetical protein 
probable short-chain dehydrogenases 
probable epoxide hydrolase 
probable aldolase 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable acyl-CoA thiolase 
conserved hypothetical protein 
hypothetical protein 
cyclohexadienyl dehydratase precursor 
autoinducer synthesis protein RhlI 
rhamnosyltransferase chain B 
rhamnosyltransferase chain A 
hypothetical protein 
hypothetical protein 
argininosuccinate synthase 
conserved hypothetical protein 
hypothetical protein 
probable acetyl-coa synthetase 
3-hydroxyisobutyrate dehydrogenase 
methylmalonate-semialdehyde dehyd.* 
hypothetical protein mmsA 
glycerol uptake facilitator protein 
glycerol kinase 
glycerol-3-phosphate regulon repressor 
glycerol-3-phosphate dehydrogenase 
transcriptional regulator MetR 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable esterase 
alcohol dehydrogenase class III 
probable amino acid permease 
ribonuclease HII 
UDP-N-acetylglucosamine acyltransferase 
1-deoxy-d-xylulose 5-phosphate 
reductoisomerase 
phosphatidate cytidylyltransferase 
uridylate kinase 
elongation factor Ts 
30S ribosomal protein S2 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable major facilitator superfamily tr.* 
probable GMC-type oxidoreductase 
hypothetical protein 
probable FMN oxidoreductase 
probable FMN oxidoreductase 
probable FMN oxidoreductase 
elastase LasB 
conserved hypothetical protein 
50S ribosomal protein L19 
tRNA (guanine-N1)-methyltransferase 
16S rRNA processing protein 
30S ribosomal protein S16 
signal recognition particle protein Ffh 
probable major facilitator superfamily tr.* 
probable metallo-oxidoreductase 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
probable oxidoreductase 
MP 
CC; TR 
TR 
CHP 
CC 
CLC  
BC ; EM 
TSM 
HUU 
EM 
ABM 
TR 
HUU 
HUU 
PE 
PE 
PE 
HUU 
HUU 
HUU 
PE 
MP 
HUU 
Ap ; ABM 
Ap 
SF 
SF 
HUU 
HUU 
ABM 
HUU 
HUU 
PE 
CC 
ABM; CC 
HUU 
TSM 
CIM 
TR 
CIM ; EM 
TR 
HUU 
HUU 
HUU 
PE 
CIM 
TSM 
DRR 
CLC 
BC 
 
FPM 
NM 
TPD 
TPD 
HUU 
HUU 
HUU 
HUU 
MP; TSM 
CC 
HUU 
PE 
PE 
PE 
SF ; TPD 
HUU 
TPD 
TRD 
TRD 
DRR  
PSE 
MP; TSM 
PE 
HUU 
HUU 
HUU 
MP 
 
2,3 
 
 
2,2 
 
 
 
 
2,4 
2,7 
 
2,2 
 
 
 
 
 
 
2,9 
 
2,6 
 
 
 
 
 
 
 
 
 
 
2,0 
 
 
 
 
 
 
 
-3,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,9 
2,0 
3,4 
2,2 
 
3,3 
 
 
 
-2,2 
-2,4 
-2,1 
-2,0 
-2,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
2,1 
2,0 
 
 
 
 
 
 
 
 
 
 
2,3 
 
 
 
-2,0 
-2,2 
 
 
 
 
 
-3,1 
 
 
 
 
 
 
 
 
 
 
 
 
2,6 
2,5 
 
 
 
 
2,1 
 
 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
 
-2,7 
-4,5 
-5,8 
-4,8 
-5,8 
-11,6 
-2,4 
 
4,2 
2,8 
2,4 
 
-3,5 
-2,7 
-2,2 
-4,2 
-2,1 
-2,4 
-2,0 
-2,8 
 
-3,1 
 
 
 
 
7,8 
10,4 
2,6 
5,1 
 
2,2 
 
 
3,2 
3,2 
6,6 
-7,4 
-8,3 
-2,0 
-2,1 
 
-2,2 
2,5 
 
 
-2,1 
 
 
 
 
 
 
 
 
 
-3,2 
2,3 
 
 
-2,5 
 
 
 
-2,4 
 
6,9 
 
 
 
 
 
 
-2,6 
 
 
 
2,0 
2,4 
-11,0 
-13,4 
-9,8 
-10,6 
-21,2 
 
4,3 
2,3 
 
 
-3,9 
-2,7 
-6,0 
-3,8 
-2,4 
-2,3 
-3,3 
 
 
-2,3 
-2,2 
-3,8 
2,6 
2,2 
2,8 
3,5 
10,6 
2,9 
2,9 
 
4,7 
2,2 
 
 
 
2,9 
-5,9 
-9,9 
 
 
 
 
 
2,4 
-2,4 
-2,8 
3,1 
2,1 
2,3 
2,1 
 
2,1 
2,5 
2,9 
2,7 
 
 
-3,0 
 
-3,9 
 
-2,2 
 
 
-8,6 
14,5 
 
4,8 
4,4 
3,4 
3,3 
2,1 
-2,3 
2,1 
-4,3 
-3,2 
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PA3795 
PA3808 
PA3809 
PA3810 
PA3811 
PA3812 
PA3813 
PA3814 
PA3815 
PA3816 
PA3817 
PA3819 
PA3820 
PA3822 
PA3824 
PA3827 
PA3833 
PA3835 
PA3836 
PA3848 
PA3857 
PA3858 
PA3860 
PA3879 
PA3880 
PA3913 
PA3919 
PA3922 
PA3923 
PA3924 
PA3925 
PA3930 
PA3934 
PA3944 
PA3945 
PA3956 
PA3957 
PA3960 
PA3962 
PA3979 
PA3981 
PA3982 
PA3985 
PA3986 
PA4006 
 
PA4007 
PA4014 
PA4015 
PA4017 
PA4023 
PA4024 
PA4025 
PA4026 
PA4031 
PA4041 
PA4067 
PA4090 
PA4108 
PA4112 
PA4115 
PA4129 
PA4129 
PA4130 
PA4131 
PA4132 
PA4133 
PA4134 
PA4135 
PA4136 
PA4141 
PA4158 
PA4205 
PA4206 
PA4207 
PA4208 
PA4209 
PA4210 
 
 
fdx2 
hscA 
hscB 
iscA 
iscU 
iscS 
 
cysE 
 
 
secF 
 
queA 
 
 
 
 
 
pcs 
 
 
narL 
 
 
 
 
 
 
 
cioA 
 
 
 
 
 
 
 
 
 
 
 
 
nadD 
 
proA 
 
 
 
 
eutB 
 
 
ppa 
 
oprG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fepC 
mexG 
mexH 
mexI 
opmD 
phzM 
phzA 
conserved hypothetical protein 
ferredoxin [2Fe-2S] 
heat shock protein HscA 
heat shock protein HscB 
probable iron-binding protein IscA 
probable iron-binding protein IscU 
L-cysteine desulphurase  
conserved hypothetical protein 
O-acetylserine synthase 
probable methyltransferase 
conserved hypothetical protein 
secretion protein SecF 
conserved hypothetical protein 
SAM-:trna ribosyltransferase-isomerase 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
phosphatidylcholine synthase 
probable amino acid-binding protein 
probable AMP-binding enzyme 
two-component response regulator NarL 
conserved hypothetical protein 
probable protease 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable medium-chain acyl-CoA ligase 
probable acyl-CoA thiolase 
cyanide insensitive terminal oxidase 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable short-chain dehydrogenase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
nicotinic acid mononucleotide 
adenylyltransferase 
gamma-glutamyl phosphate reductase 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
probable transport protein 
ethanolamine ammonia-lyase large subunit 
prob. ethanolamine ammonia-lyase light chain 
probable acetyltransferase 
inorganic pyrophosphatase 
hypothetical protein 
Outer membrane protein OprG precursor 
hypothetical protein 
cyclic di-GMP phosphodiesterase 
probable sensor/response regulator hybrid 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
probable sulfite or nitrite reductase 
probable iron-sulphur protein 
conserved hypothetical protein 
cytochrome c oxidase subunit (cbb3-type) 
hypothetical protein 
probable transcriptional regulator 
probable major facilitator superfamily tr.* 
hypothetical protein 
ferric enterobactin transport protein FepC 
hypothetical protein 
efflux membrane fusion protein precursor 
probable efflux transporter 
probable outer membrane protein precursor 
prob.* phenazine-specific methyltransferase 
probable phenazine biosynthesis protein 
probable phenazine biosynthesis protein 
PE 
HUU 
EM 
CHP 
CHP 
BC 
BC 
ABM; BC 
HUU 
BC; ABM 
PE 
MP 
PSE 
HUU 
TPD 
MP 
HUU 
HUU 
HUU 
HUU 
FPM 
TSM 
PE 
EM; TCR 
HUU 
PE 
HUU 
HUU 
HUU 
FPM 
PE 
EM 
MP 
HUU 
HUU 
HUU 
PE 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
BC 
 
ABM; BC 
MP 
HUU 
HUU 
TSM 
CIM 
CC 
PE 
CIM 
PE 
MP 
HUU 
CLC; MA 
TCR 
HUU 
HUU 
HUU 
CIM 
PE 
HUU 
EM 
HUU 
TR 
MP; TSM 
HUU 
TSM 
MP 
TSM 
MP; TSM 
MP; TSM 
PE 
SF 
 
 
 
 
 
 
 
 
 
 
 
2,3 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
 
3,4 
2,1 
 
 
-2,4 
 
 
 
2,1 
 
2,1 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
3,5 
3,9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,4 
2,3 
2,0 
 
 
-2,4 
 
 
 
 
 
 
 
 
 
-2,1 
 
 
-2,1 
 
 
2,3 
2,2 
 
 
 
-2,1 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,2 
 
-2,7 
2,3 
 
-2,5 
 
 
 
 
-2,3 
-2,4 
 
-3,2 
2,5 
 
-2,3 
 
2,7 
 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
 
3,1 
 
 
 
 
 
2,1 
-2,5 
 
 
 
-4,8 
2,4 
3,8 
2,2 
 
-11,8 
-10,2 
-4,8 
-5,5 
 
 
 
 
-2,1 
 
-2,1 
-2,2 
 
-2,1 
 
 
3,1 
 
 
 
 
-5,4 
 
 
 
 
-2,2 
-2,0 
 
6,1 
 
 
 
 
17,8 
 
12,5 
15,6 
12,6 
10,0 
15,5 
-3,8 
2,4 
19,5 
2,2 
3,0 
4,4 
2,7 
 
11,0 
28,4 
-2,2 
 
2,5 
3,0 
2,3 
2,2 
 
 
2,3 
2,3 
2,1 
 
2,1 
2,2 
2,1 
2,2 
-3,1 
 
 
-2,9 
-2,6 
-2,2 
-4,9 
 
 
 
-5,1 
-10,9 
-8,3 
-5,8 
 
-2,9 
 
-2,6 
-2,9 
-2,2 
 
 
 
3,1 
-2,5 
-2,1 
2,5 
 
2,8 
 
2,1 
2,3 
-4,5 
-2,6 
-4,3 
-5,1 
-2,0 
 
 
-2,0 
3,0 
 
-2,2 
-2,2 
-2,9 
7,9 
 
6,7 
6,4 
4,6 
4,6 
5,8 
 
 
8,7 
 
8,8 
7,8 
5,5 
2,8 
13,4 
31,4 
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PA4211 
PA4217 
PA4218 
PA4219 
PA4220 
PA4221 
PA4222 
PA4223 
PA4224 
PA4225 
PA4226 
PA4227 
PA4228 
PA4229 
PA4230 
PA4231 
PA4236 
PA4237 
PA4238 
PA4239 
PA4240 
PA4241 
PA4242 
PA4243 
PA4244 
PA4245 
PA4246 
PA4247 
PA4248 
PA4249 
PA4250 
PA4251 
PA4252 
PA4253 
PA4254 
PA4256 
PA4257 
PA4258 
PA4259 
PA4260 
PA4261 
PA4262 
PA4263 
PA4264 
PA4266 
PA4267 
PA4268 
PA4269 
PA4270 
PA4271 
PA4272 
PA4273 
PA4274 
PA4275 
PA4293 
PA4294 
PA4296 
PA4297 
PA4298 
PA4299 
PA4300 
PA4301 
PA4302 
PA4303 
PA4304 
PA4305 
PA4306 
PA4309 
PA4311 
PA4312 
PA4314 
PA4324 
PA4325 
PA4328 
PA4335 
PA4337 
PA4346 
PA4348 
phzB 
phzS 
 
 
 
fptA 
 
 
pchG 
pchF 
pchE 
pchR 
pchD 
pchC 
pchB 
pchA 
katA 
rplQ 
rpoA 
rpsD 
rpsK 
rpsM 
rpmJ 
secY 
rplO 
rpmD 
rpsE 
rplR 
rplF 
rpsH 
rpsN 
rplE 
rplX 
rplN 
rpsQ 
rplP 
rpsC 
rplV 
rpsS 
rplB 
rplW 
rplD 
rplC 
rpsJ 
fusA1 
rpsG 
rpsL 
rpoC 
rpoB 
rplL 
rplJ 
rplA 
rplK 
nusG 
pprA 
 
pprB 
tadG 
 
tadD 
tadC 
tadB 
tadA 
tadZ 
rcpA 
rcpC 
flp 
pctA 
 
 
purU1 
 
 
 
 
 
 
 
flavin-containing monooxygenase 
probable transporter 
hypothetical protein 
hypothetical protein 
Fe(III)-pyochelin o.m.* receptor prc.* 
probable ATP-binding component of ABC tr.* 
probable ATP-binding component of ABC tr.* 
pyochelin biosynthetic protein PchG 
pyochelin synthetase 
dihydroaeruginoic acid synthetase 
transcriptional regulator PchR 
pyochelin biosynthesis protein PchD 
pyochelin biosynthetic protein PchC 
salicylate biosynthesis protein PchB 
salicylate biosynthesis isochorismate syn.* 
catalase 
50S ribosomal protein L17 
DNA-directed RNA polymerase alpha chain 
30S ribosomal protein S4 
30S ribosomal protein S11 
30S ribosomal protein S13 
50S ribosomal protein L36 
secretion protein SecY 
50S ribosomal protein L15 
50S ribosomal protein L30 
30S ribosomal protein S5 
50S ribosomal protein L18 
50S ribosomal protein L6 
30S ribosomal protein S8 
30S ribosomal protein S14 
50S ribosomal protein L5 
50S ribosomal protein L24 
50S ribosomal protein L14 
30S ribosomal protein S17 
50S ribosomal protein L16 
30S ribosomal protein S3 
50S ribosomal protein L22 
30S ribosomal protein S19 
50S ribosomal protein L2 
50S ribosomal protein L23 
50S ribosomal protein L4 
50S ribosomal protein L3 
30S ribosomal protein S10 
elongation factor G 
30S ribosomal protein S7 
30S ribosomal protein S12 
DNA-directed RNA polymerase beta* chain 
DNA-directed RNA polymerase beta chain 
50S ribosomal protein L7 / L12 
50S ribosomal protein L10 
50S ribosomal protein L1 
50S ribosomal protein L11 
transcription antitermination protein NusG 
two-component sensor PprA 
hypothetical protein 
two-component response regulator, PprB 
TadG 
hypothetical protein 
TadD 
TadC 
TadB 
TadA ATPase 
TadZ 
RcpA 
RcpC 
Type IVb pilin, Flp 
chemotactic transducer PctA 
conserved hypothetical protein 
conserved hypothetical protein 
formyltetrahydrofolate deformylase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
SF 
PE 
MP; TSM 
MP 
HUU 
TSM 
TSM 
MP; TSM 
TSM; MP 
SF ; TSM 
SF ; TSM 
TR 
SF ; TSM 
SF ; TSM 
SF ; TSM 
SF ; TSM 
Ap 
TPD 
TRD 
TPD 
TPD 
TPD 
TPD 
MP; PSE 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TPD 
TRD 
TPD 
TRD  
TPD 
TPD 
TPD 
TRD 
TRD 
TPD 
TPD 
TPD 
TPD 
TRD 
TCR ; 
HUU 
TR; TCR  
MP ; MA 
HUU 
MA 
MP ; MA 
MP ; MA 
PSE; MA 
MA 
PSE; MA 
MA 
MA 
Ap ;C 
HUU 
HUU 
NM 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
 
 
 
 
 
-2,2 
-2,1 
 
 
 
2,9 
4,5 
2,7 
3,6 
4,2 
4,5 
3,4 
2,8 
4,5 
3,3 
3,2 
3,2 
2,6 
2,2 
2,3 
2,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
 
 
 
 
 
 
 
 
 
2,1 
2,5 
2,2 
 
 
 
2,1 
2,1 
2,4 
2,6 
 
 
 
 
 
2,2 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
2,4 
2,1 
2,6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,2 
 
 
-2,1 
-3,7 
13,8 
22,7 
3,8 
5,8 
7,3 
4,1 
6,4 
7,1 
8,5 
7,5 
6,4 
2,2 
4,4 
8,0 
5,6 
8,2 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,0 
 
 
 
-2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,2 
2,3 
 
2,6 
 
 
2,4 
8,7 
23,3 
28,0 
4,2 
6,0 
6,9 
4,5 
5,1 
6,2 
7,5 
7,6 
6,5 
2,4 
4,1 
4,4 
4,3 
5,5 
-2,5 
2,3 
2,7 
2,0 
 
2,3 
3,4 
3,1 
3,3 
3,0 
2,6 
2,6 
2,8 
2,4 
4,7 
3,3 
2,4 
2,7 
2,6 
2,4 
2,3 
2,7 
2,4 
2,5 
3,3 
2,6 
2,6 
2,9 
2,6 
2,4 
3,1 
2,1 
2,3 
3,2 
2,6 
2,1 
2,3 
2,6 
-2,3 
-3,8 
-5,6 
-4,3 
-4,6 
-5,8 
-3,8 
-2,7 
-5,5 
-4,5 
-4,0 
-3,5 
 
-2,2 
-3,5 
-2,8 
 
 
2,3 
 
-2,6 
-2,2 
 
2,7 
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PA4349 
PA4352 
PA4357 
PA4358 
PA4359 
PA4362 
PA4366 
PA4370 
 
PA4397 
PA4401 
PA4404 
PA4407 
PA4421 
PA4432 
PA4433 
PA4442 
PA4443 
PA4465 
PA4467 
PA4468 
PA4469 
PA4470 
PA4471 
PA4481 
PA4482 
PA4494 
PA4495 
PA4496 
PA4498 
PA4499 
PA4500 
PA4501 
PA4502 
PA4503 
PA4504 
PA4506 
PA4507 
PA4508 
PA4520 
PA4531 
PA4535 
PA4536 
PA4537 
PA4545 
PA4563 
PA4567 
PA4568 
PA4570 
PA4571 
PA4573 
PA4577 
PA4578 
PA4587 
PA4589 
PA4590 
PA4592 
PA4602 
PA4605 
PA4606 
PA4607 
PA4608 
PA4610 
PA4611 
PA4625 
PA4637 
PA4641 
PA4648 
PA4649 
PA4650 
PA4651 
PA4652 
PA4653 
PA4654 
PA4657 
PA4658 
PA4659 
PA4670 
 
 
 
 
 
 
sodB 
icmP 
 
panE 
 
 
ftsZ 
 
rpsI 
rplM 
cysN 
cysD 
 
 
sodM 
 
fumC 
 
mreB 
gatC 
 
 
 
 
 
 
opdD 
 
 
 
 
 
 
 
 
 
 
 
comL 
rpsT 
rpmA 
rplU 
 
 
 
 
 
ccpR 
 
pra 
 
glyA3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
prs 
conserved hypothetical protein 
conserved hypothetical protein 
probable ferrous iron transport protein 
conserved hypothetical protein 
hypothetical protein 
superoxide dismutase 
Insulin-cleaving metalloproteinase outer 
membrane protein precursor 
ketopantoate reductase 
probable glutathione S-transferase 
hypothetical protein 
CD protein FtsZ 
conserved hypothetical protein 
30S ribosomal protein S9 
50S ribosomal protein L13 
ATP sulphurylase GTP-binding subunit 
ATP sulphurylase small subunit 
conserved hypothetical protein 
hypothetical protein 
superoxide dismutase 
hypothetical protein 
fumarate hydratase FumC1 
hypothetical protein 
rod shape-determining protein MreB 
Glu-tRNA(Gln) amidotransferase subunit C 
probable two-component sensor 
hypothetical protein 
probable binding protein com.*t of ABC tr.* 
probable metallopeptidase 
probable transcriptional regulator 
probable binding protein com.*of ABC tr.* 
Glycine-glutamate dipeptide porin OpdP 
probable binding protein com.* of ABC tr.* 
probable permease of ABC transporter 
probable permease of ABC transporter 
prob.*ATP-binding com.* of ABC dipeptide tr.* 
hypothetical protein 
probable transcriptional regulator 
probable Ctransducer 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
competence protein ComL 
30S ribosomal protein S20 
50S ribosomal protein L27 
50S ribosomal protein L21 
hypothetical protein 
probable cytochrome c 
hypothetical protein 
hypothetical protein 
hypothetical protein 
cytochrome c551 peroxidase precursor 
probable outer membrane protein precursor 
protein activator 
probable outer membrane protein precursor 
serine hydroxymethyltransferase 
conserved hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
still frameshift hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable pili assembly chaperone 
hypothetical protein 
hypothetical protein 
probable major facilitator superfamily tr.* 
hypothetical protein 
hypothetical protein 
probable transcriptional regulator 
ribose-phosphate pyrophosphokinase 
probable ribosomal protein L25 
HUU 
HUU 
HUU 
MP; TSM 
HUU 
HUU 
Ap 
MP 
 
NM ; BC 
PE 
HUU 
CD 
HUU 
TPD 
TPD 
CIM  
CIM ABM 
HUU 
MP 
Ap 
HUU 
EM 
HUU 
CLC; CD 
TPD 
TCR 
HUU 
TSM 
TPD 
TR 
TSM 
TSM; MP 
TSM 
MP; TSM 
MP; TSM 
TSM 
MP 
TR 
Ap ;C 
HUU 
HUU 
HUU 
HUU 
CLC 
CIM;TPD 
TPD 
TPD 
HUU 
EM 
HUU 
HUU 
HUU 
EM 
MP; TSM 
TSM; CC 
HUU 
ABM 
HUU 
Ap 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
HUU 
MA; CHP 
HUU 
HUU 
MP; TSM 
HUU 
HUU 
TR 
CC ; NM 
 
 
 
 
 
 
 
 
 
 
-2,2 
-2,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,3 
 
 
 
 
 
 
 
 
 
 
-12,8 
 
 
 
 
 
 
 
 
2,6 
6,9 
4,6 
3,4 
4,9 
 
2,3 
 
 
 
 
 
 
-4,2 
-3,9 
-4,4 
-3,1 
 
2,5 
2,0 
 
 
 
 
 
-2,2 
 
2,3 
 
 
 
-3,5 
-2,5 
-3,1 
-2,8 
 
2,2 
2,4 
-2,3 
 
 
 
 
2,2 
3,6 
3,6 
2,2 
2,3 
3,2 
2,2 
 
 
-3,7 
 
 
 
2,0 
4,5 
 
2,0 
 
-2,1 
-2,0 
-4,4 
 
-2,2 
 
3,3 
 
-2,4 
 
-2,2 
-2,1 
 
-2,8 
-3,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
3,1 
2,0 
10,9 
6,5 
8,7 
5,8 
 
-3,6 
 
 
 
 
 
 
 
 
 
 
 
 
14,2 
6,3 
11,1 
13,4 
5,3 
-2,1 
 
 
 
-2,2 
 
-2,2 
 
 
 
 
 
 
 
-2,2 
-2,1 
4,1 
 
 
-2,4 
-2,0 
-2,7 
 
 
11,9 
2,7 
2,8 
7,6 
-4,3 
2,4 
-2,8 
-26,0 
-2,1 
-2,6 
 
 
 
 
3,8 
4,5 
 
 
 
 
 
 
 
 
 
-4,8 
 
 
 
-2,3 
 
3,5 
 
 
2,1 
-3,2 
 
 
 
-2,8 
 
2,3 
-3,7 
 
2,6 
2,4 
3,1 
3,5 
-2,0 
3,7 
2,5 
3,4 
4,6 
3,4 
 
 
 
-2,4 
-5,0 
2,6 
 
 
 
 
 
 
 
 
-2,4 
 
 
-2,5 
-2,7 
-2,0 
 
3,2 
4,0 
2,2 
5,4 
 
 
 
-2,6 
 
-3,6 
-14,7 
 
2,1 
-2,8 
-2,4 
-2,5 
-2,5 
 
 
2,3 
2,9 
-5,2 
-11,7 
-7,4 
-5,1 
-8,7 
-2,0 
-3,0 
-3,1 
-2,2 
-2,6 
-2,1 
2,5 
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PA4671 
PA4672 
PA4680 
PA4681 
PA4682 
PA4683 
PA4689 
PA4694 
PA4695 
PA4696 
PA4702 
PA4703 
PA4708 
PA4709 
PA4713 
PA4717 
PA4733 
PA4735 
PA4737 
PA4741 
PA4742 
PA4743 
PA4744 
PA4748 
PA4754 
PA4768 
PA4781 
PA4782 
PA4784 
PA4787 
PA4788 
PA4792 
PA4801 
PA4809 
PA4810 
PA4811 
PA4812 
PA4813 
PA4846 
PA4847 
PA4848 
PA4850 
PA4852 
PA4853 
PA4872 
PA4874 
PA4880 
PA4895 
PA4896 
PA4907 
PA4908 
PA4910 
PA4911 
PA4912 
PA4913 
PA4914 
PA4915 
PA4916 
PA4917 
PA4920 
PA4921 
PA4922 
PA4925 
PA4932 
PA4933 
PA4934 
PA4935 
PA4935 
PA4951 
PA4958 
PA4965 
PA4969 
PA4972 
PA4974 
PA4985 
PA4998 
PA5013 
PA5015 
 
 
 
 
 
 
 
ilvC 
ilvH 
ilvI 
 
 
phuT 
 
 
 
acsB 
 
 
rpsO 
truB 
rbfA 
infB 
tpiA 
 
smpB 
 
 
 
 
 
 
 
fdhE 
fdnI 
fdnH 
fdnG 
lipC 
aroQ1 
accB 
accC 
prmA 
 
fis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nadE 
 
azu 
 
rplI 
 
rpsR 
rpsF 
rpsF 
orn 
 
 
 
 
 
 
 
ilvE 
aceE 
peptidyl-tRNA hydrolase 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
ketol-acid reductoisomerase 
acetolactate synthase isozyme III small sub.* 
acetolactate synthase large subunit 
hypothetical protein 
hypothetical protein 
Heme-transport protein, PhuT 
probable hemin degrading factor 
hypothetical protein 
conserved hypothetical protein 
acetyl-coenzyme A synthetase 
hypothetical protein 
hypothetical protein 
30S ribosomal protein S15 
tRNA pseudouridine 55 synthase 
ribosome-binding factor A 
translation initiation factor IF-2 
triosephosphate isomerase 
hypothetical protein 
SmpB protein 
cyclic di-GMP phosphodiesterase 
hypothetical protein 
probable transcriptional regulator 
probable transcriptional regulator 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
FdhE protein 
nitrate-inducible formate dehyd.*,gamma sub. 
nitrate-inducible formate dehyd.*, beta sub.* 
formate dehydrogenase-O, major subunit 
lipase LipC 
3-dehydroquinate dehydratase 
biotin carboxyl carrier protein (BCCP) 
biotin carboxylase 
ribosomal protein L11 methyltransferase 
conserved hypothetical protein 
DNA-binding protein Fis 
hypothetical protein 
conserved hypothetical protein 
probable bacterioferritin 
probable transmembrane sensor 
probable sigma-70 factor, ECF subfamily 
probable short-chain dehydrogenase 
hypothetical protein 
branched chain amino acid ABC tr.*ATP b.p.* 
prob. permease of ABC b.-chain* a.a.* tr.* 
b.-chain* amino acid ABC tr.* m.p.* 
prob.* binding protein component of ABC tr.* 
probable transcriptional regulator 
probable Ctransducer 
hypothetical protein 
hypothetical protein 
NH3-dependent NAD synthetase 
hypothetical protein 
azurin precursor 
conserved hypothetical protein 
50S ribosomal protein L9 
hypothetical protein 
30S ribosomal protein S18 
30S ribosomal protein S6 
30S ribosomal protein S6 
oligoribonuclease 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
hypothetical protein 
probable outer membrane protein precursor 
hypothetical protein 
conserved hypothetical protein 
branched-chain amino acid transferase 
pyruvate dehydrogenase 
peptide methionine sulfoxide reductase 
Ap ; TPD 
TPD 
HUU 
HUU 
HUU 
HUU 
HUU 
BC; ABM 
BC; ABM 
BC; ABM 
HUU 
HUU 
TSM 
PE 
HUU 
HUU 
CC ; CIM 
HUU 
HUU 
TPD 
TPD 
TPD ; Ap 
TPD 
CIM ; EM 
MP 
TPD 
TR 
HUU 
TR 
TR 
HUU 
HUU 
HUU 
EM 
EM 
EM 
EM 
FPM 
ABM 
FPM 
FPM 
TPD 
HUU 
TR; DRR  
HUU 
HUU 
CIM 
MP ; TR 
TR 
PE 
HUU 
TSM 
MP; TSM 
MP; TSM 
TSM 
TR 
Ap ;C 
HUU 
HUU 
ABM; BC 
HUU 
EM 
HUU 
TPD 
MP 
TPD 
TPD 
TPD 
TRD 
HUU 
HUU 
HUU 
HUU 
PSE 
HUU 
HUU 
ABM 
ABM; EM 
 
 
 
 
2,1 
 
 
 
 
 
2,2 
 
 
 
 
 
 
 
 
-2,5 
 
 
 
-2,0 
 
-2,1 
2,4 
 
 
 
 
 
-2,3 
 
 
2,3 
2,4 
2,2 
 
 
 
 
-2,2 
 
 
 
 
 
 
 
2,2 
2,9 
2,6 
3,2 
3,2 
 
 
 
 
 
 
 
2,1 
-2,2 
-2,2 
 
-2,0 
 
 
 
-2,1 
 
 
 
 
 
 
 
2,6 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3,0 
 
 
 
-2,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,4 
2,1 
2,3 
 
 
 
 
 
 
 
 
 
 
2,3 
 
2,6 
2,5 
 
-2,2 
 
 
 
 
 
 
2,5 
 
2,7 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
-5,6 
-4,4 
-3,2 
 
 
-5,1 
-4,5 
-4,8 
 
 
3,0 
3,1 
4,2 
 
-2,0 
 
2,2 
 
 
 
 
 
 
 
 
-2,1 
 
-2,6 
 
2,2 
 
 
 
 
 
-3,3 
 
 
 
-2,1 
 
 
-2,4 
 
 
2,7 
2,2 
-3,4 
 
-2,6 
 
-3,9 
-5,0 
 
 
 
2,5 
-2,7 
 
2,0 
 
 
 
 
 
 
 
 
 
-2,2 
 
-2,4 
 
-2,1 
-2,4 
-2,1 
3,3 
2,1 
-8,6 
-7,8 
-7,2 
-2,1 
-2,2 
-3,8 
-3,0 
-2,9 
-3,1 
-3,4 
2,9 
3,6 
 
-2,1 
-2,6 
-3,2 
 
2,8 
2,1 
2,1 
2,3 
2,3 
2,1 
2,2 
-4,7 
 
-2,5 
 
-2,0 
 
2,4 
-2,1 
-2,9 
-3,7 
-4,0 
-7,0 
 
 
 
 
3,7 
2,1 
 
-3,9 
-2,0 
 
 
-2,7 
 
-3,3 
-3,1 
-4,9 
-6,2 
-2,4 
-5,4 
2,0 
2,5 
-2,1 
-2,9 
 
-3,4 
3,0 
3,0 
3,0 
 
2,9 
-2,4 
-2,4 
 
-2,1 
-2,5 
 
-2,8 
 
 
-2,6 
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PA5018 
PA5027 
PA5028 
PA5040 
PA5041 
PA5049 
PA5054 
PA5060 
PA5075 
PA5076 
PA5091 
PA5093 
PA5097 
PA5098 
PA5099 
PA5100 
PA5101 
PA5103 
PA5104 
PA5105 
PA5106 
PA5107 
PA5108 
PA5112 
PA5117 
PA5118 
PA5122 
PA5137 
PA5139 
PA5148 
PA5150 
PA5152 
PA5153 
PA5154 
PA5155 
PA5167 
PA5168 
PA5169 
PA5170 
PA5171 
PA5172 
PA5173 
PA5174 
PA5178 
PA5182 
PA5191 
PA5192 
PA5196 
PA5197 
PA5204 
PA5207 
PA5208 
PA5210 
PA5212 
PA5213 
PA5219 
PA5220 
PA5230 
PA5231 
PA5232 
PA5233 
PA5234 
PA5245 
PA5253 
PA5261 
PA5270 
PA5271 
PA5274 
PA5279 
PA5289 
PA5298 
PA5301 
PA5302 
PA5303 
PA5304 
PA5305 
PA5306 
PA5312 
msrA 
 
 
pilQ 
pilP 
rpmE 
hslU 
phaF 
 
 
hutG 
 
 
hutH 
 
hutU 
 
 
 
hutC 
 
blc 
 
estA 
typA 
thiI 
 
 
 
 
 
 
 
 
 
 
 
 
arcD 
arcA 
arcB 
arcC 
 
 
 
 
pckA 
 
rimK 
argA 
 
 
 
 
gcvP1 
 
 
 
 
 
 
 
 
algP 
algR 
 
 
rnk 
 
 
 
 
dadX 
 
dadA 
 
 
 
hypothetical protein 
conserved hypothetical protein 
Type 4 fimbrial biogenesis o.m. p.* PilQ prc.* 
type 4 fimbrial biogenesis protein PilP 
50S ribosomal protein L31 
heat shock protein HslU 
polyhydroxyalkanoate synthesis protein PhaF 
probable permease of ABC transporter 
prob.* binding protein component of ABC tr.* 
N-formylglutamate amidohydrolase 
Prob.* histidine/phenylalanine ammonia-lyase 
probable amino acid permease 
histidine ammonia-lyase 
probable transporter 
urocanase 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
histidine utilization repressor HutC 
conserved hypothetical protein 
outer membrane lipoprotein Blc 
hypothetical protein 
esterase EstA 
regulatory protein TypA 
thiazole biosynthesis protein ThiI 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
probable short-chain dehydrogenase 
probable ATP-binding component of ABC tr.* 
a.a* ABC tr.*periplasmic binding protein 
probable permease of ABC transporter 
a.a* ABC transporter membrane protein 
probable c4-dicarboxylate-binding protein 
probable dicarboxylate transporter 
probable C4-dicarboxylate transporter 
arginine/ornithine antiporter 
arginine deiminase 
ornithine carbamoyltransferase, catabolic 
carbamate kinase 
probable beta-ketoacyl synthase 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
phosphoenolpyruvate carboxykinase 
hypothetical protein 
ribosomal protein S6 modification protein 
N-acetylglutamate synthase 
probable phosphate transporter 
conserved hypothetical protein 
probable secretion pathway ATPase 
hypothetical protein 
glycine cleavage system protein P1 
hypothetical protein 
hypothetical protein 
probable permease of ABC transporter 
prob.*ATP-binding/permease fusion ABC tr.* 
conserved hypothetical protein 
hypothetical protein 
probable oxidoreductase 
conserved hypothetical protein 
alginate regulatory protein AlgP 
alginate biosynthesis regulatory protein AlgR 
hypothetical protein 
hypothetical protein 
nucleoside diphosphate kinase regulator 
conserved hypothetical protein 
hypothetical protein 
xanthine phosphoribosyltransferase 
probable transcriptional regulator 
catabolic alanine racemase 
conserved hypothetical protein 
D-amino acid dehydrogenase, small subunit 
conserved hypothetical protein 
conserved hypothetical protein 
probable aldehyde dehydrogenase 
prob.* pyridoxal-dependent aminotransferase 
TPD 
HUU 
HUU 
MA 
MA 
TPD 
CHP 
CIM 
MP; TSM 
TSM 
ABM 
PE 
MP; TSM 
ABM 
MP; TSM 
ABM 
HUU 
HUU 
HUU 
TR 
HUU 
MP 
HUU 
SF ; FPM 
Ap 
BC 
HUU 
HUU 
HUU 
HUU 
PE 
TSM 
TSM 
MP; TSM 
MP ;TSM 
MP; TSM 
MP; TSM 
MP; TSM 
MP; ABM  
ABM 
ABM 
ABM 
FPM 
HUU 
MP 
HUU 
CC ; EM 
HUU 
TRD 
ABM 
MP; TSM 
HUU 
PSE 
HUU 
CIM;ABM 
MP 
HUU 
MP; TSM 
MP; TSM 
HUU 
HUU 
PE 
HUU 
TR 
SF ; TR  
HUU 
HUU 
TR 
HUU 
HUU 
NM 
TR 
ABM 
HUU 
EM; ABM 
HUU 
HUU 
PE 
 
 
 
 
 
-2,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,0 
 
 
2,6 
2,4 
2,5 
2,7 
3,3 
3,4 
3,2 
 
 
 
2,2 
 
 
 
 
 
 
 
5,2 
2,4 
 
 
 
 
 
 
 
 
 
 
 
2,0 
-2,2 
 
 
 
 
2,1 
4,1 
3,4 
 
 
 
 
-2,3 
 
 
 
 
 
 
 
2,4 
2,3 
 
 
 
2,2 
2,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,1 
 
 
 
 
 
 
 
 
-2,0 
-2,6 
-2,6 
-2,5 
 
 
 
 
 
 
 
 
-2,1 
-3,1 
 
 
 
 
 
-2,3 
-2,8 
-2,4 
 
 
 
 
 
 
 
 
 
 
2,2 
 
 
-2,5 
 
 
 
 
-2,0 
3,4 
-2,2 
-2,3 
-2,0 
 
-2,0 
 
-2,9 
-3,1 
 
2,0 
2,2 
 
 
 
 
 
2,8 
2,8 
8,4 
 
 
-2,8 
 
 
-2,9 
-2,5 
-2,4 
-2,5 
4,1 
-2,8 
-6,7 
-4,5 
-3,6 
-3,1 
 
-2,8 
2,6 
2,8 
2,7 
3,8 
2,1 
 
2,2 
 
 
 
 
2,0 
2,0 
2,9 
 
 
 
 
 
2,4 
2,6 
2,8 
-2,1 
-2,4 
-2,0 
-2,2 
 
-2,0 
-2,1 
-3,0 
-2,2 
-2,2 
-2,5 
-2,0 
6,4 
20,9 
6,5 
 
 
 
 
 
 
-2,2 
 
4,3 
 
-2,5 
 
 
 
 
3,5 
2,8 
2,5 
4,4 
-2,1 
-2,7 
 
 
6,0 
-2,3 
-2,2 
-3,7 
2,1 
2,1 
 
 
 
 
 
-3,6 
-7,2 
-4,1 
-3,5 
-5,5 
-3,9 
-5,3 
-2,1 
-3,1 
-3,1 
-2,1 
3,4 
-2,4 
 
-3,4 
2,3 
-2,3 
-3,1 
2,0 
 
 
-2,0 
-4,6 
-3,5 
2,4 
2,6 
 
 
 
 
 
-2,0 
-2,7 
-3,4 
 
-4,2 
 
 
 
 
 
 
2,0 
 
-2,1 
-2,4 
-2,2 
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PA5313 
PA5314 
PA5315 
PA5316 
PA5337 
PA5339 
PA5344 
PA5347 
PA5348 
PA5351 
PA5352 
PA5353 
PA5354 
PA5355 
PA5356 
PA5359 
PA5376 
PA5377 
PA5378 
PA5379 
PA5380 
PA5395 
PA5396 
PA5397 
PA5398 
PA5399 
PA5401 
PA5408 
PA5409 
PA5410 
PA5411 
PA5414 
PA5415 
PA5416 
PA5417 
PA5419 
PA5420 
PA5421 
PA5422 
PA5423 
PA5424 
PA5427 
PA5442 
PA5446 
PA5447 
PA5448 
PA5449 
PA5450 
PA5451 
PA5452 
 
PA5453 
PA5454 
PA5455 
PA5456 
PA5457 
PA5458 
PA5459 
PA5461 
PA5462 
PA5475 
PA5475 
PA5479 
PA5482 
PA5496 
 
PA5502 
PA5504 
PA5521 
PA5522 
PA5523 
PA5525 
PA5526 
PA5527 
PA5542 
PA5544 
PA5545 
PA5546 
 
 
rpmG 
rpmB 
rpoZ 
 
oxyR 
 
 
rubA1 
 
glcF 
glcE 
glcD 
glcC 
 
 
 
 
sdaB 
gbdR 
 
 
 
dgcA 
dgcB 
 
 
 
gbcA 
gbcB 
 
glyA1 
soxB 
soxD 
soxG 
purU2 
fdhA 
 
 
 
adhA 
 
 
wbpZ 
wbpY 
wbpX 
wzt 
wzm 
wbpW 
 
gmd 
rmd 
 
 
 
 
 
 
 
 
 
gltP 
 
nrdJb 
 
 
 
 
 
 
 
 
 
 
 
 
 
hypothetical protein 
50S ribosomal protein L33 
50S ribosomal protein L28 
RNA polymerase omega subunit 
conserved hypothetical protein 
OxyR 
hypothetical protein 
probable DNA-binding protein 
Rubredoxin 1 
conserved hypothetical protein 
glycolate oxidase subunit GlcF 
glycolate oxidase subunit GlcE 
glycolate oxidase subunit GlcD 
transcriptional regulator GlcC 
hypothetical protein 
probable ATP-binding component of ABC tr.* 
probable permease of ABC transporter 
hypothetical protein 
L-serine dehydratase 
GbdR 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
DgcA, Dimethylglycine catabolism 
DgcB, Dimethylglycine catabolism 
hypothetical protein 
hypothetical protein 
hypothetical protein 
GbcA 
GbcB 
hypothetical protein 
serine hydroxymethyltransferase 
sarcosine oxidase beta subunit 
sarcosine oxidase delta subunit 
sarcosine oxidase gamma subunit 
formyltetrahydrofolate deformylase 
glutathione-independent formaldehyde dehyd. 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
alcohol dehydrogenase 
conserved hypothetical protein 
hypothetical protein 
glycosyltransferase WbpZ 
glycosyltransferase WbpY 
glycosyltransferase WbpX 
ABC subunit of A-band LPS efflux transporter 
membrane subunit of A-band LPS efflux tr.* 
phosphomannose isomerase/GDP-mannose 
WbpW 
GDP-mannose 4,6-dehydratase 
oxidoreductase Rmd 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
proton-glutamate symporter 
hypothetical protein 
class II (cobalamin-dependent) ribonucleotide-
diphosphate reductase sub.*, NrdJb 
hypothetical protein 
D-methionine ABC tr.* membrane protein 
probable short-chain dehydrogenase 
probable glutamine synthetase 
probable aminotransferase 
probable transcriptional regulator 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
conserved hypothetical protein 
GlmR transcriptional regulator 
PE 
HUU 
TPD 
TPD 
TRD 
HUU 
TR ; MA 
HUU 
DRR 
CC 
HUU 
CIM ; CC 
CIM ; CC 
CIM ; CC 
TR 
HUU 
TSM 
MP; TSM 
HUU 
ABM 
TR 
HUU 
HUU 
HUU 
ABM 
ABM 
HUU 
HUU 
MP 
ABM 
ABM 
HUU 
ABM 
ABM 
ABM 
ABM 
NM 
CIM 
HUU 
HUU 
MP 
EM ; CC 
MP 
HUU 
CLC 
CLC 
CLC 
CLC  
CLC; MP  
CLC 
 
CLC 
CLC 
HUU 
HUU 
HUU 
MP 
HUU 
HUU 
HUU 
HUU 
HUU 
MP; TSM 
MP 
NM 
 
HUU 
MP; TSM 
PE 
PE 
PE 
TR 
HUU 
HUU 
PE 
MP 
HUU 
PE 
2,1 
2,1 
-2,1 
-2,0 
 
 
 
 
 
 
5,8 
5,2 
3,3 
3,9 
2,1 
 
2,1 
2,8 
2,9 
 
2,2 
 
3,0 
2,2 
 
 
 
 
 
4,0 
2,5 
 
2,5 
3,1 
3,4 
2,7 
 
3,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,0 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,2 
 
 
 
2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,4 
-3,0 
 
-2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-5,1 
 
 
 
-2,1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2,1 
-2,3 
-2,6 
-3,4 
 
-3,8 
-3,3 
-4,5 
-3,2 
 
 
 
 
-2,8 
 
-2,7 
 
 
 
 
 
 
 
 
-2,5 
-2,3 
-2,0 
 
 
 
 
 
 
 
 
 
4,9 
-2,3 
14,4 
 
-4,6 
-3,4 
-4,6 
-3,2 
-3,0 
 
-3,3 
-3,6 
-2,9 
-3,9 
-3,7 
-2,6 
-4,0 
-2,0 
-2,3 
16,9 
 
 
 
2,4 
 
 
 
 
 
 
 
 
 
-2,2 
 
-3,0 
 
-3,3 
-2,5 
4,0 
3,1 
2,0 
 
 
 
-2,1 
2,6 
-24,1 
-18,4 
-16,8 
-13,8 
-4,5 
-3,1 
-3,5 
-4,3 
-6,0 
-2,2 
-2,2 
-2,7 
-5,1 
-3,0 
-2,7 
-2,1 
-2,1 
-2,2 
-2,2 
-8,0 
-4,3 
 
-2,5 
-5,2 
-4,5 
-3,7 
-2,6 
-4,9 
-2,0 
-2,3 
-2,5 
 
 
9,4 
-2,1 
-2,7 
-3,2 
-3,0 
-2,7 
-2,6 
 
-3,3 
-2,9 
-2,2 
-2,3 
-2,1 
 
-2,9 
 
 
 
3,2 
3,3 
 
 
 
2,0 
2,1 
-2,8 
-2,1 
-2,6 
-2,7 
-2,1 
-2,3 
-2,6 
-2,4 
-4,3 
-3,4 
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PA5550 
PA5553 
PA5554 
PA5555 
PA5556 
PA5557 
PA5558 
PA5559 
PA5560 
PA5561 
PA5569 
PA5569 
PA5570 
 
glmR 
atpC 
atpD 
atpG 
atpA 
atpH 
atpF 
atpE 
atpB 
atpI 
rnpA 
rnpA 
rpmH 
ATP synthase epsilon chain 
ATP synthase beta chain 
ATP synthase gamma chain 
ATP synthase alpha chain 
ATP synthase delta chain 
ATP synthase B chain 
atp synthase C chain 
ATP synthase A chain 
ATP synthase protein I 
ribonuclease P protein component 
ribonuclease P protein component 
50S ribosomal protein L34 
TR 
EM 
EM 
EM 
EM 
EM 
EM 
EM 
EM 
MP ; EM 
TPD 
TPD 
CIM 
 
-2,4 
 
 
 
 
-2,1 
 
 
-2,2 
 
-2,1 
 
 
 
 
 
 
 
 
 
 
 
2,3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,1 
3,6 
2,2 
2,7 
2,3 
2,7 
2,9 
2,1 
2,1 
3,1 
 
2,7 
2,4 
 
Continued 
Gene IDa Gene namea PCFCa,b  
W4/ 
M4 
FC 
W12/ 
M12 
 
M4/ 
M12 
 
W4/ 
W14 
tRNA Ala 
tRNA Asn 
tRNA Cys 
tRNA Gly 
tRNA His 
tRNA Ile 
tRNA Lys 
tRNA Phe 
tRNA Pro 
tRNA Ser 
tRNA Trp 
tRNA Val 
 
PA3139.1/PA4541.3 
PA2581.1 
 
 
 
 
PA5149.1 
PA2736.1/PA3031.1/ PA4541.2/ 
PA2852.1/PA0905.1/ PA1013.1/PA2603.1/ 
 
PA2775.1/PA3094.3/PA3262.2 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
-2,2 
-2,5 
-2,2 
-2,2 
-2,5 
-3,3 
-2,9 
-2,1 
-2,2 
-2,6 
 
-2,5 
 
 
 
 
 
 
 
 
 
-2,5 
 
 
 2,1 
 
 
2,2 
2,4 
3,1 
2,4 
 
 
 
2,3 
 
a Gene ID, gene name, function and PCFC are according to the “Pseudomonas Genome Database” 
(Winsor et al., 2011). 
b Abbreviations used for PseudoCAP Function Class (PCFC) are as following Adaptation, 
Protection (AP); Amino acid biosynthesis and metabolism (ABM); Antibiotic resistance and 
susceptibility (ARS); Biosynthesis of cofactors, prosthetic groups and carriers (BC);Carbon 
compound catabolism (CC); Cell wall, LPS, capsule (CLC); Central intermediary metabolism (CIM); 
Chaperones & heat shock proteins (CHP); Chemotaxis (C); Cell division (CD); DNA replication, 
recombination, modification and repair (DRR); Energy metabolism (EM); Fatty acid and 
phospholipid metabolism (FPM); Hypothetical, unclassified, unknown (HUU); Membrane proteins 
(MP); Motility & Attachment (MA); Non-coding RNA gene (NR); Nucleotide biosynthesis and 
metabolism (NM); Protein secretion/export apparatus (PSE); Putative enzymes (PE); Related to 
phage, transposon, or plasmid (RPT); Secreted Factors (toxins, enzymes, alginate) (SF); 
Transcriptional regulators (TR); Transcription, RNA processing and degradation (TRD); Translation, 
post-translational modification, degradation (TPD); Transport of small molecules (TSM); Two-
component regulatory systems (TCR) and Unclassified genome space (UGS). 
* Other abbreviations used are amino acid (a.a.), basal-body (b-b.), branched-chain (b.-chain), 
binding protein (b.p.), biosynthesis protein (bio. p.), component (com.), dehydrogenase (dehyd.), 
dependent (dep.), electron (e.), factor (fc.), flavoprotein (fp.), membrane-bound (m.-b.), membrane 
protein (m.p.), outer membrane (o.m.), oxidase (ox.), protein (p.), protein synthase (p.s.), precursor 
(prc.), probable (prob.), subunit (sub.), synthase (syn.), transporter (tr.) and transferase (transf.) 
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